<?xml version='1.0' encoding='ASCII'?>
<html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2023"
    xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2023"
    xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL"
    xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:mrvi="http://www.maravai.com/20231231"
    xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance"
    xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US">

<head>
    <meta http-equiv="Content-Type" content="text/html" />


    <title>mrvi-20231231</title>
</head>

<body>
    <div style="display:none">
        <ix:header>
            <ix:hidden>
                <ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-34">0001823239</ix:nonNumeric>
                <ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-35">2023</ix:nonNumeric>
                <ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-36">FY</ix:nonNumeric>
                <ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-37">FALSE
                </ix:nonNumeric>
                <ix:nonNumeric contextRef="c-24" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="f-216">
                    http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201602Member</ix:nonNumeric>
                <ix:nonNumeric contextRef="c-118"
                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"
                    id="f-547">P2Y</ix:nonNumeric>
                <ix:nonNumeric contextRef="c-294"
                    name="us-gaap:GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration" id="f-980">
                    http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric>
                <ix:nonNumeric contextRef="c-295"
                    name="us-gaap:GovernmentAssistanceStatementOfFinancialPositionExtensibleEnumeration" id="f-982">
                    http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
                </ix:nonNumeric>
                <ix:nonNumeric contextRef="c-5"
                    name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-999">
                    http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
                </ix:nonNumeric>
                <ix:nonNumeric contextRef="c-6"
                    name="us-gaap:FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-1000">
                    http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
                </ix:nonNumeric>
                <ix:nonNumeric contextRef="c-6"
                    name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-1003">
                    http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric>
                <ix:nonNumeric contextRef="c-5"
                    name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-1004">
                    http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric>
                <ix:nonNumeric contextRef="c-5"
                    name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1011">
                    http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</ix:nonNumeric>
                <ix:nonNumeric contextRef="c-6"
                    name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1012">
                    http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</ix:nonNumeric>
                <ix:nonNumeric contextRef="c-6"
                    name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"
                    id="f-1019">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric>
                <ix:nonNumeric contextRef="c-5"
                    name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"
                    id="f-1020">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric>
                <ix:nonNumeric contextRef="c-373"
                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"
                    id="f-1310">P4Y</ix:nonNumeric>
                <ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-5"
                    name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-1343">
                    zero</ix:nonFraction>
                <ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-5"
                    name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:fixed-zero" scale="0"
                    id="f-1500">zero</ix:nonFraction>
                <ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-5"
                    name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:fixed-zero" scale="0"
                    id="f-1501">zero</ix:nonFraction>
            </ix:hidden>
            <ix:references xml:lang="en-US">
                <link:schemaRef xlink:type="simple" xlink:href="mrvi-20231231.xsd" />
            </ix:references>
            <ix:resources>
                <xbrli:context id="c-1">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-2">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-06-30</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:unit id="usd">
                    <xbrli:measure>iso4217:USD</xbrli:measure>
                </xbrli:unit>
                <xbrli:context id="c-3">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassAMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2024-02-21</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:unit id="shares">
                    <xbrli:measure>xbrli:shares</xbrli:measure>
                </xbrli:unit>
                <xbrli:context id="c-4">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassBMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2024-02-21</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-5">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-6">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-7">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">
                                us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-8">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">
                                us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-9">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">
                                us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-10">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">
                                us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-11">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassAMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:unit id="usdPerShare">
                    <xbrli:divide>
                        <xbrli:unitNumerator>
                            <xbrli:measure>iso4217:USD</xbrli:measure>
                        </xbrli:unitNumerator>
                        <xbrli:unitDenominator>
                            <xbrli:measure>xbrli:shares</xbrli:measure>
                        </xbrli:unitDenominator>
                    </xbrli:divide>
                </xbrli:unit>
                <xbrli:context id="c-12">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassAMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-13">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassBMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-14">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassBMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-15">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-16">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-17">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassAMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:CommonStockMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2020-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-18">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassBMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:CommonStockMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2020-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-19">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2020-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-20">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2020-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-21">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2020-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-22">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2020-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-23">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2020-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-24">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2020-01-01</xbrli:startDate>
                        <xbrli:endDate>2020-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-25">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">
                                srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2020-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-26">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">
                                srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2020-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-27">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">
                                srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2020-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-28">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassAMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:CommonStockMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-29">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassBMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:CommonStockMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-30">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-31">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-32">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-33">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-34">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassAMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:CommonStockMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2021-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-35">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassBMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:CommonStockMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2021-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-36">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2021-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-37">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2021-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-38">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2021-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-39">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2021-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-40">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2021-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-41">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassAMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:CommonStockMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-42">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-43">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-44">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-45">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassAMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:CommonStockMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-46">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassBMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:CommonStockMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-47">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-48">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-49">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-50">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-51">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassBMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:CommonStockMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-52">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-53">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-54">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassAMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:CommonStockMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-55">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-56">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassAMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:CommonStockMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-57">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassBMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:CommonStockMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-58">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-59">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-60">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-61">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">
                                us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-62">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">
                                mrvi:MaravaiLifeSciencesHoldingsLLCMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-63">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">
                                mrvi:MaravaiLifeSciencesHoldingsLLCMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-64">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">
                                mrvi:MaravaiLifeSciencesHoldingsLLCMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-65">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">
                                mrvi:MaravaiLifeSciencesHoldings2LLCMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-66">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">
                                mrvi:MaravaiLifeSciencesHoldings2LLCMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-67">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">
                                mrvi:MaravaiLifeSciencesHoldings2LLCMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:unit id="segment">
                    <xbrli:measure>mrvi:segment</xbrli:measure>
                </xbrli:unit>
                <xbrli:context id="c-68">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-69">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:BiologicsSafetyTestingSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-70">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-71">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-72">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:BiologicsSafetyTestingSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-73">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-74">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-75">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:BiologicsSafetyTestingSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-76">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-77">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">
                                mrvi:LatinAndCentralAmericaMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-78">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:BiologicsSafetyTestingSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">
                                mrvi:LatinAndCentralAmericaMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-79">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">
                                mrvi:LatinAndCentralAmericaMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-80">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-81">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:BiologicsSafetyTestingSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-82">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-83">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:BiologicsSafetyTestingSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-84">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-85">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-86">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:BiologicsSafetyTestingSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-87">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-88">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-89">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:BiologicsSafetyTestingSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-90">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-91">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">
                                mrvi:LatinAndCentralAmericaMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-92">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:BiologicsSafetyTestingSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">
                                mrvi:LatinAndCentralAmericaMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-93">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">
                                mrvi:LatinAndCentralAmericaMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-94">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-95">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:BiologicsSafetyTestingSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-96">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-97">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:BiologicsSafetyTestingSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-98">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:ProteinDetectionSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-99">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:NorthAmericaMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-100">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-101">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:BiologicsSafetyTestingSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-102">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:ProteinDetectionSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-103">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-104">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-105">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:BiologicsSafetyTestingSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-106">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:ProteinDetectionSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-107">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-108">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">
                                mrvi:LatinAndCentralAmericaMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-109">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:BiologicsSafetyTestingSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">
                                mrvi:LatinAndCentralAmericaMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-110">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:ProteinDetectionSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">
                                mrvi:LatinAndCentralAmericaMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-111">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">
                                mrvi:LatinAndCentralAmericaMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-112">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-113">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:BiologicsSafetyTestingSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-114">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:ProteinDetectionSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-115">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">
                                us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-116">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">
                                us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-117">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">
                                us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-118">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-119">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:unit id="number">
                    <xbrli:measure>xbrli:pure</xbrli:measure>
                </xbrli:unit>
                <xbrli:context id="c-120">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:OwnershipAxis">mrvi:MaravaiTopcoHoldingsLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-121">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:OwnershipAxis">mrvi:MaravaiTopcoHoldingsLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="dei:LegalEntityAxis">
                                mrvi:MaravaiLifeSciencesHoldingsLLCMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-122">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mrvi:MaravaiTopcoHoldingsLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">
                                mrvi:MaravaiLifeSciencesHoldingsLLCMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember
                                dimension="us-gaap:DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis">
                                mrvi:TaxDistributionMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-123">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mrvi:MaravaiTopcoHoldingsLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">
                                mrvi:MaravaiLifeSciencesHoldingsLLCMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember
                                dimension="us-gaap:DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis">
                                mrvi:TaxDistributionMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-124">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mrvi:MaravaiTopcoHoldingsLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">
                                mrvi:MaravaiLifeSciencesHoldingsLLCMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember
                                dimension="us-gaap:DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis">
                                mrvi:TaxDistributionMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-125">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
                                us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-126">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
                                us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-127">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
                                us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-128">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
                                us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrvi:NacalaiUSAIncMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">
                                us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-129">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrvi:NacalaiUSAIncMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
                                mrvi:AccountsReceivableBenchmarkMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">
                                us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-130">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrvi:NacalaiUSAIncMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
                                mrvi:AccountsReceivableBenchmarkMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">
                                us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-131">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrvi:CureVacMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
                                us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">
                                us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-132">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrvi:CureVacMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
                                mrvi:AccountsReceivableBenchmarkMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">
                                us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-133">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrvi:CureVacMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
                                mrvi:AccountsReceivableBenchmarkMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">
                                us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-134">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrvi:BioNTechSEMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
                                us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">
                                us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-135">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrvi:BioNTechSEMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
                                us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">
                                us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-136">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrvi:BioNTechSEMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
                                mrvi:AccountsReceivableBenchmarkMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">
                                us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-137">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
                                us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrvi:PfizerIncMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">
                                us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-138">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
                                us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrvi:PfizerIncMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">
                                us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-139">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">mrvi:PfizerIncMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">
                                mrvi:AccountsReceivableBenchmarkMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">
                                us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-140">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-18</xbrli:startDate>
                        <xbrli:endDate>2023-01-18</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-141">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-142">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-18</xbrli:startDate>
                        <xbrli:endDate>2023-06-30</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-143">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-06-01</xbrli:startDate>
                        <xbrli:endDate>2023-06-30</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-144">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">
                                mrvi:SecuritiesPurchaseAgreementMaximumPerformancePaymentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-01-18</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-145">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">
                                mrvi:SecuritiesPurchaseAgreementRetentionPaymentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-01-18</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-146">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrvi:MyChemLegacyOwnersMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-18</xbrli:startDate>
                        <xbrli:endDate>2023-01-18</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-147">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrvi:MyChemLegacyOwnersMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">
                                mrvi:SecuritiesPurchaseAgreementRetentionPaymentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">
                                us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-148">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-01-18</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-149">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-07-01</xbrli:startDate>
                        <xbrli:endDate>2023-09-30</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-150">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="mrvi:EscrowDepositReasonAxis">
                                mrvi:PotentialWorkingCapitalAdjustmentsMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-01-18</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-151">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="mrvi:EscrowDepositReasonAxis">
                                mrvi:SecureRepresentationsAndWarrantiesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-01-18</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-152">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="mrvi:EscrowDepositReasonAxis">
                                mrvi:PotentialWorkingCapitalAdjustmentsMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-04-01</xbrli:startDate>
                        <xbrli:endDate>2023-06-30</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-153">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-04-01</xbrli:startDate>
                        <xbrli:endDate>2023-06-30</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-154">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:TradeNamesMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-01-18</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-155">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:TradeNamesMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-18</xbrli:startDate>
                        <xbrli:endDate>2023-01-18</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-156">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-01-18</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-157">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-18</xbrli:startDate>
                        <xbrli:endDate>2023-01-18</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-158">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-01-18</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-159">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-18</xbrli:startDate>
                        <xbrli:endDate>2023-01-18</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-160">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">
                                us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">
                                mrvi:MeasurementInputRevenueGrowthRateMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-01-18</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-161">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">
                                us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">
                                mrvi:MeasurementInputRevenueGrowthRateMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-01-18</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-162">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">
                                us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">
                                us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-01-18</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-163">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">
                                us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">
                                mrvi:MeasurementInputObsolescentCurveMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-01-18</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-164">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-27</xbrli:startDate>
                        <xbrli:endDate>2022-01-27</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-165">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-166">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-27</xbrli:startDate>
                        <xbrli:endDate>2022-11-30</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-167">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-11-01</xbrli:startDate>
                        <xbrli:endDate>2022-11-30</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-168">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">
                                mrvi:SecuritiesPurchaseAgreementMaximumPerformancePaymentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-01-27</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-169">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">
                                mrvi:SecuritiesPurchaseAgreementRetentionPaymentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-01-27</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:unit id="employee">
                    <xbrli:measure>mrvi:employee</xbrli:measure>
                </xbrli:unit>
                <xbrli:context id="c-170">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrvi:MyChemLegacyOwnersMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-27</xbrli:startDate>
                        <xbrli:endDate>2022-01-27</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-171">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrvi:MyChemLegacyOwnersMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">
                                mrvi:SecuritiesPurchaseAgreementRetentionPaymentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">
                                us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-172">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrvi:MyChemLegacyOwnersMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">
                                mrvi:SecuritiesPurchaseAgreementRetentionPaymentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">
                                us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-173">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrvi:MyChemLegacyOwnersMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">
                                mrvi:SecuritiesPurchaseAgreementRetentionPaymentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">
                                us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-174">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">
                                mrvi:SecuritiesPurchaseAgreementCompletionOfAcquiredInventoryMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-175">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">
                                mrvi:SecuritiesPurchaseAgreementCompletionOfAcquiredInventoryMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-28</xbrli:startDate>
                        <xbrli:endDate>2023-01-28</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-176">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">
                                mrvi:SecuritiesPurchaseAgreementCompletionOfAcquiredInventoryMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-29</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-177">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-01-27</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-178">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-10-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-179">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="mrvi:EscrowDepositReasonAxis">
                                mrvi:PotentialWorkingCapitalAdjustmentsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-01-27</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-180">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="mrvi:EscrowDepositReasonAxis">
                                mrvi:SecureRepresentationsAndWarrantiesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-01-27</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-181">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="mrvi:EscrowDepositReasonAxis">
                                mrvi:PotentialWorkingCapitalAdjustmentsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-10-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-182">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="mrvi:EscrowDepositReasonAxis">
                                mrvi:SecureRepresentationsAndWarrantiesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-28</xbrli:startDate>
                        <xbrli:endDate>2023-03-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-183">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="mrvi:EscrowDepositReasonAxis">
                                mrvi:IndemnificationOfPreClosingLiabilitiesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-29</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-184">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:TradeNamesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-01-27</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-185">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:TradeNamesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-27</xbrli:startDate>
                        <xbrli:endDate>2022-01-27</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-186">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-01-27</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-187">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-27</xbrli:startDate>
                        <xbrli:endDate>2022-01-27</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-188">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-01-27</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-189">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-27</xbrli:startDate>
                        <xbrli:endDate>2022-01-27</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-190">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">
                                us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">
                                mrvi:MeasurementInputRevenueGrowthRateMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-01-27</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-191">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">
                                us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">
                                mrvi:MeasurementInputRevenueGrowthRateMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-01-27</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-192">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">
                                us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">
                                us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-01-27</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-193">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">
                                us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">
                                mrvi:MeasurementInputObsolescentCurveMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-01-27</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-194">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">
                                us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">
                                mrvi:MeasurementInputObsolescentCurveMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-01-27</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-195">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">
                                us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember
                                dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">
                                mrvi:VectorLaboratoriesIncMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-08-01</xbrli:startDate>
                        <xbrli:endDate>2021-08-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-196">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">
                                us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember
                                dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">
                                mrvi:VectorLaboratoriesIncMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-09-01</xbrli:startDate>
                        <xbrli:endDate>2021-09-30</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-197">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">
                                us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember
                                dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">
                                mrvi:VectorLaboratoriesIncMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-198">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">
                                us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember
                                dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">
                                mrvi:VectorLaboratoriesIncMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2021-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-199">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">
                                us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember
                                dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">
                                mrvi:VectorLaboratoriesIncMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-200">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">
                                us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember
                                dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">
                                mrvi:VectorLaboratoriesIncMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-201">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrvi:MLSH1IncentiveUnitMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-202">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">
                                mrvi:CostRealignmentPlanMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-11-01</xbrli:startDate>
                        <xbrli:endDate>2023-11-30</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-203">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">
                                mrvi:CostRealignmentPlanMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-204">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                us-gaap:CorporateMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">
                                mrvi:CostRealignmentPlanMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-205">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">
                                mrvi:CostRealignmentPlanMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-206">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">
                                mrvi:CostRealignmentPlanMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">
                                us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-207">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">
                                mrvi:StockBasedCompensationExpenseBenefitMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">
                                mrvi:CostRealignmentPlanMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-208">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">
                                us-gaap:FacilityClosingMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">
                                mrvi:CostRealignmentPlanMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-209">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">
                                us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">
                                mrvi:CostRealignmentPlanMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-210">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">
                                mrvi:CostRealignmentPlanMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-211">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">
                                mrvi:CostRealignmentPlanMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">
                                us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-212">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">
                                mrvi:StockBasedCompensationExpenseBenefitMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">
                                mrvi:CostRealignmentPlanMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-213">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">
                                us-gaap:FacilityClosingMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">
                                mrvi:CostRealignmentPlanMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-214">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">
                                us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">
                                mrvi:CostRealignmentPlanMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-215">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">
                                mrvi:CostRealignmentPlanMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">
                                us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-216">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">
                                mrvi:StockBasedCompensationExpenseBenefitMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">
                                mrvi:CostRealignmentPlanMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-217">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">
                                us-gaap:FacilityClosingMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">
                                mrvi:CostRealignmentPlanMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-218">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">
                                us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">
                                mrvi:CostRealignmentPlanMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-219">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">
                                mrvi:CostRealignmentPlanMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-220">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">
                                mrvi:CostRealignmentPlanMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">
                                us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2024-01-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-221">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">
                                mrvi:CostRealignmentPlanMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">
                                us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2024-01-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-222">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                us-gaap:CorporateMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">
                                mrvi:CostRealignmentPlanMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">
                                us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2024-01-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:unit id="reporting_unit">
                    <xbrli:measure>mrvi:reporting_unit</xbrli:measure>
                </xbrli:unit>
                <xbrli:context id="c-223">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:ProteinDetectionSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-224">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-10-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-225">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-226">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:BiologicsSafetyTestingSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-227">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-228">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:BiologicsSafetyTestingSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-229">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-230">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-231">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:TradeNamesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-232">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:TradeNamesMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-233">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:TradeNamesMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-234">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-235">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-236">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-237">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-238">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-239">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-240">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:TradeNamesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-241">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:TradeNamesMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-242">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:TradeNamesMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-243">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-244">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-245">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-246">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-247">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-248">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">
                                us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-249">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-03-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-250">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">
                                us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-251">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">
                                us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-252">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">
                                us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-253">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">
                                us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-254">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">
                                us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-255">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">
                                us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-256">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">
                                us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
                                us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">
                                us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-257">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
                                us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">
                                us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">
                                us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-258">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">
                                us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">
                                us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
                                us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-259">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">
                                us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">
                                us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-260">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">
                                us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">
                                us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
                                us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-261">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
                                us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">
                                us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">
                                us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-262">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">
                                us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">
                                us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
                                us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-263">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">
                                us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">
                                us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-264">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">
                                us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
                                us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-265">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
                                us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">
                                us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-266">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">
                                us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
                                us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-267">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">
                                us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-268">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">
                                us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">
                                us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
                                us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-269">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
                                us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">
                                us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">
                                us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-270">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">
                                us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">
                                us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">
                                us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-271">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">
                                us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">
                                us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-272">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">
                                us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-01-18</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:unit id="payment">
                    <xbrli:measure>mrvi:payment</xbrli:measure>
                </xbrli:unit>
                <xbrli:context id="c-273">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">
                                us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-01-27</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-274">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-04-01</xbrli:startDate>
                        <xbrli:endDate>2022-06-30</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-275">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
                                us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-276">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
                                us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-277">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
                                us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-278">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
                                us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-279">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
                                us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-280">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
                                mrvi:DepreciablePropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-281">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
                                mrvi:DepreciablePropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-282">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
                                us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-283">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">
                                us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-284">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-285">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:MyChemLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-286">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-287">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mrvi:AlphazymeLLCMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-288">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">
                                mrvi:SanDiegoCaliforniaMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-05-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:unit id="building">
                    <xbrli:measure>mrvi:building</xbrli:measure>
                </xbrli:unit>
                <xbrli:context id="c-289">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">
                                mrvi:CooperativeAgreementMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-05-01</xbrli:startDate>
                        <xbrli:endDate>2022-05-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-290">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">
                                mrvi:CooperativeAgreementMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-05-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-291">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">
                                mrvi:CooperativeAgreementMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-292">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">
                                mrvi:CooperativeAgreementMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-293">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">
                                mrvi:CooperativeAgreementMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-294">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">
                                us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">
                                mrvi:CooperativeAgreementMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-295">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">
                                us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">
                                mrvi:CooperativeAgreementMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-296">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">
                                mrvi:CooperativeAgreementMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-297">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">mrvi:JupiterFloridaMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-01-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:unit id="extension_option">
                    <xbrli:measure>mrvi:extension_option</xbrli:measure>
                </xbrli:unit>
                <xbrli:context id="c-298">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">
                                mrvi:SanDiegoCaliforniaFlandersIMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-03-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-299">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">
                                mrvi:SanDiegoCaliforniaFlandersIIMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-06-30</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-300">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrvi:NewCreditAgreementMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-301">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrvi:NewCreditAgreementMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2020-10-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-302">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrvi:NewCreditAgreementMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">
                                us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2020-10-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-303">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrvi:NewCreditAgreementMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">
                                mrvi:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-01-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-304">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrvi:NewCreditAgreementMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">
                                us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-01-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-305">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">
                                mrvi:NewCreditAgreementInitialTermLoansMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-01-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-306">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">
                                mrvi:NewCreditAgreementInitialTermLoansMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">
                                mrvi:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-01-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-307">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">
                                mrvi:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">
                                mrvi:NewCreditAgreementNonInitialTermLoansMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-01-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-308">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrvi:NewCreditAgreementMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-309">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrvi:NewCreditAgreementMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-01-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-310">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrvi:NewCreditAgreementMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-01-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-311">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrvi:NewCreditAgreementMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-01-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-312">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrvi:NewCreditAgreementMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2020-01-01</xbrli:startDate>
                        <xbrli:endDate>2020-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-313">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrvi:NewCreditAgreementMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:unit id="loan">
                    <xbrli:measure>mrvi:loan</xbrli:measure>
                </xbrli:unit>
                <xbrli:context id="c-314">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrvi:NewCreditAgreementMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-01-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-315">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrvi:NewCreditAgreementMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">
                                us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-01-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-316">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrvi:NewCreditAgreementMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">
                                us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-317">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrvi:NewCreditAgreementMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-318">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrvi:NewCreditAgreementMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-319">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrvi:NewCreditAgreementMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-03-01</xbrli:startDate>
                        <xbrli:endDate>2022-03-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-320">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrvi:NewCreditAgreementMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">
                                us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-01-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-321">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrvi:NewCreditAgreementMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">
                                us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-01-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-322">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">
                                us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2021-03-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-323">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">
                                us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-05-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-324">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">
                                us-gaap:InterestRateCapMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-325">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrvi:NewCreditAgreementMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-326">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mrvi:NewCreditAgreementMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">
                                us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-327">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassAMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2020-11-30</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-328">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassBMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2020-11-30</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-329">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2020-11-30</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:unit id="vote">
                    <xbrli:measure>mrvi:vote</xbrli:measure>
                </xbrli:unit>
                <xbrli:context id="c-330">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassAMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-331">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassBMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-332">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">
                                mrvi:SecondaryOfferingMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-04-01</xbrli:startDate>
                        <xbrli:endDate>2021-04-30</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-333">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">
                                mrvi:SecondaryOfferingByMLSH2Member</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-04-01</xbrli:startDate>
                        <xbrli:endDate>2021-04-30</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-334">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">
                                us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-04-01</xbrli:startDate>
                        <xbrli:endDate>2021-04-30</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-335">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">
                                us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2021-04-30</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-336">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">
                                mrvi:SecondaryOfferingMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="dei:LegalEntityAxis">
                                mrvi:MaravaiLifeSciencesHoldingsLLCMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-04-01</xbrli:startDate>
                        <xbrli:endDate>2021-04-30</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-337">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">
                                mrvi:SecondaryOfferingMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-09-01</xbrli:startDate>
                        <xbrli:endDate>2021-09-30</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-338">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">
                                mrvi:SecondaryOfferingByMLSH2Member</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-09-01</xbrli:startDate>
                        <xbrli:endDate>2021-09-30</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-339">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">
                                us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2021-09-30</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-340">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">
                                mrvi:SecondaryOfferingMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="dei:LegalEntityAxis">
                                mrvi:MaravaiLifeSciencesHoldingsLLCMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-09-01</xbrli:startDate>
                        <xbrli:endDate>2021-09-30</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-341">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">
                                mrvi:MaravaiTopcoHoldingsLLCMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-12-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-342">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-12-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-343">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-12-31</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-344">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassBMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2021-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-345">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mrvi:AlphazymeHoldingsIncMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-22</xbrli:startDate>
                        <xbrli:endDate>2023-01-22</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-346">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-22</xbrli:startDate>
                        <xbrli:endDate>2023-01-22</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-347">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="dei:LegalEntityAxis">
                                mrvi:MaravaiLifeSciencesHoldingsIncAndAlphazymeHoldingsIncMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-22</xbrli:startDate>
                        <xbrli:endDate>2023-01-22</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-348">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="dei:LegalEntityAxis">
                                mrvi:MaravaiLifeSciencesHoldingsLLCMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-22</xbrli:startDate>
                        <xbrli:endDate>2023-01-22</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-349">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">
                                us-gaap:CommonClassBMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-01-22</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-350">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember
                                dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
                                us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-351">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember
                                dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
                                us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-352">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember
                                dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
                                us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-353">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember
                                dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
                                us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-354">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember
                                dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
                                us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-355">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember
                                dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
                                us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-356">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember
                                dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
                                us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-357">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember
                                dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
                                us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-358">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember
                                dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
                                us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-359">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember
                                dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
                                us-gaap:CommonClassBMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-360">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember
                                dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
                                us-gaap:CommonClassBMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-361">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember
                                dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
                                us-gaap:CommonClassBMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-362">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mrvi:A2020OmnibusIncentivePlanMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2020-11-01</xbrli:startDate>
                        <xbrli:endDate>2020-11-30</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-363">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2020-11-01</xbrli:startDate>
                        <xbrli:endDate>2020-11-30</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-364">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrvi:PerformanceStockUnitsMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-365">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-366">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-367">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-368">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">
                                us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-369">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">
                                us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-370">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">
                                us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-371">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">
                                us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-372">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">
                                us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-373">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrvi:MLSH1IncentiveUnitMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-374">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrvi:MLSH1IncentiveUnitMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-375">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrvi:MLSH1IncentiveUnitMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-376">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrvi:MLSH1IncentiveUnitMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-377">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrvi:MLSH1IncentiveUnitMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-378">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrvi:MLSH1IncentiveUnitMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-379">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">
                                us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-380">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">
                                us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-381">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">
                                us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-382">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">
                                us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-383">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">
                                us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-384">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">
                                us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-385">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mrvi:PerformanceStockUnitsMember
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-386">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">
                                mrvi:MaravaiTopcoHoldingsLLCMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-387">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">
                                us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-388">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">
                                us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-389">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">
                                us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrvi:MLSH1AndMLSH2Member
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">
                                mrvi:TaxReceivableAgreementPaymentsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2023-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-390">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">
                                us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">
                                mrvi:TaxReceivableAgreementNonCurrentLiabilityDerecognizedMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-391">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">
                                us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrvi:MLSH1AndMLSH2Member
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">
                                mrvi:TaxReceivableAgreementPaymentsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-392">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">
                                mrvi:TaxReceivableAgreementInterestPaymentsMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">
                                us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrvi:MLSH1AndMLSH2Member
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-393">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">
                                us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrvi:MLSH1AndMLSH2Member
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">
                                mrvi:TaxReceivableAgreementPaymentsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-394">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">
                                mrvi:TaxReceivableAgreementInterestPaymentsMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">
                                us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrvi:MLSH1AndMLSH2Member
                            </xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-395">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">
                                us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrvi:MLSH1AndMLSH2Member
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">
                                mrvi:TaxReceivableAgreementPaymentsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:instant>2022-12-31</xbrli:instant>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-396">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mrvi:MaravaiTopcoHoldingsLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember
                                dimension="us-gaap:DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis">
                                mrvi:TaxDistributionMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-397">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">
                                mrvi:MaravaiLifeSciencesHoldingsIncMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mrvi:MaravaiTopcoHoldingsLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember
                                dimension="us-gaap:DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis">
                                mrvi:TaxDistributionMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-398">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mrvi:MaravaiTopcoHoldingsLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember
                                dimension="us-gaap:DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis">
                                mrvi:TaxDistributionMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-399">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">
                                mrvi:MaravaiLifeSciencesHoldingsIncMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mrvi:MaravaiTopcoHoldingsLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember
                                dimension="us-gaap:DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis">
                                mrvi:TaxDistributionMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-400">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mrvi:MaravaiTopcoHoldingsLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember
                                dimension="us-gaap:DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis">
                                mrvi:TaxDistributionMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-401">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">
                                mrvi:MaravaiLifeSciencesHoldingsIncMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mrvi:MaravaiTopcoHoldingsLLCMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember
                                dimension="us-gaap:DistributionsMadeToMemberOrLimitedPartnerByDistributionTypeAxis">
                                mrvi:TaxDistributionMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-402">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrvi:CuriaGlobalMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">
                                us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">
                                mrvi:ConsultingServicesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-403">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">
                                us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">
                                mrvi:MaravaiLifeSciencesFoundationMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">
                                mrvi:CharitableFoundationContributionMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-404">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrvi:CuriaGlobalMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">
                                us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">
                                mrvi:ConsultingServicesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-405">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mrvi:CuriaGlobalMember
                            </xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">
                                us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">
                                mrvi:ConsultingServicesMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-406">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">
                                us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-407">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">
                                us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-408">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">
                                us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:NucleicAcidProductionSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-409">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">
                                us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:BiologicsSafetyTestingSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-410">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">
                                us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:BiologicsSafetyTestingSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-411">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">
                                us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:BiologicsSafetyTestingSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-412">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">
                                us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:ProteinDetectionSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-413">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">
                                us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:ProteinDetectionSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-414">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">
                                us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                            <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">
                                mrvi:ProteinDetectionSegmentMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-415">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">
                                us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-416">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">
                                us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-417">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">
                                us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-418">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">
                                us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2023-01-01</xbrli:startDate>
                        <xbrli:endDate>2023-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-419">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">
                                us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2022-01-01</xbrli:startDate>
                        <xbrli:endDate>2022-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
                <xbrli:context id="c-420">
                    <xbrli:entity>
                        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001823239</xbrli:identifier>
                        <xbrli:segment>
                            <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">
                                us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                        </xbrli:segment>
                    </xbrli:entity>
                    <xbrli:period>
                        <xbrli:startDate>2021-01-01</xbrli:startDate>
                        <xbrli:endDate>2021-12-31</xbrli:endDate>
                    </xbrli:period>
                </xbrli:context>
            </ix:resources>
        </ix:header>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_1"></div>
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="text-align:center">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:98.900%" />
                <td style="width:0.1%" />
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt" />
            </tr>
        </table>
    </div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED
            STATES</span></div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES
            AND EXCHANGE COMMISSION</span></div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Washington,
            D.C. 20549</span></div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM
            <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div>
    <div>
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:2.847%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:94.953%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span
                        style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true"
                            id="f-2">&#253;</ix:nonNumeric>
                    </span></td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL
                            REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div>
                </td>
            </tr>
        </table>
    </div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For
            the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate"
                format="ixt:date-monthname-day-year-en" id="f-3">
                <ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"
                    id="f-4">December&#160;31</ix:nonNumeric>, 2023
            </ix:nonNumeric></span></div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span>
    </div>
    <div>
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:2.847%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:94.953%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span
                        style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false"
                            id="f-5">o</ix:nonNumeric>
                    </span></td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION
                        REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td>
            </tr>
        </table>
    </div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission
            file number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-39725</ix:nonNumeric>
            </span></div>
    <div style="margin-top:6pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">
            <ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">Maravai LifeSciences Holdings, Inc.
            </ix:nonNumeric>
        </span></div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact
            name of registrant as specified in its charter)</span></div>
    <div>
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:31.842%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.385%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:31.842%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.385%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:31.846%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">
                        <ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode"
                            format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric>
                    </span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">
                        <ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">85-2786970
                        </ix:nonNumeric>
                    </span></td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State
                        or other jurisdiction of incorporation or organization)</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S.
                        Employer Identification No.)</span></td>
            </tr>
            <tr style="height:9pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="margin-top:3pt;text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">
                            <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">10770
                                Wateridge Circle</ix:nonNumeric>
                            <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-11">Suite 200
                            </ix:nonNumeric>
                        </span></div>
                    <div style="margin-top:3pt;text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">
                            <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-12">San Diego
                            </ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince"
                                format="ixt-sec:stateprovnameen" id="f-13">California</ix:nonNumeric>
                        </span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">
                        <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-14">92121
                        </ix:nonNumeric>
                    </span></td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address
                            of principal executive offices)</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip
                        code)</span></td>
            </tr>
        </table>
    </div>
    <div style="margin-bottom:12pt;text-align:center"><span
            style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">______________________________</span>
    </div>
    <div style="margin-top:3pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s
            telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-15">
                858</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-16">546-0004
            </ix:nonNumeric></span></div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">______________________________</span>
    </div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities
            registered pursuant to Section 12(b) of the Act:</span></div>
    <div>
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:40.042%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.385%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:15.444%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.385%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:40.044%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title
                        of each class</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading
                        Symbol(s)</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name
                        of each exchange on which registered</span></td>
            </tr>
            <tr>
                <td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Class A common stock,
                            $0.01 par value</ix:nonNumeric>
                    </span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">MRVI</ix:nonNumeric>
                    </span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"
                            id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric>
                    </span></td>
            </tr>
        </table>
    </div>
    <div style="margin-top:1pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities
            registered pursuant to section 12(g) of the Act: None</span></div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate
            by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
            Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">Yes</ix:nonNumeric>
        </span><span
            style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x
        </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No
        </span><span
            style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span>
    </div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate
            by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of
            the Act. Yes </span><span
            style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o
        </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">
            <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric>
        </span><span
            style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span>
    </div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate
            by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d)
            of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the
            registrant was required to file such reports); and (2) has been subject to such filing requirements for the
            past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus"
                id="f-22">Yes</ix:nonNumeric>&#160;&#160;</span><span
            style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span
            style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span>
    </div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate
            by check mark whether the registrant has submitted electronically and posted on its corporate web site, if
            any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T
            (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the
            registrant was required to submit and post such files). <ix:nonNumeric contextRef="c-1"
                name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric>&#160;&#160;</span><span
            style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span
            style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span>
    </div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate
            by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated
            filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large
            accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and
            &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</span></div>
    <div style="margin-top:6pt">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:29.455%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:18.344%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:29.455%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:18.346%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory"
                            format="ixt-sec:entityfilercategoryen" id="f-24">Large accelerated filer</ix:nonNumeric>
                    </span></td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#253;</span>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated
                        filer</span></td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="margin-bottom:2pt;margin-top:3pt"><span
                            style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span>
                    </div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated
                        filer</span></td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="margin-bottom:2pt;margin-top:3pt"><span
                            style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span>
                    </div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller
                        reporting company</span></td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="margin-top:3pt"><span
                            style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">
                            <ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false"
                                id="f-25">o</ix:nonNumeric>
                        </span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging
                        growth company</span></td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="margin-bottom:2pt;margin-top:3pt"><span
                            style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">
                            <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany"
                                format="ixt:fixed-false" id="f-26">o</ix:nonNumeric>
                        </span></div>
                </td>
            </tr>
        </table>
    </div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If
            an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
            transition period for complying with any new or revised financial accounting standards provided pursuant to
            Section 13(a) of the Exchange Act. </span><span
            style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span>
    </div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate
            by check mark whether the registrant has filed a report on and attestation to its management's assessment of
            the effectiveness of its internal control over financial reporting under Section 404(b) of the
            Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its
            audit report. </span><span
            style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">
            <ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-27">x
            </ix:nonNumeric>
        </span></div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If
            securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial
            statements of the registrant included in the filing reflect the correction of an error to previously issued
            financial statements. <ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag"
                format="ixt:fixed-false" id="f-28">&#9634;</ix:nonNumeric></span></div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate
            by check mark whether any of those error corrections are restatements that required a recovery analysis of
            incentive-based compensation received by any of the registrant&#8217;s executive officers during the
            relevant recovery period pursuant to &#167;240.10D-1(b). &#9634;</span></div>
    <div style="margin-top:9pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate
            by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
            &#160;&#160;&#160;&#160;Yes&#160;</span><span
            style="color:#000000;font-family:'Quivira',sans-serif;font-size:9pt;font-weight:400;line-height:120%">
            <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-29">&#9744;
            </ix:nonNumeric>
        </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span
            style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span>
    </div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The
            aggregate market value of the registrant&#8217;s voting common equity held by non-affiliates as of
            June&#160;30, 2023, the last business day of the registrant&#8217;s most recently completed second fiscal
            quarter, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5"
                name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="f-30">1,370.0</ix:nonFraction>
            million, based on the closing price of the registrant&#8217;s common stock on the Nasdaq Global Select
            Market of $12.43 per share.</span></div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As
            of February&#160;21, 2024, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF"
                name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">
                132,305,845</ix:nonFraction> shares of the registrant&#8217;s Class A common stock were outstanding and
            <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF"
                name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-32">
                119,094,026</ix:nonFraction> shares of the registrant&#8217;s Class B common stock were outstanding.
        </span></div>
    <div style="margin-top:12pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS
            INCORPORATED BY REFERENCE</span></div>
    <ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-33" escape="true">
        <div style="margin-top:6pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                information required by Part III of this Report, to the extent not set forth herein, is incorporated
                herein by reference from the registrant&#8217;s definitive proxy statement relating to the Annual
                Meeting of Shareholders to be held in 2024, which definitive proxy statement shall be filed with the
                Securities and Exchange Commission within 120 days after the end of the fiscal year to which this Report
                relates.</span></div>
    </ix:nonNumeric>
    <div style="text-align:center">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:98.900%" />
                <td style="width:0.1%" />
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt" />
            </tr>
        </table>
    </div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_7"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:10pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE
            OF CONTENTS</span></div>
    <div style="margin-top:12pt">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:10.630%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:79.398%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:6.672%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Page</span>
                </td>
            </tr>
            <tr>
                <td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_10">Forward-Looking Statements</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_10">3</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_13">Part I.</a></span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_13">4</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_16">Item 1.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_16">Business</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_16">4</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_58">Item 1A.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_58">Risk Factors</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_58">22</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_88">Item 1B.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_88">Unresolved Staff Comments</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_88">59</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_1016">Item 1</a><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_1016">C</a><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_1016">.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_1016">C</a><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_1016">ybersecurity</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_1016">59</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_91">Item 2.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_91">Properties</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_91">60</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_94">Item 3.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_94">Legal Proceedings</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_94">61</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_97">Item 4.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_97">Mine Safety Disclosures</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_97">61</a></span></div>
                </td>
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_100">Part II.</a></span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_100">62</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_103">Item 5.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_103">Market for Registrant's Common Equity,
                                Related Stockholder Matters and Issue Purchases of Equity Securities</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_103">62</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_106">Item 6.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_106">Reserved</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_106">63</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_109">Item 7.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_109">Management&#8217;s Discussion and Analysis
                                of Financial Condition and Results of Operations</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_109">63</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_169">Item 7A.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_169">Quantitative and Qualitative
                                Disclosures</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_169">83</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_172">Item 8.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_172">Financial Statements and Supplementary
                                Data</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_172">84</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_256">Item 9.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_256">Changes in and Disagreements with
                                Accountants on Accounting and Financial Disclosure</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_256">133</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_259">Item 9A.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_259">Controls and Procedures</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_259">133</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_265">Item 9B.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_265">Other Information</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_265">135</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_268">Item 9C.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_268">Disclosure Regarding Foreign Jurisdictions
                                that Prevent Inspections</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_268">135</a></span></div>
                </td>
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_271">Part III.</a></span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_271">136</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_274">Item 10.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_274">Directors, Executive Officers and
                                Corporate Governance</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_274">136</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_277">Item 11.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_277">Executive Compensation</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_277">136</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_280">Item 12.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_280">Security Ownership of Certain Beneficial
                                Owners and Management and Related Stockholder Matters</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_280">136</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_283">Item 13.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_283">Certain Relationships and Related
                                Transactions and Director Independence</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_283">136</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_286">Item 14.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_286">Principal Accounting Fees and
                                Services</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_286">136</a></span></div>
                </td>
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_289">Part IV.</a></span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_289">137</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_292">Item 15.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_292">Exhibits and Financial Statement
                                Schedules</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_292">137</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_295">Item 16.</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_295">Form 10-K Summary</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_295">140</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_298">Signatures</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="padding-left:6pt;text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_298">141</a></span></div>
                </td>
            </tr>
        </table>
    </div>
    <div><span><br /></span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_10"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:18pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL
            NOTE REGARDING FORWARD LOOKING STATEMENTS</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This
            Annual Report on Form 10-K contains &#8220;forward-looking statements&#8221; within the meaning of the safe
            harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that
            statements which are not strictly historical statements constitute forward looking statements, including,
            without limitation, statements under the captions &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s
            Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Business&#8221;
            and are identified by words like &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;may,&#8221;
            &#8220;will,&#8221; &#8220;should,&#8221; &#8220;seek,&#8221; &#8220;anticipate,&#8221;
            &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;goal,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221;
            &#8220;likely,&#8221; or &#8220;could&#8221; and similar expressions.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking
            statements are neither historical facts nor assurances of future performance. Instead, they are based only
            on our current beliefs, expectations and assumptions regarding the future of our business, future plans and
            strategies, projections, anticipated events and trends, the economy and other future conditions. Because
            forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and
            changes in circumstances that are difficult to predict and many of which are outside of our control. Our
            actual results and financial condition may differ materially from those indicated in the forward-looking
            statements. Therefore, you should not rely on any of these forward-looking statements. Important factors
            that could cause our actual results and financial condition to differ materially from those indicated
            include those discussed under the heading &#8220;Summary of Risk Factors&#8221; and &#8220;Item 1A. Risk
            Factors&#8221; as well as those discussed elsewhere in this Annual Report on Form 10-K.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any
            forward-looking statement made by us in this report is based only on information currently available to us
            and speaks only as of the date of this report. We undertake no obligation to publicly update any
            forward-looking statement, whether written or oral, that may be made from time to time, whether as a result
            of new information, future developments or otherwise.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_13"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:18pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part
            I.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_16"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            1. Business</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_19"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maravai
            LifeSciences Holdings, Inc. (also referred to in this document as &#8220;Maravai&#8221;, &#8220;we&#8221;,
            &#8220;us&#8221; or &#8220;the Company&#8221;) is a leading life sciences company providing critical
            products to enable the development of novel vaccines, drug therapies, and diagnostics, and to support
            research on human diseases. Our customers include the top global biopharmaceutical companies ranked by
            research and development expenditures according to industry consultants, and many other emerging
            biopharmaceutical and life sciences research companies, as well as leading academic research institutions
            and </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in
            vitro</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            diagnostics companies. Our products address the key phases of biopharmaceutical development spanning
            research to commercialization and include complex nucleic acids for vaccine, therapeutic and diagnostic
            applications, custom enzymes for research and diagnostic use and antibody-based products to detect
            impurities during the production of biopharmaceutical products. We provide products that support our
            customers from discovery through commercialization of their vaccines, therapeutic agents and </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in
            vitro</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            diagnostic products.</span></div>
    <div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><img src="mrvi-20231231_g1.jpg" alt="Picture1.jpg"
            style="height:277px;margin-bottom:5pt;vertical-align:text-bottom;width:684px" /></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            businesses principally address high growth market segments in biopharmaceutical development. In particular,
            the field of cell and gene therapy has emerged as one of the fastest growing treatment modalities to address
            a host of human conditions. There are more than 4,000 nucleic acid and cell and gene therapies in
            development or launched and sales in this category are expected to grow more than 3 times by 2030, according
            to industry consultants and management estimates. Our portfolio offers key products for each stage of the
            cell and gene therapy development lifecycle. For example, our messenger RNA (&#8220;mRNA&#8221;) products
            are used in drug development to assist in the production of immune-activating antigens and to deliver gene
            editing technologies in cell and gene therapy treatments; our CleanCap&#174; technology is used to stabilize
            mRNA and streamlines mRNA manufacturing; we were one of the first companies to provide the essential
            modified uridine, N1-methyl-pseudouridine triphosphate, for research applications and under good
            manufacturing processes (&#8220;GMP&#8221;) conditions; our catalog mRNA products are frequently used by
            lipid developers to test and validate new mRNA delivery platforms; and our plasmid DNA products are used as
            templates for the production of our mRNA products. Our oligonucleotides, oligonucleotide supply products,
            enzymes and NTPs are also included in the supply chain of several diagnostic, next-gen sequencing
            (&#8220;NGS&#8221;) and research platforms, as well as DNA and RNA synthesis end-markets. We also provide
            biologics safety testing technology used to ensure the safety of the biological drug manufacturing process
            and drug products. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            proprietary capabilities and products underpin the value we aim to provide to our customers. Among other
            capabilities, we are experts in RNA and mRNA products, which are challenging and often unstable molecules
            requiring significant chemical modifications and analytical expertise to ensure their stability and efficacy
            in our customers&#8217; applications. Notably, according to research commissioned by us consisting of
            interviews with our current and former customers, our competitors and industry experts focused across our
            two ongoing business segments (the &#8220;Industry Analysis&#8221;), we believe CleanCap technology is
            viewed as a leading solution to incorporate the five prime (&#8220;5&#8217;&#8221;) cap into mRNA. CleanCap
            is a novel chemical approach to produce the 5&#8217; cap analog, which, in addition to making mRNA more
            stable, aids in protein production and helps prevent an unwanted immune response to the mRNA. CleanCap
            analogs have been incorporated into several mRNA programs targeting </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunization
            against the coronavirus, SARS-CoV-2 (&#8220;COVID-19&#8221;). These programs include commercial programs led
            by Pfizer in partnership with BioNTech and by BioNTech in partnership with Fosun Pharma, as well as two
            COVID-19 vaccines which are now approved for use in Japan.</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">
        </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            addition to these commercially approved programs, CleanCap has been incorporated into many research and
            clinical stage programs addressing stand-alone and combination vaccines for COVID-19 and other respiratory
            diseases, such as Influenza that have not yet been commercialized. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            estimate our CleanCap products have been incorporated in approximately 350 vaccine and therapeutic programs
            in development as of December&#160;31, 2023, including at least 60 molecules for which our mRNA CDMO
            services group manufactured the mRNA APIs using CleanCap. These include vaccine development programs for
            infectious diseases, including Lyme disease, malaria, HIV, tuberculosis, shingles, rabies, yellow fever,
            respiratory syncytial virus (&#8220;RSV&#8221;) and Zika, as well as other medical conditions. In addition
            to infectious diseases, these programs address a number of disease states, including ornithine
            transcarbamylase deficiency, glycogen storage disorders, Alpha-1 antitrypsin deficiency, acute lymphoblastic
            leukemia, Hurler syndrome, ovarian cancer and cardiovascular disease. These therapeutic programs also use
            multiple therapeutic modalities, including CRISPR/Cas-9, transcription activator-like effector nuclease
            (TALEN), enzyme replacement therapies, allogeneic CAR-T cells and base editing. Should one or more of these
            programs proceed to commercialization, we believe we will continue to supply our customers and our products
            will likely be incorporated in customer regulatory filings. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA
            is at the core of our capabilities. We developed our expertise in mRNA with a belief in its potential as a
            therapeutic modality. The first clinical trial for an mRNA therapeutic agent occurred in 2016. Now, more
            than 900 clinical trials are in the pipeline, principally focused on vaccines against viruses and cancer
            vaccines. With the COVID-19 pandemic, mRNA has shown its potential for more rapid vaccine design and
            manufacture when compared to traditional techniques involving culturing inactivated virus to elicit an
            immune response. COVID-19 has helped highlight the potential advantage of mRNA as a treatment modality and
            directed significant resources to the growing base of knowledge about mRNA. This knowledge is now being
            directed at future vaccine programs addressing infectious diseases as well as for therapeutic agents for a
            host of human diseases. We are positioned to serve our biopharmaceutical customers in the fast-growing field
            of mRNA across a range of clinical programs for a variety of diseases.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forming
            long-term partnerships with our customers is core to our strategy. Today, we primarily serve our customers
            during the product development and process development phases. During product development, we collaborate
            with our customers to develop and synthesize nucleic acids, which in some cases comprise the active
            pharmaceutical ingredient (&#8220;API&#8221;) of our customers&#8217; products in development. We also
            provide our customers a host of chemically complex and highly specialized raw materials. Process development
            is a complex phase that establishes highly validated procedures and determines the investment in facilities
            and equipment required to bring biopharmaceutical products to market. These decisions impact the viability
            of our customers&#8217; products for use in clinical trials and commercialization. During process
            development, we provide enzyme-linked immunosorbent assays (&#8220;ELISAs&#8221;) that reduce the risk posed
            by impurities and contaminants in biological drugs, a critical step to ensure the safety of the drug
            product.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While
            we do not provide products that are themselves regulated as drugs or </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in
            vitro</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            diagnostics, our customers frequently incorporate our products into their highly validated products and
            processes. For example, we provide oligonucleotides and antibody-based products used by </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in
            vitro</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            diagnostic product manufacturers for their on-market products. Because of the extensive validation required
            for these products, these components are frequently purchased for the life of our customers&#8217; products
            and we believe they are unlikely to be substituted. In addition, our analytical tools are used in the design
            and development of manufacturing processes and often will be used throughout the life cycle of our
            customers&#8217; manufactured products. Once our services or products are qualified by our customers, they
            are often cited in regulatory documents and standard operating procedures. As a result, our customer
            relationships frequently span many years.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            nature of our products and their uses require that they be manufactured by highly trained personnel in
            state-of-the-art facilities following exacting procedures to ensure quality. As of December&#160;31, 2023,
            approximately 24% of our workforce have earned advanced degrees and all receive rigorous training on our
            procedures. During 2023, the majority of our nucleic acid products were manufactured at our San Diego,
            California Wateridge facility (&#8220;Wateridge facility&#8221;). The Wateridge facility was purpose-built
            to address our customers&#8217; needs for critical raw materials manufactured under certain GMP conditions
            and APIs for investigational use. Our raw material products are manufactured following the voluntary quality
            standards of ISO 9001:2015. Our GMP-grade raw materials follow ISO 9001:2015 standards, additional voluntary
            GMP quality standards and customer specific requirements. Our API products are manufactured following the
            voluntary quality standards of ISO 9001:2015, the International Council for Harmonisation&#8217;s GMP Guide,
            comparable GMP principles for the European Union and customer specific requirements. We believe our products
            are exempt from compliance with the current GMP (&#8220;cGMP&#8221;) regulations of the FDA, as our products
            are further processed or incorporated into final drug products by our customers and we do not make claims
            related to their safety or effectiveness. Our other facilities are similarly designed for specific
            applications with quality systems to match our customers&#8217; requirements. All of our manufacturing
            facilities meet applicable ISO standards. </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            built our business through a combination of acquisitions and subsequent investments in our acquired
            companies to grow their commercial capabilities, upgrade and expand their research and production
            facilities, deploy stringent quality systems, integrate their back-office functions, and develop the
            personnel and management to fuel continued growth. Today, we offer an integrated portfolio that enables
            innovation across the biopharmaceutical and academic markets. Mergers, acquisitions and strategic
            partnerships that complement our capabilities in cell and gene therapy and biopharmaceutical production
            remain core to our strategy. Our strategy aims to augment our strong organic growth with the addition of
            synergistic products and capabilities.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_22"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our
            Portfolio and Capabilities</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            provide critical raw materials that support our customers from discovery through commercialization of their
            vaccines, therapeutic agents and </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in
            vitro</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            diagnostic products. Our products are frequently incorporated into our customers&#8217; products, whether as
            research products or APIs used in development or products incorporated as raw materials into on-market
            products. They may also be incorporated into the manufacturing process itself. We are therefore a critical
            part of our customers&#8217; supply chain and they frequently seek to maintain their supply relationship
            with us for the life of their products or development programs.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            products address our customers&#8217; needs for Nucleic Acid Production and Biologics Safety Testing, and
            our operations are aligned to these two segments. Within Nucleic Acid Production, we have four business
            units: TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. Our Biologics Safety Testing business is
            comprised of Cygnus Technologies. Our brands, products and the end markets they serve are depicted in the
            following image:</span></div>
    <div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><img src="mrvi-20231231_g2.jpg"
            alt="Slide2_MacD edits_revised_02.01.24.jpg"
            style="height:345px;margin-bottom:5pt;vertical-align:text-bottom;width:684px" /></div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nucleic
            Acid Production (78% of Revenue for the Year Ended December&#160;31, 2023)</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            are a global provider of highly modified, complex nucleic acids and related products. We have recognized
            expertise in complex chemistries and products provided under exacting quality standards. Our core offerings
            include mRNA, long and short oligonucleotides, our proprietary CleanCap mRNA capping technology, mRNA
            building blocks, oligonucleotide building blocks and specialty enzymes. Our offerings address key customer
            needs for critical components, from research to GMP-grade raw materials and API manufacturing. We market our
            nucleic acid products under the TriLink BioTechnologies&#174;, Glen Research and Alphazyme brands. </span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since
            the 1961 discovery of mRNA and its role in converting genetic information into proteins, countless attempts
            had been made to harness mRNA for therapeutic purposes. Today, mRNA vaccines are globally recognized for
            their success in responding to the COVID-19 pandemic. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            success of COVID-19 vaccines has helped highlight the potential advantage of mRNA as a treatment modality
            and significant investments have been made industry wide to developing future mRNA vaccines as well as for
            therapeutic agents for </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a
            host of human diseases. We are positioned to serve our biopharmaceutical customers in the fast-growing field
            of mRNA across a range of clinical programs for a variety of diseases.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            offer the following nucleic acid products: mRNA, RNA Capping (CleanCap), oligonucleotides, oligonucleotide
            inputs, nucleoside triphosphates, custom nucleic acid chemistry, plasmid DNA and specialty enzymes. </span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">mRNA.</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            mRNA is an intermediary molecule that translates the genetic information stored in DNA into proteins. The
            genetic information stored in DNA is transferred to mRNA in a cellular process called transcription. This
            process occurs in the nucleus of cells. DNA, a double stranded molecule, is unwound and copied as mRNA by
            the enzyme RNA polymerase. mRNA is then transferred out of the nucleus to the cytosol, a component of the
            cytoplasm of a cell, where it serves as a blueprint for making cellular proteins by a multi-component
            organelle complex called the ribosome.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mRNA
            has traditionally been a difficult molecule for vaccine and therapeutic purposes. mRNA is inherently
            unstable compared to DNA and is susceptible to degradation by ubiquitous enzymes called RNases. mRNAs are
            also physically and chemically fragile and can degrade at elevated temperatures and under shear forces that
            occur during downstream manufacturing processes. We have developed manufacturing processes that overcome
            many of these obstacles, resulting in highly effective mRNA.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            develop and manufacture mRNA products to support vaccine and therapeutic programs from pre-clinical
            development through and including clinical phases, including scale-up and analytical development services.
            The mRNA molecules may serve as APIs for diverse applications, such as enzyme replacement therapies, gene
            editing therapies and vaccines. We offer both research grade material and material made under GMP conditions
            for early phase clinical trials. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RNA
            Capping. </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within
            the mRNA category, we also offer our patented CleanCap technology. CleanCap analogs principally serve the
            mRNA vaccine and therapeutics markets. Cap analogs are a component of mRNA that aids in protein production
            as well as in making mRNA more stable inside cells. For mRNA to serve as a template to make a protein, it
            requires a special cap at the 5&#8217; end of the molecule. The cap structure also affects the stability of
            the mRNA. Lack of a cap can result in activation of the innate immune system, which can affect the
            production of the desired protein or elicit undesired biological effects. We offer a suite of CleanCap
            analogs that are specifically made for therapeutics and vaccines. CleanCap analogs are sold as a stand-alone
            reagents or bundled with other mRNA products. Based on the Industry Analysis, we believe our cap analogs are
            critical features of several mRNA vaccines and therapies in development.</span></div>
    <div style="margin-top:12pt;text-align:center"><img src="mrvi-20231231_g3.jpg" alt="Slide6.jpg"
            style="height:181px;margin-bottom:5pt;vertical-align:text-bottom;width:500px" /></div>
    <div style="margin-bottom:12pt;text-align:center"><img src="mrvi-20231231_g4.jpg" alt="Paragraph.jpg"
            style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:480px" /></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Traditionally,
            the 5&#8217; cap has been added in one of two ways. The cap can be added post mRNA synthesis by an enzymatic
            process. This enzymatic method has several drawbacks, including the high cost of the capping enzymes as well
            as the need to perform additional processing steps to the mRNA to remove enzymes and byproducts of the
            capping reaction. While capping efficiency is usually high, the extra processing steps typically result in
            degradation and mRNA of poorer quality. The second method is to add a synthetic cap analog into the
            transcription reaction such that the mRNA is transcribed and capped in a single step. Anti-reverse cap
            analog (&#8220;ARCA&#8221;) is an example of a cap analog that is added to the transcription reaction. This
            avoids the workflow challenges of the enzymatic process, but typically results in lower yields.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like
            ARCA, CleanCap analogs are synthetic, chemically-made mRNA 5&#8217; cap analogs added to the transcription
            process in a single step. Unlike ARCA, however, CleanCap results in significantly higher levels of capping
            efficiency, resulting in very low levels of uncapped mRNA, which in turn minimizes the risk of activation of
            the innate immune system. In addition, CleanCap&#8217;s higher mRNA yields compared to ARCA result in lower
            cost of goods. When compared to enzymatic capping, CleanCap removes the additional downstream purification
            steps required. </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            currently offer several variations of the CleanCap molecule, serving the needs of mRNA and self-amplifying
            RNA developers. CleanCap is available in two quality grades, research use only for discovery and development
            activities, and a GMP-grade for clinical and commercial applications. Our newest CleanCap analog, CleanCap
            M6, was introduced in May 2023 and is our most robust cap analog to date, enabling mRNA that delivers higher
            levels of protein production.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CleanCap
            mRNA products represented 69% of our Nucleic Acid Production revenue for the year ended December&#160;31,
            2023 (including the revenue from CleanCap products).</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oligonucleotides.</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            The oligonucleotide product category supports broad customer applications, including therapeutics,
        </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in
            vitro</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            diagnostics, NGS and CRISPR-based gene editing. Most of our TriLink BioTechnologies oligonucleotide products
            are custom manufactured DNA or RNA sequences, often highly modified and produced as research grade or under
            GMP conditions for use in development, clinical and commercial applications.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oligonucleotide
            Synthesis Inputs. </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            product offerings through Glen Research include reagents and support supplies for DNA and RNA
            oligonucleotide synthesis, labeling, modification and purification. We are a reputable and trusted vendor
            with a large portfolio, quality brand, knowledgeable technical support, and responsive customer service. In
            addition to oligonucleotide synthesis service providers, our customer base includes life science, biopharma,
            and diagnostic companies as well as academic institutions and government organizations, all of which
            internally manufacture their own oligonucleotide products.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nucleoside
            triphosphates.</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            Nucleoside triphosphates (&#8220;NTPs&#8221;) are the precursors to DNA and RNA. They are composed of a
            nitrogen base bound to either ribose or deoxyribose with three phosphate groups added to the sugar. We
            manufacture NTPs that are used in polymerase chain reactions (&#8220;PCR&#8221;), in sequencing reactions
            and in the manufacture of mRNA. The NTPs can be unmodified, composed of the four standard bases, or
            modified, with a base altered to enhance a particular biological property, such as the ability to evade the
            innate immune system in therapeutic applications. TriLink BioTechnologies NTPs are used by customers in both
            research and clinical trial applications. Our manufacturing capabilities for NTPs now includes both research
            use and GMP-grade.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Custom
            Nucleic Acid Chemistry</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.
            Through our acquisition of MyChem LLC in the first quarter of 2022, TriLink BioTechnologies expanded its
            synthetic chemistry expertise and added proprietary manufacturing processes allowing for the highest purity
            NTP, amidite and custom nucleotide services. We serve a diverse market of diagnostics and therapeutic
            developers that require novel molecules that are otherwise unavailable on the market. Typically, these
            molecules are initially manufactured in small quantities, and then scaled to meet the need of larger
            diagnostic platform or therapeutic applications once positive candidates have been identified by the
            customer.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plasmid
            DNA.</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            Unlike genomic DNA, which constitutes the chromosome, plasmid DNA exists outside the chromosome and
            represents small circular double-stranded constructs. Plasmid DNA is frequently used as a vector for
            replicating nucleic acid products. Plasmid DNA is integral to the production of mRNA, serving as the nucleic
            acid template for the DNA-dependent RNA polymerases that frequently are used in the manufacturing of mRNA.
            Our plasmid DNA offering allows us to ensure the quality and timeliness of the mRNA API manufacturing
            campaigns that we service for our customers.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Specialty
            Enzymes.</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            Through our acquisition of Alphazyme in the first quarter of 2023, our Nucleic Acid Production capabilities
            now include specialized enzymes. Enzymes are critical to almost every phase of nucleic acid production.
            Alphazyme provides custom, scalable molecular biology enzymes with a full product line of IVT, NGS, life
            science and diagnostic enzyme solutions.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discovery
            mRNA synthesis</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            Through the TriLink BioTechnologies Discovery Business unit, we offer a core set of products and services
            geared toward customers doing early-stage development work. We produce mRNA utilizing standard sequences for
            generalized research using customer supplied sequences for custom built constructs. We also provide process
            development services to optimize customers&#8217; transcription and purification processes. These services
            can be integrated with our CleanCap, NTP products and enzyme portfolios and have access to our analytical
            and QC method development. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GMP
            mRNA synthesis</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.
            Our GMP mRNA manufacturing services offer a clear pathway for customers running clinical trials. We focus on
            building partnerships with our customers in the emerging market of cell and gene therapy to ensure we are
            well-positioned to be an extension of their development teams. Our services feature robust quality
            management systems and include process development and scale-up, phase-appropriate, high-quality plasmid
            DNA, regulatory submission support, and in-house analytical services for mRNA analysis and characterization.
        </span></div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biologics
            Safety Testing (22% of Revenue for the Year Ended December&#160;31, 2023)</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            provide products and services under the Cygnus Technologies&#174;, LLC (&#8220;Cygnus Technologies&#8221;)
            brand that ensure the purity of our customers&#8217; biopharmaceutical products, including biological drugs.
            For over 25 years, the Cygnus Technologies brand has been associated with products and services that enable
            the detection of impurities present in bioproduction. Our biologics safety testing products are used during
            development and scale-up, during the regulatory approval process and </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">throughout
            commercialization. We are recognized globally for the detection of host cell proteins (&#8220;HCPs&#8221;)
            and process-related impurities during bioproduction.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            customers in this segment manufacture a broad range of biopharmaceutical products. These include monoclonal
            antibodies and recombinant proteins, both as novel biologics and biosimilars, and recombinant vaccines,
            including oncolytic vaccines to treat cancer. We also provide products that support the development and
            commercialization of cell and gene therapies. Recombinant vaccines and cell and gene therapies rely on
            manufacturing of various viral vectors produced using recombinant nucleic acid and cell culture
            technologies. Viral vector manufacturing processes require rigorous analytics, including testing for
            process-related impurities such as HCPs, host cell DNA, purification leachates, growth media additives and
            enzymes used in viral vector purification processes. Of all process-related impurities, HCPs present the
            most complex impurity. Per regulatory requirements, viral vectors used as a component of CAR-T cell
            therapies or as gene therapies must be produced in certain cell lines, purified and tested for the presence
            of host cell proteins. All of the 19 existing FDA-and EMA-approved CAR-T Cell and Gene Therapies use Cygnus
            Host Cell Protein ELISA kits for HCP testing for commercial product lot release. Four of these 19 therapies
            were approved in 2023.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ELISA
            is the benchmark method for monitoring levels of process-related impurities during the purification process
            and in product release testing. The advantages of well-developed ELISA kits include the ability to measure
            very low levels of impurities in the presence of high amounts of drug product, and are readily transferable
            across an organization from process development to manufacturing and quality control bioanalytical groups.
            Though relatively simple to run, these ELISA kits require a high level of expertise to design, develop and
            qualify.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers
            establishing biopharmaceutical manufacturing processes may use off-the-shelf or generic HCP kits provided by
            manufacturers like ourselves, or they may choose to design their own in-house assays for their specific
            processes. Some customers may choose to use generic assays early in development and migrate to
            process-specific assays later. The trend in recent years has been for customers to increasingly use generic
            assays throughout their development and commercialization pathway, relying on our expertise, the established
            performance of our assays supported by our comprehensive state-of-the-art assay qualification services. If
            customers choose to develop process-specific assays, we offer custom antibody production and assay
            development as well as characterization services to meet their needs.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            comprehensive catalog of Cygnus Technologies HCP ELISA kits cover 24 expression platforms and provides the
            specificity and sensitivity to detect impurities with reproducibility, which supports regulatory compliance.
            Our reputation for quality is recognized by the industry and global regulatory agencies, with Cygnus
            Technologies assays used as reference methods throughout the industry and to support manufacturing and
            quality control of commercialized biologics and gene therapy products.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            customers in this segment are biopharmaceutical companies, contract research organizations
            (&#8220;CROs&#8221;), contract development and manufacturing organizations (&#8220;CDMOs&#8221;) and life
            science companies.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cygnus
            Technologies product categories include HCP ELISA kits, other bioprocess impurity and contaminant ELISA
            kits, viral clearance prediction kits, ancillary reagents and custom services.</span></div>
    <div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><img src="mrvi-20231231_g5.jpg" alt="Slide4.jpg"
            style="height:295px;margin-bottom:5pt;vertical-align:text-bottom;width:684px" /></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HCP
            ELISA kits.</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            HCP ELISA kits are bioassays used to detect residual proteins from the expression system used in
            bioproduction. HCPs constitute a major group of process-related impurities produced using cell culture
            technology no matter what cell expression platform is used. HCPs pose potential health risks for patients
            and the risk of failure of safety endpoints for drug manufacturers. When present in the administered
            product, even at low levels, HCPs can induce an undesired immune response, interfere with drug efficacy and
            impact drug stability. HCPs are a critical quality attribute for biologics safety testing development and
            must be adequately removed during the downstream purification process.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other
            impurity and contaminant kits</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.
            Products in this category include kits for measuring Protein A leachate, which results from the affinity
            purification method used for monoclonal antibody therapeutic agents; ELISA kits for measuring additives in
            growth media, such as bovine serum albumin; kits for measuring host cell DNA; ELISA kits to detect and
            quantify residual endonuclease impurities in recombinant viral vector and vaccine preparations: and ELISA
            kits to quantify residual AAV2, AAV8, AAV9 ligands resulting from affinity purification method used for
            adeno associated virus (AAV)-based gene therapies.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Viral
            Clearance Prediction kits</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.
            In 2020, Cygnus Technologies introduced the MockV&#174; Minute Virus of Mice (&#8220;MVM&#8221;) kit, a
            novel, proprietary viral clearance prediction tool that includes a non-infectious &#8220;mock virus
            particle&#8221; mimicking the physicochemical properties of live virus that may be present endogenously in
            the drug substance or introduced during bioproduction. The kit enables manufacturers to conduct viral
            clearance assessments easily and economically and to predict outcomes in-house ahead of costly and
            logistically challenging live viral clearance studies. In 2022, Cygnus Technologies introduced MockV&#174;
            RVLP Kit. This kit enables bioprocess scientists to quantify the removal of Retrovirus-like Particles
            (RVLPs) produced endogenously by Chinese Hamster Ovary (CHO) cell lines during biopharmaceutical
            manufacturing. The kit includes a highly purified and concentrated stock solution of RVLP, an actual
            non-infectious retrovirus-like contaminant generated during CHO production. In the early 1990s, global
            regulatory agencies such as the FDA realized the prevalence of this particle and became concerned about the
            retroviral safety of CHO-derived biopharmaceuticals. Since then, the biopharmaceutical industry has relied
            on CROs to propagate Xenotropic Murine Leukemia Virus (XMuLV) as a model retrovirus to demonstrate effective
            clearance. With the availability of the MockV&#174; RVLP Kit, biopharmaceutical companies can now
            independently assess the removal of the original retroviral particle of regulatory concern, derived directly
            from CHO cells.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ancillary
            reagents</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.
            These products include antibodies, antigens, sample diluents and other auxiliary products necessary to
            optimize applications for customer processes. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Custom
            services</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.
            We provide process-specific antibody and ELISA development, qualification and maintenance services. In
            addition, we have pioneered advanced orthogonal methods including antibody affinity extraction (AAE&#8482;)
            and mass spectrometry for HCP antibodies coverage analysis and HCP identification, which we provide as
            custom services. </span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_25"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our
            Competitive Strengths</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            believe we are a leader in providing nucleic acid products and services and biologics safety testing
            products and services to biopharmaceutical customers worldwide. Our success is built on the ability of our
            proprietary technologies and products, provided under exacting quality standards, to reliably serve our
            customers&#8217; needs for critical raw materials, and the process innovation, quality, analytical expertise
            and reliability of our services.</span></div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leading
            Supplier of Critical Solutions for Life Sciences from Discovery to Commercialization</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            seek to be an important component of our customers&#8217; supply chain by providing inputs that are central
            to the performance of their products and processes throughout the product lifecycle. By collaborating with
            customers early in the development phase, our products frequently follow our customers&#8217; development
            path to commercialization and are likely to be incorporated as raw materials in their on-market products and
            processes. Our decades-long experience and track record, coupled with our ongoing investment in facilities
            and quality systems, allow our customers to rely on us for their critical products. Our approach is to be a
            trusted partner throughout the life cycle of our customers&#8217; products.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Innovation,
            Proprietary Technologies and Expertise Underpin Our Portfolio</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            expertise in complex chemistries leads customers to seek our collaboration in designing complex products
            that meet high performance expectations. Based on the responses to the Industry Analysis, we believe the
            solutions we provide, in many cases, cannot be provided effectively by our competitors. In certain cases,
            like our CleanCap technology, our know-how features differentiated performance characteristics and is backed
            by intellectual property. In other cases, such as our HCP products, our antibodies are proprietary and
            therefore can only be supplied by us. We believe the proprietary nature of our expertise and products
            solidifies our long-term customer relationships.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Products
            with Outstanding Quality Performance</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            believe our products stand out when compared to those of our competitors&#8217; because they present
            innovative solutions to customer needs, as indicated by the responses to the Industry Analysis, while
            providing reliable performance and quality. CleanCap, for example, offers advantages over competing capping
            technologies in yield, process efficiency, stability and safety. Our oligonucleotides address complex
            chemistry challenges, which we believe few competitors can address. The results of the Industry Analysis
            indicate that our HCP ELISA kits have defined the market for impurity detection and we believe they have
            become a </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de
            facto</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            standard in biologics safety testing. </span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trusted
            Brands</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            TriLink BioTechnologies, Glen Research, Alphazyme and Cygnus Technologies brands are well known in their
            respective markets for innovation, consistent quality, and performance. This brand recognition has been
            earned over decades. Our manufacturing processes, quality standards, technical support and high-touch
            customer service ensure that we maintain the reputation of our brands.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State-of-the-Art
            Manufacturing Facilities</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            biopharmaceutical customers manufacture their products to meet stringent quality standards under strict
            regulatory guidelines and expect their critical suppliers to meet their exacting requirements. Our customers
            further expect that we have the production capacity to meet their needs in a timely manner. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maravai
            has designed and constructed four world-class manufacturing facilities, and since 2022 has expanded the
            company&#8217;s facility footprint by over 95,000 square feet to support expanded capabilities and future
            growth.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            of December&#160;31, 2023, we had invested approximately $93.2&#160;million into our flagship San Diego,
            California Wateridge facility and its dedicated manufacturing suites to produce materials from Research Use
            Only (&#8220;RUO&#8221;) to GMP conditions, along with the required quality systems to meet requirements
            specified by our customers. This investment in our Wateridge facility allows us to meet our customers&#8217;
            demand for our nucleic acid products, including CleanCap. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            January 2023, we moved into a new state-of-the-art facility in Leland, North Carolina to increase our
            manufacturing and development capacity to further support the Biologics Safety Testing business. </span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            March 2023, we expanded our San Diego, California manufacturing campus by making a significant investment in
            additional cleanroom and small molecule manufacturing space, implementing automation systems and adding
            support areas to augment production capacity with the Flanders 1 facility (&#8220;Flanders 1
            facility&#8221;) for GMP small molecule production. This facility provides site redundancy for our Wateridge
            facility and features five GMP suites that can operate in parallel. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            June 2023, we finished construction and took occupancy of an additional 32,000 square-foot facility in San
            Diego (&#8220;Flanders 2 facility&#8221;) for GMP-grade mRNA manufacturing to support customers progressing
            into Phase II clinical trials and beyond. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            June 2023, we expanded the Alphazyme facility in Jupiter, Florida to add an additional research and
            development (&#8220;R&amp;D&#8221;) space to support our specialized enzyme development.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Experienced
            Leaders and Talented Workforce</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            management includes experienced leaders with demonstrated records of success at Maravai and other highly
            regarded industry participants. They have decades of combined experience and expertise on the forefront of
            life sciences innovation. In addition, as of December&#160;31, 2023, approximately 24% of our workforce have
            earned advanced degrees and all receive rigorous on the job training. We believe the quality of our
            personnel is critical to ensuring the collaborative, long-standing relationships we maintain with many of
            our customers.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_28"></div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our
            Markets</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            participate in two distinct market segments: Nucleic Acid Production and Biologics Safety Testing. Our
            businesses principally address high growth market segments in biopharmaceutical development. In particular,
            the field of cell and gene therapy has emerged as one of the fastest growing treatment modalities to address
            a host of human conditions. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biopharmaceutical
            customers are increasingly relying on outside parties to provide important raw material inputs and services
            for their clinical research and manufacturing, a development driving growth for suppliers with unique
            capabilities, high quality and the ability to manufacture at a relevant scale to support customer programs.
            We believe that suppliers like ourselves, with </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this
            rare combination of capabilities, proprietary products and the required investment in manufacturing and
            quality systems, are benefiting from rapid growth as biopharmaceutical customers seek to partner with a
            small number of trusted partners.</span></div>
    <div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><img src="mrvi-20231231_g6.jpg"
            alt="Slide3_MacD edits_revised_01.23.24.jpg"
            style="height:356px;margin-bottom:5pt;vertical-align:text-bottom;width:684px" /></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            addition to the continued trend toward outsourcing, several market developments should contribute to
            long-term growth in our addressable market segments, including:</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Pivot
            toward mRNA vaccines and therapeutics for non-COVID indications has been accelerated in part by
            COVID-19</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.
            The first two vaccines approved for use in combating the COVID-19 pandemic were mRNA vaccines, including the
            vaccine developed by Pfizer and BioNTech which uses our CleanCap product. Our CleanCap product is also
            incorporated into the booster vaccines developed by Pfizer and BioNTech. The mRNA platforms are gaining
            prominence as a result of their fast development time, lower relative manufacturing costs and proven safety
            profile. Pfizer and BioNTech are now developing a combined COVID-19 and Influenza vaccine that has been
            placed into a designation that can &#8220;fast-track&#8221; a regulatory decision by the FDA. In addition to
            the COVID-19 vaccines, mRNA technology is being investigated for a spectrum of other infectious diseases as
            well as cancer vaccines, including personalized medicine vaccines. RNA expertise is highly specialized, and
            customers seek partners with our expertise to provide these complex products. A small number of providers,
            like ourselves, with a successful track record for COVID-19, can provide this level of RNA capability.
        </span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Rapid
            growth in development of cell and gene therapies</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.
            Seven new cell and gene therapy approvals (Omisirge, Vyjuvek, Roctavian, Lantidra, Casgevy, Lyfgenia,
            Elvidys) were all granted FDA or EMA approval in 2023 and have added clinical credibility to cell and gene
            therapies. Our internal analysis, supported by third-party research, projects that by 2027, 20-30% of the
            mRNA pipeline assets will be for</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">
            in vivo</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            gene editing and </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex
            vivo</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            gene-edited cell therapies. We support the development of cell and gene therapies by providing products used
            in gene editing and cell therapy research. For example, our host cell protein assays are used during the
            manufacturing of viral vectors and plasmid DNA. Further, we participate by providing the critical high
            quality synthetic guide RNA and mRNA that encodes for gene-editing enzymes, such as Cas9 that are used
        </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in
            vivo</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            gene editing and </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex
            vivo</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            gene-edited cell therapies.</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Large
            and growing pipeline of protein-based therapeutics</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.
            In addition to cell and gene therapies, an increase in protein-based therapies is driving the need for
            impurity testing during process development and manufacturing from our Biologics Safety Testing business.
            Classical biologics are evolving to be expressed in </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">vivo</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            via mRNA. Our analysis suggests that therapeutic proteins and protein replacement may represent as much as
            25% of the mRNA pipeline by 2027. We are well positioned to leverage our service capabilities and deep
            understanding of mRNA biology to serve our customers&#8217; needs to express these large, complex,
            peptide-based molecules.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nucleic
            Acid Production Market</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            nucleic acid production market includes the production and synthesis of reagents for research and
            manufacturing of DNA and RNA-based biologics, including cell and gene therapies, mRNA therapeutics and
            synthetic biology approaches.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            field of mRNA-based drugs and vaccines has advanced dramatically within a few short years. Providers of
            technical expertise and manufacturing capabilities, like ourselves, with the facilities and quality systems
            demanded by biopharmaceutical customers, benefit from the demand created in the mRNA category.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biologics
            Safety Testing Market</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            biologics safety testing market includes the detection and clearance of downstream bioprocessing
            product-related and process-related impurities. We participate in the HCP and other process related
            impurities and viral contamination segments of this market for biopharmaceutical vaccine and therapeutics
            manufacturing. The growth in this market is driven by continued growth of biologics and biosimilars, viral
            vector manufacturing for rapidly-growing CAR-T and gene therapy modalities, and increased outsourcing of
            process development.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_31"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our
            Strategy</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            customers strive to improve human health. Our goal is to provide them with products and services to
            accelerate their development efforts, from basic research through clinical trials and ultimately to
            commercialization for therapeutics, diagnostics and vaccines.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Supporting
            Biopharmaceutical Customers from Discovery Through to Commercialization</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            customers include both emerging and established biopharmaceutical leaders developing novel drugs,
            therapeutics, diagnostics and vaccines. Emerging biopharmaceutical customers frequently seek the support we
            can offer in our state-of-the-art facilities under our stringent quality standards, with the capabilities
            that result from the capital and process investments we have made over the last several years. We are
            capable of manufacturing reagents from research-grade to GMP-grade, which often exceeds the in-house
            capabilities of our pre-commercial customers. The results of the Industry Analysis indicate that our
            emerging and established customers also seek us out for our leading capabilities in nucleic acid chemistries
            and process control assays. We have expertise in complex chemistries, especially in highly modified nucleic
            acids and mRNA, and we believe we are a leader in applying these capabilities to the development of vaccines
            and therapeutics. We further support our customers as they transition from product development to
            commercialization by providing critical raw materials for their drugs. A core component of our strategy is
            the continued investment in facilities, quality standards and products and services that allow us to support
            our customers through the entire life cycle of their drugs.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Developing
            Proprietary Technologies that Deepen our Relationships with Our Customers</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            believe we are experts in nucleic acids and our scientists aim to develop proprietary enabling technologies
            that become integral to our customers&#8217; products. For example, CleanCap, our proprietary chemical
            capping technology, has demonstrated its advantages in terms of the stability of the associated mRNA and its
            efficiency in protein production when compared to traditional capping technologies. This efficiency has led
            biopharmaceutical customers to employ CleanCap in their vaccine and therapeutic programs. As those products
            proceed through development into commercialization, we believe CleanCap will be a critical input in
            on-market vaccines and therapeutics. </span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Forming
            Long-Term Partnerships for Critical Biopharmaceutical Components and Process Tests</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            products are frequently incorporated into regulated and highly validated therapeutic and diagnostic products
            and processes. Our biopharmaceutical customers expect us to provide them with consistent, high-quality
            products that meet narrow specifications, and that we ensure their supply chain for such products for the
            length of their programs. In many cases, we may be the sole source of the products we provide. We therefore
            take seriously our responsibility to our biopharmaceutical partners, and by extension the patients they
            serve. Our emphasis on partnership generally leads to long-term relationships with our customers.</span>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Focusing
            Our Efforts on High Growth End Markets</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While
            biopharmaceutical research and </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in
            vitro</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            diagnostics markets are experiencing strong growth, we target the highest growth segments within those
            markets. Our product portfolio is well positioned to serve the biologic, cell and gene therapy and mRNA
            vaccine and therapeutic end markets, which are currently experiencing above-market growth. By investing in
            technologies at the forefront of biopharmaceutical and </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in
            vitro</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            diagnostics, we aim to remain focused on the highest-growth applications.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquiring
            Leading Life Sciences Businesses and Supporting Their Continued Development</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            built our business by acquiring established and emerging companies with strong scientific foundations in our
            target markets and investing in their systems, processes and people to accelerate their growth and expand
            their technologies. Going forward, we may pursue strategic acquisitions that we believe meet, or could meet
            after being acquired and expanded, the following criteria:</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">address
            our core target markets;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have
            a demonstrated adherence to high quality standards;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be
            leaders in their market niche(s);</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have
            differentiated or proprietary products and processes that provide clear value to our biopharmaceutical and
            other customers; and</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have
            a track record of attractive rates of growth and compelling returns on invested capital.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            acquisition strategy is to invest significantly in our acquired businesses. We strive to rapidly integrate
            their quality, human resources, information and financial systems into our shared services. All of our
            companies share a common enterprise resource planning system, and we implement our financial controls and
            reporting systems soon after acquisition. We seek opportunities to invest in their facilities and personnel
            to provide an operating foundation for growth. We also augment their commercial capabilities through a
            combination of sales and marketing resources dedicated to each business, supported by our global marketing
            infrastructure.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            will continue to seek a balance between driving growth organically and inorganically through
            acquisitions.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_34"></div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            have relationships with the following categories of customers: developers of therapeutics and vaccines,
            other biopharmaceutical and life science research companies, academic institutions and molecular diagnostic
            companies. Our biopharmaceutical customers include startups, established biotechnology companies and large
            pharmaceutical companies developing enzyme replacement therapies, gene editing therapies, </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex
            vivo</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            therapies and vaccines.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            commercial function includes direct sales, marketing, customer service, technical support and distributor
            management. We serve customers through direct sales in each business segment, with a primary focus on our
            biopharmaceutical and large diagnostics and commercial customers. We serve our academic customers via web,
            email and phone ordering as well as through key partnerships where our reagent products are included in
            their mRNA kits. We support all customers with live technical support and customer service.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            address customers outside the United States with a combination of direct sales and distributors. We serve
            many of our biopharmaceutical customers, especially in our nucleic acid production segment, via direct sales
            worldwide. Our distributors also sell our products in over 40 countries and provide customer service and
            local sales and marketing.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_37"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span>
    </div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            compete with a range of companies across our segments.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nucleic
            Acid Production</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within
            nucleic acid production, we compete with four primary types of companies: (1) chemistry companies that
            create and produce the basic monomers, amidites, and supports that go into the creation of an
            oligonucleotide; (2) oligonucleotide manufacturers that specialize in custom oligonucleotide development of
            varying complexities and scales; (3) mRNA biotechnology companies that create fully processed mRNA and
            specialize in custom, complex orders; and (4) CDMOs that have the capability to accept work from large
            biopharmaceutical companies and serve as the outsourcing entity for the development and manufacturing of
            nucleic acid products. However, it is important to note that CDMOs seldom offer proprietary products.</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For
            mRNA capping analogs, we compete principally with Thermo Fisher Scientific, Aldevron (a subsidiary of
            Danaher), and New England BioLabs, who offer alternatives to CleanCap with enzymatic capping solutions. Many
            biopharmaceutical companies produce capping solutions in-house using enzymatic or ARCA processes. However,
            given CleanCap&#8217;s high yield and process efficiency, many customers who previously insourced these
            processes have begun to partner with us. Based on the Industry Analysis, we believe our products and
            services are more effective than those of our competitors. Deep scientific expertise, intellectual property
            protection and specialty equipment serve as barriers to entry in this space.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For
            our mRNA offerings, we compete with Aldevron, Patheon, eTheRNA, Lonza, Catalent, and Samsung Biologics,
            among others. Based on the Industry Analysis, we believe we have a reputation for our expertise in the RNA
            space with talented scientists who are constantly pushing the frontier of RNA science. This scientific
            expertise and the required high-cost equipment serve as barriers to entry. In addition to our expertise, we
            believe our GMP cleanroom manufacturing process differentiates us from competitors.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For
            custom oligonucleotides, we compete with a number of manufacturers. Custom oligonucleotide providers include
            those that provide complex, highly modified oligonucleotides and those that provide less complex offerings.
            In the custom oligonucleotide space, complexity is based on the length of the sequence and level of
            modification to the phosphate backbone. Large manufacturers like Integrated DNA Technologies, Thermo Fisher
            Scientific and EMD Millipore Corporation (&#8220;Millipore Sigma&#8221;) serve less complex customer needs
            while we, LGC Biosearch Technologies and GenScript Biotech Corporation serve more complex customer needs. In
            the custom oligonucleotide market, we have a reputation for accepting complex orders and delivering high
            purity products that reduce researcher re-work and save money. Quick turnaround times and the ability to
            produce at scale are essential requirements in this segment.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            the oligonucleotide synthesis inputs market, we compete against large distributor-manufacturers like Thermo
            Fisher and Millipore Sigma while also serving them as customers. Our Glen Research brand has a long history
            in this industry, which drives customer loyalty, and has a reputation for high-fidelity technical service,
            focusing on supplying and sourcing highly modified inputs for its customers.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For
            our specialty enzymes offering, we compete with New England Biolabs, Thermo Fisher, QIAGEN, and Roche, among
            others. We believe that Alphazyme is uniquely positioned in the market to address customers&#8217; custom
            enzyme needs and has a reputation of being a flexible partner.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biologics
            Safety Testing</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For
            drugs in early development, we compete against other bioprocess impurity kit providers such as BioGenes
            (&#8220;BioGenes&#8221;) or Enzo Life Sciences (&#8220;Enzo&#8221;). Competitors generally offer fewer
            expression platforms (generally between one and three) compared to our offering of 24 expression platforms
            and over 100 different impurity detection kits. As a drug successfully moves forward to validation and
            approval stages, a customer may either continue with an off-the-shelf kit or they may begin the process to
            develop a custom assay that is tailored to meet their specific host cell and manufacturing process needs.
            During the entire drug development process, and especially during this decision, we are partners with the
            manufacturer and provide our expertise to help them make the best bioprocess quality control and
            testing-related decisions.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If
            a drug manufacturer continues with an off-the-shelf assay from development to validation and approval, they
            will generally stay with the incumbent kit provider due to the extensive validation they have conducted. For
            custom assay development, our main competitors are BioGenes, Rockland Immunochemicals and some CDMOs and
            CROs with custom assay development capabilities. The trend in recent years has been for CDMOs, CROs and
            large biopharmaceutical companies to focus on core competencies and outsource host cell protein assays or
            qualify off-the-shelf kits when possible.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_40"></div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Licenses
            and Collaborations</span></div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Broad
            Patent License Agreement</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            (through TriLink BioTechnologies) entered into a Nonexclusive Patent License and Material Transfer Agreement
            with The Broad Institute, Inc. (&#8220;Broad&#8221;) effective as of July&#160;5, 2017, and amended on
            September 29, 2017 (the &#8220;Broad Patent License Agreement&#8221;). Broad, together with a consortium of
            educational institutions (including Harvard University and the Massachusetts Institute of Technology), owns
            and controls certain patent rights relating to genome editing technology, including the CRISPR-Cas9 gene
            editing processes and have a licensing program for use and commercialization of technologies and products
            covered by the underlying patent rights. Under the Broad Patent License Agreement, Broad grants to us a
            non-exclusive, royalty-bearing, non-transferable and non-sublicensable, worldwide license under the licensed
            patent rights to manufacture and sell products and to perform certain </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in
            vitro</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            processes or services on a fee-for-service basis, in each case, solely as research tools for research
            purposes (excluding human, clinical or diagnostic uses). We must use diligent efforts to develop products,
            introduce products into the commercial market and make products reasonably available to the public. We are
            obligated to pay a mid-five figure annual license maintenance fee and royalties in the range of 5% to 10% on
            net sales of covered products and processes.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            term of the Broad Patent License Agreement extends through the expiration of the last to expire claim of any
            of the licensed patents. We are entitled to terminate the Broad Patent License Agreement for convenience at
            any time on at least three (3) months written notice, in which case we must continue to pay license
            maintenance fees and royalties as noted above for the sale of products that are not covered by the specific
            claims of the licensed patent rights but are otherwise derived from such </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">licensed
            patent rights or from products covered by such licensed patent rights. Broad may terminate the license for
            our uncured failure to make payments, for our uncured material breach or if we bring a patent challenge
            against any of the institutional rights holders.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_43"></div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing
            and Supply</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            occupy facilities in San Diego, California, Leland, North Carolina, Sterling, Virginia, and Jupiter,
            Florida. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            Wateridge facility in San Diego is engaged in the manufacture of reagents. The facility was designed and
            built by us in conjunction with the building owner to contain fully functional chemical and biological
            manufacturing operations from material receiving to product distribution and has its own loading dock,
            manufacturing gas delivery system, solvent delivery and waste system, ISO Class 8 and ISO Class 7 designated
            customer manufacturing suites and integrated building management systems for required site control. </span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            addition to the Wateridge facility, we have two facilities in San Diego, Flanders 1 and Flanders 2. Flanders
            1 provides us with additional GMP manufacturing capacity and provides us the optionality downstream to
            manufacture materials beyond current quality requirements for mRNA raw materials, including CleanCap.
            Flanders 1 will also support an additional increase to batch run sizes and overall throughput. Flanders 2
            was purpose built to support GMP-grade manufacturing and to support customers into Phase II clinical trials
            and beyond. Both the Flanders 1 and Flanders 2 facilities include the introduction of integrated
            manufacturing systems, quality of water improvements from Reverse Osmosis De-ionized grade water to WFI
            (&#8220;Water For Injection&#8221;), which is pharmaceutical grade water, and other facility infrastructure
            investments to support potential customer needs related to quality. We took occupancy of the Flanders
            facilities in 2023 and expect to begin manufacturing from both locations in 2024.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            early 2023, our Southport, North Carolina operations were relocated to a new state-of-the-art facility in
            Leland, North Carolina. This new facility more than doubles our operational square footage and has capacity
            to support future growth in the manufacture and processing of antibody and HCP ELISA kits. The operations
            include laboratory, manufacturing, kitting, cold storage, shipping and waste handling capabilities. The
            fully customized design includes a Mass Spectrometry Center of Excellence and specialized cell culture
            facilities. It significantly increases our manufacturing and development capacity while providing other
            R&amp;D, laboratory and automation upgrades. Extensive process flow analysis has been incorporated into the
            facility design to optimize and enhance both our manufacturing and kit packaging operations.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            Sterling, Virginia facility was designed to perform quality control, aliquoting, packaging and shipping and
            houses the appropriate space and systems.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through
            our acquisition of Alphazyme in the first quarter of 2023, we acquired a purpose-built enzyme production
            facility in Jupiter, Florida, that can produce enzymes to kilogram quantities. The facility includes
            environmental controls such as HEPA filtration, pressure, temperature, and humidity monitoring, with
            vertical integration of all enzyme development, production, and testing operations. Our enzymes are produced
            under the controls of an ISO 13485:2016 compliant QMS.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            supply chain is supported by a diverse network of specialized suppliers and transportation partners and
            undergoes regular evaluations to assess supplier quality and identify risks, including those associated with
            supply concentration. These proactive evaluations enable us to implement strategic measures to effectively
            manage and mitigate risks. By continuously optimizing our supply chain, we ensure operational resilience and
            maintain a steady supply of critical materials for our products.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_46"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government
            Regulation</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            provide products used for basic research or as raw materials used by biopharmaceutical customers for further
            processing, and active pharmaceutical ingredients used for preclinical and clinical studies. The quality of
            our products is critical to researchers looking to develop novel vaccines and therapies and for
            biopharmaceutical customers who use our products as raw materials or who are engaged in preclinical studies
            and clinical trials. Biopharmaceutical customers are subject to extensive regulations by the FDA and similar
            regulatory authorities in other countries for conducting clinical trials and commercializing products for
            therapeutic, vaccine or diagnostic use. This regulatory scrutiny results in our customers imposing rigorous
            quality requirements on us as their supplier through supplier qualification processes and customer
            contracts.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            nucleic acid and biologics safety testing segments produce materials used in research and biopharmaceutical
            production, clinical trial vaccines and vaccine support products. We produce materials in support of our
            customers&#8217; manufacturing businesses and to fulfill their validation requirements, as applicable. These
            customer activities are subject to regulation and consequently require these businesses to be inspected by
            the FDA and other national regulatory agencies under their respective cGMP regulations. These regulations
            result in our customers imposing quality requirements on us for the manufacture of our products, and
            maintain records of our manufacturing, testing and control activities. In addition, the specific activities
            of some of our businesses require us to hold specialized licenses for the manufacture, distribution and/or
            marketing of particular products.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All
            of our sites are subject to licensing and regulation, as appropriate under federal, state and local laws
            relating to:</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            surface and air transportation of chemicals, biological reagents and hazardous materials;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            handling, use, storage and disposal of chemicals (including toxic substances), biological reagents and
            hazardous waste;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            procurement, handling, use, storage and disposal of biological products for research purposes;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            safety and health of employees and visitors to our facilities; and</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">protection
            of the environment and general public.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory
            compliance programs at each of our businesses are managed by a dedicated group responsible for regulatory
            affairs and compliance, including the use of outside consultants. Our compliance programs are also managed
            by quality management systems, such as vendor supplier programs and training programs. Within each business,
            we have established Quality Management Systems (&#8220;QMS&#8221;) responsible for risk based internal audit
            programs to manage regulatory requirements and client quality expectations. Our QMS program ensures that
            management has proper oversight of regulatory compliance and quality assurance, inclusive of reviews of our
            system practices to ensure that appropriate quality controls are in place and that a robust audit strategy
            confirms requirements for compliance and quality assurance.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research
            Products</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            products and operations may be subject to extensive and rigorous regulation by the FDA and other federal,
            state, or local authorities, as well as foreign regulatory authorities. The FDA regulates, among other
            things, the research, development, testing, manufacturing, clearance, approval, labeling, storage,
            recordkeeping, advertising, promotion, marketing, distribution, post-market monitoring and reporting, and
            import and export of pharmaceutical drugs. Certain of our products are currently marketed as research use
            only (&#8220;RUO&#8221;).</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            believe that our products that are marketed as RUO products are exempt from compliance with GMP regulations
            under the FDCA. RUO products cannot make any claims related to safety, effectiveness or diagnostic utility
            and they cannot be intended for human clinical diagnostic use. In November 2013, the FDA issued a final
            guidance on products labeled RUO, which, among other things, reaffirmed that a company may not make any
            clinical or diagnostic claims about an RUO product. The FDA will also evaluate the totality of the
            circumstances to determine if the product is intended for diagnostic purposes. If the FDA were to determine,
            based on the totality of circumstances, that our products labeled and marketed for RUO are intended for
            diagnostic purposes, they would be considered medical products that will require clearance or approval prior
            to commercialization.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            do not make claims related to safety or effectiveness and they are not intended for diagnostic or clinical
            use. However, the quality of our products is critical to meeting customer needs, and we therefore
            voluntarily follow the quality standards outlined by the International Organization for Standardization for
            quality management systems (ISO 9001:2015) for the design, development, manufacture, and distribution of our
            products. Some biopharmaceutical customers desire extra requirements including quality parameters and
            product specifications, which are outlined in customer-specific quality agreements. These products are
            further processed and validated by customers for their applications. Customers qualify us as part of their
            quality system requirements, which can include a supplier questionnaire and on-site audits. Customers
            requalify us on a regular basis to ensure our quality system, processes and facilities continue to meet
            their needs and we are meeting requirements outlined in relevant customer agreements.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Active
            Pharmaceutical Ingredients (&#8220;APIs&#8221;) for Clinical Trials</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            provide APIs to customers for use in preclinical studies through and including clinical trials. We hold a
            drug manufacturing license with the California Food and Drug Branch of the California Department of Public
            Health for manufacture of APIs for clinical use and are subject to inspection to maintain licensure.
            Manufacture of APIs for use in clinical trials is regulated under &#167;&#160;501(a)(2)(B) of the FDCA, but
            is not subject to the current GMP regulations in 21 CFR &#167; 211 by operation of 21 CFR &#167;&#160;210.
            We follow the principles detailed in the International Council for Harmonisation (&#8220;ICH&#8221;) Q7,
            Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (Section 19, APIs For Use in
            Clinical Trials) in order to comply with the applicable requirements of the FDCA, and the comparable GMP
            principles for Europe; European Community, Part II, Basic Requirements for Active Substances Used as
            Starting Materials (Section 19, APIs For Use in Clinical Trials). APIs are provided to customers under
            customer contracts that outline quality standards and product specifications. As products advance through
            the clinical phases, requirements become more stringent, and we work with customers to define and agree on
            requirements and risks associated with their product.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers&#8217;
            biopharmaceutical products early in their development have a high failure rate and often do not advance
            through the clinical stages to commercialization. Our customers are required to follow regulatory pathways
            that are not always known, which may cause additional unforeseen requirements placed on us as their contract
            manufacturer and delays in advancing to the next stage of product development. We also provide novel
            compounds for cell and gene therapy applications, which result in additional challenges for our customers
            attempting to obtain regulatory approval given that this field is relatively new, and regulations are
            evolving. Customer clinical trials rely on approval from institutional review boards (&#8220;IRBs&#8221;)
            and patient and volunteer enrollment, which makes timelines unpredictable for advancing to the next stage in
            product development. Preclinical studies and clinical trials conducted by our customers are also expensive
            and data may be negative or inconclusive causing customers to abandon projects that were expected to
            continue. Regulatory requirements in both the United States and abroad are always evolving and compliance
            with future laws may require significant investment to ensure compliance.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other
            Regulatory Requirements</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental
            laws and regulations.</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            We believe that our operations comply in all material respects with applicable laws and regulations
            concerning environmental protection.&#160;To date, there have been no material effects upon our earnings or
            competitive position resulting from our compliance with applicable laws or regulations enacted or adopted
            relating to the protection of the environment.&#160;Our capital and operating expenditures for pollution
            control in 2023 and 2022 were not material and are not expected to be material in 2024.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_49"></div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual
            Property</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            success depends in part on our ability to obtain and maintain intellectual property protection for our
            products and services, defend and enforce our intellectual property rights, preserve the confidentiality of
            our trade secrets, and operate without infringing, misappropriating or otherwise violating valid and
            enforceable intellectual property rights of others. We seek to protect the investments made into the
            development of our products and services by relying on a combination of patents, trademarks, copyrights,
            trade secrets, including know-how, and license agreements. We also seek to protect our proprietary products
            and services, in part, by requiring our employees, consultants, contractors and other third parties to
            execute confidentiality agreements and invention assignment agreements.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patents.
        </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            intellectual property strategy is focused on protecting through patents and other intellectual property
            rights our core products and services, including CleanCap, and related instrumentation and applications. In
            addition, we protect our ongoing research and development into critical reagents for cell and gene therapy
            through patents and other intellectual property rights. Our patent portfolio generally includes patents and
            patent applications relating to compositions and methods for the production of CleanCap, oligonucleotides,
            nucleic acids, immunofluorescence assays, and mock viral particles. We may own provisional patent
            applications, and provisional patent applications are not eligible to become issued patents until, among
            other things, we file national stage patent applications either directly or via the PCT within 12 or 30 to
            32 months, respectively. If we do not timely file any national stage patent applications, we may lose our
            priority date with respect to our provisional patent applications and any patent protection on the
            inventions disclosed in such provisional patent applications. We cannot predict whether any such patent
            applications will result in the issuance of patents that provide us with any competitive advantage.</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issued
            patents extend for varying periods depending on the date of filing of the patent application or the date of
            patent issuance and the legal term of patents in the countries in which they are obtained. Generally,
            utility patents issued for applications are granted a term of 21 years from the earliest effective filing
            date of a non-provisional patent application. Issued patents may be extended beyond the natural 21 year term
            for regulatory or administrative delay in accordance with provisions of applicable local law. As a result,
            our patent portfolio may not provide us with sufficient rights to exclude others from commercializing
            products similar or identical to ours.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            following granted patents relate to our CleanCap products and technology.</span></div>
    <div style="margin-bottom:12pt;margin-top:12pt">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:14.566%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.532%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:14.566%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.532%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:49.705%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.532%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:14.567%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jurisdiction</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Patent
                        Number</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration</span>
                </td>
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United
                        States</span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">10494399</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Compositions
                            and methods for synthesizing 5&#8242;-Capped RNAs</span></div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United
                        States</span></td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">10519189</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Compositions
                            and methods for synthesizing 5&#8242;-Capped RNAs</span></div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United
                        States</span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">10913768C1</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Compositions
                            and methods for synthesizing 5&#8242;-Capped RNAs</span></div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United
                        States</span></td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">11414453</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Compositions
                            and methods for synthesizing 5&#8242;-Capped RNAs</span></div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United
                        States</span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">11878991</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Compositions
                            and methods for synthesizing 5&#8242;-Capped RNAs</span></div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United
                        States</span></td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">11578095</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Compositions
                            and methods for synthesizing 5&#8242;-Capped RNAs</span></div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3352584</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Compositions
                            and methods for synthesizing 5&#8242;-Capped RNAs</span></div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3954225</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Compositions
                            and methods for synthesizing 5&#8242;-Capped RNAs</span></div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3906789</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Compositions
                            and methods for synthesizing 5&#8242;-Capped RNAs</span></div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">4104687</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Compositions
                            and methods for synthesizing 5&#8242;-Capped RNAs</span></div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">4140491</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Compositions
                            and methods for synthesizing 5&#8242;-Capped RNAs</span></div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2016328645</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Compositions
                            and methods for synthesizing 5&#8242;-Capped RNAs</span></div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2021206780</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Compositions
                            and methods for synthesizing 5&#8242;-Capped RNAs</span></div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2999274</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Compositions
                            and methods for synthesizing 5&#8242;-Capped RNAs</span></div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ZL
                            202310734863.0</span></div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Compositions
                            and methods for synthesizing 5&#8242;-Capped RNAs</span></div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong
                            Kong</span></div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">40080484</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Compositions
                            and methods for synthesizing 5&#8242;-Capped RNAs</span></div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">6814997</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Compositions
                            and methods for synthesizing 5&#8242;-Capped RNAs</span></div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">7082174</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Compositions
                            and methods for synthesizing 5&#8242;-Capped RNAs</span></div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Korea,
                            Republic of</span></div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">10-2500198</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Compositions
                            and methods for synthesizing 5&#8242;-Capped RNAs</span></div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span>
                </td>
            </tr>
        </table>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            following patents relate to our MockV related products and technology.</span></div>
    <div style="margin-bottom:12pt;margin-top:12pt;text-align:justify">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:14.566%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.532%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:14.566%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.532%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:49.705%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.532%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:14.567%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jurisdiction</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Patent
                        Number</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration</span>
                </td>
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United
                        States</span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">9632087</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Methods
                            for evaluating viral clearance from a biopharmaceutical solution employing mock viral
                            particles</span></div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United
                        States</span></td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">10309963</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Methods
                            for evaluating viral clearance from a process solution employing mock viral particles</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3044339</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Methods
                            and kits for quantifying the removal of mock virus particles from a purified solution</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2014320015</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Methods
                            and kits for quantifying the removal of Mock Virus Particles from a purified solution</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2021200484</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Methods
                            and kits for quantifying the removal of Mock Virus Particles from a purified solution</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">105899684</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Methods
                            and kits for quantifying pseudoviral particles removed from purified solution</span></div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">6549126</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Methods
                            and kits for removal of mock virus particles from a purified solution</span></div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United
                            States</span></div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">11754565</span>
                    </div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Methods
                            and kits for removal of mock virus particles from a purified solution</span></div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span>
                </td>
            </tr>
        </table>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trademarks.</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            Our trademark portfolio is designed to protect the brands of our current and future products and includes
            U.S. trademark registrations for our company name, Maravai LifeSciences, subsidiary names Cygnus
            Technologies and TriLink Biotechnologies and various product names, such as CleanCap and MockV.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trade
            Secrets.</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            We also rely on trade secrets, including know-how, unpatented technology and other proprietary information,
            to strengthen our competitive position. We have determined that certain technologies, such as the production
            of antibodies for biologics safety testing, are better kept as trade secrets, rather than pursuing patent
            protection. To prevent disclosure of trade secrets to others, it is our policy to enter into nondisclosure,
            invention assignment and confidentiality agreements with parties who have access to trade secrets, such as
            our employees, collaborators, outside scientific collaborators, consultants, advisors </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and
            other third parties. These agreements also provide that all inventions resulting from work performed for us
            or relating to our business and conceived or completed during the period of employment or assignment, as
            applicable, are our exclusive property. In addition, we take other appropriate precautions, such as physical
            and technological security measures, to guard against misappropriation of our proprietary information by
            third parties.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            intend to pursue additional intellectual property protection to the extent we believe it would advance our
            business objectives. Notwithstanding these efforts, there can be no assurance that we will adequately
            protect our intellectual property or provide any competitive advantage. We cannot provide any assurance that
            any patents will be issued from our pending or any future patent applications or that any issued patents
            will adequately protect our products or technology. Our intellectual property rights may be invalidated,
            held unenforceable, circumvented, narrowed or challenged. In addition, the laws of various foreign countries
            where our products are distributed may not protect our intellectual property rights to the same extent as
            laws in the United States. Furthermore, it may be difficult to protect our trade secrets. While we have
            confidence in the measures we take to protect and preserve our trade secrets, they may be inadequate and can
            be breached, and we may not have adequate remedies for violations of such measures. In addition, our trade
            secrets may otherwise become known or be independently discovered by competitors. Moreover, our invention
            assignment agreements with employees, collaborators, outside scientific collaborators, consultants, advisors
            and other third parties may not be self-executing or otherwise provide meaningful protection for our
            intellectual property rights. If we do not adequately protect our intellectual property, third parties,
            including our competitors, may be able to use our technologies to produce and market products that compete
            with us and erode our competitive advantage. For more information regarding risks related to intellectual
            property, please see Item 1A. &#8220;Risk Factors&#8212;Risks Related to our Intellectual
            Property.&#8221;</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_52"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human
            Capital Management: Empowering Our Future</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At
            Maravai, we understand that our strength lies in the expertise and commitment of our people. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            of December&#160;31, 2023, our team had over 650 full-time employees. Following the reduction in force,
            which was completed on January 5, 2024, we had approximately 570 full-time employees. Our workforce
            represents a diversity of backgrounds, with 44% identifying as female, 56% as male, and 52% as ethnically or
            racially diverse as of December&#160;31, 2023. We take pride in the fact that, as of December&#160;31, 2023,
            24% of our team held advanced degrees, underscoring our emphasis on science and innovation.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            compensation and comprehensive benefits packages are designed to attract and retain the talent we need to be
            competitive in the markets we serve. Believing in the value of ownership, we extend equity awards to all
            full-time employees through our 2020 Omnibus Incentive Plan, alongside opportunities to participate in our
            2020 Employee Stock Purchase Plan. Our commitment to excellence ensures every employee receives thorough
            on-the-job training. We also understand that great people managers are the key to enabling and unlocking the
            potential of our employees. In 2023, we initiated a bi-monthly &#8220;Leading Together&#8221; people leader
            series with all levels of our people leaders to ensure they had the critical knowledge, perspective, and
            tools to develop their people and align their teams towards company goals and objectives. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            actively work to foster direct and open lines of communication between all levels of staff through our
            all-employee engagement survey, our quarterly all-employee town halls, management skip level meetings, and
            an emphasis on our core values (Connected, Open, Driven, and Empowered). Our 2023 company-wide engagement
            survey reached a participation rate of 97% and all levels of leadership engage in action planning based on
            the results.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            2023, all of our sites participated in process excellence initiatives and we launched &#8220;Find a Better
            Way Day&#8221; to highlight the efforts of our employees to drive quality and safety improvements and reduce
            cost. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            a leading life sciences company, we are committed to the health, safety and well-being of our employees. All
            employees that could be exposed to potential hazards are required to complete annual health and safety
            training, including laboratory chemical safety, hazard communication and hazardous waste management
            trainings. In 2023, we upgraded our electronic Safety Data Sheet (SDS) system to more readily provide
            chemical safety data electronically to employees and customers. </span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_55"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available
            Information</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            website is located at www.maravai.com, and our investor relations website is located at
            investors.maravai.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports
            on Form 8-K, and any amendments to these reports, are available through our investor relations website, free
            of charge, as soon as reasonably practicable after we electronically file or furnish them with the SEC. Our
            filings with the SEC are also available, free of charge, on the SEC's website at www.sec.gov. We webcast via
            our investor relations website our earnings calls and certain events we participate in or host with members
            of the investment community. Our investor relations website also provides notifications of news or
            announcements regarding our financial performance and other items that may be material or of interest to our
            investors, </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including
            SEC filings, investor events, press and earnings releases, and blogs. The contents of our website are not
            incorporated by reference into this Annual Report on Form 10-K or in any other report or document we file
            with the SEC, and any references to our website are intended to be inactive textual references only.</span>
    </div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_58"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            1A. Risk Factors</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            addition to the other information in this report and our other filings with the SEC, you should carefully
            consider the risks and uncertainties described below, which could materially and adversely affect our
            business operations, financial condition and results of operations. The risks and uncertainties described
            below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we
            currently believe are not material, may also become important factors that affect us. If any of the
            following risks occur, our business, financial condition, results of operations and prospects could be
            materially and adversely affected. In that event, the price of our Class A common stock could decline, and
            you could lose all or part of your investment.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_61"></div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary
            of Risk Factors</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            following is a summary of the material risks we and/or our shareholders face in the normal course of our
            business operations. The list below is not exhaustive, and is qualified in its entirety by reference to the
            full risk factor discussion that follows this summary.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks
            Related to Our Business and Strategy</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The
            level of our customers&#8217; spending on and demand for outsourced nucleic acid production and biologics
            safety testing products and services.</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Uncertainty
            regarding the extent and duration of our revenue associated with COVID-19-related products and services and
            the dependency of such revenue, in important respects, on factors outside our control.</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The
            impact of ongoing macroeconomic challenges and changes in economic conditions, including adverse
            developments affecting banks and financial institutions, follow-on effects of those events and related
            systemic pressures, on our and our customers&#8217; current and future business operations.</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The
            effects of our recent reduction in force, including on our ability to attract and/or retain qualified key
            personnel.</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Use
            of our products by customers in the production of vaccines and therapies, some of which represent relatively
            new and still-developing modes of treatment, and the impact of unforeseen adverse events, negative clinical
            outcomes, development of alternative therapies, or increased regulatory scrutiny of these modes of treatment
            and their financial cost on our customers&#8217; use of our products and services. </span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competition
            with life science, pharmaceutical and biotechnology companies who are substantially larger than us and
            potentially capable of developing new approaches that could make our products, services and technology
            obsolete. </span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The
            potential failure of our products and services to not perform as expected and the reliability of the
            technology on which our products and services are based. </span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The
            risk that our products do not comply with required quality standards. </span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market
            acceptance of our life science reagents.</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Significant
            fluctuations and unpredictability in our quarterly and annual operating results, which make our future
            operating results difficult to predict and could cause our operating results to fall below expectations or
            any guidance we may provide. </span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our
            ability to implement our strategic plan successfully.</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Natural
            disasters, geopolitical instability (including the ongoing military conflicts in Ukraine and the Gaza Strip)
            and other catastrophic events. </span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks
            related to our acquisitions, including whether we achieve the anticipated benefits of acquisitions of
            businesses or technologies. </span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product
            liability lawsuits.</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our
            dependency on a limited number of customers for a high percentage of our revenue and our ability to maintain
            our current relationships with such customers. </span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our
            reliance on a limited number of suppliers or, in some cases, sole suppliers, for some of our raw materials
            and the risk that we may not be able to find replacements or immediately transition to alternative
            suppliers. </span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The
            risk that our products become subject to more onerous regulation by the FDA or other regulatory agencies in
            the future. </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks
            Related to Our Intellectual Property and Technology</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our
            ability to obtain, maintain and enforce sufficient intellectual property protection for our current or
            future products. </span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The
            risk that a future cyber-attack or security breach cannot be prevented.</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our
            ability to protect the confidentiality of our proprietary information</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The
            risk that one of our products may be alleged (or found) to infringe on the intellectual property rights of
            third parties.</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compliance
            with our obligations under intellectual property license agreements. </span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our
            or our licensors&#8217; failure to maintain the patents or patent applications in-licensed from a third
            party.</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our
            ability to adequately protect our intellectual property and proprietary rights throughout the world.</span>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks
            Related to Our Indebtedness</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our
            existing level of indebtedness and our ability to raise additional capital on favorable terms. </span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our
            ability to generate sufficient cash flow to service all of our indebtedness.</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our
            potential failure to meet our debt service obligations.</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restrictions
            on our current and future operations under the terms applicable to the Credit Agreement.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks
            Related to Our Organizational Structure</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our
            dependence, by virtue of our principal asset being our interest in Maravai Topco Holdings, LLC (&#8220;Topco
            LLC&#8221;), on distributions from Topco LLC to pay our taxes and expenses, including payments under a tax
            receivable agreement with the former owners of Topco LLC (the &#8220;Tax Receivable Agreement&#8221; or
            &#8220;TRA&#8221;) together with various limitations and restrictions that impact Topco LLC&#8217;s ability
            to make such distributions. </span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The
            risk that conflicts of interest could arise between our shareholders and Maravai Life Sciences Holdings, LLC
            (&#8220;MLSH 1&#8221;), the only other member of Topco LLC, and impede business decisions that could benefit
            our shareholders. </span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The
            substantial future cash payments we may be required to make under the Tax Receivable Agreement to MLSH 1 and
            Maravai Life Sciences Holdings 2, LLC (&#8220;MLSH 2&#8221;), an entity through which certain of our former
            owners hold their interests in the Company and the negative effect of such payments. </span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The
            fact that our organizational structure, including the TRA, confers certain benefits upon MLSH 1 and MLSH 2
            that will not benefit our other common shareholders to the same extent as they will benefit MLSH 1 and MLSH
            2. </span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our
            ability to realize all or a portion of the tax benefits that are expected to result from the tax attributes
            covered by the Tax Receivable Agreement.</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The
            possibility that we will receive distributions from Topco LLC significantly in excess of our tax liabilities
            and obligations to make to make payments under the Tax Receivable Agreement.</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unanticipated
            changes in effective tax rates or adverse outcomes resulting from examination of our income or other tax
            returns.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks
            Related to Being a Public Company</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks
            related to our annual assessment of the effectiveness of our internal control over financial reporting,
            including the potential existence of any material weakness or significant deficiency.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks
            Related to Our Class A Common Stock</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The
            fact that investment entities affiliated with GTCR, LLC (&#8220;GTCR&#8221;) currently control a majority of
            the voting power of our outstanding common stock, and it may have interests that conflict with ours or yours
            in the future. </span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks
            related to our &#8220;controlled company&#8221; status within the meaning of the corporate governance
            standards of NASDAQ. </span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The
            potential anti-takeover effects of certain provisions in our corporate organizational documents.</span>
    </div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Potential
            sales of a significant portion of our outstanding shares of Class A common stock.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Potential
            preferred stock issuance and the anti-takeover impacts of any such issuances.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_64"></div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks
            Related to Our Business and Strategy</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We
            are dependent on the level of our customers&#8217; spending on and demand for outsourced nucleic acid
            production and biologics safety testing products and services. A reduction in spending or change in spending
            priorities of our customers could significantly reduce demand for our products and services and could have a
            material adverse effect on our business, financial condition, results of operations, cash flows and
            prospects.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            success of our business depends primarily on the number and size of contracts with our customers, primarily
            pharmaceutical and biotechnology companies, for our products and services. For example, during the COVID-19
            pandemic we benefited from a significant increase in demand for our products and service, including our
            proprietary CleanCap&#174; analogs that are used by our customers in the production of COVID-19 vaccines,
            and also benefited during 2021 and 2022, more generally, from the overall growth of the global biologics
            market, higher research and development budgets of our customers and a greater degree of outsourcing by our
            customers. The level of our customers&#8217; spending on and demand for our products and services is also
            subject to, among other things, their own financial performance, changes in their available resources, the
            timing of their commercial manufacturing initiatives, their decisions to acquire in-house manufacturing
            capacity (rather than outsource), their spending priorities, including research and development budgets, and
            their budgetary policies and practices, which, in turn, are dependent upon a number of factors outside of
            our control.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            customers determine their research and development budgets based on several factors, including their need to
            develop new biological products, their competitors&#8217; discoveries, developments and commercial
            manufacturing initiatives and the anticipated market, clinical and reimbursement scenarios for specific
            products and therapeutic areas. In addition, consolidation in the industries in which our customers operate
            may have an impact on our customers&#8217; spending as they integrate acquired operations, including
            research and development departments and associated budgets.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Access
            to capital is critical to many of our customers&#8217; ability to fund research and development,
            particularly early-stage biotechnology and pharmaceutical companies, and historically, these companies have
            funded their research and development activities by raising capital privately or in the equity markets.
            Declines and uncertainties in the capital markets, including as a result of ongoing negative macroeconomic
            challenges, rising interest rates, recent instability in the banking sector, and volatile credit markets,
            have limited access to capital and negatively affected companies&#8217; ability to fund research and
            development efforts. While 2021 and 2022 saw a significant level of investment in venture- and private
            equity-backed startup companies, funding for companies at all stages, and particularly early- and late-stage
            companies, contracted considerably during 2023, which, together with broader economic uncertainty, led
            certain of our customers to implement more stringent budgetary policies designed to conserve capital, which
            in turn, caused a reduction in research and development spending and a decline in further purchases of our
            products and services. We have no assurance as to whether, or when, such research and development spending
            may stabilize or increase, if at all. Further, if the funding of venture- and private equity-backed
            biotechnology and pharmaceutical companies remains weak or weakens further, the research and development
            budgets of our customers may be further reduced or eliminated altogether, which could impact future demand
            for our products and services.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If
            our customers reduce their spending on our products and services as a result of any of these or other
            factors, our business, financial condition, results of operations, cash flows and prospects would be
            materially and adversely affected.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover,
            we have no control over the timing and volume of purchases by our customers, and as a result, our operating
            results may fluctuate significantly, and our future revenue and operating results can be difficult to
            forecast. Our inability to forecast fluctuations in demand could harm our business, financial position and
            future results of operations. See also &#8220;&#8212;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our
            operating results may fluctuate significantly in the future, which makes our future operating results
            difficult to predict and could cause our operating results to fall below expectations or any guidance we may
            provide</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;
            below.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The
            extent and duration of our revenue associated with COVID-19 related products and services are uncertain and
            are dependent, in important respects, on factors outside our control.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain
            of our products, including our proprietary CleanCap&#174; analogs, are used by our customers in the
            production of COVID-19 vaccines. During each of the years ended December 31, 2022, 2021 and 2020, our
            results</span><span
            style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            of operations and cash flows were significantly and positively impacted by a strong demand for our
            proprietary Cle</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anCap&#174;
            ana</span><span
            style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">logs
            and highly </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">modified</span><span
            style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            RNA products, particularly mRNA. However, as a result of the general decrease in market</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            demand for COVID-19 related products and services, including the supply and manufacture of COVID-19
            vaccines, and in particular, following the end of U.S. federal public health emergency declaration and World
            Health Organization declaration of the end of the pandemic in early May 2022, we experienced substantial
            declines in COVID-19 related revenue during the year ended December 31, 2023. For the years ended
            December&#160;31, 2023, 2022 and 2021, we estimate that revenue from COVID-19 related products and services
            represented approximately 21.0%, 67.9% and 69.7%, respectively, of our total revenues. We expect to
            experience </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">further
            declines in COVID-19 related revenue for the aforementioned reasons, as well as a result of unused inventory
            of our products that our customers have on hand, which are not indication-specific. We are currently unable
            to fully estimate the impact of this unused inventory on our future revenues, nor are we able to predict
            when or if our customers will resume purchasing COVID-19 related products. Our longer-term revenue prospects
            for COVID-19 related products are highly uncertain but are expected to be substantially less than pandemic
            highs. Additionally, the ongoing manufacture and supply of COVID-19 vaccines (including bivalent booster
            doses) by our customers is uncertain and subject to various political, social, economic, and regulatory
            factors that are outside of our control, including the emergence, duration and intensity of new virus
            variants; regional resurgences of the virus globally; the availability and administration of pediatric and
            booster vaccinations, vaccine supply constraints, vaccine hesitancy and the effectiveness of vaccines
            against new virus strains; competition faced by our customers from other COVID-19 vaccine manufacturers and
            the development and availability of antiviral therapeutic alternatives; the lapsing of the public health
            emergency declaration made pursuant to Section 319 of the Public Health Service Act in January 2020 with
            respect to the COVID-19 pandemic; political and social debate relating to the need for, efficacy of, or side
            effects related to one or more specific COVID-19 vaccines; and the U.S. economy and global economy,
            including impacts resulting from supply chain constraints, labor market shortages and inflationary
            pressures. As the supply and manufacture of COVID-19 vaccines by our customers slows, or becomes no longer
            necessary, including if COVID-19 vaccines by our customers&#8217; competitors are determined or perceived to
            be more effective, we expect that demand for our COVID-19 related products and services will significantly
            decrease, which would have a material adverse effect on our revenue, results of operations and financial
            condition.</span><span
            style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
        </span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ongoing
            macroeconomic challenges and changes in economic conditions, including adverse developments affecting banks
            and financial institutions, follow-on effects of those events and related systemic pressures, could
            negatively impact, directly or indirectly, our and our customers&#8217; current and future business
            operations and our financial condition, revenue and earnings.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            reagents are sold primarily to biopharmaceutical and academic organizations developing novel vaccines and
            therapies and performing basic research. Research and development spending by our customers and the
            availability of government research funding can fluctuate due to changes in available resources, mergers of
            pharmaceutical and biotechnology companies, spending priorities, general economic conditions and
            institutional and governmental budgetary policies. Our biologics safety testing customers are
            biopharmaceutical companies, contract research organizations (&#8220;CROs&#8221;), contract development and
            manufacturing organizations (&#8220;CDMOs&#8221;) and life science companies, which largely serve the
            biopharmaceutical industry. Our nucleic acid production customers are largely vaccine and therapeutic drug
            makers or diagnostics manufacturers, which rely in part on government healthcare-related policies and
            funding. As a result, changes in government funding for certain research, decreases in or the imposition of
            limits on government spending more generally (including as a result of the ongoing appropriations process
            for the US. federal government&#8217;s fiscal year 2024), or reductions in overall healthcare spending could
            negatively impact us or our customers and, correspondingly, our sales to them. In particular, if the U.S.
            Congress fails to pass appropriate appropriations measures or enact another continuing resolution,
            reimbursements we are eligible to receive under the Cooperative Agreement we entered into with the U.S.
            Department of Defense may be jeopardized, which would negatively affect our business, operations and
            financial condition.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently,
            the U.S. and global economies are experiencing ongoing macroeconomic challenges, including labor shortages,
            supply chain disruptions and persistent inflation, which have led to increasing interest rates, volatility
            in the capital and credit markets, and fiscal and monetary policy uncertainty. Our business operations, as
            well as our customers&#8217; and suppliers&#8217; business operations, have been impacted, and are expected
            to continue to be impacted, by these negative conditions. In particular, labor shortages and wage inflation
            have affected our ability to hire, develop and retain our talented and diverse workforce, to maintain
            performance levels (especially cost and schedule), and to maintain our corporate culture. Further, if our
            raw material and other laboratory material suppliers experience operational challenges as a result of labor
            shortages, limited material availability, logistics delays and transportation capacity constraints, or are
            unable to access adequate capital to support their working capital requirements, they may be unable to
            provide raw materials or other laboratory materials to us in a timely manner or at a reasonable cost, which
            could adversely affect our profit margins and results of operations.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally,
            demand for our products and services could be adversely impacted if these ongoing macroeconomic challenges
            cause customers to reduce their operating budgets, adversely impact our customers&#8217; ability to commit
            funds to purchase our products, or otherwise cause customers to delay, cancel, decrease or forego purchases
            of our products and services. Further, since the majority of our customers&#8217; contracts can be
            terminated, delayed or reduced in scope upon short notice or no notice, this may require us to carry excess
            inventory to manage through unevenness in order activity and lead to unanticipated fluctuations in our
            quarterly revenue and earnings. If we are not able to forecast and adequately manage through changes in our
            customers&#8217; order requirements, our productivity, profitability, results of operations, cash flows and
            financial position could be negatively impacted. Further deterioration or a protracted extension of these
            negative macroeconomic conditions, a potential economic downturn or recession, or a significant reduction or
            delay in governmental funding as a result of U.S. federal budget </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issues,
            or the perception that any of these events may occur, could cause a decline in demand for our products and
            services and adversely affect our performance and result in declines in our revenue and earnings.</span>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our
            recent reduction in force may have unintended consequences, including business disruption, cause us to
            experience difficulties attracting and/or retaining qualified key personnel, which could negatively impact
            our ability to develop and market our products and services and our overall performance.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On
            November 7, 2023, we announced a workforce reduction of approximately 15% of our total full-time workforce
            (the &#8220;Reduction in Force&#8221;). The Reduction in Force resulted in the elimination of 102 full-time
            positions. Although the majority of the positions eliminated were intended to address excess manufacturing
            capacity, relative to current demand, this reduction has resulted in certain reallocations of employee
            duties. As a result, inefficiencies related to task unfamiliarity, heavier workloads, loss of knowledge and
            unfilled gaps may arise, especially if we are unable to effectively manage and implement the transition of
            impacted employees&#8217; duties and responsibilities. Any such inefficiencies may cause disruption or delay
            in our business activities. The Reduction in Force and resulting job reassignments could also negatively
            affect employee morale and make it more difficult to motivate and retain our remaining personnel. </span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            addition, our future success depends largely upon the continued service of our management and scientific
            staff and our ability to attract, retain and motivate highly skilled technical, scientific, management and
            marketing personnel, who deliver high-quality and timely services to our customers and keep pace with
            cutting-edge technologies and developments in biologics. We face significant competition in the hiring and
            retention of such personnel from other companies, other providers of outsourced biologics services, research
            and academic institutions, government and other organizations who have superior funding and resources and
            who may use these resources to pursue personnel more aggressively than we are. Additionally, certain highly
            skilled personnel that we seek to employ may be subject to non-competition or other restrictive covenants
            restricting their ability to work for us or within certain aspects of our business for a period of time.
            Although some jurisdictions (including the State of California) prohibit non-competition agreements as a
            matter of law, and the U.S. Federal Trade Commission has issued a notice of proposed rulemaking that would
            prohibit employers in the U.S. from using non-compete agreements, if we hire certain employees from
            competitors or other companies, those former employers may attempt to assert that these employees and/or we
            have breached certain legal obligations, resulting in a diversion of our time and resources.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            have, from time to time, experienced, and we expect to continue to experience, difficulty in hiring and
            retaining employees with appropriate qualifications. In recent years, recruiting, hiring and retaining
            employees with expertise in our industry and in the geographies where we operate has become increasingly
            difficult as the demand for skilled professionals has increased and as a result of labor shortages believed
            to have resulted from actions taken during the onset of the COVID-19 pandemic, but which remained following
            the recovery and which we expect will continue beyond the near-term. These difficulties may be heightened as
            a result of the Reduction in Force. The loss of key personnel or our inability to hire and retain skilled
            personnel could materially adversely affect the development of our products and services and our business,
            financial condition, results of operations, cash flows and prospects.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain
            of our products are used by customers in the production of vaccines and therapies, some of which represent
            relatively new and still-developing modes of treatment. Unforeseen adverse events, negative clinical
            outcomes, or increased regulatory scrutiny of these and their financial cost may damage public perception of
            the safety, utility, or efficacy of these vaccines and therapies or other modes of treatment and may harm
            our customers&#8217; ability to conduct their business. Such events may negatively impact our revenue and
            have an adverse effect on our performance.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gene
            therapy and nucleic acid vaccines remain relatively new and are under active development, with only a few
            gene therapies and nucleic acid vaccines, including those for COVID-19, approved to date by regulatory
            authorities. Public perception may be influenced by claims that gene therapy or nucleic acid vaccines are
            unsafe or ineffective, and gene therapy may not gain the acceptance of the public or the medical community.
            Following the release of nucleic acid COVID-19 vaccines, including those that incorporate our CleanCap&#174;
            products, segments of the population have criticized their safety and efficacy impacting vaccine demand. In
            addition, ethical, social, legal and financial concerns about gene therapy and nucleic acid vaccines,
            including COVID-19 vaccines, could result in additional regulations or limitations or even prohibitions on
            certain gene therapies or vaccine-related products. Our customers&#8217; use of our products and services in
            therapeutic and vaccine development programs for other (non-COVID-19-related) indications could be impacted
            by more restrictive regulations or negative public perception, which could negatively affect our business
            prospects, revenue and results of operation. </span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We
            compete with life science, pharmaceutical and biotechnology companies who are substantially larger than we
            are and potentially capable of developing new approaches that could make our products, services and
            technology obsolete.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            market for pharmaceutical, reagent, therapeutic and diagnostic products and services is intensely
            competitive, rapidly evolving, significantly affected by new product introductions and other market
            activities by industry participants and subject to rapid technological change. We also expect increased
            competition as additional companies enter our market and as more </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">advanced
            technologies become available. We compete with other providers of outsourced biologics products and
            services. We also compete with the in-house discovery, development and commercial manufacturing functions of
            pharmaceutical and biotechnology companies. Many of our competitors are large, well-capitalized companies
            with significantly greater resources and market share than we have. As a consequence, these competitors are
            able to spend more aggressively on product and service development, marketing, sales and other initiatives
            than we can. Many of these competitors also have:</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">broader
            name recognition;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">longer
            operating histories and the benefits derived from greater economies of scale;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">larger
            and more established distribution networks;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional
            product and service lines and the ability to bundle products and services to offer higher discounts or other
            incentives to gain a competitive advantage;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">more
            experience in conducting research and development, manufacturing and marketing;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">more
            experience in entering into collaborations or other strategic partnership arrangements; and</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">more
            financial, manufacturing and human resources to support product development, sales and marketing and patent
            and other intellectual property litigation.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These
            factors, among others, may enable our competitors to market their products and services at lower prices or
            on terms more advantageous to customers than we can offer. Competition may result in price reductions,
            reduced gross margins and loss of market share, any of which could have a material adverse effect on our
            business, financial condition, results of operations, cash flows and prospects. Additionally, our current
            and future competitors, including certain of our customers, may at any time develop additional products and
            services that compete with our products and services and new approaches by these competitors may make our
            products, services, technologies and methodologies obsolete or noncompetitive. We may not be able to compete
            effectively against these organizations.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            addition, to develop and market our new products, services, technologies and methodologies successfully, we
            must accurately assess and meet customers&#8217; needs, make significant capital expenditures, optimize our
            development and manufacturing processes to predict and control costs, hire, train and retain the necessary
            personnel, increase customer awareness and acceptance of our services, provide high-quality services in a
            timely manner, price our products and services competitively and effectively integrate customer feedback
            into our business planning. If we fail to create demand for our new products, services or technologies, our
            future business could be harmed.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If
            our products and services do not perform as expected or the reliability of the technology on which our
            products and services are based is questioned, we could experience lost revenue, delayed or reduced market
            acceptance of our products and services, increased costs and damage to our reputation.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            success depends on the market&#8217;s confidence that we can provide reliable, high-quality life science
            reagents. We believe that customers in our target markets are likely to be particularly sensitive to product
            defects and errors. Our reputation and the public image of our products, services and technologies may be
            impaired if our products or services fail to perform as expected.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although
            our products are tested prior to shipment, defects or errors could nonetheless occur. Our operating results
            depend on our ability to execute and, when necessary, improve our quality management strategy and systems
            and our ability to effectively train and maintain our employee base with respect to quality management. A
            failure of our quality control systems could result in problems with facility operations or preparation or
            provision of products. In each case, such problems could arise for a variety of reasons, including equipment
            malfunction, failure to follow specific protocols and procedures, problems with raw materials or
            environmental factors and damage to, or loss of, manufacturing operations. Such problems could affect
            production of a particular batch or series of batches of products, requiring the destruction of such
            products or a halt of facility production altogether. Furthermore, some of the products that we manufacture
            are subsequently incorporated into products that are sold by other life sciences companies and we have no
            control over the manufacture and production of those products.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            addition, in the event we, or our suppliers, fail to meet required quality standards and if our products
            experience, or are perceived to experience, a material defect or error, our products could be recalled or we
            may be unable to timely deliver products to our customers, which in turn could damage our reputation for
            quality and service. In the past, certain of our custom mRNA and CleanCap&#174; reagent products have been
            sold with insufficient capping efficiency or with incorrect transcription instructions. Additionally,
            several lots of our host cell protein (&#8220;HCP&#8221;) enzyme-linked immunosorbent assay
            (&#8220;ELISA&#8221;) biologics safety testing kits have experienced a possible instability drift and
            decrease in accuracy. Although we have taken steps to improve our quality review, product documentation and
            reference testing procedures, we cannot guarantee that we will not experience quality assurance issues with
            our products in the future. Any such failure could, among other things, lead to increased costs, delayed or
            lost revenue, delayed market acceptance, damaged reputation, diversion of development resources, </span>
    </div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">legal
            claims, reimbursement to customers for lost drug product, starting materials and active pharmaceutical
            ingredients, other customer claims, damage to and possibly termination of existing customer relationships,
            increased insurance costs, time and expense spent investigating the cause and, depending on the cause,
            similar losses with respect to other batches or products, any of which could harm our business, financial
            condition, results of operations, cash flows and prospects. Such defects or errors could also narrow the
            scope of the use of our products, which could hinder our success in the market.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even
            after any underlying concerns or problems are resolved, any lingering concerns in our target markets
            regarding our technology or any manufacturing defects or performance errors in our products or services
            could continue to result in lost revenue, delayed market acceptance, damage to our reputation and claims
            against us.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            addition, we may be unable to maintain the quality, reliability, robustness and expected turnaround times of
            our products and services to continue to satisfy customer demand as we grow. To effectively manage our
            growth, we must continue to improve our operational, manufacturing and quality control systems and processes
            and other aspects of our business and continue to effectively expand, train and manage our personnel. The
            time and resources required to improve our existing systems and procedures, implement new systems and
            procedures and to adequately staff such existing and new systems and procedures is uncertain, and failure to
            complete this in a timely and efficient manner could adversely affect our operations and negatively impact
            our business and financial results. We may need to purchase additional equipment, some of which can take
            several months or more to procure, set up and validate, establish new production processes and increase our
            personnel levels to meet increased demand. There can be no assurance that any of these increases in scale,
            personnel expansion or equipment or process enhancements will be successfully implemented, or that we will
            have adequate space, including in our laboratory and production facilities, to accommodate such required
            expansion. Failure to manage this growth or transition could result in delays in turnaround times, higher
            product costs, declining product quality, deteriorating customer service and slower responses to competitive
            challenges. A failure in any one of these areas could make it difficult for us to meet market expectations
            for our products and services and could damage our reputation and our business, financial condition, results
            of operations, cash flows and prospects could be adversely affected.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our
            products are highly complex and are subject to quality control requirements.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether
            a product is produced by us or purchased from outside suppliers, it is subject to quality control
            procedures, including the verification of stability and performance and, for certain products, additional
            validation required by certain GMP that we voluntarily follow, European Conformity (&#8220;CE&#8221;)
            marking and ISO 9001:2015 compliance, prior to final packaging. Certain of our products are manufactured
            following the voluntary GMP quality standards of the International Council for Harmonisation&#8217;s GMP
            Guide, comparable GMP principles for the European Union and customer-specific requirements. We believe these
            products are exempt from compliance with the Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and the
            current GMP (&#8220;cGMP&#8221;) regulations of the Food and Drug Administration (&#8220;FDA&#8221;), as our
            products are further processed and incorporated into final drug products by our customers and we do not make
            claims related to their safety or effectiveness. In the event we, or our suppliers, produce products that
            fail to comply with required quality standards, we may incur delays in fulfilling orders, write-downs,
            damages resulting from product liability claims and harm to our reputation.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our
            operating results may fluctuate significantly in the future, which makes our future operating results
            difficult to predict and could cause our operating results to fall below expectations or any guidance we may
            provide.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            have no control over the timing and volume of purchases by our customers. As a result,our quarterly and
            annual operating results may fluctuate significantly, which makes it difficult for us to predict our
            revenues and future operating results. These fluctuations may be driven by a variety of factors, many of
            which are outside of our control, including, but not limited to:</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unused
            inventory of our products that our customers have on hand, which are not indication-specific, and our lack
            of insight as to the amount of unused inventory of our products that such customers have on hand;</span>
    </div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes
            in the level of our customers&#8217; spending on and demand for our products and services, including as a
            result of, among other things, their own financial performance, changes in their available resources, timing
            of their commercial manufacturing initiatives, their decision to acquire in-house manufacturing capacity
            (rather than outsource), their spending priorities, including research and development budgets, and their
            budgetary policies and practices;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our
            ability to increase penetration in our existing markets and expand into new markets;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our
            customers accelerating, canceling, reducing or delaying orders as a result of developments related to their
            pre-clinical studies and clinical trials;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            relative reliability and robustness of our products and services;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes
            in governmental regulations or the regulatory posture toward our business;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            volume and mix of the products and services we sell; </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes
            in the production or sales costs related to our products and services;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            ongoing success of our newer products, such as our CleanCap&#174; and mRNA products;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            rate of introduction of other new products or product enhancements by us or others in our industry;</span>
    </div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            timing and amount of expenditures that we may incur to acquire, develop or commercialize additional
            products, services and technologies or for other purposes, such as the expansion of our facilities;</span>
    </div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes
            in governmental and academic funding of life sciences research and developments or changes that impact
            budgets, budget cycles or seasonal spending patterns of our customers;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future
            accounting pronouncements or changes in our accounting policies;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties
            encountered by our commercial carriers in delivering our products, whether as a result of external factors
            such as weather or negative macroeconomic conditions or internal issues such as labor disputes;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            timing and magnitude of any adjustments to the Tax Receivable Agreement liability;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes
            in the assessment of the realizability of our deferred tax assets;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general
            market conditions and other factors outside of our control, such as natural disasters, geopolitical unrest,
            war, terrorism, public health issues or other catastrophic events; and</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            other factors described in this &#8220;Risk Factors&#8221; section.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            impact of any one of the factors discussed above, or the cumulative effects of a combination of such
            factors, could result in significant fluctuations and unpredictability in our quarterly and annual operating
            results. As a result, comparisons of our operating results on a period-to-period basis may not be
            meaningful. Investors should not rely on our past results as an indication of our future performance.</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            a result of variability and unpredictability, we may also fail to meet the expectations of industry or
            financial analysts or investors for any period. If our revenue or operating results fall short of the
            expectations of analysts or investors or any guidance we may provide, or if the guidance we provide falls
            short of the expectations of analysts or investors, the price of our Class A common stock could decline
            substantially. Such a stock price decline could occur even when we have met or exceeded any previously
            publicly stated guidance we may have provided.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If
            we are unable to manufacture in specific quantities, our operating results will be harmed.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            revenue and other operating results depend in large part on our ability to manufacture and ship our products
            in sufficient quantities. Any interruptions we experience in the manufacturing or shipping of our products
            could delay our ability to recognize revenue in a particular quarter. Manufacturing problems can and do
            arise, and as demand for our products increases, any such problems could have an increasingly significant
            impact on our operating results. While we have not generally experienced problems with, or delays in, our
            production capabilities that resulted in delays in our ability to ship finished products, there can be no
            assurance that we will not encounter such problems in the future. We may not be able to quickly ship
            products and recognize anticipated revenue for a given period if we experience significant delays in the
            manufacturing process. In addition, we must maintain sufficient production capacity in order to meet
            anticipated customer demand, and we may be unable to offset the associated fixed costs if orders slow, which
            would adversely affect our operating margins. If we are unable to manufacture and ship our products
            consistently, in sufficient quantities and on a timely basis, our revenue, cash flow, gross margins and our
            other results of operations will be materially and adversely affected.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Natural
            disasters, geopolitical unrest, war, terrorism, public health issues or other catastrophic events could
            disrupt the supply, delivery or demand of products and services, as well as our sites, which could
            negatively affect our operations and performance.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            are subject to the risk of disruption by earthquakes, hurricanes, floods and other natural disasters, fire,
            power shortages, geopolitical unrest, war (including any escalation of the ongoing military conflicts in
            Ukraine or the Gaza Strip), terrorist attacks and other hostile acts, public health issues, epidemics or
            pandemics and other events beyond our control and the control of the third parties on which we depend. Any
            of these catastrophic events, whether in the United States or abroad, may have a significant negative impact
            on the global economy, our employees, facilities, partners, suppliers, distributors or customers, and could
            decrease demand for our products and services, create delays and inefficiencies in our supply chain and make
            it difficult or impossible for us to deliver products and services to our customers.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            rely upon our internal manufacturing, packaging and distribution operations to produce many of the products
            we sell and our warehouse facilities to store products pending sale. Any significant disruption of those
            operations for any reason, such as </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">labor
            disputes or social unrest, power interruptions, fire, hurricanes, a public health crisis (such as a
            pandemic), earthquakes or other events beyond our control, could adversely affect our sales and customer
            relationships and therefore adversely affect our business and results of operations. We have significant
            operations in California, near major earthquake faults, which make us susceptible to earthquake risk.</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            addition, a catastrophic event that results in damage to specific equipment that would be difficult to
            replace, the destruction or disruption of our research and production facilities or our critical business or
            information technology systems would severely affect our ability to conduct normal business operations and,
            as a result, our operating results would be adversely affected.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic
            transactions or acquisitions may require us to seek additional financing, which we may not be able to secure
            on favorable terms, if at all.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            plan to continue a strategy of growth and development for our business. To this end, we actively evaluate
            various strategic transactions on an ongoing basis, including licensing or acquiring complementary products,
            technologies or businesses that would complement our existing portfolio of products and services. In order
            to complete such strategic transactions, we may need to seek additional financing to fund these investments
            and acquisitions. Should we need to do so, we may not be able to secure such financing, or obtain such
            financing on favorable terms, for reasons including rising interest rates and continued volatility and
            uncertainty in the U.S. and global capital and credit markets. Our credit agreement also contains a number
            of restrictive covenants that impose significant restrictions on our ability to make acquisitions or certain
            other investments, as well as to incur additional indebtedness to finance such acquisitions or other
            investments. In addition, future acquisitions may require the issuance or sale of additional equity, or
            equity-linked securities, which may result in additional dilution to our shareholders. </span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our
            commercial success depends on the market acceptance of our life science reagents. Our reagents may not
            achieve or maintain significant commercial market acceptance.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            commercial success is dependent upon our ability to continue to successfully market and sell our life
            science reagents. Our ability to achieve and maintain commercial market acceptance of our products and
            services and provide customers access to our life science reagents will depend on a number of factors,
            including:</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our
            ability to increase awareness of the capabilities of our technology and solutions;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our
            customers&#8217; willingness to adopt new products, services and technologies;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether
            our products and services reliably provide advantages over legacy and other alternative technologies and are
            perceived by customers to be cost effective;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our
            ability to execute on our strategy to scale-up our CleanCap&#174; technology to meet increasing demand and
            provide channels to access our CleanCap&#174; technology and life science reagents;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            rate of adoption of our products and services by biopharmaceutical companies, academic institutions and
            others;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            relative reliability and robustness of our products and services as a whole and the components of our life
            science offerings, including, for example, CleanCap&#174; and our assays for detecting host cell
            proteins;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our
            ability to develop new tools and solutions for customers;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether
            competitors develop and commercialize products and services that provide comparable features and benefits at
            scale;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            impact of our investments in product innovation and commercial growth;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative
            publicity regarding our or our competitors&#8217; products resulting from defects or errors; and</span>
    </div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our
            ability to further validate our technology through research and accompanying publications.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            cannot assure you that we will be successful in addressing these criteria or other criteria that might
            affect the market acceptance of our products and services. If we are unsuccessful in achieving and
            maintaining market acceptance of our products and services, our business, financial condition, results of
            operations, cash flows and prospects could be adversely affected.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The
            market may not be receptive to our new products and services upon their introduction.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            expect a portion of our future revenue growth to come from introducing new products, including plasmid DNA
            and GMP-grade mRNA. The commercial success of all of our products and services will depend upon their
            acceptance by the life science and biopharmaceutical industries. Some of the products and services that we
            are developing are based upon new technologies or approaches. As a result, there can be no assurance that
            these new products and services, even if successfully developed and </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">introduced,
            will be accepted by customers. If customers do not adopt our new products, services and technologies, our
            results of operations may suffer and, as a result, the market price of our Class A common stock may
            decline.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It
            may be difficult for us to implement our strategies for revenue growth in light of competitive
            challenges.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            face significant competition across many of our product lines. In addition, consolidation trends in the
            pharmaceutical, biotechnology and diagnostics industries have served to create fewer customer accounts and
            to concentrate purchasing decisions for some customers, resulting in increased pricing pressure on us.
            Moreover, customers may believe that larger companies are better able to compete as sole source vendors, and
            therefore prefer to purchase from such businesses. Failure to anticipate and respond to competitors&#8217;
            actions may impact our future revenue and profitability.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our
            estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the
            market in which we compete achieves the forecasted growth, our business could fail to grow at similar rates,
            if at all.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressable
            market estimates and growth forecasts are subject to significant uncertainty and are based on assumptions
            and estimates that may not prove to be accurate. These estimates and forecasts are based on a number of
            complex assumptions and third-party estimates and other business data, including assumptions and estimates
            relating to our ability to generate revenue from existing products and services and the development of new
            products and services. Our estimates and forecasts relating to the size and expected growth of our markets
            may prove to be inaccurate. Even if the markets in which we compete meet our size estimates and growth
            forecasts, our business could fail to grow at the rate we anticipate, if at all.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If
            we are unable to successfully implement our strategic plan on a timely basis or at all, our business and
            future result of operations may be adversely impacted.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            strategic plan was developed based upon market and technology trends that we currently believe present
            revenue growth opportunities, and in turn, long-term shareholder value creation. Our strategic plan includes
            a series of strategic priorities and cost realignment initiatives designed to drive growth and improve
            operational efficiency. Our ability to achieve our strategic initiatives is subject to a number of risks,
            including those discussed herein under the heading &#8220;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks
            Related to Our Business and Strategy</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221;
            as well as challenges we face with executing multiple initiatives simultaneously. For example, our
            commercial initiatives may not succeed, or we may lose market share due to challenges in choosing the right
            products to develop or the right customers to target for these products, or integrating products of acquired
            companies into our sales and marketing strategy. We cannot assure you that we will overcome the risks
            associated with our strategic initiatives. If we fail to manage or overcome those risks, we may not realize
            the intended benefits of our strategic plan and may incur additional expenses without related revenue
            growth. Our business, financial position and results of operations will be adversely affected if we fail to
            successfully implement our strategic initiatives or if we invest resources in a growth strategy that
            ultimately proves to be unsuccessful.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product
            liability lawsuits against us could cause us to incur substantial liabilities, limit sales of our existing
            products and limit commercialization of any products that we may develop.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            business exposes us to the risk of product liability claims that are inherent in the development,
            production, distribution, and sale of biotechnology products. We face an inherent risk of product liability
            exposure related to the use of certain of our products in our customers&#8217; human clinical trials and
            product liability lawsuits may allege that our products or services identified inaccurate or incomplete
            information or otherwise failed to perform as designed. We may also be subject to liability for errors in, a
            misunderstanding of or inappropriate reliance upon, the information we provide in the ordinary course of our
            business activities. If any of our products harm people due to our negligence, willful misconduct, unlawful
            activities or material breach, or if we cannot successfully defend ourselves against claims that our
            products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome,
            liability claims may result in the following, any of which could impact our business, financial condition,
            results of operations, cash flows and prospects:</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased
            demand for our products and any products that we may develop;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury
            to our reputation;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs
            to defend the related litigation;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss
            of revenue; and</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            inability to commercialize products that we may develop.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            maintain product liability insurance, but this insurance is subject to deductibles, limits and exclusions
            and may not fully protect us from the financial impact of defending against product liability claims or the
            potential loss of revenue that may result. </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any
            product liability claim brought against us, with or without merit, could increase our insurance rates or
            prevent us from securing insurance coverage in the future.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We
            may be unable to efficiently manage growth as a larger and more geographically diverse organization.</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            strategic acquisitions, the continued expansion of our commercial sales operations and our organic growth
            have increased the scope and complexity of our business. As a result, we will face challenges inherent in
            efficiently managing a more complex business with an increased number of employees over large geographic
            distances, including the need to implement appropriate systems, policies, benefits and compliance programs.
            Our inability to manage successfully the geographically more diverse and substantially larger combined
            organization could materially adversely affect our operating results.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opportunistic
            acquisitions may pose risks and challenges that could adversely affect our business, and we may not achieve
            the anticipated benefits of acquisitions of businesses or technologies.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            have made in the past, and may make in the future, selected opportunistic acquisitions of complementary
            businesses, products, services or technologies. In January 2022, we acquired MyChem LLC, a provider of
            proprietary, ultra-pure nucleotides to customers in the diagnostics, pharma, genomics and research markets
            to complement our nucleic acid business and in January 2023, we completed the acquisition of Alphazyme, LLC,
            an original equipment manufacturer provider of custom molecular biology enzymes, servicing customers in the
            genetic analysis and nucleic acid synthesis markets to complement our nucleic acid production business.
            However, we may be unable to continue to identify or complete promising acquisitions for many reasons,
            including competition among buyers, the high valuations of businesses in our industry, the need for
            regulatory and other approvals and the availability of capital, particularly during a period of disruption
            and volatility within the global capital and credit markets.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any
            acquisition involves numerous risks, uncertainties and operational, financial, and managerial challenges,
            including the following, any of which could adversely affect our business, financial condition, results of
            operations, cash flows and prospects:</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties
            in integrating new operations, systems, technologies, products, services and personnel of acquired
            businesses effectively and in a timely manner;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties
            in implementing and maintaining controls, procedures and policies with respect to our financial accounting
            systems, including disclosure controls and procedures and internal control over financial reporting, at
            acquired businesses that, prior to the acquisition, had lacked such controls, procedures and
            policies;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack
            of synergies or the inability to realize expected synergies and cost-savings, including enhanced revenue,
            technology, human resources, cost savings, operating efficiencies and other synergies;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties
            in obtaining and verifying the financial statements and other business information of acquired
            businesses;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties
            in managing geographically dispersed operations, including risks associated with entering new or foreign
            markets in which we have no or limited prior experience;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">underperformance
            of any acquired technology, product, or business relative to our expectations and the price we paid;</span>
    </div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative
            near-term impacts on financial results after an acquisition, including acquisition-related earnings
            charges;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            potential loss of key employees, customers, contractual relationships, and strategic partners of acquired
            companies;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">declining
            employee morale and retention issues affecting employees of businesses that we acquire, which may result
            from changes in compensation, or changes in management, reporting relationships, future prospects or the
            direction of the acquired business;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">claims
            by terminated employees and shareholders of acquired companies or other third parties related to the
            transaction;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            assumption or incurrence of historical liabilities, obligations and expenses of the acquired business,
            including unforeseen and contingent or similar liabilities that are difficult to identify or accurately
            quantify, or other litigation-related liabilities and regulatory actions;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            assumption or incurrence of additional debt obligations or expenses, or use of substantial portions of our
            cash;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            issuance of equity or equity-linked securities to finance or as consideration for any acquisitions that
            dilute the ownership of our shareholders;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            issuance of equity securities to finance or as consideration for any acquisitions may not be an option if
            the price of our Class A common stock is low or volatile which could preclude us from completing any such
            acquisitions;</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            assumption of certain collaboration, strategic alliance and licensing arrangement may require us to
            relinquish valuable rights to our technologies or products, or grant licenses on terms that are not
            favorable to us;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption
            of our ongoing operations, diversion of management&#8217;s attention and company resources from existing
            operations of the business, and the dedication of significant efforts and expense across all operational
            areas, including sales and marketing, research and development, manufacturing, finance, legal and
            information technologies;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            impairment of intangible assets as a result of technological advancements, or worse-than-expected
            performance of acquired companies;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            need to later divest acquired assets at a loss if an acquisition does not meet our expectations;</span>
    </div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks
            associated with acquiring intellectual property, including potential disputes regarding acquired
            companies&#8217; intellectual property; and</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties
            relating to operating with increased leverage and incurring additional interest expense as a result of
            financing acquisitions with additional indebtedness, which could make us more vulnerable to
            downturns.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There
            can be no assurance we will identify promising acquisition opportunities. Even if we do, there can be no
            assurance that any of the acquisitions we have made, or that we may make, will be successful or will be, or
            will remain, profitable. Our failure to successfully address the foregoing risks may prevent us from
            achieving the anticipated benefits from any past or future acquisition in a reasonable time frame, or at
            all.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our
            ability to use net operating loss and tax credit carryforwards and certain built-in losses to reduce future
            tax payments is limited by provisions of the Internal Revenue Code, and it is possible that changes in laws
            or certain transactions or a combination of certain transactions may result in material additional
            limitations on our ability to use our net operating loss and tax credit carryforwards.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sections
            382 and 383 of the Internal Revenue Code of 1986, as amended, contain rules that limit the ability of a
            company that undergoes an ownership change, which is generally any change in ownership of more than 50% of
            its stock over a three-year period, to utilize its net operating loss and tax credit carryforwards and
            certain built-in losses recognized in years after the ownership change. These rules generally operate by
            focusing on ownership changes involving stockholders owning directly or indirectly 5% or more of the stock
            of a company and any change in ownership arising from a new issuance of stock by the company. Generally, if
            an ownership change occurs, the yearly taxable income limitation on the use of net operating loss and tax
            credit carryforwards and certain built-in losses is equal to the product of the applicable long-term,
            tax-exempt rate and the value of the company&#8217;s stock immediately before the ownership change. As a
            result, following any such ownership change, we might be unable to offset our taxable income with losses, or
            our tax liability with credits, before such losses and credits expire, in which event we could incur larger
            federal and state income tax liabilities than we would have had we not experienced an ownership change. In
            addition, under the 2017 Tax Cuts and Jobs Act (&#8220;TCJA&#8221;), tax losses generated in taxable years
            beginning after December 31, 2017, may be utilized to offset no more than 80% of taxable income annually. On
            March 27, 2020, the Coronavirus Aid Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was signed
            into law and changed certain provisions of the TCJA. Under the CARES Act, NOLs arising in taxable years
            beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five taxable
            years preceding the tax year of such loss, but NOLs arising in taxable years beginning after December 31,
            2020 may not be carried back. In addition, the CARES Act eliminates the limitation on the deduction of NOLs
            to 80% of current year taxable income for taxable years beginning before January 1, 2021, but the 80%
            limitation applies to tax years beginning after December 31, 2020. As such, we may not be able to realize a
            tax benefit from the use of our NOLs</span><span
            style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We
            may be required to record a significant charge to earnings if our goodwill and other amortizable intangible
            assets, or other investments become impaired.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            are required under U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) to test goodwill for
            impairment at least annually and to review our goodwill, amortizable intangible assets and other assets
            acquired through merger and acquisition activity for impairment when events or changes in circumstance
            indicate the carrying value may not be recoverable. Factors that could lead to impairment of goodwill,
            amortizable intangible assets and other assets acquired via acquisitions include significant adverse changes
            in the business climate and actual or projected operating results (affecting our company as a whole or
            affecting any particular segment) and declines in the financial condition of our business. We may be
            required in the future to record additional charges to earnings if our goodwill, amortizable intangible
            assets or other investments become impaired. Any such charge would adversely impact our consolidated
            financial results.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes
            in accounting principles and guidance could result in unfavorable accounting charges or effects.</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            prepare our consolidated financial statements in accordance with GAAP. These principles are subject to
            interpretation by the SEC and various bodies formed to create and interpret appropriate accounting
            principles and guidance. A change in these principles or guidance, or in their interpretations, may have a
            material effect on our reported results, as well as our processes and related controls, and may
            retroactively affect previously reported results. </span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our
            revenue recognition and other factors may impact our financial results in any given period and make them
            difficult to predict.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            recognize revenue when our performance obligations have been satisfied in an amount that reflects the
            consideration that we expect to receive in exchange for those performance obligations. Our revenue includes
            revenue from the sale of manufactured products, including products that can be purchased out of a catalog
            and custom manufactured products, and services, including custom antibody and assay development contracts,
            antibody affinity extraction and stability and feasibility studies, as well as certain licensing and royalty
            arrangements. The majority of our contracts include only one performance obligation, namely the delivery of
            products, both custom and catalog, and services. We also recognize revenue from other contracts that may
            include a combination of products and services, the provision of solely services, or from license fee
            arrangements which may be associated with the delivery of product. Our application of the revenue
            recognition accounting guidance with respect to the nature of future contractual arrangements could impact
            the forecasting of our revenue for future periods, as both the mix of products and services we will sell in
            a given period, as well as the size of contracts, is difficult to predict. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore,
            the presentation of our financial results requires us to make estimates and assumptions that may affect
            revenue recognition. In some instances, we could reasonably use different estimates and assumptions, and
            changes in estimates may occur from period to period. See Part II, Item 7, &#8220;Management&#8217;s
            Discussion and Analysis of Financial Condition and Results of Operations&#8212;Critical Accounting
            Estimates&#8212;Revenue Recognition.&#8221;</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given
            the foregoing factors, comparing our revenue and operating results on a period-to-period basis may not be
            meaningful, and our past results may not be indicative of our future performance.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fluctuations
            in our effective tax rate may adversely affect our results of operations and cash flows.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            are subject to a variety of tax liabilities, including federal, state, foreign and other taxes such as
            income, sales/use, payroll, withholding, and </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad
            valorem</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            taxes. Changes in tax laws or their interpretations could decrease our net income, the value of any tax loss
            carryforwards, the value of tax credits recorded on our balance sheet and our cash flows, and accordingly
            could have a material adverse effect on our business, financial condition, results of operations, cash flows
            and prospects. In addition, our tax liabilities are subject to periodic audits by the relevant taxing
            authority, which could increase our tax liabilities.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our
            business is subject to a number of environmental risks.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            manufacturing business involves the controlled use of hazardous materials and chemicals and is therefore
            subject to numerous environmental and safety laws and regulations and to periodic inspections for possible
            violations of these laws and regulations. The costs of compliance with environmental and safety laws and
            regulations are significant. Any violations, even if inadvertent or accidental, of current or future
            environmental and safety laws or regulations and the cost of compliance with any resulting order or fine
            could adversely affect our operations.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_67"></div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks
            Related to Our Reliance on Third Parties</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We
            depend on a limited number of customers for a high percentage of our revenue. If we cannot maintain our
            current relationships with customers, fail to sustain recurring sources of revenue with our existing
            customers, or if we fail to enter into new relationships, our future operating results will be adversely
            affected.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue
            from our largest customers were 19.3%, 61.2% and 68.1% of total revenue for the years ended
            December&#160;31, 2023, 2022 and 2021, respectively. The revenue attributable to our top customers has
            fluctuated in the past and may fluctuate in the future, which could have a material adverse effect on our
            business, financial condition, results of operations, cash flows and prospects. In addition, the termination
            of these relationships, including following any failure to renew a long-term contract, could result in a
            temporary or permanent loss of revenue. See also &#8220;&#8212;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The
            extent and duration of our revenue associated with COVID-19 related products and services are uncertain and
            are dependent, in important respects, on factors outside our control.&#8221;</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            future success depends on our ability to maintain these relationships, to increase our penetration among
            these existing customers and to establish new relationships. We engage in conversations with other companies
            and institutions regarding </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential
            commercial opportunities on an ongoing basis, which can be time consuming. There is no assurance that any of
            these conversations will result in a commercial agreement, or if an agreement is reached, that the resulting
            relationship will be successful. Speculation in the industry about our existing or potential commercial
            relationships can be a catalyst for adverse speculation about us, our products, our services and our
            technology, which can adversely affect our reputation and our business. In addition, if our customers order
            our products or services, but fail to pay on time or at all, our liquidity, financial condition, results of
            operations, cash flows and prospects could be materially and adversely affected.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            cannot assure investors that we will be able to further penetrate our existing markets or that our products
            or services will gain adequate market acceptance. Any failure to increase penetration in our existing
            markets would adversely affect our ability to improve our operating results.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We
            rely on distribution arrangements to market and sell our products and services, including in certain
            international markets, and our failure to maintain and successfully manage these arrangements or to renew or
            identify and implement additional arrangements on favorable terms, if at all, may impair our ability to
            effectively distribute and market our products and adversely impact our revenues and future results of
            operations.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            rely on certain distributors in order to market and sell our </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products</span><span
            style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            and services in in certain international markets, particularly our biologics safety testing products and
            services in China. Our distributor in China accounted for 4.8</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%
            of our total revenues in the year ended December 31, 2023. If we are unable to maintain this distributor or
            enter into a similar arrangement with another distributor, or our current or future distributors do not
            perform adequately, our revenues and results of operations would likely be adversely impacted, at least
            temporarily. Additionally, changes in the inventory levels of our products owned and held by our
            distributors can result in significant variability in our revenues. Furthermore, our revenues from such
            distributors could be negatively impacted by macroeconomic conditions specific to the geographic markets in
            which our products and services are marketed and sold, geopolitical risks and other risks described below
            under &#8220;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We
            are subject to financial, operating, legal and compliance risks associated with global
            operations</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            may pursue additional arrangements regarding the sales and marketing and distribution of one or more of our
            products and services, including if we intend to grow our business internationally in certain geographic
            markets, and the success of our strategic initiatives and our future revenue growth may depend, in part, on
            our ability to enter into and maintain arrangements with other companies having sales, marketing and
            distribution capabilities and the ability of such companies to successfully market and sell any such
            products and services. Any failure to enter into such arrangements and marketing alliances on favorable
            terms, if at all, could delay or impair our ability to distribute or market our products and services and
            could increase our costs of distribution and marketing. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            use of distribution arrangements and marketing alliances to commercialize our products and services subject
            us to a number of risks, including the following:</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we
            may be required to relinquish important rights to our products;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we
            may not be able to control the amount and timing of resources that our distributors or collaborators may
            devote to the distribution or marketing of our products;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our
            distributors or collaborators may experience financial difficulties; and</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business
            combinations or significant changes in a collaborator&#8217;s business strategy may adversely affect a
            collaborator&#8217;s willingness or ability to complete its obligations under any arrangement.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We
            rely on a limited number of suppliers or, in some cases, sole suppliers, for some of our raw materials and
            may not be able to find replacements or immediately transition to alternative suppliers.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain
            of our raw materials are sourced from a limited number of suppliers and some materials, including a
            proprietary DNA reagent, certain packaging materials, specific cell lines for Cygnus Technologies&#8217;
            operations and certain raw materials used in our nucleic acid production products, as well as those raw
            materials sold under the Glen Research brand, are sole sourced. Delays or difficulties in securing these raw
            materials or other laboratory materials could result in an interruption in our production operations if we
            cannot obtain an acceptable substitute. Since the onset of the COVID-19 pandemic, global supply chains have
            faced challenges, including material availability, global logistics delays and constraints arising from,
            among other things, the transportation capacity of ocean shipping containers, and these challenges have been
            exacerbated by the ongoing macroeconomic conditions as discussed above. Any interruption of our supply chain
            could significantly affect our business, financial condition, results of operations, cash flows and
            prospects. While we may identify other suppliers, raw materials furnished by such replacement suppliers may
            require us to alter our production operations or perform extensive validations, which may be time consuming
            and expensive. There can be no assurance that we will be able to secure alternative materials and revalidate
            them without experiencing interruptions in our workflow. If we should encounter delays or difficulties in
            obtaining raw materials, our business, financial condition, results of operations, cash flows and prospects
            could be adversely affected.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We
            depend on a stable and adequate supply of quality raw materials from our suppliers, and price increases or
            interruptions of such supply could have an adverse impact on our business, financial condition, results of
            operations, cash flows and prospects.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            operations depend upon our ability to obtain raw materials at reasonable prices. Cost and wage inflation,
            ongoing supply disruptions and logistics capacity constraints have increased, or may increase, our costs to
            manufacture and distribute our products and services. If we are unable to obtain the materials we need at a
            reasonable price due to inflationary pressures or other factors, we may not be able to produce certain of
            our products at marketable prices or at all, which could have a material adverse effect on our results of
            operations.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although
            we believe that we have stable relationships with our existing suppliers, we cannot assure you that we will
            be able to secure a stable supply of raw materials going forward. Our suppliers may not be able to keep up
            with our pace of growth or may reduce or cease their supply of raw materials to us at any time. In addition,
            we cannot assure you that our suppliers have obtained and will be able to obtain or maintain all licenses,
            permits and approvals necessary for their operations or comply with all applicable laws and regulations, and
            failure to do so by them may lead to interruption in their business operations, which in turn may result in
            shortages of raw materials supplied to us. Some of our suppliers are based overseas and therefore may need
            to maintain export or import licenses. If the supply of raw materials is interrupted, due to ongoing supply
            chain disruptions or other factors, our business, financial condition, results of operations, cash flows and
            prospects may be adversely affected.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because
            we rely heavily on third-party package-delivery services, a significant disruption in these services,
            damages or losses sustained during shipping or significant increases in prices could adversely affect our
            business, financial condition, results of operations, cash flows and prospects.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            ship a significant portion of our products to our customers through independent package delivery companies,
            such as World Courier, FedEx, UPS and DHL. If one or more of these third-party package-delivery providers
            were to experience a major work stoppage, preventing our products from being delivered in a timely fashion
            or causing us to incur additional shipping costs we could not pass on to our customers, our costs could
            increase and our relationships with certain of our customers could be adversely affected. In addition, if
            one or more of these third-party package-delivery providers were to increase prices, and we were not able to
            find comparable alternatives or make adjustments in our delivery network, our profitability could be
            adversely affected. Furthermore, if one or more of these third-party package-delivery providers were to
            experience performance problems or other difficulties, it could negatively impact our operating results and
            our customers&#8217; experience. In the past, some of our products have sustained serious damage in transit
            such that they were no longer usable. Although we have taken steps to improve our packaging and shipping
            containers, there is no guarantee our products will not become damaged or lost in transit in the future. If
            our products are damaged or lost in transit, it may result in a substantial delay in the fulfillment of our
            customer&#8217;s order and, depending on the type and extent of the damage, it may result in a substantial
            financial loss. If our products are not delivered in a timely fashion or are damaged or lost during the
            delivery process, our customers could become dissatisfied and cease using our products or our services,
            which would adversely affect our business, financial condition, results of operations, cash flows and
            prospects.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_70"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks
            Related to Laws and Regulations</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our
            products could become subject to more onerous regulation by the FDA or other regulatory agencies in the
            future, which could increase our costs and delay or prevent commercialization of our products, thereby
            materially and adversely affecting our business, financial condition, results of operations, cash flows and
            prospects.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            make certain of our products available to customers as research-use-only (&#8220;RUO&#8221;) products. RUO
            products are regulated by the FDA as medical devices, and include </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in
            vitro</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            diagnostic products in the laboratory research phase of development that are being shipped or delivered for
            an investigation that is not subject to the FDA&#8217;s investigational device exemption requirements.
            Although medical devices are subject to stringent FDA oversight, products that are intended for RUO and are
            labeled as RUO are exempt from compliance with most FDA requirements, including premarket clearance or
            approval, manufacturing requirements, and others. A product labeled RUO but which is actually intended for
            clinical diagnostic use may be viewed by the FDA as adulterated and misbranded under the FDCA, and subject
            to FDA enforcement action. The FDA has indicated that when determining the intended use of a product labeled
            RUO, the FDA will consider the totality of the circumstances surrounding distribution and use of the
            product, including how the product is marketed and to whom. The FDA could disagree with our assessment that
            our products are properly marketed as RUO, or could conclude that products labeled as RUO are actually
            intended for clinical diagnostic use, and could take enforcement action against us, including requiring us
            to stop distribution of our products until we are in compliance with applicable regulations, which would
            reduce our revenue, increase our costs and adversely affect our business, prospects, results of operations
            and financial condition. In the event that the FDA requires us to obtain marketing authorization of our RUO
            products in the future, there can be no assurance that the FDA will grant any clearance or approval
            requested by us in a timely manner, or at all.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            raw material products are manufactured following the voluntary quality standards of ISO 9001:2015. Our
            GMP-grade raw material products follow ISO 9001:2015 standards, additional voluntary GMP quality standards
            and customer specific requirements. We believe these raw material products, including our GMP-grade raw
            material products, are exempt from compliance with the FDCA and the cGMP regulations of the FDA, as our
            products are further processed by our customers and we do not make claims related to their safety or
            effectiveness. We provide API products to customers for use in preclinical studies through and including
            clinical trials. Our API products are manufactured following the principles detailed in the International
            Council for Harmonisation (ICH) Q7, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients
            (Section 19, APIs For Use in Clinical Trials) in order to comply with the applicable requirements of the
            FDCA, and the comparable GMP principles for Europe; European Community, Part II, Basic Requirements for
            Active Substances Used as Starting Materials (Section 19, APIs For Use in Clinical Trials). Manufacture of
            APIs for use in clinical trials is regulated under &#167; 501(a)(2)(B) of the FDCA, but is not subject to
            the current GMP regulations in 21 CFR &#167; 211 by operation of 21 CFR &#167; 210. Our API products are
            provided to customers under customer contracts that outline quality standards and product specifications. As
            products advance through the clinical phases, requirements become more stringent and we work with customers
            to define and agree on requirements and risks associated with their product.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            FDA could disagree with our assessment that our products are exempt from current GMP regulations. In
            addition, the FDA could conclude that the raw material and API products we provide to our customers are
            actually subject to the pharmaceutical or drug quality-related regulations for manufacturing, processing,
            packing or holding of drugs or finished pharmaceuticals, and could take enforcement action against us,
            including requiring us to stop distribution of our products until we are in compliance with applicable
            regulations, which would reduce our revenue, increase our costs and adversely affect our business,
            prospects, results of operations and financial condition. In the event that the FDA requires us to comply
            with FDA regulations, for our raw material and API products in the future, including the FDA&#8217;s current
            GMP regulations, there can be no assurance that the FDA will find our operations are in compliance in a
            timely manner, or at all.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We
            are subject to stringent privacy laws, information security laws, regulations, policies and contractual
            obligations related to data privacy and security and changes in such laws, regulations, policies and
            contractual obligations could adversely affect our business, financial condition, results of operations,
            cash flows and prospects.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            are subject to data privacy and protection laws and regulations that apply to the collection, transmission,
            storage and use of proprietary information and personally identifiable information (&#8220;PII&#8221;),
            which among other things, imposes certain requirements relating to the privacy, security and transmission of
            certain individually identifiable information.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous
            other federal and state laws, including state security breach notification laws, state health information
            privacy laws and federal and state consumer protection laws, govern the collection, use, disclosure and
            security of personal information. These laws continue to change and evolve and are increasing in breadth and
            impact. Failure to comply with any of these laws and regulations could result in enforcement action against
            us, including fines, imprisonment of company officials and public censure, claims for damages by affected
            individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse
            effect on our business, financial condition, results of operations, cash flows and prospects. Additionally,
            if we are unable to properly protect the privacy and security of personal information, we could be found to
            have breached our contracts.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many
            states in which we operate have laws that protect the privacy and security of personal information. For
            example, the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;), which increases privacy rights
            for California residents and imposes obligations on companies that process their personal information, came
            into effect on January 1, 2020. Among other things, the CCPA requires covered companies to provide new
            disclosures to California consumers and provide such consumers new data protection and privacy rights,
            including the ability to opt-out of certain sales of personal information. The CCPA provides for civil
            penalties for violations, as well as a private right of action for certain data breaches that result in the
            loss of personal information. Further, the California Privacy Rights Act (the &#8220;CPRA&#8221;), which
            took effect on January 1, 2023 (with certain provisions having retroactive effect to January 1, 2022),
            amended the CCPA. Amongst other things, the CPRA and eliminated the &#8220;employee exemption&#8221; under
            the CCPA, makes a distinction between &#8220;personal information&#8221; and &#8220;sensitive personal
            information,&#8221; imposing heightened protections for &#8220;sensitive personal information,&#8221; and
            brings business-to-business transactions under its purview. These laws and others like it are yet to be
            tested and may subject us to increased regulatory scrutiny, litigation, and overall risk. Further, there is
            discussion in Congress of a new federal data protection and privacy law to which we would become subject, if
            it is enacted.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various
            foreign countries in which we operate also have, or are developing, laws that govern the collection, use,
            disclosure, security and cross-border transmission of personal information. For example, in the European
            Union (the &#8220;EU&#8221;) and the United Kingdom, the collection and use of personal data is governed by
            the provisions of the General Data Protection Regulation (&#8220;GDPR&#8221;), in addition to other
            applicable laws and regulations. The GDPR came into effect in May 2018,and has resulted in, and will
            continue to result in, significantly greater compliance burdens and costs for companies like us. Any data
            security breach could require notifications to the data subject and/or owners under U.S. federal, U.S.
            state, and/or international data </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">breach
            notification laws and regulations. Other jurisdictions outside the EU are similarly introducing or enhancing
            privacy and data security laws, rules and regulations, which could increase our compliance costs and the
            risks associated with noncompliance. We cannot guarantee that we are, or will be, in compliance with all
            applicable international regulations as they are enforced now or as they evolve.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It
            is possible that these laws may be interpreted and applied in a manner that is inconsistent with our
            practices and our efforts to comply with the evolving data protection rules may be unsuccessful. We must
            devote significant resources to understanding and complying with this changing landscape. Failure to comply
            with federal, state and international laws regarding privacy and security of personal information could
            expose us to penalties under such laws, orders requiring that we change our practices, claims for damages or
            other liabilities, regulatory investigations and enforcement action, litigation and significant costs for
            remediation, any of which could adversely affect our business. Even if we are not determined to have
            violated these laws, government investigations into these issues typically require the expenditure of
            significant resources and generate negative publicity, which have a material adverse effect on our business,
            financial condition, results of operations, cash flows and prospects.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We
            are subject to export and import control laws and regulations that could impair our ability to compete in
            international markets or subject us to liability if we violate such laws and regulations.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            are subject to U.S. export controls and sanctions regulations that restrict the shipment or provision of
            certain products and services to certain countries, governments and persons. While we take precautions to
            prevent our products and services from being exported in violation of these laws, we cannot guarantee that
            the precautions we take will prevent violations of export control and sanctions laws. If we are found to be
            in violation of U.S. sanctions or export control laws, it could result in substantial fines and penalties
            for us and for the individuals working for us. We may also be adversely affected through other penalties,
            reputational harm, loss of access to certain markets, or otherwise. Complying with export control and
            sanctions regulations may be time consuming and may result in the delay or loss of sales opportunities or
            impose other costs. Any change in export or import regulations, economic sanctions or related legislation,
            or change in the countries, governments, persons or technologies targeted by such regulations, could result
            in our decreased ability to export or sell certain products and services to existing or potential customers
            in affected jurisdictions.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes
            in political, economic or governmental regulations may reduce demand for our products and services or
            increase our expenses.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            compete in many markets in which we and our customers must comply with federal, state, local and
            international regulations, such as environmental, health and safety and food and drug regulations. We
            develop, configure and market our products and services to meet customer needs created by those regulations.
            The U.S. and international healthcare industry is subject to changing political, economic and regulatory
            influences that could significantly affect the drug development process, research and development costs and
            the pricing and reimbursement for pharmaceutical products, and also may increase the likelihood of
            legislative or regulatory changes that could impact us or our business operations. Any significant change in
            regulations could have an adverse effect on both our customers&#8217; business and our business, which could
            result in reduced demand for our products and services or increases in our expenses. For example, we provide
            products and services used for basic research, raw materials used by biopharmaceutical customers for further
            processing, and active pharmaceutical ingredients used for preclinical studies and clinical trials.</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes
            in the FDA&#8217;s regulation of the drug discovery and development process may have a negative impact on
            the ability of our customers to conduct and fund clinical trials, which could have a material adverse effect
            on the demand for the products and services we provide these customers. Additionally, the U.S. government
            and governments worldwide have increased efforts to expand healthcare coverage while at the same time
            curtailing and better controlling the increasing costs of healthcare. If cost-containment efforts limit our
            customers&#8217; profitability, they may decrease research and development spending, which could decrease
            the demand for our products and services and materially adversely affect our growth prospects. Any of these
            factors could harm our customers&#8217; businesses, which, in turn, could materially adversely hurt our
            business, financial condition, results of operations, cash flows and prospects.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We
            are subject to financial, operating, legal and compliance risk associated with global operations.</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            engage in business globally, with approximately 51%, 62% and 60% of our revenue for the years ended
            December&#160;31, 2023, 2022 and 2021, respectively, coming from outside the U.S. In addition, one of our
            strategies is to expand geographically, both through distribution and through direct sales. This subjects us
            to a number of risks, including international economic, political, and labor conditions; currency
            fluctuations; tax laws (including U.S. taxes on income earned by foreign subsidiaries); increased financial
            accounting and reporting burdens and complexities; unexpected changes in, or impositions of, legislative or
            regulatory requirements; failure of laws to protect intellectual property rights adequately; inadequate
            local infrastructure and difficulties in managing and staffing international operations; delays resulting
            from difficulty in obtaining export licenses for </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain
            technology; tariffs, quotas and other trade barriers and restrictions; transportation delays; operating in
            locations with a higher incidence of corruption and fraudulent business practices; and other factors beyond
            our control, including terrorism, war, natural disasters, climate change and diseases.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            application of laws and regulations implicating global transactions is often unclear and may at times
            conflict. Compliance with these laws and regulations may involve significant costs or require changes in our
            business practices that result in reduced revenue and profitability. Non-compliance could also result in
            fines, damages, criminal sanctions, prohibited business conduct, and damage to our reputation. We incur
            additional legal compliance costs associated with our global operations and could become subject to legal
            penalties in foreign countries if we do not comply with local laws and regulations, which may be
            substantially different from those in the U.S.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            may expand our operations in countries with developing economies, where it may be common to engage in
            business practices that are prohibited by anti-corruption and anti-bribery laws and regulations that apply
            to us, such as the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), the U.S. Travel Act, and the UK
            Bribery Act 2010, which prohibit improper payments or offers of payment to foreign governments and political
            parties by us for the purpose of obtaining or retaining business. Although we implement policies and
            procedures designed to ensure compliance with these laws, there can be no assurance that all of our
            employees, contractors, distributors and agents, including those based in foreign countries where practices
            which violate such U.S. laws may be customary, will comply with our internal policies. Any such
            non-compliance, even if prohibited by our internal policies, could have an adverse effect on our business
            and result in significant fines or penalties.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our
            activities are and will continue to be subject to extensive government regulation, which is expensive and
            time consuming.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            are subject to various local, state, federal, foreign and transnational laws and regulations, and, in the
            future, any changes to such laws and regulations could adversely affect us.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            provide products and services used for basic research, raw materials and life science reagents used by
            biopharmaceutical customers for further processing, assays for biologics safety testing and active
            pharmaceutical ingredients used for preclinical studies and clinical trials. The quality of our products and
            services is critical to researchers looking to develop novel vaccines and therapies and for
            biopharmaceutical customers who use our products as raw materials or who are engaged in preclinical studies
            and clinical trials. Biopharmaceutical customers are subject to extensive regulations by the FDA and similar
            regulatory authorities in other countries for conducting clinical trials and commercializing products for
            therapeutic or diagnostic use. This regulatory scrutiny results in our customers imposing rigorous quality
            requirements on us as their supplier through supplier qualification processes and customer contracts.</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally,
            regulatory authorities and our customers may conduct scheduled or unscheduled periodic inspections of our
            facilities to monitor our regulatory compliance or compliance with our quality agreements with our
            customers. There are significant risks at each stage of the regulatory scheme for our customers.</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory
            agencies may in the future take action against us or our customers for failure to comply with applicable
            regulations governing clinical trials and the development and testing of therapeutic products. Failure by us
            or by our customers to comply with the requirements of these regulatory authorities, including without
            limitation, remediating any inspectional observations to the satisfaction of these regulatory authorities,
            could result in warning letters, product recalls or seizures, monetary sanctions, injunctions to halt
            manufacture and distribution, restrictions on our operations, civil or criminal sanctions, or withdrawal of
            existing or denial of pending approvals, including those relating to products or facilities. In addition,
            such a failure could expose us to contractual or product liability claims, contractual claims from our
            customers, including claims for reimbursement for lost or damaged active pharmaceutical ingredients, as well
            as ongoing remediation and increased compliance costs, any or all of which could be significant.</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            are also subject to a variety of federal, state, local and international laws and regulations that govern,
            among other things, the importation and exportation of products, the handling, transportation and
            manufacture of substances that could be classified as hazardous, and our business practices in the U.S. and
            abroad such as anti-corruption and anti-competition laws. Any noncompliance by us with applicable laws and
            regulations or the failure to maintain, renew or obtain necessary permits and licenses could result in
            criminal, civil and administrative penalties and could have an adverse effect on our results of
            operations.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increasing
            scrutiny and changing expectations from investors, lenders, customers, government regulators and other
            market participants with respect to our Environmental, Social and Governance (&#8220;ESG&#8221;) policies
            and activities may impose additional costs on us or expose us to additional risks.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies
            across all industries and around the globe are facing increasing scrutiny relating to their ESG policies,
            initiatives and activities by investors, lenders, customers, government regulators and other market
            participants. In particular, these constituencies are increasingly focusing on environmental stewardship,
            including climate change, water use, deforestation, </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">waste,
            and other sustainability concerns, as well as diversity and inclusion, workplace conduct, support for local
            communities, and other human capital and social issues. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There
            is no guarantee that any ESG or sustainability goals set forth in our ESG initiatives will be achieved on
            the desired timeframe or at all, and the achievement of any such goals may require the incurrence of
            additional costs or the implementation of operational changes, any of which could adversely affect the
            Company&#8217;s results of operations.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally,
            changes in legal and regulatory requirements related to ESG have been issued in the E.U., its Member States
            and other countries, particularly with respect to climate change, emission reduction and environmental
            stewardship in the U.S., amongst other regulatory efforts, the SEC has proposed rules to enhance and
            standardize climate-related disclosures in public company filings. We expect legal, regulatory and reporting
            requirements related to ESG matters to continue to expand globally and increase our costs of
            compliance.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If
            we are unable to meet our ESG initiatives or evolving investor, industry, or customer expectations and
            standards, or we are perceived to have not responded adequately on any number of ESG matters, we risk damage
            to our brand and reputation, adverse impacts to our ability to secure government contracts, decreased
            desirability of our common stock to investors, or limited access to capital markets and other sources of
            financing.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_73"></div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks
            Related to Our Intellectual Property and Technology </span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If
            we are unable to obtain, maintain and enforce intellectual property protection for our current or future
            products, or if the scope of our intellectual property protection is not sufficiently broad, our ability to
            commercialize our products successfully and to compete effectively may be materially adversely
            affected.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            success depends on our ability to obtain and maintain patent and other intellectual property protection in
            the United States and other countries with respect to our current and future proprietary products. We rely
            upon a combination of patents and trade secret protection to protect the intellectual property related to
            our technology, manufacturing processes, and products. Our commercial success depends in part on obtaining
            and maintaining patent and trade secret protection for our current and future products, if any, and the
            methods used to manufacture them, as well as successfully defending and protecting such patents and trade
            secrets against third-party challenges. Our ability to stop third parties from making, using, selling,
            offering to sell or importing our products is dependent upon the extent to which we have rights under valid
            and enforceable patents and other intellectual property that covers these activities.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            patent prosecution process is expensive and time consuming, and we may not be able to file and prosecute all
            necessary or desirable patent applications at a reasonable cost or in a timely manner or in all
            jurisdictions where protection may be commercially advantageous. It is also possible that we may fail to
            identify patentable aspects of our research and development output before it is too late to obtain patent
            protection. In addition, we or our collaborators may only pursue, obtain or maintain patent protection in a
            limited number of countries. There is no assurance that all potentially relevant prior art relating to our
            patents and patent applications has been found. We may be unaware of prior art that could be used to
            invalidate or narrow the scope of an issued patent or prevent our pending patent applications from issuing
            as patents. This may be (1) because patent applications in the United States, Europe and many other non-U.S.
            jurisdictions are typically not published until 18 months after filing, or in some cases not at all, (2)
            because publications of discoveries in scientific literature lag behind actual discoveries, and (3) because
            we cannot be certain that we or our licensors were the first to make the inventions claimed in any of our
            owned or any in-licensed issued patents or pending patent applications, or that we or our licensors were the
            first to file for protection of the inventions set forth in our patents or patent applications. As a result,
            we may not be able to obtain or maintain protection for certain inventions. Even if patents do successfully
            issue, such patents may not adequately protect our intellectual property, provide exclusivity for our
            current or future products, prevent others from designing around our claims or otherwise provide us with a
            competitive advantage. We cannot offer any assurances about which, if any, patents will issue, the breadth
            of any such patents or whether any issued patents will be found invalid or unenforceable or will be
            threatened by third parties. In addition, third parties may challenge the validity, enforceability,
            ownership, inventorship or scope of any of our patents. Any successful challenge to any of our patents could
            deprive us of rights necessary for the successful commercialization of our current or future products and
            could impair or eliminate our ability to collect future revenue and royalties with respect to such products.
            If any of our patent applications with respect to our current or future products fail to result in issued
            patents, if their breadth or strength of protection is narrowed or threatened, or if they fail to provide
            meaningful exclusivity or competitive position, it could dissuade companies from collaborating with us or
            otherwise adversely affect our competitive position.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            patent positions of life science companies can be highly uncertain and involve complex legal and factual
            questions for which important legal principles remain unresolved. No consistent policy regarding the breadth
            of claims allowed in life science patents has emerged to date in the United States. The standards applied by
            the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) and foreign patent offices in
            granting patents are not always applied uniformly or predictably and can change. </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally,
            the laws of some foreign countries do not protect intellectual property rights to the same extent as the
            laws of the United States, and many companies have encountered significant problems in protecting and
            defending such rights in foreign jurisdictions. The legal systems of certain countries, particularly certain
            developing countries, do not favor the enforcement of patents and other intellectual property rights,
            particularly those relating to biotechnology, which could make it difficult for us to stop the infringement,
            misappropriation, or other violation of our patents or other intellectual property, including the
            unauthorized reproduction of our manufacturing or other know-how or the marketing of competing products in
            violation of our intellectual property rights generally. Any of these outcomes could impair our ability to
            prevent competition from third parties, which may have a material adverse effect on our business, financial
            condition, results of operations, cash flows and prospects.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further,
            the existence of issued patents does not guarantee our right to practice the patented technology or
            commercialize products covered by such a patent. Third parties may have or obtain rights to patents which
            they may use to prevent or attempt to prevent us from practicing our patented technology or commercializing
            our patented products. If any of these other parties are successful in obtaining valid and enforceable
            patents, and establishing our infringement of those patents, we could be prevented from selling our products
            unless we were able to obtain a license under such third-party patents, which may not be available on
            commercially reasonable terms or at all. In addition, third parties may seek approval to market their own
            products similar to or otherwise competitive with our products. In these circumstances, we may need to
            defend or assert our patents, including by filing lawsuits alleging patent infringement. In any of these
            types of proceedings, a court or agency of competent jurisdiction may find our patents invalid or
            unenforceable. Our competitors and other third parties may also be able to circumvent our patents by
            developing similar or alternative products in a non-infringing manner. Any of the foregoing could have a
            material adverse effect on our business, financial condition, results of operations, cash flows and
            prospects.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            addition, competitors may use our technologies in jurisdictions where we have not obtained or are unable to
            adequately enforce patent protection to develop their own products and further, may export otherwise
            infringing products to territories where we have patent protection, but enforcement is not as strong as that
            in the United States and Europe. These products may compete with our products, and our patents or other
            intellectual property rights may not be effective or sufficient to prevent them from competing with us.
            Proceedings to enforce our patent rights, whether or not successful, could result in substantial costs and
            divert our efforts and attention from other aspects of our business, could put our patents at risk of being
            invalidated or held unenforceable, or interpreted narrowly and our patent applications at risk of not
            issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits
            that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.
            Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to
            obtain a significant commercial advantage from the intellectual property that we develop, acquire or
            license.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual
            property that we own or in-license may be subject to a reservation of rights by one or more third parties.
            For example, one of our patents is co-owned with third parties and some of our patent rights in the future
            may be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party
            co-owners&#8217; interest in such patent rights, such co-owners may be able to license their rights to other
            third parties, including our competitors, and our competitors could market competing products and
            technology. In addition, we may need the cooperation of any such co-owners of such patent rights in order to
            enforce such patent rights against third parties, and such cooperation may not be provided to us. Any of the
            foregoing could have a material adverse effect on our competitive position, business, financial conditions,
            results of operations, and prospects.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover,
            the research resulting in certain of our patents and technology was funded in part by the U.S. government.
            As a result, the U.S. government has certain rights to such patent rights and technology, which include
            march-in rights. When new technologies are developed with government funding, in order to secure ownership
            of such patent rights, the recipient of such funding is required to comply with certain government
            regulations, including timely disclosing the inventions claimed in such patent rights to the U.S. government
            and timely electing title to such inventions. Additionally, the U.S. government generally obtains certain
            rights in any resulting patents, including a nonexclusive license authorizing the government to use the
            invention or to have others use the invention on its behalf. Accordingly, we or our licensors have granted
            the U.S. government a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have
            practiced for or on behalf of the United States, the inventions described in the patents and patent
            applications relating to such inventions. If the U.S. government decides to exercise these rights, it is not
            required to engage us as its contractor in connection with doing so. The government&#8217;s rights may also
            permit it to disclose our confidential information to third parties and to exercise march-in rights to use
            or allow third parties to use such government-funded technology. The government can exercise its march-in
            rights if it determines that action is necessary because we fail to achieve practical application of the
            government-funded technology, or because action is necessary to alleviate health or safety needs, to meet
            requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such
            inventions may be subject to certain requirements to manufacture products embodying such inventions in the
            United States. If we fail to comply with those requirements, we could lose our ownership of or other rights
            to any patents subject to such regulations. Any exercise by the government of any of the foregoing rights or
            by any third party of its reserved rights could have a material adverse effect on our competitive position,
            business, financial condition, results of operations, and prospects.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore,
            patents have a limited lifespan. In the United States, the unextended expiration of a patent is generally 20
            years after its non-provisional application filing date. Various extensions may be available, however, the
            life of a patent and the protection it affords is limited. Given the amount of time required for the
            development, testing, regulatory review and approval of new products, our patents protecting such candidates
            might expire before or shortly after such candidates are commercialized. If we encounter delays in obtaining
            regulatory approvals, the period of time during which we could market a product under patent protection
            could be further reduced. Even if patents covering our future products are obtained, once such patents
            expire, we may be vulnerable to competition from similar products. The launch of a similar version of one of
            our products would likely result in an immediate and substantial reduction in the demand for our product. As
            a result, our patent portfolio may not provide us with sufficient rights to exclude others from
            commercializing products similar or identical to ours. Any of the foregoing could have a material adverse
            effect on our business, financial condition, results of operations, cash flows and prospects.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If
            we are prevented from enforcing our intellectual property rights because of governmental regulatory policies
            or political pressure or action, our sales and profitability may be materially adversely affected.</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            ability to maintain and grow our product sales and profitability depends, in part, on our ability to
            maintain and enforce our patents and other intellectual property rights. Proposed actions to waive
            intellectual property protections for COVID-19 vaccines and associated technology, such as those under
            discussion at the World Trade Organization, which are supported by the U.S. government, may impact our
            ability to fully assert our intellectual property rights related to our Clea</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nCap&#174;
            pro</span><span
            style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">duct
            in connection with the production of COVID-19 vaccines. Further, these policy actions may complicate our
            analysis and decision-making with respect to both research and development and capital investment, given the
            potential for lower returns on those investments that could result from our inability to fully protect our
            intellectual property. If we are unable to successfully navigate these considerations, the future revenues
            and profitability of our business could be negatively impacted. We are unable to estimate the impact of
            these potential policies given that they remain undefined and their adoption is uncertain. </span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our
            internal computer systems, or those of our customers, collaborators or other contractors, have been and may
            in the future be subject to cyber-attacks or security breaches, which could result in a material disruption
            of our product development programs or otherwise adversely affect our business, financial condition, results
            of operations, cash flows and prospects.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite
            the implementation of security measures, our internal computer systems and those of our customers are
            vulnerable to damage from computer viruses and unauthorized access. Cyber-attacks are increasing in their
            frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks
            could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering
            and other means to affect service reliability and threaten the confidentiality, integrity and availability
            of information. Cyber-attacks also could include phishing attempts or e-mail fraud to cause unauthorized
            payments or information to be transmitted to an unintended recipient. A material cyber-attack or security
            breach could cause interruptions in our operations and could result in a material disruption of our business
            operations, damage to our reputation, financial condition, results of operations, cash flows and
            prospects.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            the ordinary course of our business, we collect and store sensitive data, including, among other things,
            personally identifiable information about our employees, intellectual property, and proprietary business
            information. Any cyber-attack or security breach that leads to unauthorized access, use or disclosure of
            personal or proprietary information could harm our reputation, cause us not to comply with federal and/or
            state breach notification laws and foreign law equivalents and otherwise subject us to liability under laws
            and regulations that protect the privacy and security of personal information. In addition, we could be
            subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental
            release or loss of information maintained in the information systems and networks of our company and our
            vendors, including personal information of our employees, and company and vendor confidential data. In
            addition, outside parties have previously attempted and may in the future attempt to penetrate our systems
            or those of our vendors or fraudulently induce our personnel or the personnel of our vendors to disclose
            sensitive information in order to gain access to our data and/or systems or make unauthorized payments to
            third parties. Like other companies, we have on occasion experienced, and will continue to experience, data
            security incidents involving access to company data, unauthorized payments and threats to our data and
            systems, including malicious codes and viruses, phishing, business email compromise attacks, or other
            cyber-attacks. The number and complexity of these threats continue to increase over time. If a material
            breach of our information technology systems or those of our vendors occurs, the market perception of the
            effectiveness of our security measures could be harmed and our reputation and credibility could be
            damaged.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            could be required to expend significant amounts of money and other resources to respond to these threats or
            breaches and to repair or replace information systems or networks and could suffer financial loss or the
            loss of valuable confidential information. In addition, we could be subject to regulatory actions and/or
            claims made by individuals and groups in private litigation involving privacy issues related to data
            collection and use practices and other data privacy laws and regulations, </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including
            claims for misuse or inappropriate disclosure of data, as well as unfair or deceptive practices. Although we
            develop and maintain systems and controls designed to prevent these events from occurring, and we have a
            process to identify and mitigate threats, the development and maintenance of these systems, controls and
            processes is costly and requires ongoing monitoring and updating as technologies change and efforts to
            overcome security measures become increasingly sophisticated. Moreover, despite our efforts, the possibility
            of these events occurring cannot be eliminated entirely and there can be no assurance that any measures we
            take will prevent cyber-attacks or security breaches that could adversely affect our business, financial
            condition, results of operations, cash flows and prospects.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If
            we are unable to protect the confidentiality of our proprietary information, the value of our technology and
            products could be materially adversely affected.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            also may rely on trade secrets to protect our technology, especially where we do not believe patent
            protection is appropriate or obtainable. To maintain the confidentiality of trade secrets and other
            proprietary information, we enter into confidentiality agreements with our employees, consultants,
            contractors, collaborators, CDMOs, CROs and others upon the commencement of their relationships with us.
            These agreements require that all confidential information developed by the individual or entity or made
            known to the individual or entity by us during the course of the individual&#8217;s or entity&#8217;s
            relationship with us be kept confidential and not disclosed to third parties. Our agreements with employees
            as well as our personnel policies also generally provide that any inventions conceived by the individual in
            the course of rendering services to us shall be our exclusive property or that we may obtain full rights to
            such inventions at our election. However, trade secrets are difficult to protect. Although we use reasonable
            efforts to protect our trade secrets, our employees, consultants, contractors, collaborators, CDMOs, CROs
            and others may unintentionally or willfully disclose our information to competitors. We also face the risk
            that present or former employees could continue to hold rights to intellectual property used by us, demand
            the registration of intellectual property rights in their name, and seek payment of damages for our use of
            such intellectual property.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enforcing
            a claim that a third party illegally obtained or is using any of our trade secrets is expensive and time
            consuming, and the outcome is unpredictable. We may not have adequate remedies in the event of unauthorized
            use or disclosure of our trade secrets or other proprietary information in the case of a breach of any such
            agreements and our trade secrets and other proprietary information could be disclosed to third parties,
            including our competitors. Many of our partners also collaborate with our competitors and other third
            parties. The disclosure of our trade secrets to our competitors, or more broadly, would impair our
            competitive position and may materially harm our business, financial condition, results of operations, cash
            flows and prospects. Costly and time-consuming litigation could be necessary to enforce and determine the
            scope of our rights, and failure to maintain trade secret protection could adversely affect our competitive
            business position. The enforceability of confidentiality agreements may vary from jurisdiction to
            jurisdiction. Courts outside the United States are sometimes less willing to protect trade secrets.
            Moreover, our competitors may independently develop substantially equivalent or superior knowledge, methods
            and know-how, and the existence of our own trade secrets affords no protection against such independent
            discovery.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We
            may become involved in lawsuits to protect or enforce our patents, which could be expensive, time-consuming
            and unsuccessful and could result in a court or administrative body finding our patents to be invalid or
            unenforceable.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even
            if the patent applications we own or license are issued, third parties may challenge or infringe upon our
            patents. To counter infringement, we may be required to file infringement claims, which can be expensive and
            time-consuming. In patent litigation in the United States, defendant counterclaims alleging invalidity or
            unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any
            of several statutory requirements, including novelty, non-obviousness (or inventive step), written
            description or enablement. In addition, patent validity challenges may, under certain circumstances, be
            based upon non-statutory obviousness-type double patenting, which, if successful, could result in a finding
            that the claims are invalid for obviousness-type double patenting or the loss of patent term if a terminal
            disclaimer is filed to obviate a finding of obviousness-type double patenting. Grounds for an
            unenforceability assertion could be an allegation that someone connected with prosecution of the patent
            withheld information material to patentability from the USPTO, or made a misleading statement, during
            prosecution.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third
            parties may raise similar claims before administrative bodies in the United States or abroad, even outside
            the context of litigation. Such mechanisms include re-examination, post-grant review, </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter
            partes</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign
            jurisdictions (e.g., opposition proceedings). Such proceedings could result in the revocation or
            cancellation of or amendment to our patents in such a way that they no longer cover our current or future
            products or provide any competitive advantage. The outcome following legal assertions of invalidity and
            unenforceability is unpredictable. If a third party were to prevail on a legal assertion of invalidity or
            unenforceability, we could lose part or all of the patent protection on one or more of our current or future
            products, which could result in our competitors and other third parties using our technology to compete with
            us. Such a loss of patent protection could have a material adverse impact on our business, financial
            condition, results of operations, cash flows and prospects.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference
            proceedings, or other similar enforcement and revocation proceedings, provoked by third parties or brought
            by us may be necessary to determine the priority of inventions with respect to our patents or patent
            applications. An unfavorable outcome could require us to cease using the related technology or to attempt to
            license rights to it from the prevailing party. Our business could be harmed if the prevailing party does
            not offer us a license on commercially reasonable terms. Our defense of litigation or interference
            proceedings may fail and, even if successful, may result in substantial costs and distract our management
            and other employees. We may not be able to prevent, alone or with our licensors, infringement,
            misappropriation or other violation of our intellectual property rights, particularly in countries where the
            laws may not protect those rights as fully as in the United States.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            an infringement proceeding, even one initiated by us, there is a risk that a court will decide that our
            patents are not valid and that we do not have the right to stop the other party from using the inventions
            they describe. There is also the risk that, even if the validity of such patents is upheld, the court will
            refuse to stop the other party on the ground that such other party&#8217;s activities do not infringe our
            rights to these patents.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some
            of our competitors may be able to sustain the costs of complex patent litigation more effectively than we
            can because they have substantially greater resources. In addition, any uncertainties resulting from the
            initiation and continuation of any litigation could have a material adverse effect on our ability to raise
            the funds necessary to continue our operations. In addition, patent holding companies that focus solely on
            extracting royalties and settlements by enforcing patent rights may target us, especially as we gain greater
            visibility and market exposure as a public company.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An
            adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our
            patents against competitors, affect our ability to receive royalties or other licensing consideration from
            our licensees, and may curtail or preclude our ability to exclude third parties from making, using and
            selling similar or competitive products. Any of these occurrences could have a material adverse effect on
            our business, financial condition, results of operations, cash flows and prospects.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If
            we are sued for infringing, misappropriating, or otherwise violating intellectual property rights of third
            parties, such litigation could be costly and time consuming and could prevent or delay us from developing or
            commercializing our current or future products.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            products may infringe on, or be accused of infringing on, one or more claims of an issued patent or may fall
            within the scope of one or more claims in a published patent application that may be subsequently issued and
            to which we do not hold a license or other rights.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because
            patent applications in the United States and many foreign jurisdictions are typically not published until 18
            months after filing, or in some cases not at all, and publications in the scientific literature often lag
            behind actual discoveries, we cannot be certain that others have not filed patent applications for
            technology covered by our issued patents or our pending applications, or that we were the first to invent
            the technology. Others, including our competitors, may have filed, and may in the future file, patent
            applications covering technology similar to ours. Any such patent application may have priority over our
            patent applications or patents, which could further require us to obtain rights to issued patents by others
            covering such technologies. If another party has filed a U.S. patent application on inventions similar to
            ours, we may have to participate in an interference proceeding declared by the USPTO to determine priority
            of invention in the United States. The costs of these proceedings could be substantial, and it is possible
            that such efforts would be unsuccessful if, unbeknownst to us, the other party had independently arrived at
            the same or similar invention prior to our own invention, resulting in a loss of our U.S. patent position
            with respect to such inventions.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally,
            pending patent applications that have been published can, subject to certain limitations, be later amended
            in a manner that could cover our current or future products or the use of our current or future products.
            After issuance, the scope of patent claims remains subject to construction based on interpretation of the
            law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of
            the relevance or the scope of a patent or a pending application may be incorrect. In addition, third parties
            may obtain patents in the future and claim that use of our technologies infringes upon these patents. These
            third parties could bring claims against us or our collaborators that would cause us to incur substantial
            expenses and, if successful against us, could cause us to pay substantial damages.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            life sciences industry has produced a proliferation of patents, and it is not always clear to industry
            participants, including us, which patents cover various types of products or methods of use. Because the
            patent granting process is imperfect, the manufacture, distribution, or sale of our products may require us
            to challenge intellectual property rights by third parties that we believe to have been improperly granted.
            The coverage of patents is subject to interpretation by the courts, and the interpretation is not always
            uniform. If we are sued for patent infringement, we would need to demonstrate that our products or methods
            of use either do not infringe the patent claims of the relevant patent and/or that the patent claims are
            invalid or unenforceable, and we may not be able to do this. Proving invalidity, in particular, is difficult
            since it requires a showing of clear and convincing evidence in trial court litigation to overcome the
            presumption of validity enjoyed by issued patents. Third parties have, and may </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in
            the future have, U.S. and non-U.S. issued patents and pending patent applications that may cover our current
            or future products. Such a third party may claim that we or our manufacturing or commercialization partners
            are using inventions covered by the third party&#8217;s patent rights and may go to court or a tribunal to
            stop us from engaging in our normal operations and activities, including making or selling our current or
            future products. In the event that any of these patent rights were asserted against us, we believe that we
            have defenses against any such action, including that such patents would not be infringed by our current or
            future products and/or that such patents are not valid. However, if any such patent rights were to be
            asserted against us and our defenses to such assertion were unsuccessful, unless we obtain a license to such
            patents, we could be liable for damages, which could be significant and include treble damages and
            attorneys&#8217; fees if we are found to willfully infringe such patents, and we could be precluded from
            commercializing any future products that were ultimately held to infringe such patents, any of which could
            have a material adverse effect on our business, financial condition, results of operations, cash flows and
            prospects.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If
            we are found to infringe the patent rights of a third party, or in order to avoid potential claims, we or
            our collaborators may choose or be required to seek a license from a third party and be required to pay
            license fees or royalties or both. These licenses may not be available on reasonable terms, or at all. In
            particular, any of our competitors that control intellectual property that we are found to infringe may be
            unwilling to provide us a license under any terms. Even if we or our collaborators were able to obtain a
            license, the rights may be nonexclusive, which could result in our competitors gaining access to the same
            intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to
            cease some aspect of our business operations, if, as a result of actual or threatened patent infringement
            claims, we or our collaborators are unable to enter into licenses on acceptable terms. In addition, we could
            be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to
            have willfully infringed a patent. Further, if a patent infringement suit is brought against us or our
            third-party service providers and if we are unable to successfully obtain rights to required third-party
            intellectual property, we may be required to expend significant time and resources to redesign our current
            or future products, or to develop or license replacement technology, all of which may not be feasible on a
            technical or commercial basis, and may delay or require us to abandon our development, manufacturing or
            sales activities relating to our current or future products. A finding of infringement could prevent us from
            commercializing our future products or force us to cease some of our business operations, which could harm
            our business. Claims that we have misappropriated the confidential information or trade secrets of third
            parties could have a similar negative impact on our business. Any of the foregoing could have a material
            adverse effect on our business, financial condition, results of operations, cash flows and prospects.</span>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual
            property litigation and other proceedings could cause us to spend substantial resources and distract our
            personnel from their normal responsibilities.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even
            if resolved in our favor, intellectual property litigation or other legal proceedings relating to our, our
            licensors&#8217; or other third parties&#8217; intellectual property claims may cause us to incur
            significant expenses and could distract our personnel from their normal responsibilities. Patent litigation
            and other proceedings may also absorb significant management time. If not resolved in our favor, litigation
            may require us to pay any portion of our opponents&#8217; legal fees. Such litigation or proceedings could
            substantially increase our operating losses and reduce the resources available for development activities or
            any future sales, marketing, or distribution activities. We may not have sufficient financial or other
            resources to conduct such litigation or proceedings adequately. Our competitors or other third parties may
            be able to sustain the cost of such litigation and proceedings more effectively than we can because of their
            substantially greater resources. Uncertainties resulting from our participation in patent litigation or
            other proceedings could have a material adverse effect on our ability to compete in the marketplace.
            Furthermore, because of the substantial amount of discovery required in certain jurisdictions in connection
            with intellectual property litigation, there is a risk that some of our confidential information could be
            compromised by disclosure during this type of litigation. There could also be public announcements of the
            results of hearings, motions or other interim proceedings or developments. If securities analysts or
            investors perceive these results to be negative, the perceived value of our current or future products or
            intellectual property could be diminished. Accordingly, the market price of our Class A common stock may
            decline. Uncertainties resulting from the initiation and continuation of patent litigation or other
            proceedings could have a material adverse effect on our business, financial condition, results of
            operations, and prospects.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If
            we fail to comply with our obligations under any license agreements, disagree over contract interpretation,
            or otherwise experience disruptions to our business relationships with our licensors, we could lose
            intellectual property rights that are necessary to our business.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            rely, in part, on intellectual property and technology which we have in-licensed. We may also need to obtain
            additional licenses in the future to advance our research or allow commercialization of our future products
            and it is possible that we may be unable to do so at a reasonable cost or on reasonable terms, if at all.
            Moreover, such licenses may not provide exclusive rights to use such intellectual property and technology in
            all relevant fields of use and in all territories in which we may wish to develop or commercialize our
            future products.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            addition, our existing license agreements impose, and any future license agreements we enter into may
            impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing,
            insurance, patent prosecution and enforcement or other obligations on us. Our license agreements, and any
            future license agreement we enter into, may also impose restrictions on our ability to license certain of
            our intellectual property to third parties or to develop or commercialize certain current or future products
            or technologies. In spite of our best efforts, our counterparties may conclude that we have breached our
            obligations under our agreements, or that we have used the intellectual property licensed to us in an
            unauthorized manner, in which case, we may be required to pay damages and the counterparty may have the
            right to terminate the agreement. Any of the foregoing could result in us being unable to develop,
            manufacture and sell products that are covered by the licensed intellectual property or technology, or
            enable a competitor to gain access to the licensed intellectual property or technology.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            might not have the necessary rights or the financial resources to develop, manufacture or market our current
            or future products without the rights granted under our license agreements, and the loss of sales or
            potential sales in current or future products covered by such license agreements could have a material
            adverse effect on our business, financial condition, results of operations, cash flows and prospects.</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes
            may arise regarding intellectual property subject to license agreements, including:</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            scope of rights granted under the license agreement and other interpretation related issues;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            extent to which our technology and processes infringe on intellectual property of the licensor that is not
            subject to the license agreement;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            sublicensing of patent and other rights under our collaborative development relationships;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our
            diligence obligations under the license agreement and what activities satisfy those diligence
            obligations;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our
            financial obligations under the license agreement;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            inventorship and ownership of inventions and know-how resulting from the joint creation or use of
            intellectual property by our licensors and us and our partners; and</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            priority of invention of patented technology.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            addition, the agreements under which we currently license intellectual property or technology to or from
            third parties are complex, and certain provisions in such agreements may be susceptible to multiple
            interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what
            we believe to be the scope of our rights to the relevant intellectual property or technology, or increase
            what we believe to be our financial or other obligations under the relevant agreement, either of which could
            have a material adverse effect on our business, financial condition, results of operations, and prospects.
            Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to
            maintain our current licensing arrangements on commercially acceptable terms, we may be unable to
            successfully develop and commercialize the affected future products.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            some cases, we may not have primary control over prosecution, maintenance, enforcement and defense of
            patents and patent applications that we have in-licensed from third parties, and instead we rely on our
            licensors for these activities. We cannot be certain that such activities have been or will be conducted in
            compliance with applicable laws and regulations or in a manner consistent with the best interests of our
            business. If we do undertake any enforcement of our in-licensed patents or defense of any claims asserting
            the invalidity of such patents, such actions may be subject to the cooperation of our licensors or other
            third parties. If our licensors or other third parties fail to prosecute, maintain, enforce and defend
            intellectual property licensed to us, or lose their own rights to such intellectual property, the rights we
            have licensed may be impaired or eliminated and our ability to develop and commercialize any of our products
            that are subject to such rights could be adversely affected.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-licensing
            or acquisition of third-party intellectual property is a competitive area and a number of more established
            companies are also pursuing strategies to in-license or acquire third-party intellectual property rights
            that we may consider attractive or necessary for our business. These companies may have a competitive
            advantage over us due to their size, cash resources and greater capabilities with respect to clinical
            development and commercialization. Furthermore, companies that perceive us as a competitor may be unwilling
            to assign or license rights to us. If we are unable to successfully obtain rights to required third-party
            intellectual property rights or maintain the existing intellectual property rights we have on reasonable
            terms or at all, we may have to abandon development of the relevant program or current or future product and
            our business, financial condition, results of operations, cash flows and prospects could suffer.</span>
    </div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes
            to the patent law in the United States and other jurisdictions could increase the uncertainties and costs
            surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents,
            thereby impairing our ability to protect our technologies and current or future products.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            is the case with other life sciences companies, our success is heavily dependent on intellectual property,
            particularly patents. Obtaining and enforcing patents in the life sciences industry involves both
            technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes
            in either the patent laws or in interpretations of patent laws in the United States and other countries may
            increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement
            or defense of issued patents.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For
            example, the Leahy-Smith America Invents Act (the &#8220;America Invents Act&#8221;), was signed into law on
            September 16, 2011, and many of the substantive changes became effective on March 16, 2013. The America
            Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of
            our patent applications and the enforcement or defense of our issued patents, all of which could have a
            material adverse effect on our business, financial condition, results of operations, and prospects.
            Specifically, the America Invents Act reforms United States patent law in part by changing the U.S. patent
            system from a &#8220;first to invent&#8221; system to a &#8220;first inventor to file&#8221; system. Under a
            &#8220;first inventor to file&#8221; system, assuming the other requirements for patentability are met, the
            first inventor to file a patent application generally will be entitled to the patent on an invention
            regardless of whether another inventor was the first to invent the invention. This will require us to be
            cognizant going forward of the time from invention to filing of a patent application and be diligent in
            filing patent applications. Circumstances may arise that could prevent us from promptly filing patent
            applications on our inventions and allow third parties to file patents claiming our inventions before we are
            able to do so. The America Invents Act also includes a number of significant changes that affect the way
            patent applications will be prosecuted and may also affect patent litigation. These include allowing
            third-party submission of prior art to the USPTO during patent prosecution and additional procedures to
            attack the validity of a patent by the USPTO administered post grant proceedings, including reexamination
            proceedings, </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter
            partes</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            review, post grant review and derivation proceedings. These adversarial proceedings at the USPTO review
            patent claims without the presumption of validity afforded to U.S. patents in lawsuits in U.S. federal
            courts, and use a lower burden of proof than used in litigation in U.S. federal courts. Therefore, it is
            generally considered easier for a competitor or third party to have a U.S. patent invalidated in a USPTO
            post-grant review or </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter
            partes</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            review proceeding than in a litigation in a U.S. federal court.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            addition, the patent positions of companies in the life sciences industry are particularly uncertain. Recent
            U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances
            and weakened the rights of patent owners in certain situations. This combination of events has created
            uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future
            actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents
            could change in unpredictable ways. In addition, the complexity and uncertainty of European patent laws have
            also increased in recent years. Complying with these laws and regulations could have a material adverse
            effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in
            the future.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining
            and maintaining our patent protection depends on compliance with various procedural, documentary, fee
            payment and other requirements imposed by governmental patent agencies, and our patent protection could be
            reduced or eliminated for noncompliance with these requirements.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic
            maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and patent
            applications will be due to be paid to the USPTO and various government patent agencies outside the United
            States over the lifetime of our patents and patent applications and any patent rights we may own or license
            in the future. Additionally, the USPTO and various government patent agencies outside the United States
            require compliance with a number of procedural, documentary, fee payment and other similar provisions during
            the patent application process. In certain cases, an inadvertent lapse can be cured by payment of a late fee
            or by other means in accordance with rules applicable to the particular jurisdiction. However, there are
            situations in which noncompliance can result in abandonment or lapse of the patent or patent application,
            resulting in partial or complete loss of patent rights in the relevant jurisdiction. If we or our licensors
            fail to maintain the patents and patent applications covering or otherwise protecting our current or future
            products, it could have a material adverse effect on our business. In addition, to the extent that we have
            responsibility for taking any action related to the prosecution or maintenance of patents or patent
            applications in-licensed from a third party, any failure on our part to maintain the in-licensed
            intellectual property could jeopardize our rights under the relevant license and may have a material adverse
            effect on our business, financial condition, results of operations, cash flows and prospects.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We
            may be subject to claims by third parties asserting that our employees, consultants, independent contractors
            or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own
            intellectual property and proprietary technology.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many
            of our employees were previously employed at universities or other life science, biotechnology or
            pharmaceutical companies, including our competitors or potential competitors. We try to ensure that our
            employees do not use the proprietary information or know-how of others in their work for us. We may,
            however, be subject to claims that we or these employees have inadvertently or otherwise used or disclosed
            intellectual property, trade secrets or other proprietary information of any such employee&#8217;s former
            employer or that patents and applications we have filed to protect inventions of these individuals, even
            those related to one or more of our current or future products, are rightfully owned by their former or
            concurrent employer. Litigation may be necessary to defend against these claims. Even if we are successful
            in defending ourselves, such litigation could result in substantial costs to us or be distracting to our
            management. If we fail to defend any such claims, in addition to paying monetary damages, we may lose
            valuable intellectual property rights or personnel or we could be required to obtain a license from such
            third party to commercialize our technology or products. Such a license may not be available on an exclusive
            basis or on commercially reasonable terms or at all.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            addition, while we typically require our employees, consultants and independent contractors who may be
            involved in the development of intellectual property to execute agreements assigning such intellectual
            property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops
            intellectual property that we regard as our own, or such agreements may be breached or alleged to be
            ineffective, and the assignment may not be self-executing, which may result in claims by or against us
            related to the ownership of such intellectual property or may result in such intellectual property becoming
            assigned to third parties. If we fail in enforcing or defending any such claims, in addition to paying
            monetary damages, we may lose valuable intellectual property rights. Even if we are successful in
            prosecuting or defending against such claims, litigation could result in substantial costs and be a
            distraction to our senior management and scientific personnel. Any of the foregoing could have a material
            adverse effect on our business, financial condition, results of operations, cash flows and prospects.</span>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We
            may not be able to protect our intellectual property and proprietary rights throughout the world.</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing,
            prosecuting, and defending patents on current or future products in all countries throughout the world would
            be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent
            as the laws of the United States. For example, patent scope or coverage varies between countries based on
            the differences between the respective patent laws in each country or jurisdiction. Consequently, we may not
            be able to prevent third parties from practicing our inventions in all countries outside the United States,
            or from selling or importing products made using our inventions in and into the United States or other
            jurisdictions. Third parties may use our technologies in jurisdictions where we have not obtained or are
            unable to adequately enforce patent protection to develop their own products and, further, may export
            otherwise infringing products to territories where we have patent protection but enforcement is not as
            strong as that in the United States. These products may compete with our products, and our patents or other
            intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many
            companies have encountered significant problems in protecting and defending intellectual property rights in
            foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do
            not favor the enforcement of patents, trade secrets, and other intellectual property protection,
            particularly those relating to biotechnology products, which could make it difficult for us to stop the
            infringement of our patents or marketing of competing products in violation of our intellectual property and
            proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in
            foreign jurisdictions could result in substantial costs and divert our efforts and attention from other
            aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could
            put our patent applications at risk of not issuing, and could provoke third parties to assert claims against
            us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any,
            may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and
            proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the
            intellectual property that we develop or license.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many
            countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to
            third parties. In addition, many countries limit the enforceability of patents against government agencies
            or government contractors. In these countries, the patent owner may have limited remedies, which could
            materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to
            third parties with respect to any patents relevant to our business, our competitive position may be
            impaired, and our business, financial condition, results of operations, cash flows and prospects may be
            adversely affected.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We
            rely on confidentiality agreements that, if breached, may be difficult to enforce and could have a material
            adverse effect on our business and competitive position.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            policy is to enter agreements relating to the non-disclosure and non-use of confidential information with
            third parties, including our contractors, consultants, advisors and research collaborators, as well as
            agreements that purport to require the disclosure and assignment to us of the rights to the ideas,
            developments, discoveries and inventions of our employees and consultants while we employ them. However,
            these agreements can be difficult and costly to enforce. Moreover, to the extent that our contractors,
            consultants, advisors and research collaborators apply or independently develop intellectual property in
            connection with any of our projects, disputes may arise as to the proprietary rights to the intellectual
            property. If a dispute arises, a court may determine that the right belongs to a third party, and
            enforcement of our rights can be costly and unpredictable. In addition, we rely on trade secrets and
            proprietary know-how that we seek to protect in part by confidentiality agreements with our employees,
            contractors, consultants, advisors or others. Despite the protective measures we employ, we still face the
            risk that:</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">these
            agreements may be breached;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">these
            agreements may not provide adequate remedies for the applicable type of breach; or</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our
            trade secrets or proprietary know-how will otherwise become known.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any
            breach of our confidentiality agreements or our failure to effectively enforce such agreements would have a
            material adverse effect on our business and competitive position.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If
            our trademarks, trade dress, and trade names are not adequately protected, we may not be able to build name
            recognition in our markets of interest and our business, financial condition, results of operations, cash
            flows and prospects may be adversely affected.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            trademarks, trade dress, or trade names may be challenged, infringed, circumvented or declared generic or
            determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and
            trade names or may be forced to stop using these names or marks which we need for name recognition by
            potential partners or customers in our markets of interest. During trademark registration proceedings, we
            may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be
            unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign
            jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek
            to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks,
            and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on
            our trademarks and trade names, we may not be able to compete effectively and our business, financial
            condition, results of operations, cash flows and prospects may be adversely affected.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual
            property rights do not necessarily address all potential threats.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            degree of future protection afforded by our proprietary and intellectual property rights is uncertain
            because such rights offer only limited protection and may not adequately protect our rights or permit us to
            gain or keep our competitive advantage. For example:</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others
            may be able to develop products that are similar to, or better than, our current or future products in a way
            that is not covered by the claims of the patents we license or may own currently or in the future;</span>
    </div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we,
            or our licensing partners or current or future collaborators, might not have been the first to make the
            inventions covered by issued patents or pending patent applications that we license or may own currently or
            in the future;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we,
            or our licensing partners or current or future collaborators, might not have been the first to file patent
            applications for certain of our or their inventions;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our
            pending owned or in-licensed patent applications may not lead to issued patents;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we
            may choose not to file a patent for certain trade secrets or know-how, and a third party may subsequently
            file a patent covering such intellectual property;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our
            competitors or other third parties might conduct research and development activities in countries where we
            do not have patent rights and then use the information learned from such activities to develop competitive
            products for sale in our major commercial markets;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it
            is possible that there are prior public disclosures that could invalidate our or our licensors&#8217;
            patents;</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            patents of third parties or pending or future applications of third parties, if issued, may have an adverse
            effect on our business;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any
            patents that we obtain may not provide us with any competitive advantages or may ultimately be found not to
            be owned by us, invalid or unenforceable; or</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we
            may not develop additional proprietary technologies that are patentable.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should
            any of these events occur, they could significantly harm our business, financial conditions, results of
            operations, cash flows and prospects.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_76"></div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks
            Related to Our Indebtedness</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our
            existing level of indebtedness may increase and adversely affect our business and growth prospects, growth
            prospects, and financial condition, as well as our ability to raise additional capital on favorable terms,
            which could, in turn, limit our ability to develop or acquire new products, services, technologies and
            methodologies.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            of December&#160;31, 2023, we had total current and long-term indebtedness outstanding of approximately
            $524.1 million, including term loans of $533.1 million, and unamortized debt issuance costs of $9.0 million.
            We may incur significant additional indebtedness in the future. If we increase our current indebtedness
            levels, the risks related to our indebtedness as set forth herein could intensify.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            indebtedness, or any additional indebtedness we may incur, could require us to divert funds identified for
            other purposes for debt service and impair our liquidity position. If we cannot generate sufficient cash
            flow from operations to service our debt, we may need to refinance our debt, dispose of assets or issue
            equity to obtain necessary funds. We do not know whether we will be able to take any of these actions on a
            timely basis, on terms satisfactory to us or at all.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            indebtedness, the cash flow needed to satisfy our debt and the covenants contained in the Credit Agreement
            have important consequences, including:</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limiting
            funds otherwise available for financing our capital expenditures by requiring us to dedicate a portion of
            our cash flows from operations to the repayment of debt and the interest on this debt;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limiting
            our ability to incur or prepay existing indebtedness, pay dividends or distributions, dispose of assets,
            engage in mergers and consolidations, make acquisitions or other investments and make changes in the nature
            of the business, among other things;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">making
            us more vulnerable to rising interest rates, as certain of our borrowings, including borrowings under the
            Credit Agreement, bear variable rates of interest; and</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">making
            us more vulnerable in the event of a downturn in our business.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            level of indebtedness may place us at a competitive disadvantage to our competitors that are not as highly
            leveraged. Fluctuations in interest rates can increase borrowing costs. Increases in interest rates may
            directly impact the amount of interest we are required to pay and reduce earnings accordingly. In addition,
            tax laws, including the disallowance or deferral of tax deductions for interest paid on outstanding
            indebtedness, could have an adverse effect on our liquidity and our business, financial condition, results
            of operations, cash flows and prospects. Further, our Credit Agreement contains customary affirmative and
            negative covenants and certain restrictions on operations that could impose operating and financial
            limitations and restrictions on us, including restrictions on our ability to enter into particular
            transactions and to engage in other actions that we may believe are advisable or necessary for our
            business.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable
            rate indebtedness that we have incurred or may in the future incur will subject us to interest rate risk,
            which could cause our debt service obligations to increase significantly.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain
            borrowings under our Credit Agreement bear variable rates of interest. Increase in interest rates directly
            increase the amount of interest we are required to pay, and negatively impacts our net income and cash
            flows, including cash available for servicing our indebtedness more generally.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We
            may not be able to generate sufficient cash flow to service all of our indebtedness and may be forced to
            take other actions to satisfy our debt service obligations, which actions may not be adequate or may impose
            additional restrictions on us.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            ability to make scheduled debt service payments or to refinance outstanding debt obligations depends on our
            financial and operating performance, which is subject to prevailing economic, industry and competitive
            conditions and certain financial, business, economic and other factors beyond our control, including those
            discussed under &#8220;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks
            Related to Our Business and Strategy</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;
            above. We may not be able to maintain a sufficient level of cash flow from operating activities to permit us
            to pay the principal, premium, if any, and interest on our indebtedness. If we cannot meet our debt service
            obligations, the holders of our indebtedness would have the right to accelerate such indebtedness and, to
            the extent such indebtedness is secured, foreclose on our assets. This could have serious consequences to
            our business, financial condition and results of operations and could cause us to become bankrupt or
            insolvent.</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">
        </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even
            if this does not occur, any failure to make payments of interest and principal on our outstanding
            indebtedness on a timely basis would likely result in a reduction of our creditworthiness, which would also
            harm our ability to incur additional indebtedness.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If
            our cash flows and other capital resources are insufficient to fund our debt service obligations, we may be
            forced to reduce or delay capital expenditures and acquisitions, sell assets, raise additional capital or
            seek to restructure or refinance our indebtedness. If we issue additional equity to repay all or a portion
            of our indebtedness, our shareholders may experience significant dilution of their equity interests. Any
            refinancing of our indebtedness could be at higher interest rates and may require us to comply with more
            onerous covenants, including the requirement to maintain specified liquidity or other ratios or restrictions
            on our ability to pay dividends or make acquisitions. If these alternative measures are not successful, we
            may be required to sell material assets or operations to attempt to meet our debt service obligations.
            Further, we may not be able to consummate these asset sales (including as a result of restrictions imposed
            on us under the Credit Agreement) or sell assets at prices and on terms that we believe are fair, and any
            proceeds that we do receive may not be adequate to meet any debt service obligations then due. </span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The
            terms of the financing documents governing our Credit Agreement restrict our current and future operations,
            particularly our ability to respond to changes or to take certain actions.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            financing documents governing our Credit Agreement contain a number of restrictive covenants that impose
            significant operating and financial restrictions on us and may limit our ability to engage in acts that may
            be in our long-term best interests, including restrictions on our ability to:</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur
            additional indebtedness;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur
            liens;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">merge,
            dissolve, liquidate, amalgamate, consolidate or sell all or substantially all of our assets;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">declare
            or pay certain dividends, payments or distribution or repurchase or redeem certain capital stock;</span>
    </div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">permit
            our subsidiaries to enter into agreements restricting their ability to pay dividends, make loans, incur
            liens and sell assets; and</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make
            certain investments.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These
            restrictions could limit, potentially significantly, our operational flexibility and affect our ability to
            finance our future operations or capital needs or to execute our business strategy.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_79"></div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks
            Related to Our Organizational Structure</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our
            principal asset is our interest in Maravai Topco Holdings LLC (&#8220;Topco LLC&#8221;), and, accordingly,
            we depend on distributions from Topco LLC to pay our taxes and expenses, including payments under the Tax
            Receivable Agreement. Topco LLC&#8217;s ability to make such distributions may be subject to various
            limitations and restrictions.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            are a holding company and have no material assets other than our ownership of equity interests in Topco LLC.
            As such, we have no independent means of generating revenue or cash flow, and our ability to pay our taxes,
            satisfy our obligations under the Tax Receivable Agreement and pay operating expenses or declare and pay
            dividends, if any, in the future depends on the financial results and cash flows of Topco LLC and its
            subsidiaries and distributions we receive from Topco LLC. There can be no assurance that Topco LLC and its
            subsidiaries will generate sufficient cash flow to distribute funds to us or that applicable state law and
            contractual restrictions, including negative covenants in debt instruments of Topco LLC and its
            subsidiaries, will permit such distributions.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Topco
            LLC is treated as a partnership for U.S. federal income tax purposes and, as such, is not subject to any
            entity-level U.S. federal income tax. For U.S. federal income tax purposes, taxable income of Topco LLC is
            allocated to the LLC Unitholders of Topco LLC, including us. Accordingly, we incur income taxes on our
            distributive share of any net taxable income of Topco LLC. Under the terms of the Topco LLC operating
            agreement (the &#8220;LLC Operating Agreement&#8221;), Topco LLC is obligated to make tax distributions to
            LLC Unitholders, including us. In addition to tax and dividend payments, we also incur expenses related to
            our operations, including obligations to make payments under the Tax Receivable Agreement. Due to the
            uncertainty of various factors, we cannot estimate the likely tax benefits we may realize as a result of our
            purchase of LLC Units in Topco LLC (the &#8220;LLC Units&#8221;) and LLC Unit exchanges, and the resulting
            amounts we are likely to pay out to LLC Unitholders pursuant to the Tax Receivable Agreement; however, such
            payments may be substantial. Under the LLC Operating Agreement, tax distributions shall be made on a pro
            rata basis among the LLC Unitholders, and will be calculated without regard to any applicable basis
            adjustment under Section 743(b) of The Internal Revenue Code (&#8220;the Code&#8221;).</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            expect Topco LLC will continue to make cash distributions to the owners of LLC Units in amounts sufficient
            to (1) fund all or part of their tax obligations in respect of taxable income allocated to them and (2)
            cover our operating expenses, including payments under the Tax Receivable Agreement.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However,
            Topco LLC&#8217;s ability to make such distributions may be subject to various limitations and restrictions,
            such as restrictions on distributions that would violate either any contract or agreement to which Topco LLC
            or its subsidiaries is then a party, including debt agreements, or any applicable law, or that would have
            the effect of rendering Topco LLC or its subsidiaries insolvent. In addition, effective for taxable years
            beginning after December 31, 2017, liability for adjustments to a partnership&#8217;s tax return may be
            imputed on the partnership itself in certain circumstances, absent an election to the contrary. Topco LLC
            may be subject to material liabilities pursuant to this legislation and related guidance if, for example,
            its calculations of taxable income are incorrect. If we do not have sufficient funds to pay tax or other
            liabilities or to fund our operations, we may have to borrow funds, which could materially adversely affect
            our liquidity and financial condition and subject us to various restrictions imposed by any such lenders. To
            the extent that we are unable to make payments under the Tax Receivable Agreement, such payments generally
            will be deferred and will accrue interest until paid. Nonpayment for a specified period, however, may
            constitute a breach of a material obligation under the Tax Receivable Agreement and therefore accelerate
            payments due under the Tax Receivable Agreement, unless, generally, such nonpayment is due to a lack of
            sufficient funds. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments
            under the Tax Receivable Agreement will be based on the tax reporting positions we determine. Although we
            are not aware of any issue that would cause the IRS to challenge existing tax basis, a tax basis increase or
            other tax attributes subject to the Tax Receivable Agreement, if any subsequent disallowance of tax basis or
            other benefits were so determined by the IRS, we would not be reimbursed for any payments previously made
            under the applicable Tax Receivable Agreement (although we would reduce future amounts otherwise payable
            under such Tax Receivable Agreement). In addition, the actual state or local tax savings we realize may be
            different than the amount of such tax savings we are deemed to realize under the Tax Receivable Agreement,
            which will be based on an assumed combined state and local tax rate applied to our reduction in taxable
            income as determined for U.S. federal income tax purposes as a result of the tax attributes subject to the
            Tax Receivable Agreement. As a result, payments could be made under the Tax Receivable Agreement in excess
            of the tax savings we realize in respect of the attributes to which the Tax Receivable Agreement
            relate.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conflicts
            of interest could arise between our shareholders and Maravai Life Sciences Holdings, LLC (&#8220;MLSH
            1&#8221;), which may impede business decisions that could benefit our shareholders.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MLSH
            1, which is controlled by GTCR, LLC (&#8220;GTCR&#8221;) and is the only holder of LLC Units other than us,
            has the right to consent to certain amendments to the LLC Operating Agreement, as well as to certain other
            matters. MLSH 1 may exercise these voting rights in a manner that conflicts with the interests of our
            shareholders. Circumstances may arise in the future when the interests of MLSH 1 conflict with the interests
            of our shareholders. As we control Topco LLC, we have certain obligations to MLSH 1 as an LLC Unitholder in
            Topco LLC that may conflict with fiduciary duties our officers and directors owe to our shareholders. These
            conflicts may result in decisions that are not in the best interests of shareholders.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The
            Tax Receivable Agreement requires us to make cash payments to MLSH 1 and MLSH 2 in respect of certain tax
            benefits to which we may become entitled, and we expect that the payments we may be required to make could
            be substantial.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant
            to the Tax Receivable Agreement we are required to make cash payments to MLSH 1 and MLSH 2, collectively,
            equal to 85% of the tax benefits, if any, that we actually realize, or, in some circumstances, are deemed to
            realize, as a result of (i) certain increases in the tax basis of assets of Topco LLC and its subsidiaries
            resulting from purchases or exchanges of LLC Units, (ii) certain tax attributes related to the LLC Units
            held by the corporations that merged into our corporate structure as part of the Organizational Transactions
            (as discussed in Note 11 to our consolidated financial statements), Topco LLC and subsidiaries of Topco LLC
            that existed prior to our initial public offering and (iii) certain other tax benefits related to our
            entering into the Tax Receivable Agreement, including tax benefits attributable to payments that we make
            under the Tax </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivable
            Agreement. Any payments made by us to MLSH 1 and MLSH 2 under the Tax Receivable Agreement will generally
            reduce the amount of overall cash flow that might have otherwise been available to us. To the extent that we
            are unable to make payments under the Tax Receivable Agreement, such payments generally will be deferred and
            will accrue interest until paid. Nonpayment for a specified period, however, may constitute a breach of a
            material obligation under the Tax Receivable Agreement and therefore accelerate payments due under the Tax
            Receivable Agreement, unless, generally, such nonpayment is due to a lack of sufficient funds. Furthermore,
            our future obligation to make payments under the Tax Receivable Agreement could make us a less attractive
            target for an acquisition, particularly in the case of an acquirer that cannot use some or all of the tax
            benefits that may be deemed realized under the Tax Receivable Agreement. The payments under the Tax
            Receivable Agreement are also not conditioned upon MLSH 1 maintaining a continued ownership interest in
            Topco LLC. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating
            the amount and timing of our realization of tax benefits subject to the Tax Receivable Agreement is by its
            nature imprecise. The actual amount and timing of any payments under the Tax Receivable Agreement will vary
            depending upon a number of factors, including the timing of exchanges by MLSH 1, the amount of gain
            recognized by MLSH 1, the amount and timing of the taxable income we generate in the future and the federal
            tax rates then applicable. Accordingly, estimating the amount and timing of payments that may become due
            under the Tax Receivable Agreement is also by its nature imprecise. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            expect that the aggregate payments that we may be required to make under the Tax Receivable Agreement may be
            substantial. Assuming no material changes in the relevant tax law, we expect that probable future payments
            under the Tax Receivable Agreement relating to the purchase by Maravai LifeSciences Holdings, Inc. of LLC
            Units from MLSH 1 and the corresponding tax attributes to be approximately $7.1 million. This determination
            is based on our estimate of taxable income for the year ended December&#160;31, 2023. Future payments in
            respect of subsequent exchanges or financings and tax attributes relating to the purchase by the Company of
            LLC Units from MLSH 1 would be in addition to this amount and may be substantial. The foregoing numbers are
            merely estimates&#8212;the actual payments could differ materially. It is possible that future transactions
            or events could increase or decrease the actual tax benefits realized and the corresponding Tax Receivable
            Agreement payments. There may be a material negative effect on our liquidity if, as a result of timing
            discrepancies or otherwise, the payments under the Tax Receivable Agreement exceed the actual benefits we
            realize in respect of the tax attributes subject to the Tax Receivable Agreement and/or distributions to
            Maravai LifeSciences Holdings, Inc. by Topco LLC are not sufficient to permit Maravai LifeSciences Holdings,
            Inc. to make payments under the Tax Receivable Agreement after it has paid taxes. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments
            under the Tax Receivable Agreement will be based on the tax reporting positions that we determine. Although
            we are not aware of any issue that would cause the Internal Revenue Service (&#8220;IRS&#8221;) to challenge
            a tax basis increase or the availability of tax attributes of the corporations merged into our corporate
            structure as part of the Organizational Transactions, if any, we will not be reimbursed for any cash
            payments previously made to MLSH 1 and MLSH 2 pursuant to the Tax Receivable Agreement if any tax benefits
            initially claimed by us are subsequently disallowed, in whole or in part, by the IRS or other applicable
            taxing authority. For example, if the IRS later asserts that we did not obtain a tax basis increase or
            disallows (in whole or in part) the availability of Net Operating Losses (&#8220;NOLs&#8221;) due to a
            potential ownership change under Section 382 of the Internal Revenue Code (&#8220;IRC&#8221; or &#8220;the
            Code&#8221;), among other potential challenges, then we would not be reimbursed for any cash payments
            previously made to MLSH 1 and MLSH 2 pursuant to the Tax Receivable Agreement with respect to such tax
            benefits that we had initially claimed. Instead, any excess cash payments made by us pursuant to the Tax
            Receivable Agreement will be netted against any future cash payments that we might otherwise be required to
            make under the terms of the Tax Receivable Agreement. Nevertheless, any tax benefits initially claimed by us
            may not be disallowed for a number of years following the initial time of such payment or, even if
            challenged early, such excess cash payment may be greater than the amount of future cash payments that we
            might otherwise be required to make under the terms of the Tax Receivable Agreement. Accordingly, there may
            not be sufficient future cash payments against which to net. The applicable U.S. federal income tax rules
            are complex, and there can be no assurance that the IRS or a court will not disagree with our tax reporting
            positions. As a result, it is possible that we could make cash payments under the Tax Receivable Agreement
            that are substantially greater than our actual cash tax savings. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            Tax Receivable Agreement liability is recorded on the consolidated balance sheets as a contingent liability
            under ASC 450, &#8220;Liabilities,&#8221; and reflects management&#8217;s assessment that positive future
            taxable income and realization of cash tax savings are probable. Management&#8217;s assessment of whether
            payment of the Tax Receivable Agreement liability is probable is generally based on the determination as to
            whether it is more likely than not that the deferred tax assets will be realized. We evaluate the
            realizability of our deferred tax assets on a quarterly basis and establish valuation allowances when it is
            more likely than not that all or a portion of a deferred tax asset may not be realized. As of
            December&#160;31, 2023, we established a full valuation allowance against our deferred tax assets and
            derecognized the remaining non-current liability under the Tax Receivable Agreement after concluding it was
            not probable that we would generate sufficient future taxable income to utilize deferred tax assets that
            would result in payments due under the Tax Receivable Agreement. If revised forecasts of our future taxable
            income or other relevant factors result in us releasing all or a portion of the valuation allowance recorded
            against the deferred tax assets applicable to the aforementioned tax attributes in a future period, the
            remaining Tax Receivable Agreement liability may be </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">considered
            probable at that time and recorded on the consolidated balance sheet and within earnings. It is impossible
            to predict when and to what extent, if at all, such valuation allowance will be released, and therefore
            whether we would again be required to recognize all or a portion of the Tax Receivable Agreement liability,
            which would adversely impact our future results of operations, possibly in a material manner.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under
            the Tax Receivable Agreement, we are required to provide MLSH 1 and MLSH 2 with a schedule setting forth the
            calculation of payments that are due under the TRA with respect to each taxable year in which a payment
            obligation arises within ninety (90) days after the extended due date of our U.S. federal income tax return
            for such taxable year. This calculation will be based upon the advice of our tax advisors. The calculation
            will become final thirty (30) days after it is provided assuming that no objections are made. Payments under
            the Tax Receivable Agreement will generally be made within five (5) business days after this schedule
            becomes final pursuant to the procedures set forth in the Tax Receivable Agreement. Interest on such
            payments will begin to accrue at a rate of Intercontinental Exchange London Interbank Offer Rate
            (&#8220;LIBOR&#8221;) for a period of one month (or, if LIBOR ceases to be published, at a rate selected by
            us in good faith, with characteristics similar to LIBOR or consistent with market practices generally, any
            such rate, a &#8220;Replacement Rate&#8221;) plus 100 basis points from the due date (without extensions) of
            such tax return. Generally, any late payments that may be made under the Tax Receivable Agreement will
            continue to accrue interest at LIBOR (or a Replacement Rate, as applicable) plus 500 basis points until such
            payments are made, including any late payments that we may subsequently make because we did not have enough
            available cash to satisfy our payment obligations at the time at which they originally arose. Given the
            cessation of LIBOR, we have transitioned to the Secured Overnight Financing Rate (&#8220;SOFR&#8221;) as the
            applicable Replacement Rate as allowable under the Tax Receivable Agreement.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The
            amounts that we may be required to pay to MLSH 1 and MLSH 2 under the Tax Receivable Agreement may be
            accelerated in certain circumstances and may also significantly exceed the actual tax benefits that we
            ultimately realize.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            Tax Receivable Agreement provides that if (1) certain mergers, asset sales, other forms of business
            combination or other changes of control were to occur, (2) we breach any of our material obligations under
            the Tax Receivable Agreement or (3) at any time, we elect an early termination of the Tax Receivable
            Agreement, then the Tax Receivable Agreement will terminate and our obligations, or our successor&#8217;s
            obligations, to make payments under the Tax Receivable Agreement would accelerate and become immediately due
            and payable. The amount due and payable in that circumstance is based on certain assumptions, including an
            assumption that we would have sufficient taxable income to fully utilize all potential future tax benefits
            that are subject to the Tax Receivable Agreement. We may need to incur debt to finance payments under the
            Tax Receivable Agreement to the extent our cash resources are insufficient to meet our obligations under the
            Tax Receivable Agreement as a result of timing discrepancies or otherwise.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            a result of a change in control, material breach or our election to terminate the Tax Receivable Agreement
            early, (1) we could be required to make cash payments to MLSH 1 and MLSH 2 that are greater than the
            specified percentage of the actual benefits we ultimately realize in respect of the tax benefits that are
            subject to the Tax Receivable Agreement and (2) we would be required to make an immediate cash payment equal
            to the anticipated future tax benefits that are the subject of the Tax Receivable Agreement discounted in
            accordance with the Tax Receivable Agreement, which payment may be made significantly in advance of the
            actual realization, if any, of such future tax benefits. In these situations, our obligations under the Tax
            Receivable Agreement could have a substantial negative impact on our liquidity and could have the effect of
            delaying, deferring or preventing certain mergers, asset sales, other forms of business combination, or
            other changes of control. There can be no assurance that we will be able to finance our obligations under
            the Tax Receivable Agreement.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our
            organizational structure, including the Tax Receivable Agreement, confers certain benefits upon MLSH 1 and
            MLSH 2 that will not benefit the other common shareholders to the same extent as they will benefit MLSH 1
            and MLSH 2.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            organizational structure, including the Tax Receivable Agreement, confers certain benefits upon MLSH 1, as
            the only other LLC Unitholder in Topco LLC, and MLSH 2 that will not benefit the other holders of our Class
            A common stock to the same extent. We have entered into a Tax Receivable Agreement with MLSH 1 and MLSH 2,
            which will provide for the payment by us to MLSH 1 and MLSH 2, collectively, of 85% of the amount of tax
            benefits, if any, that we actually realize, or in some circumstances are deemed to realize, as a result of
            (i) certain increases in the tax basis of assets of Topco LLC and its subsidiaries resulting from purchases
            or exchanges of LLC Units, (ii) certain tax attributes of certain of the entities through which GTCR and
            other existing members of MLSH 1 and MLSH 2 held their ownership interests in MLSH 1, Topco LLC and
            subsidiaries of Topco LLC that existed prior to our initial public offering and (iii) certain other tax
            benefits related to our entering into the Tax Receivable Agreement, including tax benefits attributable to
            payments that we make under the Tax Receivable Agreement. Due to the uncertainty of various factors, we
            cannot estimate the likely tax benefits we will realize as a result of purchases of LLC Units and LLC Unit
            exchanges, and the resulting amounts we are likely to pay out to MLSH 1 and MLSH 2 pursuant to the Tax
            Receivable Agreement; however, we estimate that such payments may be substantial. Although </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we
            will retain 15% of the amount of such tax benefits, this and other aspects of our organizational structure
            may adversely impact the future trading market for the Class A common stock.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We
            may not be able to realize all or a portion of the tax benefits that are currently expected to result from
            the tax attributes covered by the Tax Receivable Agreement and from payments made under the Tax Receivable
            Agreement.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            ability to realize the tax benefits that we currently expect to be available as a result of the attributes
            covered by the Tax Receivable Agreement, the payments made pursuant to the Tax Receivable Agreement, and the
            interest deductions imputed under the Tax Receivable Agreement all depend on a number of assumptions,
            including that we earn sufficient taxable income each year during the period over which such deductions are
            available and that there are no adverse changes in applicable law or regulations. Additionally, if our
            actual taxable income were insufficient or there were additional adverse changes in applicable law or
            regulations, we may be unable to realize all or a portion of the expected tax benefits and our cash flows
            and shareholders&#8217; equity could be negatively affected. </span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In
            certain circumstances, Topco LLC will be required to make distributions to us and MLSH 1 and the
            distributions may be substantial.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Topco
            LLC is treated as a partnership for U.S. federal income tax purposes and, as such, is not subject to U.S.
            federal income tax. Instead, taxable income is allocated to its members, including us. We expect Topco LLC
            will continue to make tax distributions quarterly to the LLC Unitholders in Topco LLC (including us), in
            each case on a pro rata basis based on Topco LLC&#8217;s net taxable income and without regard to any
            applicable basis adjustment under Section 743(b) of the Code. Funds used by Topco LLC to satisfy its tax
            distribution obligations will not be available for reinvestment in our business. Moreover, these tax
            distributions may be substantial, and will likely exceed (as a percentage of Topco LLC&#8217;s income) the
            overall effective tax rate applicable to a similarly situated corporate taxpayer. As a result, it is
            possible that we will receive distributions significantly in excess of our tax liabilities and obligations
            to make payments under the Tax Receivable Agreement. While our Board may choose to distribute such cash
            balances as dividends on our Class A common stock, they will not be required to do so, and may in their sole
            discretion choose to use such excess cash for any purpose (including an investment of such cash into Topco
            LLC) depending upon the facts and circumstances at the time of determination. See &#8220;Dividend
            Policy.&#8221;</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unanticipated
            changes in effective tax rates or adverse outcomes resulting from examination of our income or other tax
            returns could adversely affect our operating results and financial condition.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            are subject to income taxes in the U.S. and certain foreign jurisdictions. Our tax liabilities will be
            subject to the allocation of expenses in differing jurisdictions. Our future effective tax rates could be
            subject to volatility or adversely affected by a number of factors, including:</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes
            in the amount and realizability of our deferred tax assets and liabilities;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes
            in any tax valuation allowances;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expiration
            of, or detrimental changes in, research and development tax credit laws; or</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes
            in tax laws, regulations or interpretations thereof.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            addition, we may be subject to audits of our income, sales and other transaction taxes by U.S. federal,
            state and foreign authorities. Outcomes from these audits could have an adverse effect on our operating
            results and financial condition.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If
            we were deemed to be an investment company under the 1940 Act, applicable restrictions could make it
            impractical for us to continue our business as contemplated and could have a material adverse effect on our
            business, financial condition, results of operations, cash flows and prospects.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under
            Sections 3(a)(1)(A) and (C) of the 1940 Act, a company generally will be deemed to be an &#8220;investment
            company&#8221; for purposes of the 1940 Act if it (1) is, or holds itself out as being, engaged primarily,
            or proposes to engage primarily, in the business of investing, reinvesting or trading in securities or (2)
            is engaged, or proposes to engage, in the business of investing, reinvesting, owning, holding or trading in
            securities and it owns or proposes to acquire investment securities having a value exceeding 40% of the
            value of its total assets (exclusive of U.S. government securities and cash items) on an unconsolidated
            basis. We do not believe that we are an &#8220;investment company,&#8221; as such term is defined in either
            of those sections of the 1940 Act.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            the sole managing member of Topco LLC, we will control and manage Topco LLC. On that basis, we believe that
            our interest in Topco LLC is not an &#8220;investment security&#8221; under the 1940 Act. Therefore, we have
            less than 40% of the value of our total assets (exclusive of U.S. government securities and cash items) in
            &#8220;investment securities.&#8221; However, if we were to lose the </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">right
            to manage and control Topco LLC, interests in Topco LLC could be deemed to be &#8220;investment
            securities&#8221; under the 1940 Act.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            intend to conduct our operations so that we will not be deemed to be an investment company. However, if we
            were deemed to be an investment company, restrictions imposed by the 1940 Act, including limitations on our
            capital structure and our ability to transact with affiliates, could make it impractical for us to continue
            our business as contemplated and could have a material adverse effect on our business, financial condition,
            results of operations, cash flows and prospects.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_82"></div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks
            Related to Being a Public Company</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We
            are obligated to develop and maintain proper and effective internal control over financial reporting in
            order to comply with Section 404 of the Sarbanes-Oxley Act. We may not complete our analysis of our internal
            control over financial reporting in a timely manner, or to the extent these internal controls are determined
            by us or our auditors to not be operating effectively, investor confidence in us and the value of our Class
            A common stock could be adversely affected.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            management is responsible for establishing and maintaining adequate internal control over financial
            reporting. Internal control over financial reporting is a process designed to provide reasonable assurance
            regarding the reliability of financial reporting and the preparation of financial statements in accordance
            with GAAP. Developing the system and processing documentation necessary to perform the evaluation needed to
            comply with Section 404 of the Sarbanes-Oxley Act is a costly and challenging process. If we are unable to
            assert that our internal control over financial reporting is effective, investors could lose confidence in
            the accuracy and completeness of our financial reports, which could cause the price of our Class A common
            stock to decline, and we may be subject to investigation or sanctions by the SEC.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            are required, pursuant to Section 404 of the Sarbanes-Oxley Act, to furnish a report by management on, among
            other things, the effectiveness of our internal control over financial reporting. This assessment must be
            made yearly and must include disclosure of any material weaknesses identified by our management in our
            internal control over financial reporting. We also must disclose changes made in our internal control and
            procedures on a quarterly basis. Further, our independent registered public accounting firm must report on
            the effectiveness of our internal control over financial reporting pursuant to Section 404 of the
            Sarbanes-Oxley Act. Our independent registered public accounting firm may issue a report that is adverse in
            the event it is not satisfied with the level at which our controls are documented, designed or operating,
            which could cause the price of our Class A common stock to decline, and we may be subject to investigation
            or sanctions by the SEC.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally,
            the existence of a material weakness or significant deficiency would require management to devote
            significant time and incur significant expense to remediate any such material weaknesses or significant
            deficiencies and management may not be able to remediate any such material weaknesses or significant
            deficiencies in a timely manner. The existence of any material weakness in our internal control over
            financial reporting could also result in errors in our financial statements that could require us to restate
            our financial statements, cause us to fail to meet our reporting obligations and cause shareholders to lose
            confidence in our reported financial information, all of which could materially and adversely affect our
            business and stock price.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_85"></div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks
            Related to Our Class A Common Stock</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GTCR
            controls us, and its interests may conflict with ours or yours in the future.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            of December&#160;31, 2023, investment entities affiliated with GTCR collectively controlled approximately
            56% of the voting power of our outstanding common stock and therefore GTCR controls the outcome of all
            matters submitted to a vote of our shareholders. This control enables GTCR to control the election of the
            members of the Board and all other corporate decisions. Even when GTCR ceases to control a majority of the
            total voting power, for so long as GTCR continues to own a significant percentage of our Class A common
            stock, GTCR will still be able to significantly influence the composition of our Board and the approval of
            actions requiring shareholder approval. Accordingly, for such period of time, GTCR will have significant
            influence with respect to our management, business plans and policies, including the appointment and removal
            of our officers, decisions on whether to raise future capital and amending our charter and bylaws, which
            govern the rights attached to our Class A common stock. In particular, for so long as GTCR continues to own
            a significant percentage of our Class A common stock, GTCR will be able to cause or prevent a change of
            control of us or a change in the composition of our Board and could preclude any unsolicited acquisition of
            us. The concentration of ownership could deprive you of an opportunity to receive a premium for your shares
            of Class A common stock as part of a sale of us and ultimately might affect the market price of our Class A
            common stock.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            entered into a Director Nomination Agreement with GTCR that provides GTCR the right to nominate to the Board
            a number of designees equal to at least: (i) 100% of the total number of directors comprising the Board, so
            long as GTCR </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">beneficially
            owns shares of Class A common stock and Class B common stock representing at least 40% of the total amount
            of shares of Class A common stock and Class B common stock it beneficially owned as of November 19, 2020,
            (ii) 40% of the total number of directors, in the event that GTCR beneficially owns shares of Class A common
            stock and Class B common stock representing at least 30% but less than 40% of the total amount of shares of
            Class A common stock and Class B common stock it owned as of November 19, 2020, (iii) 30% of the total
            number of directors, in the event that GTCR beneficially owns shares of Class A common stock and Class B
            common stock representing at least 20% but less than 30% of the total amount of shares of Class A common
            stock and Class B common stock it owned as of November 19, 2020, (iv) 20% of the total number of directors,
            in the event that GTCR beneficially owns shares of Class A common stock and Class B common stock
            representing at least 10% but less than 20% of the total amount of shares of Class A common stock and Class
            B common stock it owns as of November 19, 2020 and (v) one director, in the event that GTCR beneficially
            owns shares of Class A common stock and Class B common stock representing at least 5% of the total amount of
            shares of Class A common stock and Class B common stock it owned as of November 19, 2020. The Director
            Nomination Agreement provides that GTCR may assign such right to a GTCR affiliate. The Director Nomination
            Agreement prohibits us from increasing or decreasing the size of our Board without the prior written consent
            of GTCR.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GTCR
            and its affiliates engage in a broad spectrum of activities, including investments in our industry
            generally. In the ordinary course of their business activities, GTCR and its affiliates may engage in
            activities where their interests conflict with our interests or those of our other shareholders, such as
            investing in or advising businesses that directly or indirectly compete with certain portions of our
            business or are suppliers or customers of ours. Our certificate of incorporation provides that none of GTCR,
            any of its affiliates or any director who is not employed by us (including any non-employee director who
            serves as one of our officers in both his or her director and officer capacities) or its affiliates has any
            duty to refrain from engaging, directly or indirectly, in the same business activities or similar business
            activities or lines of business in which we operate. GTCR also may pursue acquisition opportunities that may
            be complementary to our business, and, as a result, those acquisition opportunities may not be available to
            us. In addition, GTCR may have an interest in pursuing acquisitions, divestitures and other transactions
            that, in its judgment, could enhance its investment, even though such transactions might involve risks to
            you or may not prove beneficial.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We
            are a &#8220;controlled company&#8221; within the meaning of the rules of NASDAQ and, as a result, we
            qualify for and rely on exemptions from certain corporate governance requirements. You will not have the
            same protections as those afforded to shareholders of companies that are subject to such governance
            requirements.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently,
            GTCR controls a majority of the voting power of our outstanding common stock. As a result, we are a
            &#8220;controlled company&#8221; within the meaning of the corporate governance requirements of NASDAQ.
            Under these rules, a company of which more than 50% of the voting power for the election of directors is
            held by an individual, group or another company is a &#8220;controlled company&#8221; and may elect not to
            comply with certain corporate governance requirements of NASDAQ, including:</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            requirement that a majority of our Board is composed of &#8220;independent directors&#8221; as defined under
            NASDAQ rules;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            requirement that we have a nominations committee that is composed entirely of independent directors;
            and</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            requirement that we have a compensation committee that is composed entirely of independent directors.</span>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From
            time to time, we may rely on these exceptions. Although a majority of our Board is currently composed of
            independent directors, neither our Compensation and Leadership Development Committee, nor our Nominating,
            Governance and Risk Committee, consists entirely of independent directors. Accordingly, you may not have the
            same protections afforded to shareholders of companies that are subject to all of the corporate governance
            requirements of NASDAQ.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions
            of our corporate governance documents could make an acquisition of us more difficult and may prevent
            attempts by our shareholders to replace or remove our current management, even if beneficial to our
            shareholders.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            certificate of incorporation and bylaws and the Delaware General Corporation Law (the &#8220;DGCL&#8221;)
            contain provisions that could make it more difficult for a third party to acquire us, even if doing so might
            be beneficial to our shareholders. Among other things:</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">these
            provisions allow us to authorize the issuance of undesignated preferred stock, the terms of which may be
            established and the shares of which may be issued without shareholder approval, and which may include
            supermajority voting, special approval, dividend, or other rights or preferences superior to the rights of
            shareholders;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">these
            provisions provide for a classified board of directors with staggered three-year terms;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">these
            provisions provide that, at any time when GTCR controls, in the aggregate, less than 40% of the outstanding
            shares of our Class A common stock, directors may only be removed for cause, and only by the affirmative
            vote of </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">holders
            of at least 66 2&#8260;3% in voting power of all the then-outstanding shares of our stock entitled to vote
            thereon, voting together as a single class;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">these
            provisions prohibit shareholder action by written consent from and after the date on which GTCR controls, in
            the aggregate, less than 35% in voting power of our stock entitled to vote generally in the election of
            directors;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">these
            provisions provide that for as long as GTCR controls, in the aggregate, at least 50% in voting power of our
            stock entitled to vote generally in the election of directors, any amendment, alteration, rescission or
            repeal of our bylaws by our shareholders will require the affirmative vote of a majority in voting power of
            the outstanding shares of our capital stock and at any time when GTCR controls, in the aggregate, less than
            50% in voting power of all outstanding shares of our stock entitled to vote generally in the election of
            directors, any amendment, alteration, rescission or repeal of our bylaws by our shareholders will require
            the affirmative vote of the holders of at least 66 2&#8260;3% in voting power of all the then-outstanding
            shares of our stock entitled to vote thereon, voting together as a single class; and</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">these
            provisions establish advance notice requirements for nominations for elections to our Board or for proposing
            matters that can be acted upon by shareholders at shareholder meetings; provided, however, at any time when
            GTCR controls, in the aggregate, at least 10% in voting power of our stock entitled to vote generally in the
            election of directors, such advance notice procedure will not apply to GTCR.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            opted out of Section 203 of the DGCL, which generally prohibits a Delaware corporation from engaging in any
            of a broad range of business combinations with any interested shareholder for a period of three years
            following the date on which the shareholder became an interested shareholder. However, our certificate of
            incorporation contains a provision that provides us with protections similar to Section 203, and prevents us
            from engaging in a business combination with a person (excluding GTCR and any of its direct or indirect
            transferees and any group as to which such persons are a party) who acquires at least 85% of our Class A
            common stock for a period of three years from the date such person acquired such common stock, unless board
            or shareholder approval is obtained prior to the acquisition. These provisions could discourage, delay or
            prevent a transaction involving a change in control of our company. These provisions could also discourage
            proxy contests and make it more difficult for you and other shareholders to elect directors of your choosing
            and cause us to take other corporate actions you desire, including actions that you may deem advantageous,
            or negatively affect the trading price of our Class A common stock. In addition, because our Board is
            responsible for appointing the members of our management team, these provisions could in turn affect any
            attempt by our shareholders to replace current members of our management team.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These
            and other provisions in our certificate of incorporation, bylaws and Delaware law could make it more
            difficult for shareholders or potential acquirers to obtain control of our Board or initiate actions that
            are opposed by our then-current Board, including actions to delay or impede a merger, tender offer or proxy
            contest involving our company. The existence of these provisions could negatively affect the price of our
            Class A common stock and limit opportunities for you to realize value in a corporate transaction.</span>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our
            certificate of incorporation designates the Court of Chancery of the State of Delaware as the exclusive
            forum for certain litigation that may be initiated by our shareholders and the federal district courts of
            the United States as the exclusive forum for litigation arising under the Securities Act, which could limit
            our shareholders&#8217; ability to obtain a favorable judicial forum for disputes with us.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant
            to our certificate of incorporation, unless we consent in writing to the selection of an alternative forum,
            the Court of Chancery of the State of Delaware is the sole and exclusive forum for any claims in state court
            for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of
            breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our
            shareholders, (3) any action asserting a claim against us arising pursuant to any provision of the DGCL, our
            certificate of incorporation or our bylaws or (4) any other action asserting a claim against us that is
            governed by the internal affairs doctrine; provided that for the avoidance of doubt, the forum selection
            provision that identifies the Court of Chancery of the State of Delaware as the exclusive forum for certain
            litigation, including any &#8220;derivative action,&#8221; will not apply to suits to enforce a duty or
            liability created by the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the
            Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or any other claim for which
            the federal courts have exclusive jurisdiction. Our certificate of incorporation also provides that, unless
            we consent in writing to the selection of an alternative forum, the federal district courts of the United
            States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising
            under the Securities Act. Our certificate of incorporation further provides that any person or entity
            purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of
            and consented to the provisions of our certificate of incorporation described above. The forum selection
            provisions in our certificate of incorporation may have the effect of discouraging lawsuits against us or
            our directors and officers and may limit our shareholders&#8217; ability to obtain a favorable judicial
            forum for disputes with us. If the enforceability of our forum selection provisions were to be challenged,
            we may incur additional costs associated with resolving such challenge. While we currently have no basis to
            expect any such challenge would be successful, if a court were to find our forum selection provisions to be
        </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inapplicable
            or unenforceable with respect to one or more of these specified types of actions or proceedings, we may
            incur additional costs associated with having to litigate in other jurisdictions, which could have an
            adverse effect on our business, financial condition, results of operations, cash flows and prospects and
            result in a diversion of the time and resources of our employees, management and board of directors.</span>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our
            stock price may be volatile for reasons unrelated to our operating performance and financial
            condition.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital
            markets worldwide have experienced, and are likely to continue to experience, significant volatility,
            including as a result of the current challenging macroeconomic environment, fiscal and monetary policy
            uncertainty, as well as political instability and continued or worsening hostilities or military conflicts
            in certain regions. This market volatility, as well as other general economic, market or political
            conditions, could subject the trading price of our Class A common stock to wide price fluctuations
            regardless of our underlying operating performance and financial position. </span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If
            our existing investors sell a significant portion of our total outstanding shares of Class A common stock,
            the market price of our Class A common stock could drop significantly, even if our business is doing
            well.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales
            of a substantial number of shares of our Class A common stock in the public market could occur at any time.
            As of December&#160;31, 2023, we had 132,227,632 outstanding shares of Class A common stock, 21,681,033 of
            which held by MLSH 2, and further, as of December&#160;31, 2023, an additional 119,094,026 shares of Class A
            common stock are issuable upon the exchange by MLSH 1 of its interest in Topco. Because each of MLSH 1 and
            MLSH 2 is controlled by GTCR and is considered an &#8220;affiliate&#8221; of ours, the shares of Class A
            common stock held by MLSH 1 and MLSH 2 are subject to certain restrictions on resale imposed by U.S. federal
            securities laws. However, pursuant to a registration rights agreement, MLSH 1 and MLSH 2 have the right to
            request that we register these shares in which case the shares would be able to be freely sold in the public
            market without such restrictions. These sales, or the perception in the market that the holders of a large
            number of shares of Class A common stock intend to sell shares, could reduce the market price of our Class A
            common stock.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because
            we have no current plans to pay regular cash dividends on our Class A common, you may not receive any return
            on investment unless you sell your Class A common stock for a price greater than that which you paid for
            it.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            do not anticipate paying any regular cash dividends on our Class A common stock. Any decision to declare and
            pay dividends in the future will be made at the discretion of our Board and will depend on, among other
            things, our results of operations, financial condition, cash requirements, contractual restrictions and
            other factors that our Board may deem relevant. In addition, our ability to pay dividends is, and may be,
            limited by covenants of existing and any future outstanding indebtedness we or our subsidiaries incur.
            Therefore, any return on investment in our Class A common stock is solely dependent upon the appreciation of
            the price of our Class A common stock on the open market, which may not occur. </span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We
            may issue shares of preferred stock in the future, which could make it difficult for another company to
            acquire us or could otherwise adversely affect holders of our Class A common stock, which could depress the
            price of our Class A common stock.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            certificate of incorporation authorizes us to issue one or more series of preferred stock. Our Board has the
            authority to determine the preferences, limitations and relative rights of the shares of preferred stock and
            to fix the number of shares constituting any series and the designation of such series, without any further
            vote or action by our shareholders. Our preferred stock could be issued with voting, liquidation, dividend
            and other rights superior to the rights of our Class A common stock. The potential issuance of preferred
            stock may delay or prevent a change in control of us, discouraging bids for our Class A common stock at a
            premium to the market price, and materially adversely affect the market price and the voting and other
            rights of the holders of our Class A common stock.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_88"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            1B. Unresolved Staff Comments</span></div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_1016"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            1C. Cybersecurity</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk
            Management and Strategy</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            cybersecurity risk management processes include technical security controls, policy enforcement mechanisms,
            monitoring systems, contractual arrangements, tools and related services, and management oversight to
            assess, identify and manage risks from cybersecurity threats. We implement risk-based controls to protect
            our information, information systems, business operations, and products and related services. We have
            adopted security-control principles based on the National Institute of </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standards
            and Technology Cybersecurity Framework (NIST), other global standards, and contractual requirements, as
            applicable. We also leverage government partnerships, industry and government associations, third-party
            benchmarking, audits, threat intelligence feeds, and other similar resources to inform our cybersecurity
            efforts and allocate resources.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            maintain an information security program that includes physical, administrative and technical safeguards,
            and we maintain plans and procedures whose objective is to help us prevent and timely and effectively
            respond to cybersecurity incidents. Through our cybersecurity risk management process, we continuously
            monitor cybersecurity vulnerabilities and potential attack vectors and evaluate the potential operational
            and financial effects of cybersecurity risk countermeasures made to defend against such threats. This
            process has been integrated into our Enterprise Risk Management program and our Compliance Risk Management
            program, both of which are overseen by our Board of Directors. In addition, we engage third-party
            consultants to assist us in assessing, enhancing, implementing, and monitoring our cybersecurity risk
            management programs, including conducting penetration testing, phishing campaigns, and vulnerability
            assessments, and responding to any incidents.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            also assess the risks from cybersecurity threats of our suppliers and third-party service providers. We also
            require our suppliers and third-party service providers to adopt security-control principles based on NIST
            or similar global standards. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            have experienced, and may in the future experience, whether directly or through our supply chain or other
            channels, cybersecurity incidents. While prior incidents have not had a material impact on us, future
            incidents could have a material impact on our business, operations, and reputation. Although our
            cybersecurity risk management processes are designed to help prevent, detect, respond to, and mitigate the
            impact of such incidents, there is no guarantee that they will be sufficient to prevent or mitigate the risk
            of a cyberattack or the potentially serious reputational, operational, legal or financial impacts that may
            result. See &#8220;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our
            internal computer systems, or those of our customers, collaborators or other contractors, have been and may
            in the future be subject to cyber-attacks or security breaches, which could result in a material disruption
            of our product development programs or otherwise adversely affect our business, financial condition, results
            of operations, cash flows and prospects</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;
            within Item 1A, &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governance</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            Board has overall responsibility for risk oversight. Oversight of certain of the Company&#8217;s key risks
            is specifically allocated to Board committees based on their respective areas of expertise. The Nominating,
            Governance and Risk Committee assists the Board in overseeing risks specific to cybersecurity. Pursuant to
            its written charter, the Nominating, Governance and Risk Committee is charged with overseeing our
            management&#8217;s efforts to identify, evaluate and mitigate major risks related to cybersecurity, data
            protection controls, business continuity/disaster recovery systems and other information security matters,
            and periodically reviews our approach to the identification, evaluation and mitigation of such risks with
            the Board. Our Vice President, Information Technology (&#8220;VP of IT&#8221;), together with our General
            Counsel, briefs the Nominating, Governance and Risk Committee on cybersecurity risks at selected meetings.
            These briefings include assessments of the threat landscape, updates on incidents, and reports on our
            investments in cybersecurity risk mitigation and governance. To the extent that a significant cybersecurity
            event occurs, the Nominating, Governance and Risk Committee would also receive periodic updates from senior
            management, including the VP of IT, the General Counsel, and the relevant Company third-party consultants on
            any significant cybersecurity events. Such updates would include, as applicable and relevant, the nature,
            scope and timing of the event; the type and scale of information or data has been accessed, exfiltrated or
            encrypted; the systems involved; what is known about the threat actor, such as capabilities and demands, if
            any; management&#8217;s ongoing assessment of the impacts or likely impacts of the intrusion; the
            possibility of litigation or regulatory investigations or actions; and any other information that management
            finds relevant and that would aid in the assessment of the materiality of the impact of the
            intrusion.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            Information Technology (IT) Department and Legal Department work together and are jointly responsible for
            developing and coordinating our enterprise-wide cybersecurity policy and strategy, including managing our
            cybersecurity risk management processes. The VP of IT and the General Counsel report to the Company&#8217;s
            senior leadership team on progress towards specific cybersecurity objectives.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vijay
            Mani is our VP of IT. He is responsible for managing our information security, developing cybersecurity
            strategy, and implementing effective information and cybersecurity programs. Mr. Mani has 16 years of
            experience working in leadership roles in information technology, as well as relevant degrees and
            certifications, including an Advanced Computer Security Certificate from Stanford University. He reports
            directly to our Chief Financial Officer and meets periodically with the Nominating, Governance and Risk
            Committee. </span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_91"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            2. Properties</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            corporate headquarters and certain of our research and development operations are located in San Diego,
            California. The facilities serve as the principal hub of operations for our nucleic acid production business
            and were purpose built to expand the capacity of this business segment while adding specialized capabilities
            in the form of clean rooms, air handling, waste and </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
        <div><span><br /></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">solvent
            handling, and GMP capabilities. Our facility leases expire at varying dates through 2038, not including
            renewals that are at our option. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All
            facilities are leased. A summary of our facilities is listed below.</span></div>
    <div style="margin-bottom:12pt;margin-top:12pt;text-align:justify">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:34.090%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:22.360%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:38.784%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approx.
                        Square Footage</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Segment</span>
                </td>
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San
                        Diego, CA</span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237,000</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nucleic
                        Acid Production</span></td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sterling,
                        VA</span></td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,000</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nucleic
                        Acid Production</span></td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leland,
                        NC</span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,000</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics
                        Safety Testing</span></td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southport,
                        NC</span></td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics
                        Safety Testing</span></td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jupiter,
                            FL</span></div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nucleic
                        Acid Production</span></td>
            </tr>
        </table>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_94"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            3. Legal Proceedings</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From
            time to time, we may be involved in various legal proceedings and subject to claims that arise in the
            ordinary course of business. Although the results of litigation and claims are inherently unpredictable and
            uncertain, we are not currently a party to any legal proceedings the outcome of which, if determined
            adversely to us, are believed to, either individually or taken together, have a material adverse effect on
            our business, operating results, cash flows or financial condition. Regardless of the outcome, litigation
            has the potential to have an adverse impact on us because of defense and settlement costs, diversion of
            management resources, and other factors. See Item 1A. &#8220;Risk Factors&#8212;Risks Related to Our
            Intellectual Property&#8212;Intellectual property litigation and other proceedings could cause us to spend
            substantial resources and distract our personnel from their normal responsibilities&#8221; and &#8220;Risk
            Factors&#8212;Risks Related to Our Intellectual Property&#8212;If we are sued for infringing,
            misappropriating, or otherwise violating intellectual property rights of third parties, such litigation
            could be costly and time consuming and could prevent or delay us from developing or commercializing our
            current or future products.&#8221;</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_97"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            4. Mine Safety Disclosures</span></div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not
            applicable.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_100"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:18pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part
            II.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_103"></div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity
            Securities</span></div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market
            Information</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            Class A common stock trades on The Nasdaq Global Select Market under the symbol &#8220;MRVI.&#8221; </span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            Class B common stock is not listed nor traded on any stock exchange. </span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock
            Performance Graph</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            following graph shows the total stockholder&#8217;s return on an investment of $100 in cash at market close
            on November 20, 2020 (the first day of trading of our common stock), through December&#160;31, 2023 for (i)
            our Class A common stock, (ii) the Nasdaq Composite Index and (iii) the Nasdaq Biotechnology Index. Pursuant
            to applicable Securities and Exchange Commission rules, all values assume reinvestment of pre-tax amount of
            all dividends; however, no dividends have been declared on our Class A common stock to date. The stockholder
            return shown in the graph below may not be indicative of future stock price performance, and we do not make
            or endorse any predictions as to future stockholder return. This graph shall not be deemed &#8220;soliciting
            material&#8221; or be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or
            otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by
            reference into any of our filings under the Securities Act whether made before or after the date hereof and
            irrespective of any general incorporation language in any such filing.</span></div>
    <div style="margin-top:6pt;text-align:center"><img src="mrvi-20231231_g7.jpg" alt="1513"
            style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:713px" /></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders
            of Common Stock</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            of February&#160;21, 2024, there were two holders of record of our Class A common stock. This number does
            not include a greater number of beneficial holders of our Class A common stock whose shares are held by
            clearing houses, banks, brokers and other financial institutions which are aggregated into a single holder
            of record. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            of February&#160;21, 2024, there was one holder of record of our Class B common stock.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend
            Policy</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            currently intend to retain all available funds and any future earnings to fund the development and growth of
            our business and to repay indebtedness and, therefore, we do not anticipate paying any cash dividends in the
            foreseeable future. Additionally, </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">because
            we are a holding company, our ability to pay dividends on our Class A common stock may be limited by
            restrictions on the ability of our subsidiaries to pay dividends or make distributions to us. Any future
            determination to pay dividends will be at the discretion of our Board, subject to compliance with covenants
            in current and future agreements governing our and our subsidiaries&#8217; indebtedness, including our
            Credit Agreement (the &#8220;Credit Agreement&#8221;) entered into in October 2020, and will depend on our
            results of operations, financial conditions, capital requirements and other factors that our Board deems
            relevant.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity
            Compensation Plan Information</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            following table sets forth information as of December&#160;31, 2023 regarding shares of our Class A common
            stock that may be issued under the Company&#8217;s equity compensation plans, consisting of our 2020 Omnibus
            Incentive Plan (the &#8220;2020 Plan&#8221;) and our 2020 Employee Stock Purchase Plan (the
            &#8220;ESPP&#8221;).</span></div>
    <div style="margin-top:6pt">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:40.920%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.532%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:17.494%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.532%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:17.494%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.532%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:17.496%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan
                        Category</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number
                        of securities to be issued upon exercise of outstanding options, warrants and rights (a)</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average
                        exercise price of outstanding options, warrants and rights</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number
                        of securities available for future issuance under equity compensation plans (excluding
                        securities reflected in column (a))</span></td>
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity
                            compensation plans approved by security holders </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)
                            (2)</span></div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,683,194</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.76&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,526,943</span>
                </td>
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,683,194</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.76&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,526,943</span>
                </td>
            </tr>
        </table>
    </div>
    <div style="margin-top:3pt"><span
            style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span>
    </div>
    <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes
            10,482,025 shares that remain available for purchase under the 2020 Employee Stock Purchase Plan and
            56,107,859 shares of common stock that remain available for grant under the 2020 Omnibus Incentive Plan. The
            2020 Omnibus Incentive Plan provides for an automatic increase in the number of shares reserved for issuance
            thereunder on January 1 of each calendar year during the term of the Plan, equal to the lesser of (a) 4.0%
            of the aggregate number of shares and shares of Class B common stock outstanding on the final day of the
            immediately preceding calendar year and (b) such smaller number of shares as determined by the Board. The
            2020 Employee Stock Purchase Plan also provides for an automatic increase in the number of shares reserved
            for issuance thereunder on January 1 of each calendar year during the term of the plan, equal to the lesser
            of (a) 1.25% of the aggregate number of shares and shares of Class B common stock outstanding on the final
            day of the immediately preceding calendar year and (b) such smaller number of shares as is determined by the
            Board, provided that the shares reserved under the ESPP shall not exceed an aggregate of 10,948,877
            shares.</span></div>
    <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The
            weighted average exercise price includes restricted stock unit and performance stock unit awards that can be
            exercised for no consideration. The weighted average exercise price excluding these restricted stock units
            and performance stock units is $20.55.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_106"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            6. Reserved</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_109"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You
            should read the following discussion and analysis of financial condition and results of operations together
            with our audited consolidated financial statements and related notes included elsewhere in this Annual
            Report on Form 10-K. This discussion and analysis reflects our historical consolidated results of operations
            and financial position, and contain forward-looking statements that involve risks and uncertainties. Our
            actual results could differ materially from those discussed in or implied by these forward-looking
            statements. Factors that could cause or contribute to such differences include, but are not limited to,
            those discussed in the section titled &#8220;Risk Factors.&#8221; Please also see the section titled
            &#8220;Forward Looking Statements.&#8221; We were incorporated in August 2020 and, pursuant to the
            organizational transactions described in Note 1 to our consolidated financial statements, became a holding
            company whose principal asset is a controlling equity interest in Topco LLC. As the sole managing member of
            Topco LLC, we operate and control the business and affairs of Topco LLC and its subsidiaries. Accordingly,
            we consolidate Topco LLC in our consolidated financial statements and report a non-controlling interest
            related to the portion of Topco LLC not owned by us. Because the organizational transactions were considered
            transactions between entities under common control, the consolidated financial statements for periods prior
            to the organizational transactions and the initial public offering have been adjusted to combine the
            previously separate entities for presentation purposes. Unless otherwise noted or the context otherwise
            requires, references in this Annual Report on Form 10-K to &#8220;we,&#8221; &#8220;us&#8221; or
            &#8220;our&#8221; refer to Maravai LifeSciences Holdings, Inc. and its subsidiaries.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This
            discussion and analysis generally addresses 2023 and 2022 items and year-over-year comparisons between 2023
            and 2022. Discussions of 2021 items and year-over-year comparisons between 2022 and 2021 that are not
            included in this Annual Report on Form 10-K can be found in Part II, Item 7 of our 2022 Annual Report on
            Form 10-K filed with the SEC on February 28, 2023.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_112"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            are a leading life sciences company providing critical products to enable the development of drug therapies,
            diagnostics, novel vaccines and support research on human diseases. Our customers include the top global
            biopharmaceutical companies ranked by research and development expenditures according to industry
            consultants, and many other emerging biopharmaceutical and life sciences research companies, as well as
            leading academic research institutions and </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in
            vitro</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            diagnostics companies. Our products address the key phases of biopharmaceutical development and include
            complex nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect
            impurities during the production of biopharmaceutical products, and products to detect the expression of
            proteins in tissues of various species.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            have and will continue to build a transformative life sciences products company by acquiring businesses and
            accelerating their growth through capital infusions and industry expertise. Biomedical innovation is
            dependent on a reliable supply of reagents in the fields of nucleic acid production, biologics safety
            testing and protein labeling. From inventive startups to the world&#8217;s leading biopharmaceutical,
            vaccine, diagnostics and gene and cell therapy companies, these customers turn to us to solve their complex
            discovery challenges and help them streamline and scale their supply chain needs beginning from research and
            development through clinical trials to commercialization.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            primary customers are biopharmaceutical companies who are pursuing novel research and product development
            programs. Our customers also include a range of government, academic and biotechnology institutions.</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            of December&#160;31, 2023, we employed a team of over 650 employees, approximately 24% of whom have advanced
            degrees. As of January 5, 2024, following the completion of a reduction in force (as described under
            &#8220;Restructuring&#8221; below), we had approximately 570 employees, approximately 25% of whom have
            advanced degrees.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            primarily utilize a direct sales model for our sales to our customers in North America. Our international
            sales, primarily in Europe and Asia Pacific, are effected through a combination of third-party distributors
            as well as via a direct sales model. The percentage of our total revenue derived from customers in North
            America was 48.8% and 38.4% for the years ended December&#160;31, 2023 and 2022, respectively.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            generated revenue of $288.9 million and $883.0 million for the years ended December&#160;31, 2023 and 2022,
            respectively. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total
            revenue by segment was $224.8 million in Nucleic Acid Production and $64.2 million in Biologics Safety
            Testing for the year ended December&#160;31, 2023. Total revenue by segment was $813.1 million in Nucleic
            Acid Production and $69.9 million in Biologics Safety Testing for the year ended December&#160;31, 2022.
        </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            focus a substantial portion of our resources supporting our core business segments. We are actively pursuing
            opportunities to expand our customer base both domestically and internationally by fostering strong
            relationships with both existing and new customers and distributors. Our management team has experience
            working with biopharmaceutical, vaccine, diagnostics and gene and cell therapy companies as well as academic
            and research scientists. We also intend to continue making investments in our overall infrastructure and
            business segments to support our growth. We incurred aggregate selling, general, and administrative expenses
            of $151.4 million and $129.3 million for the years ended December&#160;31, 2023 and 2022,
            respectively.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            research and development efforts are geared towards meeting our customers&#8217; needs. We incurred research
            and development expenses of $17.3 million and $18.4 million for the years ended December&#160;31, 2023 and
            2022, respectively. We intend to continue to invest in research and development and new products and
            technologies to support our customers&#8217; needs for the foreseeable future.</span></div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023
            and Recent Developments</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            January 2023, we completed the acquisition of Alphazyme, LLC (&#8220;Alphazyme&#8221;), a privately-held
            original equipment manufacturer (&#8220;OEM&#8221;) and provider of custom, scalable, molecular biology
            enzymes to customers in the genetic analysis and nucleic acid synthesis markets, for a total purchase
            consideration of $75.3 million. As a result of the acquisition, we own all the outstanding equity interest
            in Alphazyme. Our consolidated results of operations for the year ended December&#160;31, 2023 include the
            operating results of Alphazyme from the acquisition date. See Note 2 to our consolidated financial
            statements for additional information.</span></div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            November 2023, the Company implemented a cost realignment plan (the &#8220;Cost Realignment Plan&#8221;)
            that included the termination of approximately 15% of the Company&#8217;s workforce, the termination of
            certain leases, and other actions to reduce expenses, all as part of a plan to optimize business operations
            and match them to current market conditions. The reduction in </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">force
            was completed on January 5, 2024, following the end of the sixty-day notification period required by the
            Worker Adjustment and Retraining Notification Act. The Company expects the remaining actions under the Cost
            Realignment Plan to be substantially complete during the first quarter of 2024. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During
            the year ended December&#160;31, 2023, we incurred restructuring costs of $6.5 million, primarily related to
            severance and other employee-related costs, facility and other exit costs, professional fees and other
            restructuring costs. We do not expect to incur any additional restructuring costs, however, we expect to
            recognize a benefit of $1.2 million during the first quarter of 2024 relating to equity award forfeitures
            associated with employee terminations. We expect the Cost Realignment Plan to yield certain cost savings of
            approximately $30.0 million annually, of which $23.0 million relates to labor costs. See Note 3 to our
            consolidated financial statements for additional information.</span></div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trends
            and Uncertainties</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19
            Related Revenue Trends and Uncertainties</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            results of operations and cash flows during each of the years ended December 31, 2022, 2021 and 2020
            substantially benefited from the demand for COVID-19 related products and services, including our
            proprietary CleanCap&#174; analogs and highly modified RNA products, particularly mRNA, which are used by
            our customers in the production of COVID-19 vaccines. As a result of the general decrease in market demand
            for COVID-19 related products and services, including the supply and manufacture of COVID-19 vaccines, and
            in particular, following the end of U.S. federal public health emergency declaration and World Health
            Organization declaration of the end of the pandemic in early May 2022, we expect to experience further
            declines in COVID-19 related revenue, as discussed in further detail below. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            estimate that revenue from COVID-19 related products and services represented approximately 21.0% and 67.9%
            of our total revenues for the years ended December&#160;31, 2023 and 2022, respectively. We believe that the
            second quarter of 2022 will have represented the highest revenue quarter for revenue attributable to our
            COVID-19 related products and services, and have experienced substantial declines in COVID-19 related
            revenue since such quarter as a result of the general market trend of reduced demand for COVID-19 related
            products and services as the pandemic subsides, including the supply and manufacture of COVID-19 related
            vaccines, and the World Health Organization declaring an end to the COVID-19 pandemic. We expect further
            declines in COVID-19 related revenue for these reasons, as well as a result of unused inventory of our
            products that our customers have on hand. We are currently unable to fully estimate the impact of this
            unused inventory on our future COVID-19 related revenue, nor are we able to predict when our customers will
            resume purchasing COVID-19 related products given that our customers generally have not provided us with
            detailed inventory data. Our longer-term revenue prospects for COVID-19 related products are highly
            uncertain but are expected to be substantially less than pandemic highs. The factors that could influence
            longer-term COVID-19 related revenue include: the emergence, duration and intensity of new virus variants;
            regional resurgences of the virus globally; competition faced by our customers from other COVID-19 vaccine
            manufacturers and the development and availability of antiviral therapeutic alternatives; the availability
            and administration of pediatric and booster vaccinations, vaccine supply constraints, vaccine hesitancy and
            the effectiveness of vaccines against new virus strains; and the U.S. economy and global economy, including
            impacts resulting from supply chain constraints, labor market shortages and inflationary pressures. This
            contraction in COVID-19 related demand will significantly decrease our revenue and cash flow, which in turn
            could have a material adverse impact on our operating results and financial condition in the future.</span>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other
            Trends and Uncertainties</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While
            we believe that the long-term trend of biopharmaceutical customers relying on outside parties to provide
            important inputs and services for their clinical research and manufacturing remains a long-term growth
            driver for us, we believe that recent industry trends and uncertainties, including changes in our
            customers&#8217; spending priorities and budgetary policies and practices, which negatively impacted our
            revenue and operating results in the year ended December 31, 2023, may continue and result in slower growth
            and/or cause a further decline in our revenues during the year ending December 31, 2024. These trends and
            uncertainties, which we primarily attribute to lower levels of investment in the research and development
            funding of early-stage biotechnology companies and declines and uncertainties in the capital markets amidst
            ongoing negative macroeconomic challenges, has and may continue to cause those companies to take action to
            conserve capital, resulting in a potential reduction in research and development spending across the markets
            in which we participate. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            businesses also continue to see headwinds from a general contraction in economic activity in Asia,
            particularly in China, which may negatively impact our revenue derived from those markets. See more
            information under Part I, Item 1. Business.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">How
            We Assess Our Business</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            consider a variety of financial and operating measures in assessing the performance of our business. The key
            measures we use to determine how our business is performing are revenue and Adjusted EBITDA.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted
            EBITDA is a non-GAAP financial measure that we define as net (loss) income adjusted for interest, provision
            for income taxes, depreciation, amortization and equity-based compensation expenses. Adjusted EBITDA
            reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other
            items, that we do not consider representative of our ongoing operating performance. We also present Adjusted
            Free Cash Flow, which is a non-GAAP measure that we define as Adjusted EBITDA less capital
            expenditures.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management
            uses Adjusted EBITDA to evaluate the financial performance of our business and the effectiveness of our
            business strategies. We present Adjusted EBITDA and Adjusted Free Cash Flow because we believe they are
            frequently used by analysts, investors and other interested parties to evaluate companies in our industry,
            and they facilitate comparisons on a consistent basis across reporting periods. Further, we believe they are
            helpful in highlighting trends in our operating results because they exclude items that are not indicative
            of our core operating performance. Adjusted EBITDA is also a component of the financial covenant under our
            credit agreement that governs our ability to access more than $63.0&#160;million in aggregate letters of
            credit and available borrowings under our revolving credit facility. In addition, if we borrow more than
            $63.0&#160;million, we are required to maintain a specified net leverage ratio. See </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Liquidity
            and Capital Resources&#8212;Sources of Liquidity&#8212;Debt Covenants&#8221;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            for a discussion of this financial covenant.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted
            EBITDA and Adjusted Free Cash Flow have limitations as analytical tools and you should not consider them in
            isolation, or as substitutes for analysis of our results as reported under GAAP. We may in the future incur
            expenses similar to the adjustments in the presentation of Adjusted EBITDA. In particular, we expect to
            incur meaningful share-based compensation expense in the future. Other limitations include that Adjusted
            EBITDA and Adjusted Free Cash Flow do not reflect:</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all
            expenditures or future requirements for capital expenditures or contractual commitments;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes
            in our working capital needs;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provision
            for income taxes, which may be a necessary element of our costs and ability to operate;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            costs of replacing the assets being depreciated, which will often have to be replaced in the future;</span>
    </div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            non-cash component of employee compensation expense; and</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis,
            of our ongoing operations.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            addition, Adjusted EBITDA and Adjusted Free Cash Flow may not be comparable to similarly titled measures
            used by other companies in our industry or across different industries.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_115"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components
            of Results of Operations</span></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            revenue consists primarily of product revenue and, to a much lesser extent, service revenue. We generated
            total consolidated revenue of $288.9 million and $883.0 million for the years ended December&#160;31, 2023
            and 2022, respectively, through the following segments: (i)&#160;Nucleic Acid Production and
            (ii)&#160;Biologics Safety Testing.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nucleic
            Acid Production Segment</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids
            products to support the needs of customers&#8217; research, therapeutic and vaccine programs. This segment
            also provides research products for labeling and detecting proteins in cells and tissue samples.</span>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biologics
            Safety Testing Segment</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests
            and assay development services that are utilized by our customers in their biologic drug manufacturing
            activities.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost
            of Revenue</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost
            of revenue associated with our products primarily consists of manufacturing related costs incurred in the
            production process, including personnel and related costs, equity-based compensation expense, inventory
            write-downs, costs of materials, labor and overhead, packaging and delivery costs and allocated costs,
            including facilities, information technology, depreciation, and amortization of intangibles. Cost of revenue
            also includes adjustments for excess, obsolete or expired inventory, and idle capacity. Cost of revenue
            associated with our services primarily consists of personnel and related costs, equity-based compensation
            expense, cost of materials and allocated costs, including facilities and information technology costs. Costs
            of services were not material for the years ended December&#160;31, 2023 and 2022.</span></div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating
            Expenses</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling,
            General and Administrative</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            selling, general and administrative expenses primarily consist of salaries, benefits and equity-based
            compensation expense for our employees in our commercial sales functions, marketing, executive, accounting
            and finance, legal and human resource functions as well as travel expenses, professional services fees, such
            as consulting, audit, tax and legal fees, general corporate costs and allocated costs, including facilities,
            information technology and amortization of intangibles.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            expect that our selling, general and administrative expenses will gradually increase in future periods,
            primarily due to expanding facilities footprint to support anticipated long-term growth in the business,
            costs incurred in increasing our presence globally, and increases in marketing activities to drive awareness
            and adoption of our products and services.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research
            and Development</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research
            and development costs primarily consist of salaries, benefits, equity-based compensation expense, outside
            contracted services, cost of supplies, in-process research and development costs from asset acquisitions and
            allocated facilities costs for employees engaged in research and development of products and services. We
            expense all research and development costs in the period in which they are incurred. Payment made prior to
            the receipt of goods or services to be used in research and development are recognized as prepaid assets
            until the goods are received or services are rendered.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            expect our research and development costs to increase to support our research and development efforts,
            including meeting our customers&#8217; needs. </span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change
            in Estimated Fair Value of Contingent Consideration</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change
            in estimated fair value of contingent consideration consists of fair value adjustments to contingent
            consideration liabilities associated with completed acquisitions. These adjustments are based on our
            assessment of the probability of achieving certain revenue thresholds and other probability factors.</span>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
        </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring
            costs primarily consist of severance and other employee-related costs, facility and other exit costs,
            professional fees and other restructuring costs resulting from the Cost Realignment Plan.</span></div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other
            Income (Expense)</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest
            Expense</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest
            expense consist of interest costs and the related amortization of the debt discount and deferred issuance
            costs on our outstanding debt. Interest expense also consists of changes in the fair value of our interest
            rate cap agreement.</span></div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest
            Income</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest
            income consists of interest earned on our cash balances and short-term investments in money market funds
            held at financial institutions. </span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change
            in Payable to Related Parties Pursuant to the Tax Receivable Agreement</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During
            the year ended December&#160;31, 2023, we determined that making a payment under the Tax Receivable
            Agreement for subsequent years was not probable under </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting
            Standards Codification 450 - Contingencies</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            as a result of a valuation allowance having been recorded against our deferred tax assets, and therefore,
            that it is more likely than not that we will not </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generate
            sufficient future taxable income to utilize related tax benefits that would result in a payment under the
            Tax Receivable Agreement. As a result, we remeasured the non-current portion of the liability due under the
            Tax Receivable Agreement to zero, as of December&#160;31, 2023, and recorded a corresponding gain on Tax
            Receivable Agreement liability remeasurement.</span></div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income
            Tax Expense</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            a result of our ownership of LLC Units in Topco LLC, we are subject to U.S. federal, state and local income
            taxes with respect to our allocable share of any taxable income of Topco LLC and will be taxed at the
            prevailing corporate tax rates. In addition, we evaluate the realizability of our deferred tax assets on a
            quarterly basis and establish valuation allowances when it is more likely than not that all or a portion of
            a deferred tax asset may not be realized. During the year ended December&#160;31, 2023, we recognized a full
            valuation allowance against our deferred tax assets and recorded a corresponding income tax expense. </span>
    </div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Controlling
            Interests</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling
            interests represent the portion of profit or loss, net assets and comprehensive income or loss of our
            consolidated subsidiaries that is not allocable to the Company based on our percentage of ownership of such
            entities. </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income
            or loss attributed to the non-controlling interests is based on the LLC Units outstanding during the period
            and is presented on the consolidated statements of operations. As of December&#160;31, 2023, we held
            approximately 52.6% of the outstanding LLC Units of Topco LLC, and MLSH 1 held approximately 47.4% of the
            outstanding LLC Units of Topco LLC.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_118"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:18pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results
            of Operations </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            results of operations presented below should be reviewed in conjunction with the consolidated financial
            statements and notes included elsewhere in this Annual Report on Form 10-K. </span></div>
    <div style="margin-top:12pt">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:50.437%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:14.566%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.532%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:14.566%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.532%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:14.567%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="15"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December
                        31,</span></td>
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="9"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in
                        thousands, except per share data)</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,945&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883,001&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67.3)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating
                        expenses:</span></td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="padding-left:12pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost
                            of revenue </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,743&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,957&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.0)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="padding-left:12pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling,
                            general and administrative </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)
                        </span></div>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,390&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,259&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="padding-left:12pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research
                            and development </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,280&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,369&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change
                        in estimated fair value of contingent consideration</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,286)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,800)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.9)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="padding-left:12pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring
                        </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,466&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                        operating expenses</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,593&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,785&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss)
                            income from operations</span></div>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,648)</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">574,216&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105.5)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other
                        income (expense), net</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649,384&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,744)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2955.2)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income
                            before income taxes </span></div>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,736&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551,472&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income
                        tax expense</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756,111&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,809&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1143.4&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                        (loss) income</span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,375)</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490,663&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128.2)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                        (loss) income attributable to non-controlling interests</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,346)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270,458&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107.2)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                        (loss) income attributable to Maravai LifeSciences Holdings, Inc.</span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,029)</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,205&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154.1)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net
                        (loss) income per Class A common share attributable to Maravai LifeSciences Holdings,
                        Inc.:</span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.90)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.67&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.90)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.67&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted
                        average number of Class A common shares outstanding:</span></td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,919&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,545&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,919&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,323&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP
                        measures:</span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted
                        EBITDA</span></td>
                <td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,309&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,800&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted
                        Free Cash Flow</span></td>
                <td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,621&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586,052&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
            </tr>
        </table>
    </div>
    <div><span
            style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span>
    </div>
    <div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.5pt">Not
            meaningful</span></div>
    <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes
            equity-based compensation expense as follows (in thousands, except percentages):</span></div>
    <div style="margin-bottom:12pt;margin-top:12pt">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:50.437%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:14.566%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.532%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:14.566%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.532%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:14.567%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year
                        Ended December 31,</span></td>
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost
                        of revenue</span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,324&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,192&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.7&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling,
                        general and administrative</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,650&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,349&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.7&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research
                        and development</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,715&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,129&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140.5&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span>
                </td>
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total
                        equity-based compensation expense</span></td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,588&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,670&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.3&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
        </table>
    </div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_121"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span>
    </div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated
            revenue by segment was as follows for the periods presented (in thousands, except percentages):</span></div>
    <div style="margin-top:12pt">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:37.225%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.647%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.534%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.647%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.534%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.647%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.534%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.647%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.534%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.651%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year
                        Ended December 31,</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage
                        of Revenue</span></td>
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nucleic
                        Acid Production</span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,769&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813,069&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.4)</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.8&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.1&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics
                        Safety Testing</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,176&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,932&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.2)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                        revenue</span></td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,945&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883,001&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67.3)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
        </table>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total
            revenue was $288.9 million for the year ended December&#160;31, 2023 compared to $883.0 million for the year
            ended December&#160;31, 2022, representing a decrease of $594.1 million, or 67.3%.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nucleic
            Acid Production revenue decreased from $813.1 million for the year ended December&#160;31, 2022 to $224.8
            million for the year ended December&#160;31, 2023, representing a decrease of $588.3 million, or 72.4%. The
            decrease in Nucleic Acid Production was primarily driven by decreased revenue from our proprietary CleanCap
            analogs as demand decreased from COVID-19 vaccine manufacturers. For the year ended December&#160;31, 2023,
            we estimate that approximately $60.8 million, or 54.7%, of our $111.1 million CleanCap revenue was a result
            of customer demand attributable to COVID-19 vaccines or other COVID-19 related commercial products or
            developmental programs. For the year ended December&#160;31, 2022, we estimate that approximately $599.8
            million, or 90.8%, of our $660.5 million CleanCap revenue was a result of customer demand attributable to
            COVID-19 vaccines or other COVID-19 related commercial products or developmental programs.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biologics
            Safety Testing revenue decreased from $69.9 million for the year ended December&#160;31, 2022 to $64.2
            million for the year ended December&#160;31, 2023, representing a decrease of $5.8 million, or 8.2%. The
            decrease was primarily due to an industry-wide weak demand environment and slowdowns in biologics
            manufacturing, which continued to impact demand for our HCP ELISA kits.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_124"></div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment
            Information</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management
            has determined that adjusted earnings before interest, tax, depreciation and amortization is the profit or
            loss measure used to make resource allocation decisions and evaluate segment performance. Adjusted EBITDA
            assists management in comparing the segment performance on a consistent basis for purposes of business
            decision-making by removing the impact of certain items that management believes do not directly reflect the
            core operations and, therefore, are not included in measuring segment performance. We define Adjusted EBITDA
            as net (loss) income before interest, taxes, depreciation and amortization, certain non-cash items and other
            adjustments that we do not consider in our evaluation of ongoing operating performance from period to
            period. Corporate costs, net of eliminations, are managed on a standalone basis and are not allocated to
            segments.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            do not allocate assets to our reportable segments as they are not included in the review performed by our
            Chief Operating Decision Maker for purposes of assessing segment performance and allocating
            resources.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            of December&#160;31, 2023, all of our long-lived assets were located within the United States. </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            following schedule includes revenue and adjusted EBITDA for each of our reportable operating segments (in
            thousands): </span></div>
    <div style="margin-top:12pt;text-align:justify">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:66.835%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:14.566%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.532%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:14.567%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year
                        Ended December 31,</span></td>
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                </td>
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue:</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nucleic
                        Acid Production</span></td>
                <td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,769&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813,076&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics
                        Safety Testing</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,179&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,932&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total
                        reportable segments&#8217; revenue</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,948&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883,008&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment
                        eliminations</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288,945&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883,001&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment
                        adjusted EBITDA:</span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nucleic
                        Acid Production</span></td>
                <td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,658&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,337&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics
                        Safety Testing</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,908&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,841&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total
                        reportable segments&#8217; adjusted EBITDA</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,566&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693,178&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation
                        of total reportable segments&#8217; adjusted EBITDA to income before income taxes</span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,356)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,269)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,898)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,566)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest
                        expense</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,892)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,414)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest
                        income</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,727&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,338&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate
                        costs, net of eliminations</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,257)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,378)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other
                        adjustments:</span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition
                        contingent consideration</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,286&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,800&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition
                        integration costs</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,695)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,362)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based
                        compensation</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,588)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,670)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
            </tr>
            <tr>
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merger
                        and acquisition related expenses</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,392)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,416)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing
                        costs</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,078)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition
                        related tax adjustment</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,293)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax
                        Receivable Agreement liability adjustment</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668,886&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,102)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief
                        Executive Officer transition costs</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,426)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="padding-left:18pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring
                            costs </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,567)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,763)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,814)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income
                        before income taxes</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617,736&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551,472&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income
                        tax expense</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(756,111)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,809)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net
                            (loss) income</span></div>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,375)</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490,663&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
        </table>
    </div>
    <div style="text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">___________________</span>
    </div>
    <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Equity-based
            compensation benefit of $0.1&#160;million related to forfeited equity awards in connection with the
            restructuring is included on the equity-based compensation line item.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During
            the year ended December&#160;31, 2023 and 2022, intersegment revenue was immaterial between the Nucleic Acid
            Production and Biologics Safety Testing segments. The intersegment sales and the related gross margin on
            inventory recorded at the end of the period are eliminated for consolidation purposes. Internal selling
            prices for intersegment sales are consistent with the segment&#8217;s normal retail price offered to
            external parties. There was no commission expense recognized for intersegment sales for the years ended
            December&#160;31, 2023 and 2022.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_127"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-GAAP
            Financial Measures</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_130"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adjusted
            EBITDA</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A
            reconciliation of net (loss) income to Adjusted EBITDA, which is a non-GAAP measure, is set forth below (in
            thousands):</span></div>
    <div style="margin-top:12pt;text-align:center">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:66.835%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:14.566%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.532%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:14.567%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year
                        Ended December 31,</span></td>
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                            (loss) income</span></div>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138,375)</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490,663&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add:</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,356&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,269&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,898&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,566&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest
                        expense</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,892&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,414&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest
                        income</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,727)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,338)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income
                        tax expense</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756,111&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,809&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EBITDA</span>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676,155&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601,383&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition
                            contingent consideration </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,286)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,800)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition
                            integration costs </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,695&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,362&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based
                            compensation </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,588&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,670&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
            </tr>
            <tr>
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merger
                            and acquisition related expenses </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,392&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,416&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing
                            costs </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,078&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition
                            related tax adjustment </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,293&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax
                            Receivable Agreement liability adjustment </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(668,886)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,102&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief
                            Executive Officer transition costs </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,426&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring
                            costs </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(9)</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,567&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other
                        </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(10)</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,763&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,814&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted
                        EBITDA</span></td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,309&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,800&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
        </table>
    </div>
    <div><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span>
    </div>
    <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Refers
            to the change in the estimated fair value of contingent consideration related to completed
            acquisitions.</span></div>
    <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Refers
            to incremental costs incurred to execute and integrate completed acquisitions, and retention payments in
            connection with these acquisitions.</span></div>
    <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Refers
            to non-cash expense associated with equity-based compensation.</span></div>
    <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Refers
            to diligence, legal, accounting, tax and consulting fees incurred associated with acquisitions that were
            pursued but not consummated.</span></div>
    <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Refers
            to transaction costs related to the refinancing of our long-term debt that are not capitalizable.</span>
    </div>
    <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Refers
            to non-cash expense associated with adjustments to the carrying value of the indemnification asset recorded
            in connection with the acquisition of MyChem, LLC (&#8220;MyChem&#8221;), which was completed in January
            2022.</span></div>
    <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">For
            the year ended December&#160;31, 2023, refers to the adjustment of our Tax Receivable Agreement liability
            primarily due to remeasuring the non-current portion of the liability to zero as we no longer consider the
            payments under the agreement to be probable. For the year ended December&#160;31, 2022, refers to the
            adjustment of our Tax Receivable Agreement liability primarily due to changes in our estimated state
            apportionment and the corresponding change of our estimated state tax rate.</span></div>
    <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Refers
            to legal fees and other costs associated with the Chief Executive Officer leadership transition that
            occurred during July 2023.</span></div>
    <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(9)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Refers
            to restructuring costs associated with the Cost Realignment Plan, which was implemented in November 2023.
            Equity-based compensation benefit of $0.1&#160;million related to forfeited equity awards in connection with
            the restructuring is included on the equity-based compensation line item.</span></div>
    <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(10)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.02pt">For
            the year ended December&#160;31, 2023, refers to severance payments, legal settlement amounts, inventory
            step-up charges in connection with the acquisition of Alphazyme, certain working capital and other
            adjustments related to the acquisition of MyChem, and other non-recurring costs. For the year ended
            December&#160;31, 2022, refers to the loss recognized during the period associated with certain working
            capital and other adjustments related to the sale of Vector Laboratories, Inc., which was completed in
            September 2021, and the loss incurred on extinguishment of debt.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_133"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adjusted
            Free Cash Flow</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A
            reconciliation of Adjusted Free Cash Flow, which is a non-GAAP measure that we define as Adjusted EBITDA
            less capital expenditures, is set forth below (in thousands):</span></div>
    <div style="margin-top:12pt">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:66.882%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:14.543%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.530%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:14.545%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year
                        Ended December 31,</span></td>
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted
                        EBITDA</span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,309&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,800&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital
                            expenditures </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,688)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,748)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted
                        Free Cash Flow</span></td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,621&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586,052&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
        </table>
    </div>
    <div style="margin-top:3pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span>
    </div>
    <div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">We
            define capital expenditures as: (i) purchases of property and equipment which are included in cash flows
            from investing activities, offset by government funding received; and (ii) construction costs determined to
            be lessor improvements recorded as prepaid lease payments and right-of-use assets, offset by government
            funding received. We revised our capital expenditures definition in the quarter ended March 31, 2023 to
            exclude the portions in accounts payable and accrued expenses.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_136"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating
            Expenses</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating
            expenses include the following for the periods presented (in thousands, except percentages):</span></div>
    <div style="margin-top:12pt">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:37.225%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.647%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.534%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.647%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.534%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.647%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.534%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.647%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.534%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.651%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year
                        Ended December 31,</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage
                        of Revenue</span></td>
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost
                        of revenue</span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,743&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,957&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.0)</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.5&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling,
                        general and administrative</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151,390&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,259&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.1&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.4&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research
                        and development</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,280&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,369&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change
                        in estimated fair value of contingent consideration</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,286)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,800)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57.9)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring</span>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,466&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                        operating expenses</span></td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,593&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,785&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111.0&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
        </table>
    </div>
    <div style="margin-top:3pt"><span
            style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span>
    </div>
    <div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.5pt">Not
            meaningful</span></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost
            of Revenue</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost
            of revenue decreased by $20.2 million from $169.0 million for the year ended December&#160;31, 2022 to
            $148.7 million for the year ended December&#160;31, 2023, or 12.0%. The decrease in cost of revenue compared
            to the prior period was primarily attributable to a decrease of $42.2 million in direct product costs driven
            by overall decreased revenues. This was partially offset by an increase of $14.3 million in personnel costs
            primarily driven by retention payment accruals associated with the acquisition of MyChem, additional
            headcount to support expanded manufacturing capacity and additional headcount related to the acquisition of
            Alphazyme, an increase of $6.0 million in depreciation and amortization expense primarily due to new
            equipment and newly acquired intangible assets, and an increase of $1.6 million in facilities costs driven
            by new facilities. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross
            profit decreased by $573.8 million from $714.0 million for the year ended December&#160;31, 2022 to $140.2
            million for the year ended December&#160;31, 2023. The decrease in gross profit margin as a percentage of
            sales was primarily attributable to a decrease in volume, unfavorable product mix shift, an overall increase
            in the cost of revenue as a percentage of sales as the result of higher labor and facility costs, and
            depreciation and amortization.</span></div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling,
            General and Administrative</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling,
            general and administrative expenses increased by $22.1 million from $129.3 million for the year ended
            December&#160;31, 2022 to $151.4 million for the year ended December&#160;31, 2023, or 17.1%. The increase
            was primarily driven by an increase of $22.7 million in personnel costs largely due to additional headcount
            from the acquisition of Alphazyme and incremental equity-based compensation expense.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research
            and Development</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research
            and development expenses decreased by $1.1 million from $18.4 million for the year ended December&#160;31,
            2022 to $17.3 million for the year ended December&#160;31, 2023, or 5.9%. The decrease in expenses compared
            to the prior period was primarily driven by a decrease of $1.8 million in personnel costs largely due to
            certain retention payment accruals now being included in cost of revenue. This is partially offset by an
            increase of $0.6 million in facilities costs driven by new facilities.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change
            in Estimated Fair Value of Contingent Consideration</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            change in estimated fair value of contingent consideration changed by $4.5 million from $7.8 million for the
            year ended December&#160;31, 2022 to $3.3 million for the year ended December&#160;31, 2023, or 57.9%. The
            changes were due to the decreases in estimated fair value of the liability for the contingent payments
            associated with the acquisitions of Alphazyme and MyChem. These were due to changes in estimates associated
            with revenue projections relative to defined revenue targets or thresholds that would trigger contingent
            payments per the Securities Purchase Agreement between the Company and sellers of Alphazyme and the
            Securities Purchase Agreement between the Company and the sellers of MyChem. See Notes 2 and 5 to our
            consolidated financial statements for additional information.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring
            costs for the year ended December&#160;31, 2023 relate to the Cost Realignment Plan, which was implemented
            in November 2023. These include severance and other employee-related costs of $4.3 million, offset by a $0.1
            million equity-based compensation benefit, facility and other exit costs of $2.0 million, and professional
            fees and other associated costs of $0.3 million. See Note 3 to our consolidated financial statements for
            additional information.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_139"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other
            Income (Expense)</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other
            income (expense) includes the following for the periods presented (in thousands, except percentages):</span>
    </div>
    <div style="margin-top:12pt">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:37.225%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.647%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.534%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.647%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.534%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.647%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.534%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.647%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.534%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.651%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year
                        Ended December 31,</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage
                        of Revenue</span></td>
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest
                        expense</span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45,892)</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,414)</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.8&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.9)</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest
                        income</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,727&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,338&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1085.9&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss
                        on extinguishment of debt</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change
                        in payable to related parties pursuant to the Tax Receivable Agreement</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668,886&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,102)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231.5&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other
                            expense</span></div>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,337)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273.5&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                        other income (expense), net</span></td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649,384&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,744)</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.7&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                </td>
            </tr>
        </table>
    </div>
    <div style="margin-top:3pt"><span
            style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span>
    </div>
    <div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.5pt">Not
            meaningful</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other
            expense was $22.7 million for the year ended December&#160;31, 2022 compared to Other income of $649.4
            million for the year ended December&#160;31, 2023, representing a change of $672.1 million. The overall
            change in Other income (expense) was primarily attributable to a $668.9 million gain related to the payable
            to related parties pursuant to the Tax Receivable Agreement as we concluded that it was not probable that we
            will be able to realize the remaining tax benefits based on estimates of future taxable income. This was
            partially offset by a $0.9 million increase in Other expense relating to the indemnification asset recorded
            in connection with the acquisition of MyChem. </span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_142"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Relationship
            with GTCR, LLC (&#8220;GTCR&#8221;)</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            of December&#160;31, 2023, investment entities affiliated with GTCR collectively controlled approximately
            56% of the voting power of our common stock, which enables GTCR to control the vote of all matters submitted
            to a vote of our shareholders and to control the election of members of the Board and all other corporate
            decisions.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During
            the years ended December&#160;31, 2023 and 2022, the Company made distributions of $9.6 million and $150.2
            million, respectively, for tax liabilities to MLSH 1.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            are also a party to a Tax Receivable Agreement, or TRA, with MLSH 1, who is primarily owned by GTCR, and
            MLSH 2 (see Note 14 to our consolidated financial statements). The TRA provides for the payment by us to
            MLSH 1 and MLSH 2, collectively, of 85% of the amount of tax benefits, if any, that we actually realize, or
            in some circumstances are deemed to </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">realize,
            from exchanges of LLC Units (together with the corresponding shares of Class B common stock) for Class A
            common stock, as a result of (i) certain increases in the tax basis of assets of Topco LLC and its
            subsidiaries resulting from purchases or exchanges of LLC Units, (ii) certain tax attributes of the entities
            acquired from MLSH 1 and MLSH 2 in connection with the Organizational Transactions, Topco LLC and
            subsidiaries of Topco LLC that existed prior to the IPO, and (iii) certain other tax benefits related to our
            entering into the TRA, including tax benefits attributable to payments that we make under the TRA
            (collectively, the &#8220;Tax Attributes&#8221;). Payment obligations under the TRA are not conditioned upon
            any Topco LLC unitholders maintaining a continued ownership interest in us or Topco LLC, and the rights of
            MLSH 1 and MLSH 2 under the TRA are assignable. There is no stated term for the TRA, and the TRA will
            continue until all tax benefits have been utilized or expired unless we exercise our right to terminate the
            TRA for an agreed-upon amount.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            recognize the amount of TRA payments expected to be paid within the next 12 months and classify this amount
            as current. This determination was based on our estimate of taxable income for the year ended
            December&#160;31, 2023. As of December&#160;31, 2023, our current liability under the TRA was $7.1 million.
        </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            of December&#160;31, 2023, the Company has derecognized the remaining non-current liability under the TRA
            after concluding it was not probable that the Company will be able to realize the remaining tax benefits
            based on estimates of future taxable income. The estimation of liability under the TRA is by its nature
            imprecise and subject to significant assumptions regarding the amount, character, and timing of the taxable
            income in the future. If the valuation allowance recorded against the deferred tax assets applicable to the
            tax attributes referenced above is released in a future period, the remaining TRA liability may be
            considered probable at that time and recorded on the consolidated balance sheet and within earnings.</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            made payments of $42.6 million to MLSH 1 and MLSH 2 pursuant to the TRA during the year ended
            December&#160;31, 2023, of which $0.4 million is related to interest. This determination was based on our
            taxable income for the year ended December&#160;31, 2022. We made payments of $35.3 million to MLSH 1 and
            MLSH 2 pursuant to the TRA during the year ended December&#160;31, 2022, of which $1.1 million is related to
            interest. This determination was based on our taxable income for the year ended December&#160;31,
            2021.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_145"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity
            and Capital Resources</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_148"></div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            have financed our operations primarily from cash flow from operations, borrowings under long-term debt
            agreements and, to a lesser extent, the sale of our Class A common stock.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            of December&#160;31, 2023, we had cash and cash equivalents of $575.0 million and retained earnings of
            $285.7 million. We had a net loss of $138.4 million for the fiscal year ended December&#160;31, 2023. We
            also had positive cash flow from operations of $126.2 million.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            have relied on revenue derived from product and services sales, and equity and debt financings to fund our
            operations to date.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            principal uses of cash have been to fund operations, acquisitions and capital expenditures, as well as make
            tax distributions to MLSH 1, make TRA payments to MLSH 1 and MLSH 2 and make interest payments and mandatory
            principal payments on our long-term debt.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            plan to utilize our existing cash on hand, together with cash generated from operations, primarily to fund
            our commercial and marketing activities associated with our products and services, continued research and
            development initiatives, and ongoing investments into our manufacturing facilities to create efficiencies
            and build capacity. We believe our cash on hand, cash generated from operations and continued access to our
            credit facilities, will be sufficient to satisfy our cash requirements over the next 12 months and
            beyond.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            expect to spend approximately $2.8 million in restructuring costs primarily during the first quarter of 2024
            associated with the Cost Realignment Plan using existing cash on hand.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            a result of our ownership of LLC Units in Topco LLC, the Company is subject to U.S. federal, state and local
            income taxes with respect to its allocable share of any taxable income of Topco LLC and is taxed at the
            prevailing corporate tax rates. In addition to tax expenses, we also will incur expenses related to our
            operations and we may be required to make payments under the TRA with MLSH 1 and MLSH 2. Due to the
            uncertainty of various factors, we cannot precisely quantify the likely tax benefits we will realize as a
            result of LLC Unit exchanges and the resulting amounts we are likely to pay out to LLC Unitholders of Topco
            LLC pursuant to the TRA. Assuming no changes in the relevant tax law, we expect that probable future
            payments under the TRA relating to the purchase by the Company of LLC Units from MLSH 1 and the
            corresponding tax attributes to be approximately $7.1 million. This determination is based on our estimate
            of taxable income for the year ended December&#160;31, 2023. During the year ended December&#160;31, 2023,
            we determined that making a payment under the non-current </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">portion
            of the TRA was not probable under </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting
            Standards Codification 450 - Contingencies</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            since a valuation allowance has been recorded against our deferred tax assets and we do not believe we will
            generate sufficient future taxable income to utilize related tax benefits and result in a payment under the
            TRA. If we had determined that making a payment under the TRA and generating sufficient future taxable
            income was probable, we would have also recorded a liability pursuant to the TRA, net of current portion, of
            approximately $665.3 million in the consolidated balance sheet. Future payments in respect of subsequent
            exchanges or financings and tax attributes relating to the purchase by the Company of LLC Units from MLSH 1
            would be in addition to this amount and may be substantial. The foregoing numbers are estimates and the
            actual payments could differ materially. We expect to fund these payments using cash on hand and cash
            generated from operations. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            a result of a change of control, material breach, or our election to terminate the TRA early, (1) we could
            be required to make cash payments to MLSH 1 and MLSH 2 that are greater than the specified percentage of the
            actual benefits we ultimately realize in respect of the tax benefits that are subject to the TRA, and (2) we
            will be required to make an immediate cash payment equal to the present value of the anticipated future tax
            benefits that are the subject of the TRA, which payment may be made significantly in advance of the actual
            realization, if any, of such future tax benefits. In these situations, our obligations under the TRA could
            have a material adverse effect on our liquidity and could have the effect of delaying, deferring or
            preventing certain mergers, asset sales, other forms of business combination, or other changes of control.
            There can be no assurance that we will be able to finance our obligations under the TRA. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            addition to payments to be made under the TRA, we are also required to make tax distributions to MLSH 1
            pursuant to the LLC Operating Agreement for the portion of income passing through to them from Topco LLC.
            During the years ended December&#160;31, 2023 and 2022, the Company made distributions of $9.6 million and
            $150.2 million, respectively, for tax liabilities to MLSH 1 under this agreement.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_151"></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit
            Agreement</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            Credit Agreement among Intermediate, Cygnus and TriLink, as the borrowers, Topco LLC, as holdings, the
            lenders from time-to-time party thereto and Morgan Stanley Senior Funding, Inc., as administrative and
            collateral agent (as amended, supplemented or otherwise modified, the &#8220;Credit Agreement&#8221;),
            provides us with a term-loan facility (the &#8220;Term Loan&#8221;) totaling $600.0&#160;million and a
            revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) of $180.0&#160;million for letters
            of credit and loans to be used for working capital and other general corporate financing purposes.
            Borrowings under the Credit Agreement are unconditionally guaranteed by Topco LLC, along with the existing
            and future material domestic subsidiaries of Topco LLC (subject to certain exceptions) as specified in the
            respective guaranty agreements, and are secured by a lien and security interest in substantially all of the
            assets of existing and future material domestic subsidiaries of Topco LLC that are loan parties.</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            January 2022, the Company entered into an amendment (the &#8220;Amendment&#8221;) to refinance the term loan
            and to replace London Interbank Offered Rate (&#8220;LIBOR&#8221;) with a Term Secured Overnight Financing
            Rate (&#8220;SOFR&#8221;) based rate.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing
            with the fiscal year ended December 31, 2021, and each fiscal year thereafter, the Credit Agreement requires
            that we make mandatory prepayments on the Term Loan principal out of certain excess cash flow, subject to
            certain step-downs based on the Company&#8217;s first lien net leverage ratio. The mandatory prepayment
            shall be reduced to 25% or 0% of the calculated excess cash flow if the Company&#8217;s first lien net
            leverage ratio was equal to or less than 4.75:1.00 or 4.25:1.00, respectively; however, no prepayment is
            required to the extent excess cash flow calculated for the respective period is equal to or less than
            $10.0&#160;million. As of December&#160;31, 2023, our first lien net leverage ratio was less than 4.25:1.00.
            Thus, a mandatory prepayment on the Term Loan out of excess cash flow was not required.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            Term Loan became repayable in quarterly payments of $1.4 million beginning in March&#160;2022, with all
            remaining outstanding principal due in October&#160;2027. The Term Loan includes prepayment provisions that
            allow us, at our option, to repay all or a portion of the principal amount at any time. The Revolving Credit
            Facility allows us to repay and borrow from time to time until October&#160;2025, at which time all amounts
            borrowed must be repaid. Subject to certain exceptions and limitations, we are required to repay borrowings
            under the Term Loan and Revolving Credit Facility with the proceeds of certain occurrences, such as the
            incurrence of debt, certain equity contributions and certain asset sales or dispositions.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued
            interest under the Credit Agreement is payable by us (a)&#160;quarterly in arrears with respect to Base Rate
            loans, (b)&#160;at the end of each interest rate period (or at each three-month interval in the case of
            loans with interest periods greater than three months) with respect to Term SOFR Rate loans, (c)&#160;on the
            date of any repayment or prepayment and (d)&#160;at maturity (whether by acceleration or otherwise). An
            annual commitment fee is applied to the daily unutilized amount under the Revolving Credit Facility at
            0.375% per annum, with one stepdown to 0.25% per annum based on Intermediate&#8217;s first lien net leverage
            ratio.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt
            Covenants</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            Credit Agreement includes financial covenants. One financial covenant is a consolidated first lien coverage
            ratio measured as of the last day of each fiscal quarter. Another requires that, if as of the end of any
            fiscal quarter the aggregate amount of </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">letters
            of credit obligations and borrowings under the Revolving Credit Facility outstanding as of the end of such
            fiscal quarter (excluding cash collateralized letters of credit obligations and letter of credit obligations
            in an aggregate amount not in excess of $5.0 million at any time outstanding and for the first four fiscal
            quarters ending after October 2020, borrowings of revolving credit loans made before October 2020) exceeds
            35% of the aggregate amount of all Revolving Credit Commitments in effect as of such date, then the net
            leverage ratio of Intermediate may not be greater than 8.00 to 1.00. For purposes of this covenant, the net
            leverage ratio is calculated by dividing outstanding first lien indebtedness (net of cash) by Adjusted
            EBITDA over the preceding four fiscal quarters. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            Credit Agreement also contains negative and affirmative covenants in addition to the financial covenant,
            including covenants that restrict our ability to, among other things, incur or prepay certain indebtedness,
            pay dividends or distributions, dispose of assets, engage in mergers and consolidations, make acquisitions
            or other investments, and make changes in the nature of the business. The Credit Agreement contains certain
            events of default, including, without limitation, nonpayment of principal, interest or other obligations,
            violation of the covenants, insolvency, court ordered judgments and certain changes of control. The Credit
            Agreement also requires the Company to provide audited consolidated financial statements to the lenders no
            later than 120 days after year-end.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            of December&#160;31, 2023, we were in compliance with these covenants.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            of December&#160;31, 2023, interest rate on the Term Loan was 8.40%.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_154"></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax
            Receivable Agreement</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            are a party to the TRA with MLSH 1 and MLSH 2. The TRA provides for the payment by us to MLSH 1 and MLSH 2,
            collectively, of 85% of the amount of certain tax benefits, if any, that we actually realize, or in some
            circumstances are deemed to realize, as a result of the Organizational Transactions, IPO and any subsequent
            purchases or exchanges of LLC Units of Topco LLC. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            of December&#160;31, 2023, our current liability under the TRA was $7.1 million, representing 85% of the
            calculated tax savings we expect to utilize for the year ended December&#160;31, 2023. During the year ended
            December&#160;31, 2023, we recognized a gain of $668.9 million, in connection with a TRA liability
            adjustment due to remeasuring the non-current portion of the liability to zero as we no longer consider the
            payments under the agreement to be probable. We may record additional liabilities under the TRA when LLC
            Units are exchanged in the future and as our estimates of the future utilization of the Tax Attributes, net
            operating losses and other tax benefits change. We expect to make payments under the TRA, to the extent they
            are required, within 125 days after the extended due date of our U.S. federal income tax return for such
            taxable year. Interest on such payments will begin to accrue from the due date (without extensions) of such
            tax return at a rate of LIBOR (or, if LIBOR ceases to be published, a Replacement Rate) plus 100 basis
            points. Generally, any late payments will continue to accrue interest at LIBOR (or a Replacement Rate, as
            applicable) plus 500 basis points until such payments are made. Given the cessation of LIBOR, we have
            transitioned to the Secured Overnight Financing Rate (&#8220;SOFR&#8221;) as the applicable Replacement Rate
            as allowable under the Tax Receivable Agreement.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            payment obligations under the TRA are obligations of Maravai LifeSciences Holdings, Inc. and not of Topco
            LLC. Although the actual timing and amount of any payments that may be made under the TRA will vary, the
            aggregate payments that we will be required to make to MLSH 1 and MLSH 2 may be substantial. Any payments
            made by us under the TRA will generally reduce the amount of overall cash flow that might have otherwise
            been available to us or to Topco LLC and, to the extent that we are unable to make payments under the TRA
            for any reason, the unpaid amounts will be deferred and will accrue interest until paid by us. We anticipate
            funding ordinary course payments under the TRA from cash flow from operations of Topco LLC and its
            subsidiaries, available cash and/or available borrowings under the Credit Agreement. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During
            the year ended December&#160;31, 2023, we determined that making a payment under the non-current portion of
            the TRA was not probable under </span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting
            Standards Codification 450 - Contingencies</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            as a result of a valuation allowance having been recorded against our deferred tax assets, and therefore,
            that it is more likely than not that we will not generate sufficient future taxable income to utilize
            related tax benefits that would result in a payment under the TRA. If we had determined that making a
            payment under the TRA and generating sufficient future taxable income was probable, we would have also
            recorded a liability pursuant to the TRA, net of current portion, of approximately $665.3 million in the
            consolidated balance sheet.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_157"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash
            Flows</span></div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            following table summarizes our cash flows for the periods presented (in thousands):</span></div>
    <div style="margin-bottom:12pt;margin-top:12pt">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:66.835%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:14.566%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.532%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:14.567%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="9"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year
                        Ended December 31,</span></td>
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                        cash provided by (used in):</span></td>
                <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating
                        activities</span></td>
                <td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,224&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535,977&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing
                        activities</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(122,310)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(267,612)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing
                        activities</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,090)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,499)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                            (decrease) increase in cash and cash equivalents</span></div>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57,176)</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,866&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
        </table>
    </div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating
            Activities</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net
            cash provided by operating activities for the year ended December&#160;31, 2023 was $126.2 million, which
            was primarily attributable to a net cash inflow from the change in our operating assets and liabilities of
            $97.8 million, non-cash depreciation and amortization of $40.3 million, non-cash amortization of operating
            lease right-of-use assets of $8.5 million, non-cash amortization of deferred financing costs of $2.9
            million, non-cash equity-based compensation of $34.6 million, and non-cash deferred income taxes of $754.9
            million. These were partially offset by a net loss of $138.4 million, non-cash gain on the change in
            estimated fair value of contingent consideration of $3.3 million, and non-cash gain on the revaluation of
            liabilities under the TRA of $668.9 million. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net
            cash provided by operating activities for the year ended December&#160;31, 2022 was $536.0 million, which
            was primarily attributable to a net income of $490.7 million, non-cash depreciation and amortization of
            $31.8 million, non-cash amortization of operating lease right-of-use assets of $6.3 million, non-cash
            amortization of deferred financing costs of $2.8 million, non-cash equity-based compensation of $18.7
            million, non-cash deferred income taxes of $42.3 million, and non-cash loss on the revaluation of
            liabilities under the TRA of $4.1 million. These were partially offset by a non-cash loss on the change in
            estimated fair value of contingent consideration $7.8 million, and a net cash outflow from the change in our
            operating assets and liabilities of $45.1 million, which is net of government funding of $17.0 million. The
            net cash outflow from the change in our operating assets includes $13.4 million relating to an increase in
            prepaid lease payments for Flanders I (as defined in Note 7 to our consolidated financial
            statements).</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing
            Activities</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net
            cash used in investing activities for the year ended December&#160;31, 2023 was $122.3 million, which was
            primarily comprised of $69.8 million for the net cash consideration paid for the acquisition of Alphazyme
            and cash outflows of $65.6 million for property and equipment purchases. These were partially offset by
            proceeds from government assistance allocated to property and equipment of $12.9 million.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net
            cash used in investing activities for the year ended December&#160;31, 2022 was $267.6 million, which was
            primarily comprised of $239.0 million for the net cash consideration paid for the acquisition of MyChem, net
            cash outflows of $17.1 million for property and equipment purchases, and $13.3 million of prepaid lease
            payments for Flanders II (as defined in Note 7 to our consolidated financial statements).</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing
            Activities</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net
            cash used in financing activities for the year ended December&#160;31, 2023 was $61.1 million, which was
            primarily attributable to $42.2 million of payments to MLSH 1 and MLSH 2 pursuant to the TRA, a $9.7 million
            payment of acquisition consideration holdback relating to the acquisition of MyChem, $9.6 million of
            distributions for tax liabilities to non-controlling interest holders, required pursuant to the terms of the
            LLC Operating Agreement, and $5.4 million of principal repayments of long-term debt. This was partially
            offset by proceeds from derivative instruments of $6.2 million.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net
            cash used in financing activities for the year ended December&#160;31, 2022 was $187.5 million, which was
            primarily attributable to $150.2 million of distributions for tax liabilities to non-controlling interest
            holders, required pursuant to the terms of the LLC Operating Agreement, $34.2 million of payments to MLSH 1
            and MLSH 2 pursuant to the TRA, and $13.9 million of principal repayments of long-term debt. This was
            partially offset by proceeds from borrowings of long-term debt of $8.5 million.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_160"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital
            Expenditures</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital
            expenditures for the year ended December&#160;31, 2023 totaled $52.7 million, which is net of government
            funding of $12.9 million. Capital expenditures for the year ending December&#160;31, 2024 are projected to
            be in the range of $30.0 million to $35.0 million, which is net of anticipated government funding
            recognized. This includes leasehold improvements and equipment primarily for the Flanders San Diego
            Facility.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_163"></div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual
            Obligations and Commitments</span></div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            following table summarizes our contractual obligations and commitments as of December&#160;31, 2023 (in
            thousands):</span></div>
    <div style="margin-top:12pt">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:37.225%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.647%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.534%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.647%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.534%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.647%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.534%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.647%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.534%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.651%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments
                        due by period</span></td>
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1
                        year</span></td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2
                        - 3 years</span></td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4
                        - 5 years</span></td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5+
                        years</span></td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating
                            leases</span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">
                            (1)</span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        </span></div>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,533&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,224&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,431&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,228&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,650&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance
                            leases </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,517&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,327&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,957&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,380&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,853&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt
                            obligations </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533,120&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,440&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,880&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,800&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRA
                            payments </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,069&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,069&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unconditional
                            purchase obligations </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="padding-left:18pt;text-indent:-18pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MyChem
                            retention payments </span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,539&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,360&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,268&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,408&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,503&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
        </table>
    </div>
    <div style="margin-top:3pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________</span>
    </div>
    <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents
            operating lease payment obligations, excluding any renewal options we are reasonably certain to execute and
            have recognized as lease liabilities. See Note 8 to our consolidated financial statements for additional
            information.</span></div>
    <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents
            finance lease payment obligations, excluding any renewal options we are reasonably certain to execute and
            have recognized as lease liabilities. See Note 8 to our consolidated financial statements for additional
            information.</span></div>
    <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents
            long-term debt principal maturities, excluding interest. See Note 10 to our consolidated financial
            statements for additional information.</span></div>
    <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Reflects
            the estimated timing of the current TRA liability payment as of December&#160;31, 2023. See "Risk
            Factors-Risks Related to Our Organizational Structure" and Note 14 to our consolidated financial statements
            for additional information regarding our liability under the TRA.</span></div>
    <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents
            firm purchase commitments to our suppliers. See Note 9 to our consolidated financial statements for
            additional information.</span></div>
    <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents
            certain payments to the sellers of MyChem as of the second anniversary of the closing of the acquisition
            date as long as they continue to be employed by TriLink. See Note 2 to our consolidated financial statements
            for additional information.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax
            distributions are required under the terms of the Topco LLC Agreement. As of December&#160;31, 2023, we have
            made tax distributions equal to the estimated obligation due for 2023. See Note 14 to our consolidated
            financial statements for additional information regarding tax distributions.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing
            with the fiscal year ended December 31, 2021, and each fiscal year thereafter, the Credit Agreement requires
            that we make mandatory prepayments of the Term Loan principal upon certain excess cash flow, subject to
            certain step-downs based on our first lien net leverage ratio. The mandatory prepayment shall be reduced to
            25% or 0% of the calculated excess cash flow if the first lien net leverage ratio was equal to or less than
            4.75:1.00 or 4.25:1.00, respectively; however, no prepayment shall be required to the extent excess cash
            flow calculated for the respective period is equal to or less than $10.0 million. As of December&#160;31,
            2023, our first lien net leverage ratio was less than 4.25:1.00.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            connection with our acquisition of Alphazyme, we may be required to make additional payments of up to $75.0
            million to the sellers of Alphazyme dependent upon meeting or exceeding defined revenue targets during
            fiscal years 2023 through 2025. We may also be required to make certain payments of $9.3 million to its
            sellers and certain employees as of various dates but primarily through December 31, 2025 as long as these
            individuals continue to be employed by the Company. We cannot, at this time, determine when or if the
            related targets will be achieved or whether the events triggering the commencement of payment obligations
            will occur. Therefore, such payments were not included in the table above. See Notes 2 and 5 to our
            consolidated financial statements for additional details.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_166"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical
            Accounting Estimates</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            have prepared our consolidated financial statements in accordance with GAAP. Our preparation of these
            consolidated financial statements requires us to make estimates and assumptions that affect the reported
            amounts of assets, liabilities, revenue, expenses and related disclosures in the consolidated financial
            statements. Our estimates are based on historical </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experience
            and on various other assumptions that we believe are reasonable under the circumstances, the results of
            which form the basis for making judgments about the carrying value of assets and liabilities that are not
            readily apparent from other sources. Actual results could differ from these estimates under different
            assumptions or conditions and any such difference may be material.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            significant accounting policies are described in more detail in Note 1 to our consolidated financial
            statements. We believe the following discussion addresses our most critical accounting estimates used in the
            preparation of our consolidated financial statements, which require subjective and complex judgments.</span>
    </div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income
            Taxes</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            are subject to U.S. federal and state income taxes. We are the controlling member of Topco LLC, which has
            been, and will continue to be, treated as a partnership for U.S. federal and state income tax purposes.
            Topco LLC&#8217;s previously wholly-owned U.S. subsidiary, Maravai Life Sciences, Inc. (&#8220;Maravai
            Inc.&#8221;) and its subsidiaries, were taxpaying entities in the U.S., Canada, and the U.K. Maravai
            Inc.&#8217;s subsidiaries were sold and Maravai Inc. ceased to be a regarded entity and was deemed
            liquidated for U.S. tax purposes during the year ended December 31, 2021. Topco LLC&#8217;s wholly-owned
            subsidiary, Maravai LifeSciences International Holdings, Inc., is a taxpaying entity for U.S. and foreign
            jurisdictions and had limited activity subject to a transfer pricing arrangement during the year ended
            December&#160;31, 2023. Topco LLC&#8217;s other subsidiaries are treated as pass-through entities for
            federal and state income tax purposes. The income or loss generated by these entities is not taxed at the
            LLC level. As required by U.S. tax law, income or loss generated by these LLCs passes through to their
            owners. As such, our tax provision consists solely of the activities of Maravai Inc. and its subsidiaries,
            prior to their disposal, and Maravai LifeSciences International Holdings, Inc., as well as our share of
            income or loss generated by Topco LLC. We anticipate this structure to remain in existence for the
            foreseeable future.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            account for income taxes under the asset and liability method of accounting. We recognize deferred tax
            assets and liabilities for the future tax consequences attributable to differences between the financial
            statement carrying amounts of existing assets and liabilities and their respective tax bases, as well as for
            operating loss and tax credit carryforwards. We measure deferred tax assets and liabilities using enacted
            tax rates expected to apply to taxable income in the years in which we expect to recover or settle those
            temporary differences. We recognize the effect of a change in tax rates on deferred tax assets and
            liabilities in the results of operations in the period that includes the enactment date. We reduce the
            measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely than not
            that we will not realize some or all of the deferred tax asset.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            realizability of the Company&#8217;s deferred tax asset related to its investment in Topco LLC depends on
            the Company receiving allocations of tax deductions for its tax basis in the investment and on the Company
            generating sufficient taxable income to fully offset such deductions. We believe it is more likely than not
            that the Company will not generate sufficient taxable income in the future to fully realize any deductions
            allocated to it from Topco LLC associated with the reversal of its tax basis as of December&#160;31, 2023.
            In addition, a portion of the deferred tax asset may only be realizable through the sale or liquidation of
            the investment and our ability to generate sufficient capital gains. As such, a valuation allowance of
            $642.2&#160;million has been recorded as of December&#160;31, 2023 to reflect the deferred tax assets that
            are more likely than not to not be realized.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            account for uncertain tax positions by recognizing the financial statement effects of a tax position only
            when, based upon technical merits, it is more likely than not that the position will be sustained upon
            examination.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant
            judgment is required in determining the accounting for income taxes. In the ordinary course of business,
            many transactions and calculations arise where the ultimate tax outcome is uncertain. Our judgments,
            assumptions and estimates relative to the accounting for income taxes take into account current tax laws,
            our interpretation of current tax laws, and possible outcomes of future audits conducted by foreign and
            domestic tax authorities. Although we believe that our estimates are reasonable, the final tax outcome of
            matters could be different from our assumptions and estimates used when determining the accounting for
            income taxes. Such differences, if identified in future periods, could have a material effect on the amounts
            recorded in our consolidated financial statements.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payable
            to Related Parties Pursuant to the Tax Receivable Agreement</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            November 2020, we entered into a TRA with MLSH 1 and MLSH 2. The TRA provides for the payment by us to MLSH
            1 and MLSH 2, collectively, of 85% of the amount of tax benefits, if any, that we actually realize, or in
            some circumstances are deemed to realize from exchanges of LLC Units (together with the corresponding share
            of Class B Common stock), as a result of (i) certain increases in the tax basis of assets of Topco LLC and
            its subsidiaries resulting from purchases or exchanges of LLC Units, (ii) increase in the tax basis of
            assets of Topco LLC received form LLC Units held by entities acquired from MLSH 1 and MLSH 2 in connection
            with the Organizational Transactions, Topco LLC and subsidiaries of Topco LLC that existed prior to this
            offering and (iii) certain other tax benefits related to our entering into the TRA, including tax benefits
            attributable to payments that we make under the TRA (collectively, the &#8220;Tax Attributes&#8221;). The
            payment obligations under the TRA are not </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conditioned
            upon any LLC Unitholder maintaining a continued ownership interest in us or Topco LLC and the rights of MLSH
            1 and MLSH 2 under the TRA are assignable. We expect to benefit from the remaining 15% of the tax benefits,
            if any, that we may actually realize.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            accrue a liability for the payable to related parties for the TRA and a reduction to stockholders&#8217;
            equity, when it is deemed probable that the Tax Attributes will be used to reduce our taxable income, as the
            contractual percentage of the benefit of Tax Attributes that we expected to receive over a period of time.
            The current portion, if any, of the liability is the amount estimated to be paid within one year of the
            balance sheet date. For purposes of estimating the value of the payable to related parties for the TRA, the
            tax benefit deemed realized by us and payable to MLSH 1 and MLSH 2 is computed by taking 85% of the
            difference between undiscounted forecasted cash income tax liability over the term of benefit of the Tax
            Attributes and the forecasted amount of such taxes that we would have been required to pay had there been no
            Tax Attributes (i.e. a with-and-without analysis); provided that, for purposes of determining the tax
            benefit with respect to state and local income taxes, use simplifying assumptions. The TRA will generally
            apply to each of our taxable years, beginning with the taxable year that the TRA is entered into. There is
            no maximum term for the TRA and the TRA will continue until all such tax benefits have been utilized or
            expired unless we exercise our right to terminate the TRA for an agreed-upon amount equal to the estimated
            present value of the remaining payments to be made under the agreement (calculated with certain assumptions,
            including as to utilization of the Tax Attributes). We may record additional liabilities under the TRA when
            LLC Units of Topco LLC are exchanged in the future and as our estimates of the future utilization of the tax
            benefits change. If, due to a change in facts, these tax attributes are not utilized in future years, it is
            reasonably possible no amounts would be paid under the TRA. In this scenario, the reduction of the liability
            under the TRA would result in a benefit to our consolidated statements of operations. Subsequent adjustments
            to the payable to related parties for the TRA based on changes in anticipated future taxable income, which
            could include changes in estimated income allocated to the partners of Topco LLC or apportionment of state
            income taxes, are recorded in our consolidated statements of operations.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            actual Tax Attributes, as well as any amounts paid to MLSH 1 and MLSH 2 under the TRA, will vary depending
            on a number of factors, including:</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            timing of any future exchanges&#8212;for instance, the increase in any tax deductions will vary depending on
            the fair value, which may fluctuate over time, of the depreciable or amortizable assets of Topco LLC and its
            flow-through subsidiaries at the time of each exchange;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            price of shares of our Class A common stock at the time of any future exchanges&#8212;the increases and
            adjustments in our proportionate share of the existing tax basis of the assets of Topco LLC and its
            flow-through subsidiaries that are directly related to the price of shares of our Class A common stock at
            the time of future exchanges;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            extent to which such exchanges are taxable&#8212;if an exchange is not taxable for any reason, increased tax
            deductions as a result of legacy IRC Section 754 election in place at Topco LLC will not be available to
            generate payments under the TRA;</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the
            amount and timing of our income&#8212;the TRA generally will require us to pay 85% of the tax benefits as
            and when those benefits are treated as realized by us under the terms of the TRA. If we do not have taxable
            income in a particular taxable year, we generally will not be required (absent a change of control or other
            circumstances requiring an early termination payment) to make payments under the TRA for that taxable year
            because no tax benefits will have been actually realized. Nevertheless, any tax benefits that do not result
            in realized tax benefits in a given taxable year will likely generate tax attributes that may be utilized to
            generate tax benefits in future (and possibly previous) taxable years. The utilization of any such tax
            attributes will result in payments under the TRA; and</span></div>
    <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">applicable
            tax rates&#8212;the tax rates in effect at the time a tax benefit is recognized.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            payment obligations under the TRA are obligations of Maravai LifeSciences Holdings, Inc. and not of Topco
            LLC. Although the actual timing and amount of any payments that may be made under the TRA will vary, we
            expect that the aggregate payments that we will be required to make to MLSH 1 and MLSH 2 may be substantial.
            Any payments made by us under the TRA will generally reduce the amount of overall cash flow that might have
            otherwise been available to us or to Topco LLC and, to the extent that we are unable to make payments under
            the TRA for any reason, the unpaid amounts will be deferred and will accrue interest until paid by us. We
            anticipate funding ordinary course payments under the TRA from cash flow from operations of Topco LLC and
            its subsidiaries, available cash and/or available borrowings under the Credit Agreement.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming
            no changes in the relevant tax law, we expect that probable future payments under the TRA relating to the
            purchase by the Company of LLC Units from MLSH 1 and the tax attributes to be approximately $7.1 million.
            This determination is based on our estimate of taxable income for the year ended December 31, 2023. To the
            extent there is a change in the determination of the realizability of our deferred tax assets, this could
            impact the expected probable future payments under the TRA and the amount recorded in the consolidated
            balance sheet. Future payments in respect of subsequent exchanges or </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financings
            and tax attributes relating to the purchase by the Company of LLC Units from MLSH 1 would be in addition to
            this amount and may be substantial. The foregoing numbers are estimates and the actual payments could differ
            materially. It is possible that future transactions or events could increase or decrease the actual tax
            benefits realized and the corresponding TRA payments. There may be a material negative effect on our
            liquidity if, as a result of timing discrepancies or otherwise, the payments under the TRA exceed the actual
            benefits we realize in respect of the tax attributes subject to the TRA and/or distributions to us by Topco
            LLC are not sufficient to permit us to make payments under the TRA after we have paid taxes.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            term of the TRA commenced upon the completion of our IPO and will continue until all such tax benefits have
            been utilized or expire, unless we exercise our rights to terminate the agreements or payments under the
            agreements are accelerated in the event we materially breach any of our material obligations under the
            agreements. </span></div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            evaluate goodwill at the reporting unit level on an annual basis and between annual tests if events and
            circumstances indicate it is more likely than not that the fair value of a reporting unit is less than its
            carrying value. Such indicators could include, but are not limited to, current economic and market
            conditions, including a decline in market capitalization, a significant adverse change in legal factors,
            business climate, operational performance of the business or key personnel. We perform our annual impairment
            test in the fourth quarter.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            first assess qualitative factors to determine whether it is more likely than not that the fair value of a
            reporting unit is less than its carrying value, including goodwill. If management concludes that it is more
            likely than not that the fair value of a reporting unit is less than its carrying value, management performs
            a quantitative goodwill impairment test. In performing the quantitative impairment test, management
            considers a number of factors to determine the fair value of a reporting unit, including an independent
            valuation to conduct this test. The valuation is based upon expected future discounted operating cash flows
            of a reporting unit as well as analysis of recent sales and ratio comparisons of similar companies. We base
            the discount rate on the weighted average cost of capital, or WACC, or market participants. If the carrying
            value of a reporting unit exceeds its estimated fair value, an impairment loss will be recognized for the
            amount in which the carrying amount exceeds the reporting unit&#8217;s fair value. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due
            to the sustained decline in our stock price and the announcement of the Cost Realignment Plan in November
            2023, we performed a quantitative analysis and compared our reporting units&#8217; fair values to their
            respective carrying values to determine whether goodwill was impaired. We determined the fair values of our
            reporting units using a combination of the income approach using discounted cash flows and the market
            approach utilizing data from comparable public companies. The assumptions and estimates, including
            management&#8217;s estimated future revenue growth rates, estimated future margins and discount rates, used
            in the quantitative analysis were based on management&#8217;s best estimate about current and future
            conditions. The result of the quantitative analysis showed that the reporting units&#8217; fair values
            exceeded their carrying values and there was no impairment of the recorded goodwill as of December 31, 2023.
            However, to the extent we continue to experience declines in our stock price or experience other impairment
            indicators, such as industry and market considerations or a decline in financial performance, or that the
            fair values of our reporting units are less than their carrying values, there could be a risk of goodwill
            impairment of our reporting units in future periods.</span></div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recoverability
            and Impairment of Long-Lived Assets</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            review the recoverability of our long-lived assets (including definite-lived intangible assets) if events or
            circumstances indicate the assets may be impaired. We measure recoverability of assets by comparing the
            respective carrying value of the assets to the current and expected future cash flows, on an undiscounted
            basis, to be generated from such assets. If our analysis indicates that the carrying value of these assets
            is not recoverable, we measure an impairment based on the amount by which the net carrying amount of the
            assets exceeds the fair values of the assets. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
            conjunction with the goodwill impairment test performed during the fourth quarter of 2023, we also performed
            a recoverability assessment of our long-lived assets. The results of the analysis did not result in an
            impairment charge. </span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recognition
            of Intangible Assets as Part of a Business Combination</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            account for our business combinations using the acquisition method of accounting which requires that the
            assets acquired and liabilities assumed of acquired businesses be recorded at their respective fair values
            at the date of acquisition. The purchase price, which includes the fair value of consideration transferred,
            is attributed to the fair value of the assets acquired and liabilities assumed. The excess of the purchase
            price of the acquisition over the fair value of the identifiable net assets of the acquiree is recorded as
            goodwill.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining
            the fair value of intangible assets acquired requires management to use significant judgment and estimates,
            including the selection of valuation methodologies, assumptions about future net cash flows, discount rates
            and market </span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">participants.
            Each of these factors can significantly affect the value attributed to the identifiable intangible asset
            acquired in a business combination. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            generally utilize a discounted cash flow method under the income approach to estimate the fair value of
            identifiable intangible assets acquired in a business combination. For the acquisitions of Alphazyme, LLC
            and MyChem, LLC, the estimated fair values of the developed technology intangible assets were based on the
            multi-period excess earnings method. The estimated fair values were developed by discounting future net cash
            flows to their present value at market-based rates of return. We selected the assumptions used in the
            financial forecasts using historical data, supplemented by current and anticipated market conditions,
            estimated revenue growth rates, management&#8217;s plans, and guideline companies. Some of the more
            significant assumptions inherent in estimating the fair value of these intangible assets included revenue
            growth rates, discount rates and assumed technical obsolescent curves.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            use of alternative estimates and assumptions could increase or decrease the estimated fair value and amounts
            allocated to identifiable intangible assets acquired and future amortization expense as well as
            goodwill.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent
            Accounting Pronouncements</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See
            Note 1 to our consolidated financial statements for a discussion of recent accounting standards and
            pronouncements.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_169"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            7A. Quantitative and Qualitative Disclosures About Market Risk</span></div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest
            Rate Risk</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            of December&#160;31, 2023, our primary exposure to interest rate risk was associated with our variable rate
            long-term debt. Borrowings under our Credit Agreement bear interest at a rate equal to the Base Rate plus a
            margin of 2.00%, with respect to each Base Rate-based loan, or the Term SOFR (Secured Overnight Financing
            Rate) plus a margin of 3.00% with respect to each Term SOFR-based loan, subject in each case to an
            applicable Base Rate or Term SOFR floor (see Note 10 to our consolidated financial statements). Interest
            rates can fluctuate for a number of reasons, including changes in the fiscal and monetary policies or
            geopolitical events or changes in general economic conditions. This could adversely affect our cash flows.
        </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
            of December&#160;31, 2023, we have an interest rate cap agreement in place to hedge a portion of our
            variable interest rate risk on our outstanding long-term debt. The agreement has a contract notional amount
            of $500.0&#160;million and entitles us to receive from the counterparty at each calendar quarter end the
            amount, if any, by which a specified floating market rate exceeds the cap strike interest rate. The floating
            interest rate is reset at the end of each three-month period. The contract expires on January&#160;19,
            2025.</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            had $533.1 million of outstanding borrowings under our Term Loan and no outstanding borrowings under our
            Revolving Credit Facility as of December&#160;31, 2023. For the year ended December&#160;31, 2023, the
            effect of a hypothetical 100 basis point increase or decrease in overall interest rates would have changed
            our interest expense by approximately $5.4 million. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            had cash and cash equivalents of $575.0 million as of December&#160;31, 2023. Given the short-term nature of
            our investments, we do not believe there is any material risk to the value of our investments with increases
            or decreases in interest rates.</span></div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign
            Currency Risk</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All
            of our revenue is denominated in U.S. dollars. Although approximately 51.2% of our revenue for the year
            ended December&#160;31, 2023 was derived from international sales, primarily in Europe and Asia Pacific, all
            of these sales are denominated in U.S. dollars. The majority of our expenses are generally denominated in
            the currencies in which they are incurred, which is primarily in the United States. As we expand our
            presence in international markets, to the extent we are required to enter into agreements denominated in a
            currency other than the U.S. dollar, results of operations and cash flows may increasingly be subject to
            fluctuations due to changes in foreign currency exchange rates and may be adversely affected in the future
            due to changes in foreign currency exchange rates. To date, we have not entered into any hedging
            arrangements with respect to foreign currency risk. As our international operations grow, we will continue
            to reassess our approach to manage our risk relating to fluctuations in currency rates.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_172"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            8. Financial Statements and Supplementary Data</span></div>
    <div><span><br /></span></div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX
            TO CONSOLIDATED FINANCIAL STATEMENTS</span></div>
    <div style="margin-top:12pt">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:91.151%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:6.649%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_175">Report of Independent Registered Public
                                Accounting Firm</a></span><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                            (PCAOB ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-38">42
                            </ix:nonNumeric>)</span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_175">85</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_178">Consolidated Balance Sheets</a></span>
                    </div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_178">88</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_181">Consolidated Statements of
                                Operations</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_181">89</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_184">Consolidated Statements of Comprehensive
                                (Loss) Income</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_184">90</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_187">Consolidated Statements of Changes in
                                Stockholders&#8217; Equity</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_187">91</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_190">Consolidated Statements of Cash
                                Flows</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_190">93</a></span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_193">Notes to Consolidated Financial
                                Statements</a></span></div>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="text-align:right"><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="#ic995976d222241b98dac88a4c1bc08e5_193">95</a></span></div>
                </td>
            </tr>
        </table>
    </div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_175"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report
            of Independent Registered Public Accounting Firm</span></div>
    <div style="text-align:justify"><span><br /></span></div>
    <div style="text-align:justify"><span><br /></span></div>
    <div style="text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To
            the Stockholders and the Board of Directors of Maravai LifeSciences Holdings, Inc.</span></div>
    <div style="text-align:justify"><span><br /></span></div>
    <div style="text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion
            on the Financial Statements</span></div>
    <div style="text-align:justify"><span><br /></span></div>
    <div style="text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            have audited the accompanying consolidated balance sheets of Maravai LifeSciences Holdings, Inc. (the
            Company) as of December&#160;31, 2023 and 2022, the related consolidated statements of operations,
            comprehensive (loss) income, changes in stockholders&#8217; equity and cash flows for each of the three
            years in the period ended December&#160;31, 2023, and the related notes (collectively referred to as the
            &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements
            present fairly, in all material respects, the financial position of the Company at December&#160;31, 2023
            and 2022, and the results of its operations and its cash flows for each of the three years in the period
            ended December&#160;31, 2023, in conformity with U.S. generally accepted accounting principles.</span></div>
    <div style="text-align:justify"><span><br /></span></div>
    <div style="text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United
            States) (PCAOB), the Company's internal control over financial reporting as of December&#160;31, 2023, based
            on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring
            Organizations of the Treadway Commission (2013 framework), and our report dated February&#160;29, 2024
            expressed an unqualified opinion thereon.</span></div>
    <div style="text-align:justify"><span><br /></span></div>
    <div style="text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis
            for Opinion</span></div>
    <div style="text-align:justify"><span><br /></span></div>
    <div style="text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These
            financial statements are the responsibility of the Company's management. Our responsibility is to express an
            opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm
            registered with the PCAOB and are required to be independent with respect to the Company in accordance with
            the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange
            Commission and the PCAOB.</span></div>
    <div style="text-align:justify"><span><br /></span></div>
    <div style="text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and
            perform the audit to obtain reasonable assurance about whether the financial statements are free of material
            misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks
            of material misstatement of the financial statements, whether due to error or fraud, and performing
            procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
            regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the
            accounting principles used and significant estimates made by management, as well as evaluating the overall
            presentation of the financial statements. We believe that our audits provide a reasonable basis for our
            opinion.</span></div>
    <div style="text-align:justify"><span><br /></span></div>
    <div style="text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical
            Audit Matters</span></div>
    <div style="text-align:justify"><span><br /></span></div>
    <div style="text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            critical audit matters communicated below are matters arising from the current period audit of the financial
            statements that were communicated or required to be communicated to the audit committee and that: (1) relate
            to accounts or disclosures that are material to the financial statements and (2) involved our especially
            challenging, subjective or complex judgments. The communication of critical audit matters does not alter in
            any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by
            communicating the critical audit matters below, providing separate opinions on the critical audit matters or
            on the accounts or disclosures to which they relate. </span></div>
    <div style="text-align:justify"><span><br /></span></div>
    <div style="text-align:justify">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:18.783%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:1.408%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:77.409%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Goodwill
                            Impairment Assessment</span></div>
                </td>
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description
                            of the Matter</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="text-align:justify"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">At
                            December&#160;31, 2023, the Company has recorded goodwill of $326.0 million. As discussed in
                            Note 1 to the consolidated financial statements, goodwill is tested at the reporting unit
                            level for impairment at least annually or more frequently if indicators of potential
                            impairment exist. Under the goodwill impairment assessment, if the carrying amount of a
                            reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal
                            to the amount of the excess carrying amount of the reporting unit over its fair value.
                            During the current year the Company executed a quantitative assessment over the goodwill
                            balance assigned to each reporting unit.</span></div>
                </td>
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="text-align:justify"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Auditing
                            the Company&#8217;s recoverability test for goodwill impairment assessment was challenging
                            due to subjective estimates and assumptions used by the Company to determine fair value of
                            the reporting units. The estimates were subject to higher uncertainty due to management
                            judgements over significant assumptions, including revenue growth rates and valuation
                            related discount rates.</span></div>
                </td>
            </tr>
        </table>
    </div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="text-align:justify">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:18.783%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:1.408%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:77.409%" />
                <td style="width:0.1%" />
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How
                            We Addressed the Matter in Our Audit</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="text-align:justify"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We
                            obtained an understanding, evaluated the design, and tested the operating effectiveness of
                            controls over the Company&#8217;s goodwill impairment process, including controls over
                            management&#8217;s review of its projected financial information utilized in the valuation
                            of its reporting units.</span></div>
                </td>
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="text-align:justify"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our
                            audit procedures over the Company&#8217;s goodwill impairment assessment included, among
                            others, assessing the reasonableness of significant assumptions, specifically revenue growth
                            rates, discount rates and assessing the completeness and accuracy of the underlying data
                            used by the Company in its analyses. We evaluated whether significant assumptions were
                            reasonable by comparing them to industry data and current market forecasts, and whether such
                            assumptions were consistent with evidence obtained in other areas of the audit. We performed
                            various sensitivity analyses around the assumptions to understand the impact on the fair
                            value calculation. We also involved our valuation specialists to assist us in evaluating the
                            reasonableness of the Company&#8217;s valuation methodologies and certain significant
                            assumptions used by the Company. </span></div>
                </td>
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Payable
                            to related parties pursuant to a Tax Receivable Agreement</span></div>
                </td>
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description
                            of the Matter</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="text-align:justify"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As
                            discussed in Notes 1 and 14 of the December&#160;31, 2023 consolidated financial statements,
                            the Company has a Tax Receivable Agreement (TRA) with certain related party investors (TRA
                            investors). The TRA liability represents a contractual commitment to distribute 85% of any
                            tax benefits, realized or deemed to be realized by the Company to the TRA investors. As of
                            December&#160;31, 2023, the Company has recorded a TRA liability of $7.1 million after
                            concluding it was probable that, based on estimates of future taxable income, the Company
                            will owe a payment to the TRA investors. As of December&#160;31, 2023, the Company has not
                            recognized the remaining $665.3 million liability under the TRA after concluding it was not
                            probable that the Company will be able to realize benefits based on estimates of future
                            taxable income.</span></div>
                </td>
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="text-align:justify"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Auditing
                            management&#8217;s accounting for the TRA liability is complex because of the application of
                            the tax laws used to determine the tax basis upon which to calculate the corresponding TRA
                            liability and assumptions around the timing and amount of taxable income in the future which
                            impacts the recognition of the TRA liability. These factors involved subjective auditor
                            judgment and audit effort in performing procedures and evaluating the appropriateness of the
                            calculation of the tax basis. In addition, the audit effort involved the use of
                            professionals with specialized skill and knowledge to assist in performing these procedures
                            and evaluating the audit evidence obtained from these procedures.</span></div>
                </td>
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How
                            We Addressed the Matter in Our Audit</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="text-align:justify"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We
                            obtained an understanding, evaluated the design, and tested the operating effectiveness of
                            controls over the computation and recognition of the Company&#8217;s TRA liability,
                            including testing management's controls over the completeness and accuracy of the underlying
                            data used in the valuation and recognition, and controls over management's review of the
                            assumptions discussed above. </span></div>
                </td>
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="text-align:justify"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our
                            audit procedures included, among others, testing the information used in the calculation and
                            recognition of the TRA liability including projections of future taxable income and the
                            involvement of professionals with specialized skills and knowledge to assist in developing
                            an independent calculation of the tax basis, comparing the independent calculation to
                            management&#8217;s calculations to evaluate the reasonableness of the tax basis, assessing
                            management&#8217;s application of the tax laws, and verifying the calculation of the TRA
                            liability was in accordance with the terms set out in the TRA.</span></div>
                </td>
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Revenue
                            with distributors</span></div>
                </td>
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description
                            of the Matter</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="text-align:justify"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">During
                            the year ended December&#160;31, 2023, the Company&#8217;s revenues were $288.9 million, of
                            which a portion relates to products sold to distributors. Its distributor customers resell
                            the products to end users. Revenues from product sales are recognized when control is
                            transferred to the Company&#8217;s customer.</span></div>
                </td>
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
        </table>
    </div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="text-align:justify">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:18.783%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:1.408%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:77.409%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="text-align:justify"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Auditing
                            the Company&#8217;s product sales to distributors was challenging, specifically related to
                            the effort required to audit the respective sales activity to assess whether incentives were
                            provided that were not properly recognized. This involved judgmentally assessing factors
                            including distributor customer ordering patterns, contractual terms, incentives offered and
                            after shipment credits or free goods as described in Note 1 to the consolidated financial
                            statements.</span></div>
                </td>
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How
                            We Addressed the Matter in Our Audit</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="text-align:justify"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We
                            obtained an understanding, evaluated the design and tested the operating effectiveness of
                            internal controls over the Company&#8217;s process to monitor appropriate terms and
                            conditions for these transactions. This includes testing relevant controls over the
                            information systems that are important to the initiation, recording and billing of revenue
                            transactions as well as controls over the completeness and accuracy of the data used.</span>
                    </div>
                </td>
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="text-align:justify"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our
                            audit procedures over the Company&#8217;s product sales to distributor customers included,
                            among others, performing analytical procedures to detect and investigate anomalies within
                            the data. We also examined the terms and conditions of selected new or amended contracts
                            with distributor customers and its impact on the Company&#8217;s recognition model. We also
                            confirmed the terms and conditions of contracts directly with a selection of distributor
                            customers, including whether there are side agreements and terms not formally included in
                            the contract that may impact the Company&#8217;s revenue recognition. In addition, we
                            obtained written representations from members of the commercial organization regarding the
                            completeness of the terms and conditions reported to the legal and accounting
                            departments.</span></div>
                </td>
            </tr>
        </table>
    </div>
    <div style="margin-top:18pt;text-align:center"><span><br /></span></div>
    <div><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/
            <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-39">Ernst &amp; Young LLP</ix:nonNumeric>
            </span></div>
    <div><span><br /></span></div>
    <div><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            have served as the Company&#8217;s auditor since 2016.</span></div>
    <div><span><br /></span></div>
    <div><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            <ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-40">San Mateo, California</ix:nonNumeric>
        </span></div>
    <div><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;29,
            2024</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_178"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:10pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MARAVAI
            LIFESCIENCES HOLDINGS, INC.</span></div>
    <div style="text-align:center"><span><br /></span></div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED
            BALANCE SHEETS</span></div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in
            thousands, except par value)</span></div>
    <div style="margin-bottom:10pt;margin-top:10pt;text-align:center">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:74.706%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.630%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.631%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="9"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                        31,</span></td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current
                        assets:</span></td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash
                        and cash equivalents</span></td>
                <td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                            name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3"
                            id="f-41">574,962</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                            name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3"
                            id="f-42">632,138</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts
                        receivable, net</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                            name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3"
                            id="f-43">54,605</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                            name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3"
                            id="f-44">138,624</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryNet"
                            format="ixt:num-dot-decimal" scale="3" id="f-45">51,397</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InventoryNet"
                            format="ixt:num-dot-decimal" scale="3" id="f-46">43,152</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid
                        expenses and other current assets</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                            name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3"
                            id="f-47">17,830</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                            name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3"
                            id="f-48">25,798</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government
                        funding receivable</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                            name="us-gaap:GovernmentAssistanceAmountCumulativeCurrent" format="ixt:num-dot-decimal"
                            scale="3" id="f-49">1,118</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                            name="us-gaap:GovernmentAssistanceAmountCumulativeCurrent" format="ixt:num-dot-decimal"
                            scale="3" id="f-50">8,190</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                        current assets</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent"
                            format="ixt:num-dot-decimal" scale="3" id="f-51">699,912</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsCurrent"
                            format="ixt:num-dot-decimal" scale="3" id="f-52">847,902</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property
                        and equipment, net</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                            name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"
                            format="ixt:num-dot-decimal" scale="3" id="f-53">162,900</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                            name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"
                            format="ixt:num-dot-decimal" scale="3" id="f-54">52,694</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill"
                            format="ixt:num-dot-decimal" scale="3" id="f-55">326,029</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Goodwill"
                            format="ixt:num-dot-decimal" scale="3" id="f-56">283,668</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible
                        assets, net</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                            name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3"
                            id="f-57">220,987</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                            name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3"
                            id="f-58">216,663</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred
                        tax assets</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                            name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:fixed-zero" scale="3" id="f-59">
                            &#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                            name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-60">
                            765,799</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other
                        assets</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                            name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-61">77,622
                        </ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                            name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-62">
                            115,589</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                        assets</span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets"
                            format="ixt:num-dot-decimal" scale="3" id="f-63">1,487,450</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Assets"
                            format="ixt:num-dot-decimal" scale="3" id="f-64">2,282,315</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities
                        and stockholders&#8217; equity</span></td>
                <td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current
                        liabilities:</span></td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts
                        payable</span></td>
                <td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3"
                            name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">
                            10,729</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3"
                            name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">5,991
                        </ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued
                        expenses and other current liabilities</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                            name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">
                            60,237</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                            name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">
                            53,371</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred
                        revenue</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                            name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3"
                            id="f-69">3,360</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                            name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3"
                            id="f-70">3,088</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current
                        portion of payable to related parties pursuant to the Tax Receivable Agreement</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3"
                            name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">7,069
                        </ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3"
                            name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">
                            42,254</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current
                        portion of long-term debt</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtCurrent"
                            format="ixt:num-dot-decimal" scale="3" id="f-73">5,440</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtCurrent"
                            format="ixt:num-dot-decimal" scale="3" id="f-74">5,440</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current
                        portion of finance lease liabilities</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                            name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-75">633</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                            name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-76">
                            &#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                        current liabilities</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent"
                            format="ixt:num-dot-decimal" scale="3" id="f-77">87,468</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesCurrent"
                            format="ixt:num-dot-decimal" scale="3" id="f-78">110,144</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term
                        debt, less current portion</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                            name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-79">
                            518,707</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                            name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-80">
                            521,997</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance
                        lease liabilities, less current portion</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                            name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3"
                            id="f-81">31,897</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                            name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-82">
                            &#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payable
                        to related parties pursuant to the Tax Receivable Agreement, less current portion</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3"
                            name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3"
                            id="f-83">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3"
                            name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3"
                            id="f-84">675,956</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other
                        long-term liabilities</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                            name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-85">
                            59,494</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                            name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-86">
                            68,975</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                        liabilities</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities"
                            format="ixt:num-dot-decimal" scale="3" id="f-87">697,566</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Liabilities"
                            format="ixt:num-dot-decimal" scale="3" id="f-88">1,377,072</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments
                            and contingencies (Note 9)</span></div>
                </td>
                <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt">
                    <ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true"
                        name="us-gaap:CommitmentsAndContingencies" id="f-89"></ix:nonFraction>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt">
                    <ix:nonFraction unitRef="usd" contextRef="c-6" xsi:nil="true"
                        name="us-gaap:CommitmentsAndContingencies" id="f-90"></ix:nonFraction>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217;
                        equity:</span></td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="padding-left:18pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class
                            A common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="INF"
                                name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-91">
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="INF"
                                    name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-92">0.01
                                </ix:nonFraction>
                            </ix:nonFraction> par value - <ix:nonFraction unitRef="shares" contextRef="c-12"
                                decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal"
                                scale="3" id="f-93">
                                <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF"
                                    name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3"
                                    id="f-94">500,000</ix:nonFraction>
                            </ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-11"
                                decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal"
                                scale="3" id="f-95">
                                <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="-3"
                                    name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3"
                                    id="f-96">132,228</ix:nonFraction>
                            </ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3"
                                name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3"
                                id="f-97">
                                <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3"
                                    name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3"
                                    id="f-98">131,692</ix:nonFraction>
                            </ix:nonFraction> shares issued and outstanding as of December&#160;31, 2023 and 2022,
                            respectively</span></div>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CommonStockValue"
                            format="ixt:num-dot-decimal" scale="3" id="f-99">1,322</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CommonStockValue"
                            format="ixt:num-dot-decimal" scale="3" id="f-100">1,317</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="padding-left:18pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class
                            B common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="INF"
                                name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-101">
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="INF"
                                    name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-102">0.01
                                </ix:nonFraction>
                            </ix:nonFraction> par value - <ix:nonFraction unitRef="shares" contextRef="c-14"
                                decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal"
                                scale="3" id="f-103">
                                <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF"
                                    name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3"
                                    id="f-104">300,000</ix:nonFraction>
                            </ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-13"
                                decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal"
                                scale="3" id="f-105">
                                <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3"
                                    name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3"
                                    id="f-106">119,094</ix:nonFraction>
                            </ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3"
                                name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3"
                                id="f-107">
                                <ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3"
                                    name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3"
                                    id="f-108">123,669</ix:nonFraction>
                            </ix:nonFraction> shares issued and outstanding as of December&#160;31, 2023 and 2022</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CommonStockValue"
                            format="ixt:num-dot-decimal" scale="3" id="f-109">1,191</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CommonStockValue"
                            format="ixt:num-dot-decimal" scale="3" id="f-110">1,237</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional
                        paid-in capital</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                            name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-111">
                            128,503</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                            name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-112">
                            137,898</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained
                        earnings</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                            name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3"
                            id="f-113">285,737</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                            name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3"
                            id="f-114">404,766</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                        stockholders&#8217; equity attributable to Maravai LifeSciences Holdings, Inc.</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity"
                            format="ixt:num-dot-decimal" scale="3" id="f-115">416,753</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity"
                            format="ixt:num-dot-decimal" scale="3" id="f-116">545,218</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling
                        interest</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:MinorityInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-117">373,131</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MinorityInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-118">360,025</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                        stockholders&#8217; equity</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-119">789,884</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-120">905,243</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                        liabilities and stockholders&#8217; equity</span></td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                            name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3"
                            id="f-121">1,487,450</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                            name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3"
                            id="f-122">2,282,315</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
        </table>
    </div>
    <div style="margin-top:18pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The
            accompanying notes are an integral part of these consolidated financial statements.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_181"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:10pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MARAVAI
            LIFESCIENCES HOLDINGS, INC.</span></div>
    <div style="text-align:center"><span><br /></span></div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED
            STATEMENTS OF OPERATIONS</span></div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in
            thousands, except per share amounts)</span></div>
    <div style="text-align:center"><span><br /></span></div>
    <div style="margin-bottom:10pt;margin-top:10pt;text-align:center">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:62.243%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.630%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.630%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.631%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="15"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December
                        31,</span></td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                            format="ixt:num-dot-decimal" scale="3" id="f-123">288,945</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                            format="ixt:num-dot-decimal" scale="3" id="f-124">883,001</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                            format="ixt:num-dot-decimal" scale="3" id="f-125">799,240</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating
                        expenses:</span></td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost
                        of revenue</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfRevenue"
                            format="ixt:num-dot-decimal" scale="3" id="f-126">148,743</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CostOfRevenue"
                            format="ixt:num-dot-decimal" scale="3" id="f-127">168,957</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CostOfRevenue"
                            format="ixt:num-dot-decimal" scale="3" id="f-128">140,561</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling,
                        general and administrative</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3"
                            id="f-129">151,390</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3"
                            id="f-130">129,259</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3"
                            id="f-131">100,064</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research
                        and development</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3"
                            id="f-132">17,280</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3"
                            id="f-133">18,369</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3"
                            id="f-134">15,219</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change
                        in estimated fair value of contingent consideration</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                            name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"
                            format="ixt:num-dot-decimal" scale="3" id="f-135">3,286</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-"
                            name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"
                            format="ixt:num-dot-decimal" scale="3" id="f-136">7,800</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"
                            format="ixt:fixed-zero" scale="3" id="f-137">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="padding-left:18pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring</span>
                    </div>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestructuringCharges"
                            format="ixt:num-dot-decimal" scale="3" id="f-138">6,466</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="f-139">&#8212;
                        </ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="f-140">&#8212;
                        </ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain
                        on sale of business</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="f-141">&#8212;
                        </ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="f-142">&#8212;
                        </ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="3" id="f-143">
                            11,249</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                        operating expenses</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses"
                            format="ixt:num-dot-decimal" scale="3" id="f-144">320,593</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CostsAndExpenses"
                            format="ixt:num-dot-decimal" scale="3" id="f-145">308,785</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:CostsAndExpenses"
                            format="ixt:num-dot-decimal" scale="3" id="f-146">244,595</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss)
                        income from operations</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                            name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-147">31,648
                        </ix:nonFraction>)</span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OperatingIncomeLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-148">574,216</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OperatingIncomeLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-149">554,645</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other
                        income (expense):</span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest
                        expense</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense"
                            format="ixt:num-dot-decimal" scale="3" id="f-150">45,892</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestExpense"
                            format="ixt:num-dot-decimal" scale="3" id="f-151">20,414</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InterestExpense"
                            format="ixt:num-dot-decimal" scale="3" id="f-152">30,260</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest
                        income</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-153">
                            27,727</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-154">
                            2,338</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:InvestmentIncomeInterest" format="ixt:fixed-zero" scale="3" id="f-155">&#8212;
                        </ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss
                        on extinguishment of debt</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3"
                            id="f-156">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-"
                            name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="f-157">208</ix:nonFraction>
                        )</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3"
                            id="f-158">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change
                        in payable to related parties pursuant to the Tax Receivable Agreement</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                            name="us-gaap:RelatedPartyTaxExpenseEffectOfChangeInAllocationMethodology"
                            format="ixt:num-dot-decimal" scale="3" id="f-159">668,886</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:RelatedPartyTaxExpenseEffectOfChangeInAllocationMethodology"
                            format="ixt:num-dot-decimal" scale="3" id="f-160">4,102</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-"
                            name="us-gaap:RelatedPartyTaxExpenseEffectOfChangeInAllocationMethodology"
                            format="ixt:num-dot-decimal" scale="3" id="f-161">6,101</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other
                        (expense) income</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                            name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3"
                            id="f-162">1,337</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-"
                            name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-163">358</ix:nonFraction>
                        )</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-164">279</ix:nonFraction>
                        &#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income
                            before income taxes</span></div>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-165">617,736</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-166">551,472</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-167">530,765</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income
                        tax expense</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-168">
                            756,111</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-169">
                            60,809</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-170">
                            61,515</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net
                        (loss) income</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-171">138,375</ix:nonFraction>)</span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProfitLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-172">490,663</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ProfitLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-173">469,250</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                        (loss) income attributable to non-controlling interests</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                            name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-174">19,346</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-175">270,458</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-176">287,213</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net
                        (loss) income attributable to Maravai LifeSciences Holdings, Inc.</span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                            name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-177">119,029
                        </ix:nonFraction>)</span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetIncomeLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-178">220,205</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:NetIncomeLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-179">182,037</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net
                        (loss) income per Class A common share attributable to Maravai LifeSciences Holdings,
                        Inc.:</span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-"
                            name="us-gaap:EarningsPerShareBasic" scale="0" id="f-180">0.90</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2"
                            name="us-gaap:EarningsPerShareBasic" scale="0" id="f-181">1.67</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2"
                            name="us-gaap:EarningsPerShareBasic" scale="0" id="f-182">1.59</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-"
                            name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-183">0.90</ix:nonFraction>)</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2"
                            name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-184">1.67</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2"
                            name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-185">1.56</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted
                            average number of Class A common shares outstanding:</span></div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3"
                            name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal"
                            scale="3" id="f-186">131,919</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3"
                            name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal"
                            scale="3" id="f-187">131,545</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3"
                            name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal"
                            scale="3" id="f-188">114,791</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3"
                            name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal"
                            scale="3" id="f-189">131,919</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3"
                            name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal"
                            scale="3" id="f-190">255,323</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3"
                            name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal"
                            scale="3" id="f-191">257,803</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
        </table>
    </div>
    <div style="margin-top:18pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The
            accompanying notes are an integral part of these consolidated financial statements.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_184"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:10pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MARAVAI
            LIFESCIENCES HOLDINGS, INC.</span></div>
    <div style="text-align:center"><span><br /></span></div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED
            STATEMENTS OF COMPREHENSIVE (LOSS) INCOME</span></div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in
            thousands)</span></div>
    <div style="margin-bottom:10pt;margin-top:10pt">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:62.243%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.630%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.630%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.631%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December
                        31,</span></td>
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                            (loss) income</span></div>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-192">138,375</ix:nonFraction>)</span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProfitLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-193">490,663</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ProfitLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-194">469,250</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other
                        comprehensive income:</span></td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign
                        currency translation adjustments</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"
                            format="ixt:fixed-zero" scale="3" id="f-195">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"
                            format="ixt:fixed-zero" scale="3" id="f-196">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"
                            scale="3" id="f-197">55</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                            other comprehensive (loss) income</span></div>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                            name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-198">138,375</ix:nonFraction>)</span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-199">490,663</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-200">469,305</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive
                            (loss) income attributable to non-controlling interests</span></div>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                            name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-201">19,346</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-202">270,458</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-203">287,224</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                            comprehensive (loss) income attributable to Maravai LifeSciences Holdings, Inc.</span></div>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                            name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3"
                            id="f-204">119,029</ix:nonFraction>)</span></td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3"
                            id="f-205">220,205</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3"
                            id="f-206">182,081</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
        </table>
    </div>
    <div style="margin-top:18pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The
            accompanying notes are an integral part of the consolidated financial statements.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_187"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:10pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MARAVAI
            LIFESCIENCES HOLDINGS, INC.</span></div>
    <div style="text-align:center"><span><br /></span></div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED
            STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in
            thousands)</span></div>
    <div style="margin-bottom:10pt;margin-top:10pt">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:13.416%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:6.378%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:7.111%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:6.378%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:7.111%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:7.551%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:7.551%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.630%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:7.551%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:9.459%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class
                        A Common Stock</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class
                        B Common Stock</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional
                        Paid-In Capital</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained
                        Earnings</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated
                        Other Comprehensive Income (Loss)</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-controlling
                        Interest</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total
                            Stockholders&#8217; Equity</span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December
                        31, 2020</span></td>
                <td colspan="3"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3"
                            name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3"
                            id="f-207">96,647</ix:nonFraction>
                    </span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            scale="3" id="f-208">966</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="shares" contextRef="c-18" decimals="-3"
                            name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3"
                            id="f-209">160,974</ix:nonFraction>
                    </span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-210">1,610</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-211">85,125</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            scale="3" id="f-212">854</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            scale="3" id="f-213">44</ix:nonFraction>)</span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-214">66,235</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-215">154,746</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span
                            style="-sec-ix-hidden:f-216">Cumulative effect of adoption of ASC 842, net of
                            tax</span></span></td>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-217">1,670</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-218">2,784</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-219">4,454</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect
                        of exchanges of LLC Units</span></td>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-3"
                            name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" format="ixt:num-dot-decimal"
                            scale="3" id="f-220">34,734</ix:nonFraction>
                    </span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3"
                            name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" id="f-221">348
                        </ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" sign="-"
                            name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" format="ixt:num-dot-decimal"
                            scale="3" id="f-222">34,734</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-"
                            name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="3" id="f-223">348
                        </ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3"
                            name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" format="ixt:num-dot-decimal"
                            scale="3" id="f-224">31,003</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-"
                            name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" format="ixt:num-dot-decimal"
                            scale="3" id="f-225">31,003</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" format="ixt:fixed-zero"
                            scale="3" id="f-226">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recognition
                        of impact of Tax Receivable Agreement due to exchanges of LLC Units</span></td>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3"
                            name="mrvi:AdjustmentsToAdditionalPaidInCapitalTaxReceivableAgreementImpact"
                            format="ixt:num-dot-decimal" scale="3" id="f-227">53,000</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="mrvi:AdjustmentsToAdditionalPaidInCapitalTaxReceivableAgreementImpact"
                            format="ixt:num-dot-decimal" scale="3" id="f-228">53,000</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance
                        of Class A common stock under employee equity plans, net of shares withheld for employee
                        taxes</span></td>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-3"
                            name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="f-229">107
                        </ix:nonFraction>
                    </span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3"
                            name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-230">1</ix:nonFraction>
                        &#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3"
                            name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3"
                            id="f-231">1,669</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3"
                            id="f-232">1,670</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impact
                        of cash contribution to Topco LLC, exchange and forfeiture of LLC Units, and forfeiture of Class
                        B common stock by MLSH 1</span></td>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="shares" contextRef="c-29" decimals="-3" sign="-"
                            name="mrvi:NoncontrollingInterestIncreaseFromCashDistributionShares"
                            format="ixt:num-dot-decimal" scale="3" id="f-233">2,571</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-"
                            name="mrvi:NoncontrollingInterestIncreaseFromCashDistributionValue" scale="3" id="f-234">25
                        </ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-"
                            name="mrvi:NoncontrollingInterestIncreaseFromCashDistributionValue"
                            format="ixt:num-dot-decimal" scale="3" id="f-235">46,206</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3"
                            name="mrvi:NoncontrollingInterestIncreaseFromCashDistributionValue"
                            format="ixt:num-dot-decimal" scale="3" id="f-236">51,451</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="mrvi:NoncontrollingInterestIncreaseFromCashDistributionValue"
                            format="ixt:num-dot-decimal" scale="3" id="f-237">5,220</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-controlling
                        interest adjustment for changes in proportionate ownership in Topco LLC</span></td>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-"
                            name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3"
                            id="f-238">809</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3"
                            name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3"
                            id="f-239">809</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"
                            format="ixt:fixed-zero" scale="3" id="f-240">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-based
                            compensation</span></div>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3"
                            name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"
                            format="ixt:num-dot-decimal" scale="3" id="f-241">4,645</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3"
                            name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"
                            format="ixt:num-dot-decimal" scale="3" id="f-242">5,813</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"
                            format="ixt:num-dot-decimal" scale="3" id="f-243">10,458</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distribution
                        for tax liabilities to non-controlling interest holder</span></td>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3"
                            name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"
                            scale="3" id="f-244">41</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3"
                            name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"
                            format="ixt:num-dot-decimal" scale="3" id="f-245">153,451</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"
                            format="ixt:num-dot-decimal" scale="3" id="f-246">153,492</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net
                        income</span></td>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span>
                </td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:ProfitLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-247">182,037</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:ProfitLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-248">287,213</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ProfitLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-249">469,250</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign
                        currency translation adjustment</span></td>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3"
                            name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"
                            scale="3" id="f-250">44</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3"
                            name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"
                            scale="3" id="f-251">11</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"
                            scale="3" id="f-252">55</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December
                        31, 2021</span></td>
                <td colspan="3"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="shares" contextRef="c-34" decimals="-3"
                            name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3"
                            id="f-253">131,488</ix:nonFraction>
                    </span></td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-254">1,315</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="shares" contextRef="c-35" decimals="-3"
                            name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3"
                            id="f-255">123,669</ix:nonFraction>
                    </span></td>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-256">1,237</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-257">128,386</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-258">184,561</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:fixed-zero" scale="3" id="f-259">&#8212;</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-260">229,862</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-261">545,361</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance
                        of Class A common stock under employee equity plans, net of shares withheld for employee
                        taxes</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-3"
                            name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="f-262">204
                        </ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3"
                            name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-263">2</ix:nonFraction>
                        &#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3"
                            name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3"
                            id="f-264">2,303</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3"
                            id="f-265">2,305</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
        </table>
    </div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-bottom:10pt;margin-top:10pt">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:13.416%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:6.378%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:7.111%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:6.378%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:7.111%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:7.551%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:7.551%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.630%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:7.551%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:9.459%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class
                        A Common Stock</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class
                        B Common Stock</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional
                        Paid-In Capital</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained
                        Earnings</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated
                        Other Comprehensive Income (Loss)</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-controlling
                        Interest</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total
                            Stockholders&#8217; Equity</span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-controlling
                        interest adjustment for changes in proportionate ownership in Topco LLC</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-"
                            name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3"
                            id="f-266">864</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3"
                            name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3"
                            id="f-267">864</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"
                            format="ixt:fixed-zero" scale="3" id="f-268">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-based
                            compensation</span></div>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3"
                            name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"
                            format="ixt:num-dot-decimal" scale="3" id="f-269">9,623</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3"
                            name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"
                            format="ixt:num-dot-decimal" scale="3" id="f-270">9,047</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"
                            format="ixt:num-dot-decimal" scale="3" id="f-271">18,670</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distribution
                        for tax liabilities to non-controlling interest holder</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-"
                            name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"
                            scale="3" id="f-272">141</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3"
                            name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"
                            format="ixt:num-dot-decimal" scale="3" id="f-273">150,206</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"
                            format="ixt:num-dot-decimal" scale="3" id="f-274">150,065</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impact
                        of change to deferred tax asset associated with cash contribution to Topco LLC</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3"
                            name="mrvi:AdjustmentsToAdditionalPaidInCapitalChangeInDeferredTaxAsset"
                            format="ixt:num-dot-decimal" scale="3" id="f-275">1,691</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="mrvi:AdjustmentsToAdditionalPaidInCapitalChangeInDeferredTaxAsset"
                            format="ixt:num-dot-decimal" scale="3" id="f-276">1,691</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net
                        income</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:ProfitLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-277">220,205</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:ProfitLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-278">270,458</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProfitLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-279">490,663</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December
                        31, 2022</span></td>
                <td colspan="3"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="shares" contextRef="c-45" decimals="-3"
                            name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3"
                            id="f-280">131,692</ix:nonFraction>
                    </span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-281">1,317</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="shares" contextRef="c-46" decimals="-3"
                            name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3"
                            id="f-282">123,669</ix:nonFraction>
                    </span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-283">1,237</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-284">137,898</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-285">404,766</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:fixed-zero" scale="3" id="f-286">&#8212;</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-287">360,025</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-288">905,243</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effects
                        of Structuring Transactions</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="shares" contextRef="c-51" decimals="-3"
                            name="mrvi:EffectsOfOrganizationalTransactionsShares" format="ixt:num-dot-decimal" scale="3"
                            id="f-289">4,575</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-"
                            name="mrvi:EffectsOfOrganizationalTransactionsValue" scale="3" id="f-290">46
                        </ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-"
                            name="mrvi:EffectsOfOrganizationalTransactionsValue" format="ixt:num-dot-decimal" scale="3"
                            id="f-291">25,404</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3"
                            name="mrvi:EffectsOfOrganizationalTransactionsValue" format="ixt:num-dot-decimal" scale="3"
                            id="f-292">26,392</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="mrvi:EffectsOfOrganizationalTransactionsValue" scale="3" id="f-293">942
                        </ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance
                        of Class A common stock under employee equity plans, net of shares withheld for employee
                        taxes</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="shares" contextRef="c-54" decimals="-3"
                            name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="f-294">536
                        </ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3"
                            name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-295">5</ix:nonFraction>
                        &#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3"
                            name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-296">116
                        </ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-297">121
                        </ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-controlling
                        interest adjustment for changes in proportionate ownership in Topco LLC</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3"
                            name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3"
                            id="f-298">754</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" sign="-"
                            name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest" scale="3"
                            id="f-299">754</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest"
                            format="ixt:fixed-zero" scale="3" id="f-300">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity-based
                            compensation</span></div>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3"
                            name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"
                            format="ixt:num-dot-decimal" scale="3" id="f-301">18,167</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3"
                            name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"
                            format="ixt:num-dot-decimal" scale="3" id="f-302">16,421</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"
                            format="ixt:num-dot-decimal" scale="3" id="f-303">34,588</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Distribution
                        for tax liabilities to non-controlling interest holder</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3"
                            name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"
                            format="ixt:num-dot-decimal" scale="3" id="f-304">9,607</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"
                            format="ixt:num-dot-decimal" scale="3" id="f-305">9,607</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impact
                            of change to deferred tax asset associated with equity-based compensation</span></div>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3"
                            name="mrvi:AdjustmentsToAdditionalPaidInCapitalChangeInDeferredTaxAsset"
                            format="ixt:num-dot-decimal" scale="3" id="f-306">3,028</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="mrvi:AdjustmentsToAdditionalPaidInCapitalChangeInDeferredTaxAsset"
                            format="ixt:num-dot-decimal" scale="3" id="f-307">3,028</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net
                        loss</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" sign="-" name="us-gaap:ProfitLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-308">119,029</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" sign="-" name="us-gaap:ProfitLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-309">19,346</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-310">138,375</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December
                        31, 2023</span></td>
                <td colspan="3"
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="shares" contextRef="c-56" decimals="-3"
                            name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3"
                            id="f-311">132,228</ix:nonFraction>
                    </span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-312">1,322</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3"
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="-3"
                            name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3"
                            id="f-313">119,094</ix:nonFraction>
                    </span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-314">1,191</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-315">128,503</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-316">285,737</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:fixed-zero" scale="3" id="f-317">&#8212;</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-318">373,131</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                            name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"
                            format="ixt:num-dot-decimal" scale="3" id="f-319">789,884</ix:nonFraction>
                    </span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
        </table>
    </div>
    <div style="margin-top:18pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The
            accompanying notes are an integral part of the consolidated financial statements.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_190"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:10pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MARAVAI
            LIFESCIENCES HOLDINGS, INC.</span></div>
    <div style="text-align:center"><span><br /></span></div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED
            STATEMENTS OF CASH FLOWS</span></div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in
            thousands)</span></div>
    <div style="margin-bottom:10pt;margin-top:10pt;text-align:center">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:62.243%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.630%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.630%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.631%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="15"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December
                        31,</span></td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating
                        activities:</span></td>
                <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                        (loss) income</span></td>
                <td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-320">138,375</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProfitLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-321">490,663</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ProfitLoss"
                            format="ixt:num-dot-decimal" scale="3" id="f-322">469,250</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments
                            to reconcile net (loss) income to net cash provided by operating activities:</span></div>
                </td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation"
                            format="ixt:num-dot-decimal" scale="3" id="f-323">12,898</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:Depreciation"
                            format="ixt:num-dot-decimal" scale="3" id="f-324">7,566</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:Depreciation"
                            format="ixt:num-dot-decimal" scale="3" id="f-325">6,413</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization
                        of intangible assets</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3"
                            id="f-326">27,356</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3"
                            id="f-327">24,269</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3"
                            id="f-328">18,339</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="padding-left:18pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization
                            of operating lease right-of-use assets</span></div>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal"
                            scale="3" id="f-329">8,527</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal"
                            scale="3" id="f-330">6,268</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal"
                            scale="3" id="f-331">8,792</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization
                        of deferred financing costs</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3"
                            id="f-332">2,929</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3"
                            id="f-333">2,788</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3"
                            id="f-334">2,676</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based
                        compensation expense</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-335">
                            34,588</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-336">
                            18,670</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-337">
                            10,458</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss
                        on extinguishment of debt</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3"
                            id="f-338">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-"
                            name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="f-339">208</ix:nonFraction>
                        &#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3"
                            id="f-340">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred
                        income taxes</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3"
                            id="f-341">754,942</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3"
                            id="f-342">42,318</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3"
                            id="f-343">46,904</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change
                        in estimated fair value of contingent consideration</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                            name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"
                            format="ixt:num-dot-decimal" scale="3" id="f-344">3,286</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-"
                            name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"
                            format="ixt:num-dot-decimal" scale="3" id="f-345">7,800</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"
                            format="ixt:fixed-zero" scale="3" id="f-346">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain
                        on sale of business</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="f-347">&#8212;
                        </ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="f-348">&#8212;
                        </ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="3" id="f-349">
                            11,249</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation
                        of liabilities under the Tax Receivable Agreement</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="mrvi:GainLossOnTaxReceivableAgreement" format="ixt:num-dot-decimal" scale="3"
                            id="f-350">668,886</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-"
                            name="mrvi:GainLossOnTaxReceivableAgreement" format="ixt:num-dot-decimal" scale="3"
                            id="f-351">4,102</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="mrvi:GainLossOnTaxReceivableAgreement" format="ixt:num-dot-decimal" scale="3"
                            id="f-352">6,101</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-353">
                            2,313</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-354">
                            7,993</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="f-355">281</ix:nonFraction>)</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes
                        in operating assets and liabilities:</span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts
                        receivable</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                            name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3"
                            id="f-356">84,395</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3"
                            id="f-357">22,272</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3"
                            id="f-358">70,391</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                            name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="f-359">649</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-"
                            name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3"
                            id="f-360">9,459</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3"
                            id="f-361">21,574</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid
                        expenses and other assets</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                            name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"
                            format="ixt:num-dot-decimal" scale="3" id="f-362">8,136</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"
                            format="ixt:num-dot-decimal" scale="3" id="f-363">52,873</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"
                            format="ixt:num-dot-decimal" scale="3" id="f-364">9,513</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government
                        funding receivable</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="mrvi:IncreaseDecreaseInGovernmentFundingReceivable" format="ixt:fixed-zero" scale="3"
                            id="f-365">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-"
                            name="mrvi:IncreaseDecreaseInGovernmentFundingReceivable" format="ixt:num-dot-decimal"
                            scale="3" id="f-366">16,973</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="mrvi:IncreaseDecreaseInGovernmentFundingReceivable" format="ixt:fixed-zero" scale="3"
                            id="f-367">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts
                        payable</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3"
                            id="f-368">5,284</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-"
                            name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3"
                            id="f-369">1,578</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-370">676</ix:nonFraction>
                        &#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued
                        expenses and other current liabilities</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3"
                            id="f-371">15,108</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3"
                            id="f-372">8,503</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-"
                            name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3"
                            id="f-373">3,457</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred
                        revenue</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-374">250
                        </ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-"
                            name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal"
                            scale="3" id="f-375">7,123</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-"
                            name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal"
                            scale="3" id="f-376">67,851</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3"
                    style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other
                        long-term liabilities</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                            name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal"
                            scale="3" id="f-377">15,978</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal"
                            scale="3" id="f-378">3,829</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-"
                            name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal"
                            scale="3" id="f-379">4,521</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                        cash provided by operating activities</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal"
                            scale="3" id="f-380">126,224</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal"
                            scale="3" id="f-381">535,977</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal"
                            scale="3" id="f-382">368,570</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing
                        activities:</span></td>
                <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash
                        paid for acquisition, net of cash acquired</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal"
                            scale="3" id="f-383">69,622</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal"
                            scale="3" id="f-384">238,969</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero"
                            scale="3" id="f-385">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases
                        of property and equipment</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal"
                            scale="3" id="f-386">65,553</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal"
                            scale="3" id="f-387">17,090</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal"
                            scale="3" id="f-388">14,850</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds
                            from government assistance allocated to property and equipment</span></div>
                </td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="mrvi:ProceedsFromGovernmentAssistanceAllocatedToPropertyAndEquipment"
                            format="ixt:num-dot-decimal" scale="3" id="f-389">12,865</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="mrvi:ProceedsFromGovernmentAssistanceAllocatedToPropertyAndEquipment"
                            format="ixt:num-dot-decimal" scale="3" id="f-390">1,105</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="mrvi:ProceedsFromGovernmentAssistanceAllocatedToPropertyAndEquipment"
                            format="ixt:fixed-zero" scale="3" id="f-391">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid
                        lease payments on finance lease yet to commence</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="mrvi:FinanceLeasePrepaymentsLeaseNotYetCommenced" format="ixt:fixed-zero" scale="3"
                            id="f-392">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="mrvi:FinanceLeasePrepaymentsLeaseNotYetCommenced" format="ixt:num-dot-decimal"
                            scale="3" id="f-393">13,278</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="mrvi:FinanceLeasePrepaymentsLeaseNotYetCommenced" format="ixt:fixed-zero" scale="3"
                            id="f-394">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds
                        from sale of building</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:ProceedsFromSaleOfBuildings" format="ixt:fixed-zero" scale="3" id="f-395">
                            &#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:ProceedsFromSaleOfBuildings" format="ixt:fixed-zero" scale="3" id="f-396">
                            &#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:ProceedsFromSaleOfBuildings" scale="3" id="f-397">548</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds
                        from sale of business, net of cash divested</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" format="ixt:fixed-zero"
                            scale="3" id="f-398">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="3" id="f-399">620
                        </ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested"
                            format="ixt:num-dot-decimal" scale="3" id="f-400">119,957</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                        cash (used in) provided by investing activities</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                            name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal"
                            scale="3" id="f-401">122,310</ix:nonFraction>)</span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-"
                            name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal"
                            scale="3" id="f-402">267,612</ix:nonFraction>)</span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal"
                            scale="3" id="f-403">105,655</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing
                        activities:</span></td>
                <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions
                        to non-controlling interests holders</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:PaymentsOfDividendsMinorityInterest" format="ixt:num-dot-decimal" scale="3"
                            id="f-404">9,607</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:PaymentsOfDividendsMinorityInterest" format="ixt:num-dot-decimal" scale="3"
                            id="f-405">150,206</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:PaymentsOfDividendsMinorityInterest" format="ixt:num-dot-decimal" scale="3"
                            id="f-406">153,451</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds
                        from borrowings of long-term debt, net of discount</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3"
                            id="f-407">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3"
                            id="f-408">8,455</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3"
                            id="f-409">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal
                        repayments of long-term debt</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-410">
                            5,440</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-411">
                            13,895</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-412">
                            6,000</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments
                        of finance lease liabilities</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-413">332</ix:nonFraction>
                        )</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:fixed-zero" scale="3" id="f-414">
                            &#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:fixed-zero" scale="3" id="f-415">
                            &#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds
                        from derivative instruments</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities"
                            format="ixt:num-dot-decimal" scale="3" id="f-416">6,168</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" format="ixt:fixed-zero"
                            scale="3" id="f-417">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:ProceedsFromDerivativeInstrumentFinancingActivities" format="ixt:fixed-zero"
                            scale="3" id="f-418">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment
                        of acquisition consideration holdback</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="mrvi:PaymentOfAcquisitionContingentConsiderationHoldback" format="ixt:num-dot-decimal"
                            scale="3" id="f-419">9,706</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="mrvi:PaymentOfAcquisitionContingentConsiderationHoldback" format="ixt:fixed-zero"
                            scale="3" id="f-420">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="mrvi:PaymentOfAcquisitionContingentConsiderationHoldback" format="ixt:fixed-zero"
                            scale="3" id="f-421">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments
                        to MLSH 1 pursuant to the Tax Receivable Agreement</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3"
                            name="mrvi:PaymentsForTaxReceivableAgreement" format="ixt:num-dot-decimal" scale="3"
                            id="f-422">35,661</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3"
                            name="mrvi:PaymentsForTaxReceivableAgreement" format="ixt:num-dot-decimal" scale="3"
                            id="f-423">29,108</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3"
                            name="mrvi:PaymentsForTaxReceivableAgreement" format="ixt:num-dot-decimal" scale="3"
                            id="f-424">1,115</ix:nonFraction>)</span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments
                        to MLSH 2 pursuant to the Tax Receivable Agreement</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3"
                            name="mrvi:PaymentsForTaxReceivableAgreement" format="ixt:num-dot-decimal" scale="3"
                            id="f-425">6,492</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3"
                            name="mrvi:PaymentsForTaxReceivableAgreement" format="ixt:num-dot-decimal" scale="3"
                            id="f-426">5,103</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3"
                            name="mrvi:PaymentsForTaxReceivableAgreement" scale="3" id="f-427">192</ix:nonFraction>
                        )</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares
                        withheld for employee taxes, net of proceeds from issuance of Class A common stock under
                        employee equity plans</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                            name="mrvi:ShareBasedPaymentArrangementValueSharesWithheldForTaxWithholdingObligation"
                            scale="3" id="f-428">20</ix:nonFraction>)</span></td>
                <td
                    style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="mrvi:ShareBasedPaymentArrangementValueSharesWithheldForTaxWithholdingObligation"
                            format="ixt:num-dot-decimal" scale="3" id="f-429">2,358</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="mrvi:ShareBasedPaymentArrangementValueSharesWithheldForTaxWithholdingObligation"
                            format="ixt:num-dot-decimal" scale="3" id="f-430">1,709</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
        </table>
    </div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-bottom:10pt;margin-top:10pt;text-align:center">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:62.243%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.630%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.630%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.533%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.631%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="15"
                    style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December
                        31,</span></td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                </td>
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3"
                    style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                            cash used in financing activities</span></div>
                </td>
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                            name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal"
                            scale="3" id="f-431">61,090</ix:nonFraction>)</span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-"
                            name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal"
                            scale="3" id="f-432">187,499</ix:nonFraction>)</span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-"
                            name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal"
                            scale="3" id="f-433">159,049</ix:nonFraction>)</span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effects
                        of exchange rate changes on cash</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"
                            format="ixt:fixed-zero" scale="3" id="f-434">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"
                            format="ixt:fixed-zero" scale="3" id="f-435">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-"
                            name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"
                            scale="3" id="f-436">88</ix:nonFraction>)</span></td>
                <td
                    style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                        (decrease) increase in cash and cash equivalents</span></td>
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                            name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"
                            format="ixt:num-dot-decimal" scale="3" id="f-437">57,176</ix:nonFraction>)</span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"
                            format="ixt:num-dot-decimal" scale="3" id="f-438">80,866</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"
                            format="ixt:num-dot-decimal" scale="3" id="f-439">315,088</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash
                        and cash equivalents, beginning of period</span></td>
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                            name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"
                            format="ixt:num-dot-decimal" scale="3" id="f-440">632,138</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3"
                            name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"
                            format="ixt:num-dot-decimal" scale="3" id="f-441">551,272</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="2"
                    style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3"
                            name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"
                            format="ixt:num-dot-decimal" scale="3" id="f-442">236,184</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash
                        and cash equivalents, end of period</span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                            name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"
                            format="ixt:num-dot-decimal" scale="3" id="f-443">574,962</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                            name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"
                            format="ixt:num-dot-decimal" scale="3" id="f-444">632,138</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3"
                            name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"
                            format="ixt:num-dot-decimal" scale="3" id="f-445">551,272</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental
                        cash flow information:</span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash
                        paid for interest</span></td>
                <td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet"
                            format="ixt:num-dot-decimal" scale="3" id="f-446">44,256</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestPaidNet"
                            format="ixt:num-dot-decimal" scale="3" id="f-447">20,198</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:InterestPaidNet"
                            format="ixt:num-dot-decimal" scale="3" id="f-448">27,234</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash
                        (refunded) paid for income taxes, net</span></td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                            name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-449">2,987
                        </ix:nonFraction>)</span></td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxesPaidNet"
                            format="ixt:num-dot-decimal" scale="3" id="f-450">23,032</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:IncomeTaxesPaidNet"
                            format="ixt:num-dot-decimal" scale="3" id="f-451">22,473</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental
                        disclosures of non-cash activities:</span></td>
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property
                        and equipment included in accounts payable and accrued expenses</span></td>
                <td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal"
                            scale="3" id="f-452">2,011</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal"
                            scale="3" id="f-453">1,701</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal"
                            scale="3" id="f-454">2,149</ix:nonFraction>&#160;
                    </span></td>
                <td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued
                        receivable for capital expenditures to be reimbursed under a government contract</span></td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="mrvi:AccruedReceivableForCapitalExpendituresToBeReimbursedUnderGovernmentContract"
                            format="ixt:num-dot-decimal" scale="3" id="f-455">1,118</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="mrvi:AccruedReceivableForCapitalExpendituresToBeReimbursedUnderGovernmentContract"
                            format="ixt:fixed-zero" scale="3" id="f-456">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="mrvi:AccruedReceivableForCapitalExpendituresToBeReimbursedUnderGovernmentContract"
                            format="ixt:fixed-zero" scale="3" id="f-457">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use
                        assets obtained in exchange for new finance lease liabilities</span></td>
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"
                            format="ixt:num-dot-decimal" scale="3" id="f-458">32,862</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"
                            format="ixt:fixed-zero" scale="3" id="f-459">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"
                            format="ixt:fixed-zero" scale="3" id="f-460">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use
                        assets obtained in exchange for new operating lease liabilities</span></td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"
                            format="ixt:num-dot-decimal" scale="3" id="f-461">3,931</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"
                            format="ixt:num-dot-decimal" scale="3" id="f-462">17,513</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"
                            format="ixt:fixed-zero" scale="3" id="f-463">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
                <td colspan="3" style="display:none" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair
                        value of contingent consideration liability recorded in connection with acquisition of a
                        business</span></td>
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="mrvi:NoncashBusinessCombinationContingentConsiderationArrangementsLiability"
                            format="ixt:num-dot-decimal" scale="3" id="f-464">5,289</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="mrvi:NoncashBusinessCombinationContingentConsiderationArrangementsLiability"
                            format="ixt:num-dot-decimal" scale="3" id="f-465">7,800</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="mrvi:NoncashBusinessCombinationContingentConsiderationArrangementsLiability"
                            format="ixt:fixed-zero" scale="3" id="f-466">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued
                        consideration payable for MyChem acquisition</span></td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1" format="ixt:fixed-zero"
                            scale="3" id="f-467">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1" format="ixt:num-dot-decimal"
                            scale="3" id="f-468">10,000</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1" format="ixt:fixed-zero"
                            scale="3" id="f-469">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition
                            of deferred tax assets as a result of exchanges of LLC Units and cash contribution</span>
                    </div>
                </td>
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="mrvi:ConversionOfStockDeferredTaxAsset" format="ixt:fixed-zero" scale="3" id="f-470">
                            &#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="mrvi:ConversionOfStockDeferredTaxAsset" format="ixt:fixed-zero" scale="3" id="f-471">
                            &#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="mrvi:ConversionOfStockDeferredTaxAsset" format="ixt:num-dot-decimal" scale="3"
                            id="f-472">423,361</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
            <tr>
                <td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition
                        of liabilities under the Tax Receivable Agreement</span></td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                            name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"
                            format="ixt:fixed-zero" scale="3" id="f-473">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                            name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"
                            format="ixt:fixed-zero" scale="3" id="f-474">&#8212;</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                </td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom">
                    <span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                        <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                            name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"
                            format="ixt:num-dot-decimal" scale="3" id="f-475">366,179</ix:nonFraction>&#160;
                    </span></td>
                <td
                    style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
            </tr>
        </table>
    </div>
    <div style="margin-top:18pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The
            accompanying notes are an integral part of the consolidated financial statements.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_193"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:10pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MARAVAI
            LIFESCIENCES HOLDINGS, INC.</span></div>
    <div style="text-align:center"><span><br /></span></div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES
            TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_196"></div>
    <div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span>
        <ix:nonNumeric contextRef="c-1"
            name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"
            id="f-476" continuedAt="f-476-1" escape="true"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Organization
                and Significant Accounting Policies</span></ix:nonNumeric>
    </div>
    <ix:continuation id="f-476-1" continuedAt="f-476-2">
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description
                of Business</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maravai
                LifeSciences Holdings, Inc. (the &#8220;Company&#8221;, and together with its consolidated subsidiaries,
                &#8220;Maravai&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, and &#8220;our&#8221;) provides critical
                products to enable the development of drugs, therapeutics, diagnostics, vaccines and support research on
                human diseases. Our products address the key phases of biopharmaceutical development and include complex
                nucleic acids for diagnostic and therapeutic applications and antibody-based products to detect
                impurities during the production of biopharmaceutical products.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                Company is headquartered in San Diego, California and has historically operated in <ix:nonFraction
                    unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments"
                    format="ixt-sec:numwordsen" scale="0" id="f-477">three</ix:nonFraction> principal businesses:
                Nucleic Acid Production, Biologics Safety Testing and Protein Detection. In September 2021, the Company
                completed the divestiture of its Protein Detection business (see Note 2). Our Nucleic Acid Production
                business manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside
                chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical
                synthesis, modification, labelling and purification of deoxyribonucleic acid (&#8220;DNA&#8221;) and
                ribonucleic acid (&#8220;RNA&#8221;). Our core Nucleic Acid Production offerings include messenger
                ribonucleic acid (&#8220;mRNA&#8221;), long and short oligonucleotides, our proprietary CleanCap&#174;
                capping technology and oligonucleotide building blocks, and custom enzyme development and manufacturing.
                Our Biologics Safety Testing business sells highly specialized analytical products for use in biologic
                manufacturing process development, including custom product-specific development antibody and assay
                development services. Our Protein Detection business sold innovative labeling and detection reagents for
                researchers in immunohistochemistry.</span></div>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization</span>
        </div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
                were incorporated as a Delaware corporation in August 2020 for the purpose of facilitating an initial
                public offering (&#8220;IPO&#8221;). Immediately prior to the IPO, we effected a series of
                organizational transactions (the &#8220;Organizational Transactions&#8221;), which, together with the
                IPO, were completed in November 2020, that resulted in the Company operating, controlling all of the
                business affairs and becoming the ultimate parent company of Maravai Topco Holdings, LLC (&#8220;Topco
                LLC&#8221;) and its consolidated subsidiaries. Maravai Life Sciences Holdings, LLC (&#8220;MLSH
                1&#8221;), which is controlled by investment entities affiliated with GTCR, is the only other member of
                Topco LLC.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                Company is the sole managing member of Topco LLC, which operates and controls TriLink Biotechnologies,
                LLC (&#8220;TriLink&#8221;), Glen Research, LLC, MockV Solutions, LLC, Cygnus Technologies, LLC and
                Alphazyme, LLC (&#8220;Alphazyme&#8221;) and their respective subsidiaries. Prior to the Company&#8217;s
                divestiture of its Protein Detection business in September 2021, Topco LLC also operated and controlled
                Vector Laboratories, Inc. and its subsidiaries (&#8220;Vector&#8221;).</span></div>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-478" escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis
                    of Presentation</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company operates and controls all of the business and affairs of Topco LLC, and, through Topco LLC
                    and its subsidiaries, conducts its business. Because we manage and operate the business and control
                    the strategic decisions and day-to-day operations of Topco LLC and also have a substantial financial
                    interest in Topco LLC, we consolidate the financial results of Topco LLC, and a portion of our net
                    (loss) income is allocated to the non-controlling interests in Topco LLC held by MLSH 1.</span>
            </div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    accompanying consolidated financial statements have been prepared in accordance with accounting
                    principles generally accepted in the United States of America ("U.S. GAAP") pursuant to the rules
                    and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and include our
                    accounts and the accounts of our subsidiaries. </span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All
                    intercompany transactions and accounts between the businesses comprising the Company have been
                    eliminated in the accompanying consolidated financial statements.</span></div>
        </ix:nonNumeric>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="f-479"
            escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Variable
                    Interest Entities</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company consolidates all entities that it controls through a majority voting interest or as the
                    primary beneficiary of a variable interest entity (&#8220;VIE&#8221;). In determining whether the
                    Company is the primary beneficiary of an entity, the Company applies a qualitative approach that
                    determines whether it has both (i) the power to direct the economically significant activities of
                    the entity and (ii) the obligation to absorb losses of, or the right to receive benefits from, the
                    entity that could potentially be significant to that entity. The Company&#8217;s determination about
                    whether it should consolidate such VIEs is made continuously as changes to existing relationships or
                    future transactions may result in a consolidation event.</span></div>
        </ix:nonNumeric>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-476-2" continuedAt="f-476-3">
        <ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-480" escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use
                    of Estimates</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    preparation of consolidated financial statements in accordance with GAAP requires the Company to
                    make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities,
                    equity, revenue and expenses, and related disclosures. These estimates form the basis for judgments
                    the Company makes about the carrying values of assets and liabilities that are not readily apparent
                    from other sources. The Company bases its estimates and judgments on historical experience and on
                    various other assumptions that the Company believes are reasonable under the circumstances. These
                    estimates are based on management&#8217;s knowledge about current events and expectations about
                    actions the Company may undertake in the future. Significant estimates include, but are not limited
                    to, the measurement of right-of-use assets and lease liabilities and related incremental borrowing
                    rate, the payable to related parties pursuant to the Tax Receivable Agreement (as defined in Note
                    14), the realizability of our net deferred tax assets, and valuation of goodwill and intangible
                    assets acquired in business combinations. Actual results could differ materially from those
                    estimates.</span></div>
        </ix:nonNumeric>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-481"
            continuedAt="f-481-1" escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue
                    Recognition</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company generates revenue primarily from the sale of products, and to a much lesser extent, services
                    in the fields of nucleic acid production and biologics safety testing. Prior to September 2021, the
                    Company also generated revenue from its Protein Detection business. Products are sold primarily
                    through a direct sales force and through distributors in certain international markets where the
                    Company does not have a direct commercial presence.</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue
                    is recognized when control of promised goods or services is transferred to a customer or distributor
                    in an amount that reflects the consideration to which the entity expects to be entitled in exchange
                    for those goods or services. Distributors are the principal in all sales transactions with its
                    customers. To determine revenue recognition for its arrangements with customers, the Company
                    performs the following five steps: (i)&#160;identify the contract(s) with a customer;
                    (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction
                    price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and
                    (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. </span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    majority of the Company&#8217;s contracts include only one performance obligation. A performance
                    obligation is a promise in a contract to transfer a distinct good or service to the customer and is
                    defined as the unit of account for revenue recognition. The Company also recognizes revenue from
                    other contracts that may include a combination of products and services, the provision of solely
                    services, or from license fee arrangements which may be associated with the delivery of product.
                    Where there is a combination of products and services, the Company accounts for the promises as
                    individual performance obligations if they are concluded to be distinct. Performance obligations are
                    considered distinct if they are both capable of being distinct and distinct within the context of
                    the contract. In determining whether performance obligations meet the criteria for being distinct,
                    the Company considers a number of factors, such as the degree of interrelation and interdependence
                    between obligations, and whether or not the good or service significantly modifies or transforms
                    another good or service in the contract. As a practical expedient, we do not adjust the transaction
                    price for the effects of a significant financing component if, at contract inception, the period
                    between customer payment and the transfer of goods or services is expected to be one year or less.
                    Contracts with customers are evaluated on a contract-by-contract basis as contracts may include
                    multiple types of goods and services as described below.</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue
                    from sales to customers through distributors are recognized consistent with the policies and
                    practices for direct sales to customers, as described above.</span></div>
            <div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nucleic
                    Acid Production</span></div>
            <div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nucleic
                    Acid Production revenue is generated from the manufacture and sale of highly modified, complex
                    nucleic acids products to support the needs of our of customers&#8217; research, therapeutic and
                    vaccine programs. The primary offering of products includes CleanCap, mRNA, specialized
                    oligonucleotides, and enzymes. Contracts typically consist of a single performance obligation. We
                    also sell nucleic acid products for labeling and detecting proteins in cells and tissue samples
                    research. The Company recognizes revenue from these products in the period in which the performance
                    obligation is satisfied by transferring control to the customer or distributor. Revenue for nucleic
                    acid catalog products is recognized at a single point in time, generally upon shipment to the
                    customer or distributor. Revenue for contracts for certain custom nucleic acid products, with an
                    enforceable right to payment and a reasonable margin for work performed to date, is recognized over
                    time, based on a cost-to-cost input method over the manufacturing period. Payments received from
                    customers in advance of manufacturing their products is recorded as deferred revenue until the
                    products were delivered.</span></div>
            <div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biologics
                    Safety Testing</span></div>
            <div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company&#8217;s Biologics Safety Testing revenue is associated with the sale of host cell protein,
                    bioprocess impurity detection, viral clearance prediction kits and associated products. We also
                    enter into contracts that include custom </span></div>
        </ix:nonNumeric>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-476-3" continuedAt="f-476-4">
        <ix:continuation id="f-481-1" continuedAt="f-481-2">
            <div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">antibody
                    development, assay development, antibody affinity extraction and mass spectrometry services. These
                    products and services enable the detection of impurities that occur in the manufacturing of biologic
                    drugs and other therapeutics including cell and gene therapies. The Company recognizes revenue from
                    the sale of kits and products in the period in which the performance obligation is satisfied by
                    transferring control to the customer. Custom antibody development contracts consist of a single
                    performance obligation, typically with an enforceable right to payment and a reasonable margin for
                    work performed to date. Revenue is recognized over time based on a cost-to-cost input method over
                    the contract term. Where an enforceable right to payment does not exist, revenue is recognized at a
                    point in time when control is transferred to the customer. Assay development service contracts
                    consist of a single performance obligation, revenue is recognized at a point in time when a
                    successful antigen test and report is provided to the customer. Affinity extraction, mass
                    spectrometry and other analytical services, which generally occur over a short period of time,
                    consist of a single performance obligation to perform the service and provide a summary report to
                    the customer. Revenue is recognized upon delivery of the report to the customer.</span></div>
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company elected the practical expedient to&#160;not&#160;disclose the unfulfilled performance
                    obligations for contracts with an original length of&#160;one&#160;year or less.&#160;The Company
                    had no material unfulfilled performance obligations for contracts with an original length greater
                    than&#160;one year for any period presented.</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company accepts returns only if the products do not meet customer specifications and historically,
                    the Company&#8217;s volume of product returns has not been significant. Further, no warranties are
                    provided for promised goods and services other than assurance type warranties.</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue
                    for an individual contract is recognized at the related transaction price, which is the amount the
                    Company expects to be entitled to in exchange for transferring the products and/or services. The
                    transaction price for product sales is calculated at the contracted product selling price. The
                    transaction price for a contract with multiple performance obligations is allocated to the separate
                    performance obligations on a relative standalone selling price basis. Standalone selling prices for
                    products are determined based on the prices charged to customers, which are directly observable.
                    Standalone selling price of services are mostly based on time and materials. Generally, payments
                    from customers are due when goods and services are transferred. As most contracts contain a single
                    performance obligation, the transaction price is representative of the standalone selling price
                    charged to customers. Revenue is recognized only to the extent that it is probable that a
                    significant reversal of the cumulative amount recognized will not occur in future periods. Variable
                    consideration has not been material to our consolidated financial statements.</span></div>
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales
                    taxes</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales
                    taxes collected by the Company are not included in the transaction price as revenue as they are
                    ultimately remitted to a governmental authority.</span></div>
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shipping
                    and handling costs</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company has elected to account for shipping and handling activities related to contracts with
                    customers as costs to fulfill the promise to transfer the associated products. Accordingly, revenue
                    for shipping and handling is recognized at the same time that the related product revenue is
                    recognized.</span></div>
            <div style="margin-top:12pt"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract
                    costs</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company recognizes the incremental costs of obtaining contracts as an expense when incurred when the
                    amortization period of the assets that otherwise would have been recognized is one year or less.
                    These costs are included in sales and marketing and general and administrative expenses. The costs
                    to fulfill the contracts are determined to be immaterial and are recognized as an expense when
                    incurred.</span></div>
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract
                    balances</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract
                    assets are generated when contractual billing schedules differ from revenue recognition timing and
                    the Company records contract receivable when it has an unconditional right to consideration. There
                    were <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF"
                        name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="6" id="f-482">
                        <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF"
                            name="us-gaap:ContractWithCustomerAssetNet" format="ixt:fixed-zero" scale="6" id="f-483">no
                        </ix:nonFraction>
                    </ix:nonFraction> contract asset balances as of December&#160;31, 2023 or 2022.</span></div>
        </ix:continuation>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
                <ix:continuation id="f-481-2" continuedAt="f-481-3">Contract liabilities include billings in excess of
                    revenue recognized, such as customer deposits and deferred revenue. Customer deposits, which are
                    included in accrued expenses, are recorded when cash payments are received or due in advance of
                    performance. Deferred revenue is recorded when the Company has unsatisfied performance obligations.
                </ix:continuation> Total contract liabilities were $<ix:nonFraction unitRef="usd" contextRef="c-5"
                    decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6"
                    id="f-484">5.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6"
                    decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6"
                    id="f-485">4.8</ix:nonFraction> million as of December&#160;31, 2023 and 2022, respectively.
                Contract liabilities are expected to be recognized into revenue within the next twelve months.
            </span></div>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-476-4" continuedAt="f-476-5">
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation
                of Revenue</span></div>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock"
            id="f-486" escape="true">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    following tables summarize the revenue by segment and region for the periods presented (in
                    thousands):</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:62.243%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.631%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year
                                Ended December 31, 2023</span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nucleic&#160;Acid
                                Production</span></td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Biologics
                                Safety Testing</span></td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North
                                America</span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-487">114,459</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-488">26,596</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-489">141,055</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe,
                                the Middle East and Africa</span></td>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-490">34,390</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-491">15,532</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-492">49,922</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia
                                Pacific</span></td>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-493">75,716</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-494">21,725</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-495">97,441</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin
                                and Central America</span></td>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3"
                                    id="f-496">204</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3"
                                    id="f-497">323</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3"
                                    id="f-498">527</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                revenue</span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-499">224,769</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-500">64,176</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-501">288,945</ix:nonFraction>
                            </span></td>
                    </tr>
                </table>
            </div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:62.243%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.631%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year
                                Ended December 31, 2022</span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nucleic&#160;Acid
                                Production</span></td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Biologics
                                Safety Testing</span></td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North
                                America</span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-502">312,119</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-503">27,354</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-504">339,473</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe,
                                the Middle East and Africa</span></td>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-505">415,298</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-506">17,628</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-507">432,926</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia
                                Pacific</span></td>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-508">85,508</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-509">24,286</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-510">109,794</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin
                                and Central America</span></td>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3"
                                    id="f-511">144</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3"
                                    id="f-512">664</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3"
                                    id="f-513">808</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                revenue</span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-514">813,069</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-515">69,932</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-516">883,001</ix:nonFraction>
                            </span></td>
                    </tr>
                </table>
            </div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:49.779%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.632%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year
                                Ended December 31, 2021</span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nucleic&#160;Acid
                                Production</span></td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Biologics
                                Safety Testing</span></td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Protein
                                Detection</span></td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North
                                America</span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-517">280,369</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-518">25,686</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-519">11,016</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-520">317,071</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe,
                                the Middle East and Africa</span></td>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-521">377,325</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-522">15,597</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-523">4,752</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-524">397,674</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia
                                Pacific</span></td>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-525">54,114</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-526">26,471</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-527">3,068</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-528">83,653</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin
                                and Central America</span></td>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3"
                                    id="f-529">56</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3"
                                    id="f-530">663</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3"
                                    id="f-531">123</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3"
                                    id="f-532">842</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                revenue</span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-533">711,864</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-534">68,417</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-535">18,959</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                    format="ixt:num-dot-decimal" scale="3" id="f-536">799,240</ix:nonFraction>
                            </span></td>
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total
                revenue is attributed to geographic regions based on the bill-to location of the transaction. For all
                periods presented, the majority of our revenue was recognized at a point in time.</span></div>
        <ix:continuation id="f-481-3" continuedAt="f-481-4">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping
                    and Handling Costs</span></div>
        </ix:continuation>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
                <ix:continuation id="f-481-4" continuedAt="f-481-5">Shipping and handling costs, which are charged to
                    customers, are included in revenue. Shipping and handling charges included in revenue were
                    approximately </ix:continuation>$<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5"
                    name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="f-537">3.5</ix:nonFraction>
                million, $<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="us-gaap:CostOfRevenue"
                    format="ixt:num-dot-decimal" scale="6" id="f-538">3.2</ix:nonFraction> million and $<ix:nonFraction
                    unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:CostOfRevenue"
                    format="ixt:num-dot-decimal" scale="6" id="f-539">3.6</ix:nonFraction> million for the years ended
                December&#160;31, 2023, 2022 and 2021, respectively. <ix:continuation id="f-481-5">Freight and supplies
                    costs directly associated with shipping products to customers are included as a component of cost of
                    revenue.</ix:continuation>
            </span></div>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-540" escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research
                    and Development</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research
                    and development (&#8220;R&amp;D&#8221;) expenses include personnel costs, including salaries,
                    benefits and equity-based compensation for laboratory personnel, outside contracted services, and
                    costs of supplies. R&amp;D costs are expensed as incurred. Payments made prior to the receipt of
                    goods or services to be used in R&amp;D are recognized as prepaid assets until the goods are
                    received or services are rendered.</span></div>
        </ix:nonNumeric>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="f-541" continuedAt="f-541-1"
            escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising
                    Costs</span></div>
        </ix:nonNumeric>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
                <ix:continuation id="f-541-1">The Company expenses advertising costs as incurred.</ix:continuation>
                Advertising costs incurred were approximately $<ix:nonFraction unitRef="usd" contextRef="c-1"
                    decimals="-5" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="f-542">
                    2.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5"
                    name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="f-543">2.5
                </ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5"
                    name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="f-544">1.3
                </ix:nonFraction> million during the years ended December&#160;31, 2023, 2022 and 2021, respectively.
            </span></div>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"
            id="f-545" continuedAt="f-545-1" escape="true">
            <div style="margin-top:12pt"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring
                    Costs</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring
                    costs relate to a cost realignment plan implemented by the Company in November 2023 to optimize
                    business operations and match them to current market conditions. Restructuring costs are comprised
                    of severance and other employee-related costs, facility and other exit costs, professional fees and
                    other restructuring costs. </span></div>
        </ix:nonNumeric>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-476-5" continuedAt="f-476-6">
        <ix:continuation id="f-545-1">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee
                    separation costs principally consist of one-time termination benefits and other post-employment
                    benefits. One-time termination benefits are expensed at the date the entity notifies the employee,
                    unless the employee must provide future service, in which case the benefits are expensed over the
                    future service period. Other post-employment benefits are expensed when the obligation is probable
                    and the benefit amounts are estimable. Other costs associated with restructuring activities,
                    including facility and other exist costs and professional fees, are expensed as they are
                    incurred.</span></div>
        </ix:continuation>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-546"
            escape="true">
            <div style="margin-top:12pt"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-Based
                    Compensation</span></div>
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based
                    Compensation</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company recognized stock-based compensation for all equity awards made to employees based upon the
                    awards&#8217; estimated grant date fair value. For equity awards that vest subject to the
                    satisfaction of service requirements, compensation expense is measured based on the fair value of
                    the award on the date of grant and expense is recognized on a straight-line basis over the requisite
                    service period, which is typically between <span style="-sec-ix-hidden:f-547">two</span> to
                    <ix:nonNumeric contextRef="c-119"
                        name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"
                        format="ixt-sec:durwordsen" id="f-548">four years</ix:nonNumeric>. We account for forfeitures as
                    they occur. Stock-based compensation is classified in the accompanying consolidated statements of
                    operations based on the function to which the related services are provided. </span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company estimates the fair value of stock option grants using the Black-Scholes option pricing
                    model. The assumptions used in estimating the fair value of these awards, such as expected term,
                    expected dividend yield, volatility and risk-free interest rate, represent management&#8217;s best
                    estimates and involve inherent uncertainties and the application of management&#8217;s judgment. If
                    actual results are not consistent with the Company&#8217;s assumptions and judgments used in making
                    these estimates, the Company may be required to increase or decrease compensation expense, which
                    could be material to the Company&#8217;s consolidated results of operations. </span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    fair value of restricted stock units (&#8220;RSUs&#8221;) is determined based on the number of
                    shares granted and the quoted market price of the Company&#8217;s Class A common stock on the date
                    of grant.</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For
                    performance stock units (&#8220;PSUs&#8221;) which are subject to service and market conditions,
                    compensation expense is measured based on the fair value of the award on the date of grant and
                    expense is recognized on a straight-line basis over the requisite service period regardless if the
                    market condition is satisfied. If the grantee is terminated prior to meeting both conditions, any
                    previously recognized expense is reversed. The Company estimates the fair value of PSUs using the
                    Monte Carlo simulation model. The assumptions used in estimating the fair value of these awards,
                    such as expected term, volatility and risk-free interest rate, represent management&#8217;s best
                    estimates and involve inherent uncertainties and the application of management&#8217;s
                    judgment.</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For
                    PSUs which are subject to a performance condition, compensation expense is recognized on a
                    straight-line basis over the requisite service period when the achievement of such performance
                    condition is determined probable, and upon achieving such performance condition that was not
                    previously considered as probable, records a cumulative catch-up adjustment to reflect the portion
                    of the grantee&#8217;s requisite service that has been provided to date. If a performance condition
                    is not determined probable or is not met, no compensation expense is recognized, and any previously
                    recognized expense is reversed. The fair value of such PSUs is determined based on the quoted market
                    price of the Company&#8217;s Class A common stock on the date of grant.</span></div>
            <div style="margin-top:12pt"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unit-Based
                    Compensation</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up
                    until the IPO, MLSH 1 had granted unit-based awards to certain executives of Topco LLC who are also
                    executives of the Company in the form of non-vested units. Topco LLC&#8217;s controlled subsidiary,
                    MLSC, also granted unit-based awards only to certain employees of its subsidiaries (collectively,
                    the &#8220;Incentive Units&#8221;). All awards of Incentive Units were measured based on the fair
                    value of the award on the date of grant. The Company recognizes compensation expense for MLSH 1
                    awards in its consolidated financial statements as MLSH 1 is considered to be the economic interest
                    holder in Topco LLC. Compensation expense for the Incentive Units is recognized over their requisite
                    service period. Forfeitures are recognized when they occur.</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    grant date fair value of Incentive Unit awards was determined by the Company&#8217;s Board of
                    Directors with the assistance of management and an independent third-party valuation
                    specialist.</span></div>
        </ix:nonNumeric>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-549" continuedAt="f-549-1"
            escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income
                    Taxes</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
                    are subject to U.S. federal and state income taxes. We are the controlling member of Topco LLC,
                    which has been, and will continue to be, treated as a partnership for U.S. federal and state income
                    tax purposes. Topco LLC&#8217;s previously wholly-owned U.S. subsidiary, Maravai Life Sciences, Inc.
                    (&#8220;Maravai Inc.&#8221;) and its subsidiaries, were taxpaying entities in the U.S., Canada, and
                    the U.K. Maravai Inc.&#8217;s subsidiaries were sold and Maravai Inc. ceased to be a regarded entity
                    and was deemed liquidated for U.S. tax purposes during the year ended December 31, 2021. Topco
                    LLC&#8217;s wholly-owned subsidiary, Maravai LifeSciences International Holdings, Inc., is a
                    taxpaying entity for U.S. and foreign jurisdictions and had limited activity subject to a transfer
                    pricing arrangement during the year ended December&#160;31, 2023. Topco LLC&#8217;s other
                    subsidiaries are treated as pass-through </span></div>
        </ix:nonNumeric>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-476-6" continuedAt="f-476-7">
        <ix:continuation id="f-549-1">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entities
                    for federal and state income tax purposes. The income or loss generated by these entities is not
                    taxed at the LLC level. As required by U.S. tax law, income or loss generated by these LLCs passes
                    through to their owners. As such, our tax provision consists solely of the activities of Maravai
                    Inc. and its subsidiaries, prior to their disposal, and Maravai LifeSciences International Holdings,
                    Inc., as well as our share of income or loss generated by Topco LLC. </span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
                    account for income taxes under the asset and liability method of accounting. Current income tax
                    expense or benefit represents the amount of income taxes expected to be payable or refundable for
                    the current year. We recognize deferred tax assets and liabilities for the future tax consequences
                    attributable to differences between the financial statement carrying amounts of existing assets and
                    liabilities and their respective tax bases, as well as for operating loss and tax credit
                    carryforwards. We measure deferred tax assets and liabilities using enacted tax rates expected to
                    apply to taxable income in the years in which we expect to recover or settle those temporary
                    differences. We recognize the effect of a change in tax rates on deferred tax assets and liabilities
                    in the results of operations in the period that includes the enactment date. We reduce the
                    measurement of a deferred tax asset, if necessary, by a valuation allowance if it is more likely
                    than not that we will not realize some or all of the deferred tax asset.</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company&#8217;s tax positions are subject to income tax audits. We account for uncertain tax
                    positions by recognizing the financial statement effects of a tax position only when, based upon
                    technical merits, it is more likely than not that the position will be sustained upon examination.
                    Significant judgment is required in determining the accounting for income taxes. In the ordinary
                    course of business, many transactions and calculations arise where the ultimate tax outcome is
                    uncertain. Our judgments, assumptions and estimates relative to the accounting for income taxes take
                    into account current tax laws, our interpretation of current tax laws, and possible outcomes of
                    future audits conducted by foreign and domestic tax authorities. Although we believe that our
                    estimates are reasonable, the final tax outcome of matters could be different from our assumptions
                    and estimates used when determining the accounting for income taxes. Such differences, if identified
                    in future periods, could have a material effect on the amounts recorded in our consolidated
                    financial statements. Interest and penalties related to unrecognized tax benefits are recognized in
                    income tax expense in the accompanying consolidated statements of operations. The provision for
                    income taxes includes the effects of any accruals that the Company believes are appropriate, as well
                    as any related net interest and penalties.</span></div>
        </ix:continuation>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Payables
                to Related Parties Pursuant to the Tax Receivable Agreement</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                November 2020, we entered into a Tax Receivable Agreement (&#8220;TRA&#8221;) with MLSH 1 and MLSH 2.
                The TRA provides for the payment by us to MLSH 1 and MLSH 2, collectively, of <ix:nonFraction
                    unitRef="number" contextRef="c-1" decimals="INF"
                    name="mrvi:TaxReceivableAgreementPercentageOfTaxBenefitsPaid" scale="-2" id="f-550">85
                </ix:nonFraction>% of the amount of tax benefits, if any, that we actually realize, or in some
                circumstances are deemed to realize from exchanges of LLC Units (together with the corresponding shares
                of Class B common stock) for Class A common stock, as a result of (i) certain increases in the tax basis
                of assets of Topco LLC and its subsidiaries resulting from purchases or exchanges of LLC Units, (ii)
                certain tax attributes of the Organization Transactions and (iii) certain other tax benefits related to
                our entering into the TRA, including tax benefits attributable to payments that we make under the TRA
                (collectively, the &#8220;Tax Attributes&#8221;). The payment obligations under the TRA are not
                conditioned upon any LLC Unitholder maintaining a continued ownership interest in us or Topco LLC and
                the rights of MLSH 1 and MLSH 2 under the TRA are assignable. We expect to benefit from the remaining
                <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF"
                    name="mrvi:TaxReceivableAgreementPercentageOfTaxBenefitsUnpaid" scale="-2" id="f-551">15
                </ix:nonFraction>% of the tax benefits, if any, that we may actually realize.</span></div>
        <ix:nonNumeric contextRef="c-1" name="mrvi:PayablesToRelatedPartiesPolicyTextBlock" id="f-552" escape="true">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
                    accrue a liability for the payable to related parties for the TRA and a reduction to
                    stockholders&#8217; equity, when it is deemed probable that the Tax Attributes will be used to
                    reduce our taxable income, as the contractual percentage of the benefit of Tax Attributes that we
                    expected to receive over a period of time. The current portion, if any, of the liability is the
                    amount estimated to be paid within one year of the consolidated balance sheet date. For purposes of
                    estimating the value of the payable to related parties for the TRA, the tax benefit deemed realized
                    by us and payable to MLSH 1 and MLSH 2 is computed by taking <ix:nonFraction unitRef="number"
                        contextRef="c-1" decimals="INF" name="mrvi:TaxReceivableAgreementPercentageOfTaxBenefitsPaid"
                        scale="-2" id="f-553">85</ix:nonFraction>% of the difference of between our undiscounted
                    forecasted cash income tax liability over the term of benefit of the Tax Attributes and the
                    forecasted amount of such taxes that we would have been required to pay had there been no Tax
                    Attributes. The TRA applies to each of our taxable years, beginning with the taxable year that the
                    TRA is entered into. There is no maximum term for the TRA and the TRA will continue until all such
                    tax benefits have been utilized or expired unless we exercise our right to terminate the TRA for an
                    agreed-upon amount equal to the estimated present value of the remaining payments to be made under
                    the agreement. We may record additional liabilities under the TRA when LLC Units of Topco LLC are
                    exchanged in the future and as our estimates of the future utilization of the tax benefits change.
                    If, due to a change in facts, these tax attributes are not utilized in future years, it is
                    reasonably possible no amounts would be paid under the TRA. In this scenario, the reduction of the
                    liability under the TRA would result in a benefit to our consolidated statements of operations.
                    Subsequent adjustments to the payable to related parties for the TRA based on changes in anticipated
                    future taxable income are recorded in our consolidated statements of operations.</span></div>
        </ix:nonNumeric>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-476-7" continuedAt="f-476-8">
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-554" escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Controlling
                    Interests</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling
                    interests re</span><span
                    style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">present
                    the portion of profit or loss, net assets and comprehensive (loss) income of our consolidated
                    subsidiaries that is not allocable to the Company based on our percentage of ownership of such
                    entities. </span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                    November 2020, following the completion of the Organizational Transactions, we became the sole
                    managing member of Topco LLC. As of December&#160;31, 2023</span><span
                    style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
                    we held approximately <ix:nonFraction unitRef="number" contextRef="c-120" decimals="3"
                        name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="f-555">52.6
                    </ix:nonFraction>% of the outstanding LLC Units of Topco LLC, and MLSH 1 held approximately
                    <ix:nonFraction unitRef="number" contextRef="c-121" decimals="3"
                        name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-556">
                        47.4</ix:nonFraction>% of the outstanding LLC Units of Topco LLC. Therefore, we report
                    non-controlling interests based on the percentage of LLC Units of Topco LLC held by MLSH 1 on our
                    consolidated balance sheet as of December&#160;31, 2023. Income or loss attributed to the
                    non-controlling interest in Topco LLC is based on the LLC Units outstanding during the period for
                    which the income or loss is generated and is presented on the consolidated statements of operations
                    and consolidated statements of comprehensive (loss) income.</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MLSH
                    1 is entitled to exchange LLC Units, together with an equal number of shares of our Class B common
                    stock (together referred to as &#8220;Paired Interests&#8221;), for shares of Class A common stock
                    on a <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF"
                        name="mrvi:ConversionOfStockConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-557">
                        one</ix:nonFraction>-for-one basis or, at our election, for cash, from a substantially
                    concurrent public offering or private sale (based on the price of our Class A common stock in such
                    public offering or private sale). As such, future exchanges of Paired Interests by MLSH 1 will
                    result in a change in ownership and reduce or increase the amount recorded as non-controlling
                    interests and increase or decrease additional paid-in-capital when Topco LLC has positive or
                    negative net assets, respectively.</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Distributions
                    of $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5"
                        name="us-gaap:DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid"
                        format="ixt:num-dot-decimal" scale="6" id="f-558">9.6</ix:nonFraction> million, $<ix:nonFraction
                        unitRef="usd" contextRef="c-123" decimals="-5"
                        name="us-gaap:DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid"
                        format="ixt:num-dot-decimal" scale="6" id="f-559">150.2</ix:nonFraction> million and $
                    <ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5"
                        name="us-gaap:DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid"
                        format="ixt:num-dot-decimal" scale="6" id="f-560">153.5</ix:nonFraction> million for tax
                    liabilities were made to MLSH 1 during the years ended December&#160;31, 2023, 2022 and 2021,
                    respectively.</span></div>
        </ix:nonNumeric>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-561" escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment
                    Information</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company has historically operated in <ix:nonFraction unitRef="segment" contextRef="c-15"
                        decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0"
                        id="f-562">three</ix:nonFraction> reportable segments. Operating segments are defined as
                    components of an enterprise for which separate financial information is evaluated regularly by the
                    Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;) in deciding how to allocate
                    resources and assessing performance. The CODM allocates resources and assesses performance based
                    upon discrete financial information at the segment level. All of our long-lived assets are located
                    in the United States. After the divestiture of Vector in September 2021, the Company no longer has
                    the Protein Detection segment. The Company has reported the historical results of the Protein
                    Detection business as such discrete financial information evaluated by the CODM for the periods
                    presented included the information for this legacy segment. As of December&#160;31, 2023, the
                    Company operated in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF"
                        name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-563">two
                    </ix:nonFraction> reportable segments: Nucleic Acid Production and Biologics Safety Testing.</span>
            </div>
        </ix:nonNumeric>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-564" escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash
                    and Cash Equivalents</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company considers all highly liquid investments with original maturities of three months or less to
                    be cash equivalents. The carrying value of these cash equivalents approximates fair value. Cash and
                    cash equivalents consist of deposits held at financial institutions and money market funds.</span>
            </div>
        </ix:nonNumeric>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-565" escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts
                    Receivable and Allowance for Credit Losses</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts
                    receivable primarily consist of amounts due from customers for product sales and services. The
                    Company&#8217;s expected credit losses are developed using an estimated loss rate method that
                    considers historical collection experience, current conditions, and reasonable and supportable
                    forecasts that affect the collectability of the reported amount. The estimated loss rates are
                    applied to trade receivables with similar risk characteristics such as the length of time the
                    balance has been outstanding, liquidity and financial position of the customer, and the geographic
                    location of the customer. In certain instances, the Company may identify individual accounts
                    receivable assets that do not share risk characteristics with other accounts receivable, in which
                    case the Company records its expected credit losses on an individual asset basis.</span></div>
        </ix:nonNumeric>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                allowance for credit losses was approximately $<ix:nonFraction unitRef="usd" contextRef="c-5"
                    decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal"
                    scale="6" id="f-566">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd"
                    contextRef="c-6" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable"
                    format="ixt:num-dot-decimal" scale="6" id="f-567">2.2</ix:nonFraction> million as of
                December&#160;31, 2023 and 2022, respectively. Write-offs of accounts receivable were $<ix:nonFraction
                    unitRef="usd" contextRef="c-1" decimals="-5"
                    name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" format="ixt:num-dot-decimal"
                    scale="6" id="f-568">0.7</ix:nonFraction> million during the year ended December&#160;31, 2023.
                Write-offs of accounts receivable were <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5"
                    name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" format="ixt:fixed-zero" scale="6"
                    id="f-569">
                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5"
                        name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" format="ixt:fixed-zero" scale="6"
                        id="f-570">not</ix:nonFraction>
                </ix:nonFraction> significant during the years ended December&#160;31, 2022 and 2021. There were $
                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5"
                    name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" format="ixt:num-dot-decimal"
                    scale="6" id="f-571">0.5</ix:nonFraction> million of recoveries during the year ended
                December&#160;31, 2023. Recoveries were <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5"
                    name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" format="ixt:fixed-zero" scale="6"
                    id="f-572">
                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5"
                        name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" format="ixt:fixed-zero"
                        scale="6" id="f-573">not</ix:nonFraction>
                </ix:nonFraction> significant during the years ended December&#160;31, 2022 and 2021.</span></div>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-574" continuedAt="f-574-1"
            escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory</span>
            </div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories
                    consist of raw materials, work-in-process and finished goods. Inventories are stated at the lower of
                    cost (weighted average cost) or net realizable value. Inventory costs, which relate to the purchase
                    or production of inventories, include materials, direct labor and manufacturing overhead. The
                    Company regularly monitors for excess and obsolete inventory based on its estimates of expected
                    sales volumes, production capacity and expiration of raw materials, work-in-process and finished
                    products, and reduces the carrying value of inventory accordingly. The Company writes down inventory
                    that has become </span></div>
        </ix:nonNumeric>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-476-8" continuedAt="f-476-9">
        <ix:continuation id="f-574-1">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obsolete,
                    inventory that has a cost basis in excess of its expected net realizable value, and inventory in
                    excess of expected manufacturing requirements. Any write-downs of inventories are charged to cost of
                    revenue.</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A
                    change in the estimated timing or amount of demand for the Company&#8217;s products could result in
                    reduction to the recorded value of inventory quantities on hand. Any significant unanticipated
                    changes in demand or unexpected quality failures could have a significant impact on the value of
                    inventory and reported operating results. During all periods presented in the accompanying
                    consolidated financial statements, there have been no material adjustments related to a revised
                    estimate of our inventory valuations.</span></div>
        </ix:continuation>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:GovernmentAssistancePolicyTextBlock" id="f-575" escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government
                    Assistance</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    consideration awarded to the Company by the U.S. Department of Defense is outside the scope of the
                    contracts with customers, income tax, funded research and development, and contribution guidance.
                    This is because the awarding entity is not considered to be a customer, the receipt of the funding
                    is not predicated on the Company&#8217;s income tax position, there are no refund provisions, and
                    the entity is not receiving reciprocal value for their support provided to the Company. The
                    Company&#8217;s elected policy is to recognize such assistance as a reduction to the carrying amount
                    of the assets associated with the award when it is reasonably assured that the funding will be
                    received as evidenced through the existence of an arrangement, amounts eligible for reimbursement
                    are determinable and have been incurred or paid, the applicable conditions under the arrangement
                    have been met, and collectability of amounts due is reasonably assured.</span></div>
        </ix:nonNumeric>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-576"
            continuedAt="f-576-1" escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property
                    and Equipment</span></div>
        </ix:nonNumeric>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
                <ix:continuation id="f-576-1" continuedAt="f-576-2">Property and equipment are stated at cost, less
                    accumulated depreciation.</ix:continuation>
                <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-577"
                    continuedAt="f-577-1" escape="true">Depreciation is computed using the straight-line method over the
                    following estimated useful lives:</ix:nonNumeric>
            </span></div>
        <ix:continuation id="f-577-1" continuedAt="f-577-2">
            <div style="margin-bottom:12pt;margin-top:12pt;text-align:center">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:82.501%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.532%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.567%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span>
                        </td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated
                                Useful Life</span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold
                                improvements</span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="text-align:right"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonNumeric contextRef="c-125" name="us-gaap:PropertyPlantAndEquipmentUsefulLife"
                                        format="ixt-sec:duryear" id="f-578">12</ix:nonNumeric> years
                                </span></div>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture,
                                fixtures, equipment and software</span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="text-align:right"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonNumeric contextRef="c-126" name="us-gaap:PropertyPlantAndEquipmentUsefulLife"
                                        format="ixt-sec:duryear" id="f-579">3</ix:nonNumeric> - <ix:nonNumeric
                                        contextRef="c-127" name="us-gaap:PropertyPlantAndEquipmentUsefulLife"
                                        format="ixt-sec:duryear" id="f-580">7</ix:nonNumeric> years
                                </span></div>
                        </td>
                    </tr>
                </table>
            </div>
        </ix:continuation>
        <ix:continuation id="f-576-2">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold
                    improvements are amortized over the shorter of the related lease term or useful life.</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintenance
                    and repairs are charged to operations when incurred, while betterments or renewals are capitalized.
                    When property and equipment are sold or otherwise disposed of, the asset account and related
                    accumulated depreciation account are relieved, and any gain or loss is included in the results of
                    operations.</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company records certain government grants earned related to capital projects as a reduction to
                    property and equipment.</span></div>
        </ix:continuation>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-581"
            continuedAt="f-581-1" escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span>
            </div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill
                    represents the excess of consideration transferred over the estimated fair value of assets acquired
                    and liabilities assumed in a business combination. Goodwill is not amortized but is reviewed for
                    impairment. Goodwill is allocated to the Company&#8217;s reporting units, which are components of
                    our business for which discrete cash flow information is available one level below its operating
                    segment. The Company conducts a goodwill impairment analysis at least annually and more frequently
                    if changes in facts and circumstances indicate that the fair value of the Company&#8217;s reporting
                    units may be less than carrying amount. In performing each annual impairment assessment and any
                    interim impairment assessment, the Company determines if it should qualitatively assess whether it
                    is more likely than not that the fair value of goodwill is less than its carrying amount (the
                    qualitative impairment test). If it is more likely than not that the fair value of the reporting
                    unit is less than its carrying amount, or if the Company elects not to perform the qualitative
                    impairment test, the Company then performs a quantitative impairment test. </span></div>
        </ix:nonNumeric>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
                <ix:continuation id="f-581-1">The quantitative impairment test is performed using a one-step process.
                    The process is to compare the fair value of a reporting unit with its carrying amount. If the fair
                    value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is not
                    impaired. If the carrying amount of a reporting unit exceeds its fair value, goodwill of the
                    reporting unit is impaired and an impairment loss is recognized in an amount equal to that excess up
                    to the total amount of goodwill included in the reporting unit.</ix:continuation>
            </span></div>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="f-582"
            continuedAt="f-582-1" escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible
                    Assets</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company&#8217;s finite-lived intangible assets represent purchased intangible assets and primarily
                    consist of trade names, customer relationships, patents, and developed technology. Certain criteria
                    are used in determining whether intangible assets acquired in a business combination must be
                    recognized and reported separately. Finite-lived intangible assets are initially </span></div>
        </ix:nonNumeric>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-476-9" continuedAt="f-476-10">
        <ix:continuation id="f-582-1">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized
                    at fair value, are subject to amortization and are subsequently stated at amortized cost. The
                    Company&#8217;s finite-lived intangible assets are amortized using a method that reflects the
                    pattern in which the economic benefits of the intangible assets are consumed or otherwise used. If
                    that pattern cannot be reliably determined, the intangible assets are amortized using the
                    straight-line method over their estimated useful lives and are tested for impairment along with
                    other long-lived assets. Amortization related to patents and developed technology is allocated to
                    cost of revenue whereas amortization associated with trade names and customer relationships is
                    allocated to selling, general and administrative expenses.</span></div>
        </ix:continuation>
        <ix:nonNumeric contextRef="c-1"
            name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"
            id="f-583" escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment
                    of Long-Lived and Intangible Assets </span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company periodically reviews long-lived assets, including property and equipment, right-of-use lease
                    assets and finite-lived intangible assets, to determine whether current events or circumstances
                    indicate that such carrying amounts may not be recoverable. If such facts or circumstances are
                    determined to exist, an estimate of the undiscounted future cash flows of these assets is compared
                    to the carrying value of the assets to determine whether impairment exists. If the assets are
                    determined to be impaired, the loss is measured based on the difference between the fair value and
                    carrying value of the assets. If we determine that events and circumstances warrant a revision to
                    the remaining period of amortization or depreciation for a specific long-lived asset, its remaining
                    estimated useful life will be revised, and the remaining carrying amount of the long-lived asset
                    will be depreciated or amortized prospectively over the revised remaining estimated useful life. No
                    impairment loss was recognized for long-lived or intangible assets for any period presented.</span>
            </div>
        </ix:nonNumeric>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtPolicyTextBlock" id="f-584" escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt
                    Issuance Costs</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs
                    incurred in connection with obtaining new debt financing are deferred and amortized over the life of
                    the related financing. If such financing is settled or replaced prior to maturity with debt
                    instruments that have substantially different terms, the settlement is treated as an extinguishment
                    and the unamortized costs are charged to gain or loss on extinguishment of debt. If such financing
                    is settled or replaced with debt instruments from the same lender that do not have substantially
                    different terms, the new debt agreement is accounted for as a modification for the prior debt
                    agreement and the unamortized costs remain capitalized, the new original issuance discount costs are
                    capitalized, and any new third-party costs are charged to expense. Deferred costs are recognized as
                    a direct reduction in the carrying amount of the debt instrument on the consolidated balance sheets
                    and are amortized to interest expense over the term of the related debt using the effective interest
                    method.</span></div>
        </ix:nonNumeric>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-585"
            escape="true">
            <div style="margin-top:12pt"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accumulated
                    Other Comprehensive Income (Loss)</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive
                    income (loss) and its components encompass all changes in equity other than those with stockholders
                    or member. Comprehensive income (loss) for the Company consists of foreign currency translation
                    adjustments. There were no reclassifications out of accumulated other comprehensive loss during the
                    periods presented.</span></div>
        </ix:nonNumeric>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-586" escape="true">
            <div style="margin-top:12pt"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair
                    Value of Financial Instruments</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company defines fair value as the amount that would be received to sell an asset, or paid to
                    transfer a liability, in an orderly transaction between market participants at the measurement date.
                    The Company follows accounting guidance that has a three-level hierarchy for fair value measurements
                    based upon the transparency of inputs to the valuation of the asset or liability as of the
                    measurement date. Instruments with readily available actively quoted prices, or for which fair value
                    can be measured from actively quoted prices in an orderly market, will generally have a higher
                    degree of market price transparency and a lesser degree of judgment used in measuring fair value.
                    The three levels of the hierarchy are defined as follows:</span></div>
            <div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Observable
                    inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active
                    markets;</span></div>
            <div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Include
                    other inputs that are directly or indirectly observable in the marketplace; and</span></div>
            <div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable
                    inputs which are supported by little or no market activity.</span></div>
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
                    of December&#160;31, 2023 and 2022, the carrying value of current assets and liabilities
                    approximates fair value due to the short maturities of these instruments. The fair values of the
                    Company&#8217;s long-term debt approximate carrying value, excluding the effect of unamortized debt
                    discount, as it is based on borrowing rates currently available to the Company for debt with similar
                    terms and maturities (Level 2 inputs).</span></div>
        </ix:nonNumeric>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationsPolicy" id="f-587" continuedAt="f-587-1"
            escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions</span>
            </div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company evaluates mergers, acquisitions and other similar transactions to assess whether or not the
                    transaction should be accounted for as a business combination or an acquisition of assets. The
                    Company first identifies the acquiring entity by determining if the target is a legal entity or a
                    group of assets or liabilities. If control over a legal entity is being evaluated, the Company also
                    evaluates if the target is a variable interest or voting interest entity. For acquisitions of voting
                    interest entities, the </span></div>
        </ix:nonNumeric>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-476-10" continuedAt="f-476-11">
        <ix:continuation id="f-587-1">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company
                    applies a screen test to determine if substantially all of the fair value of the gross assets
                    acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If
                    the screen test is met, the transaction is accounted for as an acquisition of assets. If the screen
                    is not met, further determination is required as to whether or not the Company has acquired inputs
                    and processes that have the ability to create outputs which would meet the definition of a
                    business.</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company accounts for its business combinations using the acquisition method of accounting which
                    requires that the assets acquired and liabilities assumed of acquired businesses be recorded at
                    their respective fair values at the date of acquisition. The purchase price, which includes the fair
                    value of consideration transferred, is attributed to the fair value of the assets acquired and
                    liabilities assumed. The purchase price may also include contingent consideration. The Company
                    assesses whether such contingent consideration is subject to liability classification and fair value
                    measurement or meets the definition of a derivative. Contingent consideration liabilities are
                    recognized at their estimated fair value on the acquisition date. Contingent consideration
                    arrangements that are determined to be compensatory in nature are recognized as post combination
                    expense in our consolidated statements of operations ratably over the implied service period
                    beginning in the period it becomes probable such amounts will become payable. The excess of the
                    purchase price of the acquisition over the fair value of the identifiable net assets of the acquiree
                    is recorded as goodwill. The fair value of assets acquired and liabilities assumed in certain cases
                    may be subject to revision based on the final determination of fair value during a period of time
                    not to exceed twelve months from the acquisition date. The results of acquired businesses are
                    included in the Company&#8217;s consolidated financial statements from the date of acquisition.
                    Transaction costs directly attributable to acquired businesses are expensed as incurred.</span>
            </div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining
                    the fair value of assets acquired and liabilities assumed requires management to use significant
                    judgment and estimates, including the selection of valuation methodologies and assumptions about
                    future net cash flows, discount rates and market participants. Each of these factors can
                    significantly affect the value attributed to the identifiable intangible asset acquired in a
                    business combination.</span></div>
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent
                    Consideration</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent
                    consideration represents additional consideration that may be transferred to former owners of an
                    acquired entity in the future if certain future events occur or conditions are met. Contingent
                    consideration resulting from the acquisition of a business is recorded at fair value on the
                    acquisition date. Such contingent consideration is re-measured to its estimated fair value at each
                    reporting date with the change in fair value recognized within operating expenses in the
                    Company&#8217;s consolidated statements of operations. Subsequent changes in the fair value of the
                    contingent consideration are classified as an adjustment to cash flows from operating activities in
                    the consolidated statements of cash flows because the change in fair value is an input in
                    determining net (loss) income. Cash paid in settlement of contingent consideration liabilities are
                    classified as cash flows from financing activities up to the acquisition date fair value with any
                    excess classified as cash flows from operating activities.</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes
                    in the fair value of contingent consideration liabilities associated with the acquisition of a
                    business can result from updates to assumptions such as the expected timing or probability of
                    achieving customer-related performance targets, specified sales milestones, changes in projected
                    revenue or changes in discount rates. Judgment is used in determining those assumptions as of the
                    acquisition date and for each subsequent reporting period. Therefore, any changes in the fair value
                    will impact the Company&#8217;s results of operations in such reporting period, thereby resulting in
                    potential variability in the Company&#8217;s operating results until such contingencies are
                    resolved.</span></div>
        </ix:continuation>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-588" continuedAt="f-588-1"
            escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span>
            </div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company determines whether the arrangement is or contains a lease based on the unique facts and
                    circumstances present at the inception of the arrangement and if such a lease is classified as a
                    finance lease or operating lease. Finance leases with a term greater than one year are included in
                    property and equipment, current portion of finance lease liabilities, and finance lease liabilities,
                    less current portion on our consolidated balance sheets. Operating leases with a term greater than
                    one year are included in other assets, accrued expenses and other current liabilities, and other
                    long-term liabilities on our consolidated balance sheets. The Company has elected not to recognize
                    on the consolidated balance sheet leases with terms of one year or less. </span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use
                    (&#8220;ROU&#8221;) assets represents the Company&#8217;s right to use an underlying asset for the
                    lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments
                    arising from the lease contract. Lease liabilities and their corresponding ROU assets are recorded
                    based on the present value of lease payments over the expected lease term. In determining the net
                    present value of lease payments, the interest rate implicit in lease contracts is typically not
                    readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate,
                    which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal
                    to the lease payments in a similar economic environment. Certain adjustments to the ROU asset may be
                    required for items such as initial direct costs paid or incentives received and impairment charges
                    if we determine the ROU asset is impaired.</span></div>
        </ix:nonNumeric>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-476-11" continuedAt="f-476-12">
        <ix:continuation id="f-588-1">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company considers a lease term to be the noncancelable period that it has the right to use the
                    underlying asset, including any periods where it is reasonably assured the Company will exercise the
                    option to extend the contract. Periods covered by an option to extend are included in the lease term
                    if the lessor controls the exercise of that option.</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company recognizes lease expense on a straight-line basis over the expected lease term. Variable
                    lease payments, for items such as maintenance and utilities, are not included in the calculation of
                    the ROU asset and the related lease liability and are recognized as this lease expense is
                    incurred.</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company has elected to not separate lease and non-lease components for its leased assets and
                    accounts for all lease and non-lease components of its agreements as a single lease component. The
                    lease components resulting in a ROU asset have been recorded on the balance sheet and amortized as
                    lease expense on a straight-line basis over the lease term.</span></div>
        </ix:continuation>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-589" continuedAt="f-589-1"
            escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration
                    of Credit Risk</span></div>
        </ix:nonNumeric>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
                <ix:continuation id="f-589-1">Financial instruments that potentially subject the Company to significant
                    concentrations of credit risk consist principally of cash and accounts receivable. The Company
                    maintains the majority of its cash balances at multiple financial institutions that management
                    believes are of high-credit quality and financially stable. Cash is deposited with major financial
                    institutions in excess of Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) insurance
                    limits. The Company believes it is not exposed to significant credit risk due to the financial
                    strength of the depository institutions in which the cash is held. The Company provides credit, in
                    the normal course of business, to international and domestic distributors as well as certain
                    customers, which are geographically dispersed. The Company attempts to limit its credit risk by
                    performing ongoing credit evaluations of its customers and maintaining adequate allowances for
                    potential credit losses.</ix:continuation>
            </span></div>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-590"
            escape="true">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    following table summarizes revenue from each of our customers who individually accounted for 10% or
                    more of our total revenue or accounts receivable for the periods presented:</span></div>
            <div style="margin-top:12pt;text-align:justify">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:37.225%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.647%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.534%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.647%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.534%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.647%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.534%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.647%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.534%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.651%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="15"
                            style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span>
                        </td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="9"
                            style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accounts
                                Receivable, net</span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="15"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years
                                Ended December 31,</span></td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="9"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As
                                of December 31,</span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                        </td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                        </td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span>
                        </td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                        </td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nacalai
                                USA, Inc.</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-128" decimals="3"
                                    name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-591">19.3
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-129" decimals="3"
                                    name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-592">27.3
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-130" decimals="3"
                                    name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-593">20.3
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CureVac
                                N.V.</span></td>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span>
                        </td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span>
                        </td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-131" decimals="3"
                                    name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-594">15.3
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-132" decimals="3"
                                    name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-595">13.0
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-133" decimals="3"
                                    name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-596">15.7
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BioNTech
                                SE</span></td>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-134" decimals="3"
                                    name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-597">34.8
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-135" decimals="3"
                                    name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-598">29.5
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-136" decimals="3"
                                    name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-599">12.0
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer
                                Inc.</span></td>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span>
                        </td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-137" decimals="3"
                                    name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-600">26.4
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-138" decimals="3"
                                    name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-601">23.3
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span>
                        </td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-139" decimals="3"
                                    name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-602">19.2
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                    </tr>
                </table>
            </div>
            <div style="text-align:justify"><span
                    style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span>
            </div>
            <div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.5pt">Less
                    than 10%</span></div>
        </ix:nonNumeric>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For
                the year ended December&#160;31, 2023, all of the revenue recorded for Nacalai USA, Inc. was generated
                by the Nucleic Acid Production Segment. For the year ended December&#160;31, 2022, substantially all of
                the revenue recorded for BioNTech SE and Pfizer Inc. was generated by our Nucleic Acid Production
                segment. For the year ended December&#160;31, 2021, substantially all of the revenue recorded for
                BioNTech SE, Pfizer Inc and CureVac N.V. was generated by our Nucleic Acid Production segment. </span>
        </div>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-603" escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net
                    (Loss) Income per Class A Common Share Attributable to Maravai LifeSciences Holdings, Inc.</span>
            </div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic
                    net (loss) income per Class A common share attributable to Maravai LifeSciences Holdings, Inc. is
                    computed by dividing net (loss) income attributable to us by the weighted average number of Class A
                    common shares outstanding during the period. Diluted net income per Class A common share is
                    calculated by giving effect to all potential weighted average dilutive stock options, restricted
                    stock units, performance stock units and Topco LLC Units, that together with an equal number of
                    shares of our Class B common stock are convertible into shares of our Class A common stock. The
                    dilutive effect of outstanding awards, if any, is reflected in diluted earnings per share by
                    application of the treasury stock method or if-converted method, as applicable. In periods in which
                    the Company reports a net loss attributable to Maravai LifeSciences Holdings, Inc., diluted net loss
                    per Class A common share attributable to the Company is the same as basic net loss per Class A
                    common share attributable to the Company, since dilutive equity instruments are not assumed to have
                    been issued if their effect is anti-dilutive. The Company reported a net loss attributable to
                    Maravai LifeSciences Holdings, Inc. for the year ended December&#160;31, 2023.</span></div>
        </ix:nonNumeric>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-604"
            continuedAt="f-604-1" escape="true">
            <div style="margin-top:12pt"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently
                    Adopted Accounting Pronouncements Not Yet Adopted</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                    November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting
                    Standards Update (&#8220;ASU&#8221;) 2023-07, </span><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment
                    Reporting (Topic 280) - Improvements to Reportable Segment Disclosures </span><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU
                    2023-07&#8221;), which improves segment disclosure requirements, primarily through enhanced
                    disclosures about significant expenses. ASU 2023-07 requires disclosures to include significant
                    segment expenses that are regularly provided to the CODM and included within each </span></div>
        </ix:nonNumeric>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-604-1">
        <ix:continuation id="f-476-12">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reported
                    measure of segment profit or loss, an amount for other segment items by reportable segment and a
                    description of its composition, any additional measures of a segment&#8217;s profit or loss used by
                    the CODM when deciding how to allocate resources, and the title and position of the CODM and an
                    explanation of how the CODM uses the reported measures of segment profit or loss in assessing
                    segment performance and deciding how to allocate resources. The ASU also requires all annual
                    disclosures currently required by Topic 280 to be included in interim periods. ASU 2023-07 is
                    effective for the Company for fiscal years beginning after December 15, 2023, and interim periods
                    within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments
                    in this ASU should be applied retrospectively to all prior periods presented in the consolidated
                    financial statements. The Company is currently evaluating the impact of adopting this standard on
                    its consolidated financial statements and disclosures.</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                    December 2023, the FASB issued ASU 2023-09, </span><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income
                    Taxes (Topic 740) - Improvements to Income Tax Disclosures </span><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU
                    2023-09&#8221;). The amendments in this ASU address investor requests for more transparency about
                    income tax information through improvements to tax disclosures primarily related to the rate
                    reconciliation and income taxes paid information. The ASU also includes certain other amendments to
                    improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for the Company for
                    annual periods beginning after December 15, 2024, with early adoption permitted. The amendments in
                    this ASU should be applied on a prospective basis, with retrospective application permitted. The
                    Company is currently evaluating the impact of adopting this standard on its consolidated financial
                    statements and disclosures.</span></div>
        </ix:continuation>
    </ix:continuation>
    <div id="ic995976d222241b98dac88a4c1bc08e5_199"></div>
    <div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="f-605"
            continuedAt="f-605-1" escape="true"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Acquisitions
                and Divestiture</span></ix:nonNumeric>
    </div>
    <ix:continuation id="f-605-1" continuedAt="f-605-2">
        <div style="margin-top:12pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span>
        </div>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Alphazyme,
                LLC</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On
                January 18, 2023, the Company completed the acquisition of Alphazyme, LLC (&#8220;Alphazyme&#8221;), a
                privately-held original equipment manufacturer (&#8220;OEM&#8221;) and provider of custom, scalable,
                molecular biology enzymes to customers in the genetic analysis and nucleic acid synthesis markets. The
                acquisition will expand the Company&#8217;s internal enzyme product portfolio and increase the
                Company&#8217;s differentiated mRNA manufacturing services and product offerings. Alphazyme&#8217;s
                ability to manufacture custom enzymes allows the Company to expand into near adjacent markets and raise
                our enzyme vertical. </span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                Company acquired Alphazyme for a total purchase consideration of $<ix:nonFraction unitRef="usd"
                    contextRef="c-140" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1"
                    format="ixt:num-dot-decimal" scale="6" id="f-606">75.3</ix:nonFraction> million, which is inclusive
                of net working capital adjustments. As a result of the acquisition, the Company owns all the outstanding
                equity interest in Alphazyme. The total cash consideration was paid using existing cash on hand. The
                transaction was accounted for as an acquisition of a business as Alphazyme consisted of inputs and
                processes applied to those inputs that had the ability to contribute to the creation of outputs.</span>
        </div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For
                the year ended December&#160;31, 2023, the Company incurred $<ix:nonFraction unitRef="usd"
                    contextRef="c-141" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts"
                    format="ixt:num-dot-decimal" scale="6" id="f-607">4.1</ix:nonFraction> million in transaction costs
                associated with the acquisition of Alphazyme, which were recorded within selling, general and
                administrative expenses in the consolidated statements of operations. </span></div>
        <ix:nonNumeric contextRef="c-1"
            name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="f-608"
            continuedAt="f-608-1" escape="true">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    acquisition date fair value of consideration transferred to acquire Alphazyme consisted of the
                    following (in thousands):</span></div>
            <div style="margin-top:12pt;text-align:justify">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:83.233%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.567%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash
                                    paid </span><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span>
                            </div>
                        </td>
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3"
                                    name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal"
                                    scale="3" id="f-609">70,037</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair
                                value of contingent consideration</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3"
                                    name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred"
                                    format="ixt:num-dot-decimal" scale="3" id="f-610">5,289</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                consideration transferred</span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3"
                                    name="us-gaap:BusinessCombinationConsiderationTransferred1"
                                    format="ixt:num-dot-decimal" scale="3" id="f-611">75,326</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
            <div style="text-align:justify"><span
                    style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span>
            </div>
            <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents
                    cash consideration paid at closing of $<ix:nonFraction unitRef="usd" contextRef="c-140"
                        decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal"
                        scale="6" id="f-612">70.1</ix:nonFraction>&#160;million, net of a purchase price adjustment
                    received in June 2023 of $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5"
                        name="mrvi:BusinessCombinationConsiderationTransferredPostAdjustment"
                        format="ixt:num-dot-decimal" scale="6" id="f-613">0.1</ix:nonFraction>&#160;million.</span>
            </div>
        </ix:nonNumeric>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant
                to the Securities Purchase Agreement (the &#8220;Alphazyme SPA&#8221;) between the Company and sellers
                of Alphazyme, additional payments to the sellers of Alphazyme are dependent upon meeting or exceeding
                defined revenue targets during fiscal years 2023 through 2025 (the &#8220;Alphazyme Performance
                Payments&#8221;). The Alphazyme SPA provides for a total maximum Alphazyme Performance Payments of $
                <ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5"
                    name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal"
                    scale="6" id="f-614">75.0</ix:nonFraction> million. The Alphazyme Performance Payments were recorded
                as contingent consideration and was included as part of the purchase consideration. The Company
                estimated the fair value of the Alphazyme Performance Payments contingent consideration based on a
                Monte-Carlo simulation model which utilized an income approach. The estimated fair value was based on
                Alphazyme revenue projections, expected payout term, volatility and risk adjusted discount rates which
                are Level 3 inputs (see Note 5). The first performance period applicable to the Alphazyme Performance
                Payments ended on December&#160;31, 2023, and it was determined that the defined revenue target was not
                achieved. Consequently, no payment was made to the sellers of Alphazyme.</span></div>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-605-2" continuedAt="f-605-3">
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                Alphazyme SPA also provides that the Company will pay certain employees of Alphazyme an additional
                amount totaling $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5"
                    name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal"
                    scale="6" id="f-615">9.3</ix:nonFraction> million (the &#8220;Alphazyme Retention Payments&#8221;)
                as of various dates but primarily through December 31, 2025 as long as these individuals continue to be
                employed by the Company. The Company considers the payment of the Alphazyme Retention Payments as
                probable and is recognizing compensation expense related to these payments in the post-acquisition
                period ratably over the service period of approximately <ix:nonNumeric contextRef="c-146"
                    name="mrvi:BusinessCombinationContingentConsiderationLiabilityExpectedServicePeriod"
                    format="ixt-sec:durwordsen" id="f-616">three years</ix:nonNumeric>. For the year ended
                December&#160;31, 2023, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-147"
                    decimals="-5" name="mrvi:BusinessCombinationContingentConsiderationLiabilityCompensationExpense"
                    format="ixt:num-dot-decimal" scale="6" id="f-617">2.2</ix:nonFraction> million of compensation
                expense related to the Alphazyme Retention Payments within selling, general and administrative expenses
                in the consolidated statements of operations. Compensation expense related to the Alphazyme Retention
                Payments recorded within cost of revenue and research and development expenses were not material.</span>
        </div>
        <ix:continuation id="f-608-1" continuedAt="f-608-2">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    following table summarizes the estimated fair values of the assets acquired and liabilities assumed
                    at the acquisition date (in thousands):</span></div>
            <div style="margin-top:12pt;text-align:justify">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:83.233%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.567%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span>
                        </td>
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"
                                    scale="3" id="f-618">288</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"
                                    format="ixt:num-dot-decimal" scale="3" id="f-619">7,246</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other
                                current assets</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"
                                    scale="3" id="f-620">660</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible
                                assets, net</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"
                                    format="ixt:num-dot-decimal" scale="3" id="f-621">31,680</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other
                                assets</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"
                                    format="ixt:num-dot-decimal" scale="3" id="f-622">5,043</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                identifiable assets acquired</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"
                                    format="ixt:num-dot-decimal" scale="3" id="f-623">44,917</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current
                                liabilities</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"
                                    scale="3" id="f-624">482</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other
                                long-term liabilities</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"
                                    format="ixt:num-dot-decimal" scale="3" id="f-625">11,470</ix:nonFraction>)</span>
                        </td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                liabilities assumed</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"
                                    format="ixt:num-dot-decimal" scale="3" id="f-626">11,952</ix:nonFraction>)</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                                identifiable assets acquired</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"
                                    format="ixt:num-dot-decimal" scale="3" id="f-627">32,965</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:Goodwill"
                                    format="ixt:num-dot-decimal" scale="3" id="f-628">42,361</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                                assets acquired</span></td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"
                                    format="ixt:num-dot-decimal" scale="3" id="f-629">75,326</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:continuation>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
                recorded the preliminary purchase price allocation in the first quarter of 2023. During the third
                quarter of 2023, we recorded a measurement period adjustment resulting in a decrease to goodwill of $
                <ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" sign="-"
                    name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6"
                    id="f-630">0.4</ix:nonFraction> million, with an equal offset to other long-term liabilities.
            </span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                acquisition was accounted for under the acquisition method of accounting, and therefore, the total
                purchase price was allocated to the identifiable tangible and intangible assets acquired and the
                liabilities assumed based on their respective fair values as of the acquisition date. Purchase
                consideration in excess of the amounts recognized for the net assets acquired was recognized as
                goodwill. Goodwill is primarily attributable to expanded synergies expected from the acquisition
                associated with a vertical supply integration. All of the goodwill acquired in connection with the
                acquisition of Alphazyme was allocated to the Company&#8217;s Nucleic Acid Production segment.
                <ix:nonFraction unitRef="usd" contextRef="c-148" decimals="INF"
                    name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"
                    format="ixt:fixed-zero" scale="0" id="f-631">None</ix:nonFraction> of the goodwill recognized is
                expected to be deductible for income tax purposes.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon
                closing of the acquisition, approximately $<ix:nonFraction unitRef="usd" contextRef="c-150"
                    decimals="-5" name="us-gaap:EscrowDeposit" format="ixt:num-dot-decimal" scale="6" id="f-632">1.5
                </ix:nonFraction> million was placed into escrow to cover potential working capital adjustments and
                approximately $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5"
                    name="us-gaap:EscrowDeposit" format="ixt:num-dot-decimal" scale="6" id="f-633">3.0</ix:nonFraction>
                million was placed into escrow to secure certain representations and warranties pursuant to the terms of
                the Alphazyme SPA. These amounts are included in the total purchase consideration of $<ix:nonFraction
                    unitRef="usd" contextRef="c-140" decimals="-5"
                    name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6"
                    id="f-634">75.3</ix:nonFraction> million. The $<ix:nonFraction unitRef="usd" contextRef="c-152"
                    decimals="-5" name="mrvi:EscrowDepositReleased" format="ixt:num-dot-decimal" scale="6" id="f-635">
                    1.5</ix:nonFraction> million was released from escrow during the second quarter of 2023, of which
                the Company received $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5"
                    name="mrvi:BusinessCombinationConsiderationTransferredPostAdjustment" format="ixt:num-dot-decimal"
                    scale="6" id="f-636">0.1</ix:nonFraction> million related to net working capital adjustments.
                Because the remaining $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5"
                    name="us-gaap:EscrowDeposit" format="ixt:num-dot-decimal" scale="6" id="f-637">3.0</ix:nonFraction>
                million held in escrow is not controlled by the Company, this amount is not included in the accompanying
                consolidated balance sheet as of December&#160;31, 2023.</span></div>
        <ix:nonNumeric contextRef="c-1"
            name="us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock"
            id="f-638" continuedAt="f-638-1" escape="true">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    following table summarizes the estimated fair values of Alphazyme&#8217;s identifiable intangible
                    assets as of the date of acquisition and their estimated useful lives:</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt;text-align:justify">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:66.935%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.589%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.386%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.590%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated
                                Fair Value<br />(in thousands)</span></td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated
                                Useful Life<br />(in years)</span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade
                                names</span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"
                                    scale="3" id="f-639">220</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonNumeric contextRef="c-155"
                                    name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"
                                    format="ixt-sec:duryear" id="f-640">5</ix:nonNumeric>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed
                                technology</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"
                                    format="ixt:num-dot-decimal" scale="3" id="f-641">31,000</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonNumeric contextRef="c-157"
                                    name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"
                                    format="ixt-sec:duryear" id="f-642">12</ix:nonNumeric>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer
                                relationships</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"
                                    scale="3" id="f-643">460</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonNumeric contextRef="c-159"
                                    name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"
                                    format="ixt-sec:duryear" id="f-644">12</ix:nonNumeric>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"
                                    format="ixt:num-dot-decimal" scale="3" id="f-645">31,680</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-605-3" continuedAt="f-605-4">
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                trade name and customer relationship intangible assets are related to Alphazyme&#8217;s name, customer
                loyalty and customer relationships. The developed technology intangible asset is related to its unique
                manufacturing process optimization capability to both scale production and achieve quality standards.
                The fair value of these intangible assets was based on Alphazyme&#8217;s projected revenues and was
                estimated using an income approach, specifically the relief from royalty method for trade names, the
                multi-period excess earnings method for developed technology, and the distributor method for customer
                relationships. Under the income approach, an intangible asset&#8217;s fair value is equal to the present
                value of future economic benefits to be derived from ownership of the asset. The estimated fair value
                was developed by discounting future net cash flows to their present value at market-based rates of
                return utilizing Level 3 inputs. The useful lives for these intangible assets were determined based upon
                the remaining period for which the assets were expected to contribute directly or indirectly to future
                cash flows. Key quantitative assumptions used in the determination of fair value of the developed
                technology intangible included revenue growth rates ranging from <ix:nonFraction unitRef="number"
                    contextRef="c-160" decimals="3" name="mrvi:BusinessCombinationIntangibleAssetsMeasurementInput"
                    scale="-2" id="f-646">3.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-161"
                    decimals="3" name="mrvi:BusinessCombinationIntangibleAssetsMeasurementInput" scale="-2" id="f-647">
                    55.0</ix:nonFraction>%, a discount rate of <ix:nonFraction unitRef="number" contextRef="c-162"
                    decimals="3" name="mrvi:BusinessCombinationIntangibleAssetsMeasurementInput" scale="-2" id="f-648">
                    17.8</ix:nonFraction>% and an assumed technical obsolescent curve of <ix:nonFraction
                    unitRef="number" contextRef="c-163" decimals="3"
                    name="mrvi:BusinessCombinationIntangibleAssetsMeasurementInput" scale="-2" id="f-649">5.0
                </ix:nonFraction>%.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                carrying value of the remaining assets acquired or liabilities assumed was estimated to equal their fair
                values based on their short-term nature. These estimates were based on the assumption that the Company
                believes to be reasonable; however, actual results may differ from these estimates.</span></div>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MyChem,
                LLC</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On
                January 27, 2022, the Company completed the acquisition of MyChem, LLC (&#8220;MyChem&#8221;), a
                privately-held San Diego, California-based provider of ultra-pure nucleotides to customers in the
                diagnostics, pharma, genomics and research markets. The acquisition will vertically integrate the
                Company&#8217;s supply chain and expand its product offerings for inputs used in the development of
                therapeutics and vaccines. </span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                Company acquired MyChem for a total purchase consideration of $<ix:nonFraction unitRef="usd"
                    contextRef="c-164" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1"
                    format="ixt:num-dot-decimal" scale="6" id="f-650">257.9</ix:nonFraction> million, which is inclusive
                of net working capital adjustments. As a result of the acquisition, the Company owns all the outstanding
                equity interest in MyChem. The total cash consideration was paid using existing cash on hand. The
                transaction was accounted for as an acquisition of a business as MyChem consisted of inputs and
                processes applied to those inputs that had the ability to contribute to the creation of outputs.</span>
        </div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For
                the year ended December&#160;31, 2022, the Company incurred $<ix:nonFraction unitRef="usd"
                    contextRef="c-165" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts"
                    format="ixt:num-dot-decimal" scale="6" id="f-651">3.5</ix:nonFraction> million in transaction costs
                associated with the acquisition of MyChem, which were recorded within selling, general and
                administrative expenses in the consolidated statements of operations.</span></div>
        <ix:continuation id="f-608-2" continuedAt="f-608-3">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    acquisition date fair value of consideration transferred to acquire MyChem consisted of the
                    following (in thousands):</span></div>
            <div style="margin-top:12pt;text-align:justify">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:83.233%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.567%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash
                                    paid </span><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span>
                            </div>
                        </td>
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3"
                                    name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal"
                                    scale="3" id="f-652">240,145</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration
                                payable</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3"
                                    name="mrvi:BusinessCombinationConsiderationPayable" format="ixt:num-dot-decimal"
                                    scale="3" id="f-653">10,000</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair
                                value of contingent consideration</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3"
                                    name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred"
                                    format="ixt:num-dot-decimal" scale="3" id="f-654">7,800</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                consideration transferred</span></td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3"
                                    name="us-gaap:BusinessCombinationConsiderationTransferred1"
                                    format="ixt:num-dot-decimal" scale="3" id="f-655">257,945</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
            <div style="text-align:justify"><span
                    style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span>
            </div>
            <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents
                    cash consideration paid at closing of $<ix:nonFraction unitRef="usd" contextRef="c-164"
                        decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal"
                        scale="6" id="f-656">240.0</ix:nonFraction> million and a purchase price adjustment paid in
                    November 2022 of $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5"
                        name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6"
                        id="f-657">0.1</ix:nonFraction> million.</span></div>
        </ix:continuation>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant
                to the Securities Purchase Agreement (the &#8220;MyChem SPA&#8221;) between the Company and sellers of
                MyChem, additional payments to the sellers of MyChem are dependent upon meeting or exceeding defined
                revenue targets during fiscal 2022 (the &#8220;MyChem Performance Payment&#8221;). The MyChem SPA
                provides for a total maximum Performance Payment of $<ix:nonFraction unitRef="usd" contextRef="c-168"
                    decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability"
                    format="ixt:num-dot-decimal" scale="6" id="f-658">40.0</ix:nonFraction> million. The MyChem
                Performance Payment was recorded as contingent consideration and was included as part of the purchase
                consideration. The Company estimated the fair value of the MyChem Performance Payment contingent
                consideration based on a Monte-Carlo simulation model which utilized an income approach. The estimated
                fair value was based on MyChem revenue projections, expected payout term, volatility and risk adjusted
                discount rates which are Level 3 inputs (see Note 5). The performance period applicable to the MyChem
                Performance Payment ended as of December 31, 2022 and it was determined that none of the defined revenue
                thresholds were achieved. Consequently, no payment was made to the sellers of MyChem.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                MyChem SPA also provides that the Company will pay to the sellers of MyChem an additional $
                <ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5"
                    name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal"
                    scale="6" id="f-659">20.0</ix:nonFraction> million (the &#8220;MyChem Retention Payment&#8221;) as
                of the second anniversary of the closing of the acquisition date as long as <ix:nonFraction
                    unitRef="employee" contextRef="c-169" decimals="INF"
                    name="mrvi:BusinessCombinationContingentConsiderationLiabilityNumberOfEmployeesStillEmployed"
                    format="ixt-sec:numwordsen" scale="0" id="f-660">two</ix:nonFraction> senior employees who are also
                the sellers of MyChem continue to be employed by TriLink. The Company considers the payment of the
                Retention Payment as probable and is recognizing compensation expense related to this payment in the
                post-acquisition period ratably over the expected service period of <ix:nonNumeric contextRef="c-170"
                    name="mrvi:BusinessCombinationContingentConsiderationLiabilityExpectedServicePeriod"
                    format="ixt-sec:durwordsen" id="f-661">two years</ix:nonNumeric>. For the year ended
                December&#160;31, 2023, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-171"
                    decimals="-5" name="mrvi:BusinessCombinationContingentConsiderationLiabilityCompensationExpense"
                    format="ixt:num-dot-decimal" scale="6" id="f-662">4.3</ix:nonFraction>&#160;million of compensation
                expense related to the MyChem Retention Payment within cost of revenue in the consolidated statements of
                operations. For the years ended December&#160;31, 2023 and 2022, the Company recorded $<ix:nonFraction
                    unitRef="usd" contextRef="c-172" decimals="-5"
                    name="mrvi:BusinessCombinationContingentConsiderationLiabilityCompensationExpense"
                    format="ixt:num-dot-decimal" scale="6" id="f-663">5.1</ix:nonFraction> million and $<ix:nonFraction
                    unitRef="usd" contextRef="c-173" decimals="-5"
                    name="mrvi:BusinessCombinationContingentConsiderationLiabilityCompensationExpense"
                    format="ixt:num-dot-decimal" scale="6" id="f-664">9.3</ix:nonFraction> </span></div>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-605-4" continuedAt="f-605-5">
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million,
                respectively, of compensation expense related to the MyChem Retention Payment within research and
                development expenses in the consolidated statements of operations.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                MyChem SPA further provides that the Company will pay to the sellers of MyChem an additional amount of
                up to $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5"
                    name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal"
                    scale="6" id="f-665">10.0</ix:nonFraction> million subject to the completion of certain calculations
                associated with acquired inventory, which has been recorded within accrued expenses and other current
                liabilities on the consolidated balance sheet as of December 31, 2022. During the first quarter of 2023,
                but subsequent to the end of the measurement period, these calculations were completed and a payment of
                $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5"
                    name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-666">
                    9.7</ix:nonFraction> million was made by the Company to the sellers. The remaining $<ix:nonFraction
                    unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross"
                    format="ixt:num-dot-decimal" scale="6" id="f-667">0.3</ix:nonFraction> million was recorded as
                non-cash gain within current year operations. </span></div>
        <ix:continuation id="f-608-3">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    following table summarizes the estimated fair values of the assets acquired and liabilities assumed
                    at the acquisition date (in thousands):</span></div>
            <div style="margin-top:12pt;text-align:justify">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:83.233%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.567%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span>
                        </td>
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"
                                    format="ixt:num-dot-decimal" scale="3" id="f-668">1,176</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current
                                assets</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"
                                    format="ixt:num-dot-decimal" scale="3" id="f-669">2,741</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible
                                assets, net</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"
                                    format="ixt:num-dot-decimal" scale="3" id="f-670">123,360</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other
                                assets</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"
                                    format="ixt:num-dot-decimal" scale="3" id="f-671">8,585</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                identifiable assets acquired</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"
                                    format="ixt:num-dot-decimal" scale="3" id="f-672">135,862</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current
                                liabilities</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"
                                    scale="3" id="f-673">420</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other
                                long-term liabilities</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"
                                    format="ixt:num-dot-decimal" scale="3" id="f-674">8,399</ix:nonFraction>)</span>
                        </td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                liabilities assumed</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"
                                    format="ixt:num-dot-decimal" scale="3" id="f-675">8,819</ix:nonFraction>)</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                                identifiable assets acquired</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"
                                    format="ixt:num-dot-decimal" scale="3" id="f-676">127,043</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:Goodwill"
                                    format="ixt:num-dot-decimal" scale="3" id="f-677">130,902</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                                assets acquired</span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"
                                    format="ixt:num-dot-decimal" scale="3" id="f-678">257,945</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:continuation>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
                recorded the preliminary purchase price allocation in the first quarter of 2022. During the fourth
                quarter of 2022, we recorded measurement period adjustments resulting in an increase to goodwill of $
                <ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5"
                    name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6"
                    id="f-679">0.1</ix:nonFraction> million and a decrease to other assets and current liabilities of $
                <ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" sign="-"
                    name="mrvi:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentOtherAssets"
                    format="ixt:num-dot-decimal" scale="6" id="f-680">
                    <ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" sign="-"
                        name="mrvi:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentLiabilitiesCurrent"
                        format="ixt:num-dot-decimal" scale="6" id="f-681">0.7</ix:nonFraction>
                </ix:nonFraction> million. </span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                acquisition was accounted for under the acquisition method of accounting, and therefore, the total
                purchase price was allocated to the identifiable tangible and intangible assets acquired and the
                liabilities assumed based on their respective fair values as of the acquisition date. Purchase
                consideration in excess of the amounts recognized for the net assets acquired was recognized as
                goodwill. Goodwill is primarily attributable to expanded synergies expected from the acquisition
                associated with a vertical supply integration. There were no tax impacts associated with the acquisition
                due to the pass-through income tax treatment of MyChem. All of the goodwill acquired in connection with
                the acquisition of MyChem was allocated to the Company&#8217;s Nucleic Acid Production segment and is
                deductible to Topco LLC for income tax purposes.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon
                closing of the acquisition, approximately $<ix:nonFraction unitRef="usd" contextRef="c-179"
                    decimals="-5" name="us-gaap:EscrowDeposit" format="ixt:num-dot-decimal" scale="6" id="f-682">1.0
                </ix:nonFraction> million was placed into escrow to cover potential working capital adjustments and
                approximately $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5"
                    name="us-gaap:EscrowDeposit" format="ixt:num-dot-decimal" scale="6" id="f-683">12.5</ix:nonFraction>
                million was placed into escrow to secure certain representations and warranties pursuant to the terms of
                the MyChem SPA. These amounts are included in the total purchase consideration of $<ix:nonFraction
                    unitRef="usd" contextRef="c-164" decimals="-5"
                    name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6"
                    id="f-684">257.9</ix:nonFraction> million. The Company released the $<ix:nonFraction unitRef="usd"
                    contextRef="c-179" decimals="-5" name="us-gaap:EscrowDeposit" format="ixt:num-dot-decimal" scale="6"
                    id="f-685">1.0</ix:nonFraction> million in escrow and paid out an additional $<ix:nonFraction
                    unitRef="usd" contextRef="c-181" decimals="-5" name="mrvi:AdditionalPaymentsForEscrowDeposits"
                    format="ixt:num-dot-decimal" scale="6" id="f-686">0.1</ix:nonFraction> million related to net
                working capital adjustments during the fourth quarter of 2022. During the first quarter of 2023, but
                subsequent to the end of the measurement period, $<ix:nonFraction unitRef="usd" contextRef="c-182"
                    decimals="-5" name="mrvi:ProceedsFromReleaseOfEscrowDeposit" format="ixt:num-dot-decimal" scale="6"
                    id="f-687">12.4</ix:nonFraction> million of the amounts in escrow to secure certain representations
                and warranties was released to the sellers and the remaining $<ix:nonFraction unitRef="usd"
                    contextRef="c-183" decimals="-5" name="mrvi:ProceedsFromReleaseOfEscrowDeposit"
                    format="ixt:num-dot-decimal" scale="6" id="f-688">0.1</ix:nonFraction> million was released to the
                Company for indemnification of pre-closing liabilities, which was recorded within current year
                operations.</span></div>
        <ix:continuation id="f-638-1">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    following table summarizes the estimated fair values of MyChem&#8217;s identifiable intangible
                    assets as of the date of acquisition and their estimated useful lives:</span></div>
            <div style="margin-top:12pt;text-align:justify">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:66.935%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.589%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.386%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.590%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated
                                Fair Value<br />(in thousands)</span></td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated
                                Useful Life<br />(in years)</span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade
                                names</span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"
                                    scale="3" id="f-689">460</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonNumeric contextRef="c-185"
                                    name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"
                                    format="ixt-sec:duryear" id="f-690">3</ix:nonNumeric>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed
                                technology</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"
                                    format="ixt:num-dot-decimal" scale="3" id="f-691">121,000</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonNumeric contextRef="c-187"
                                    name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"
                                    format="ixt-sec:duryear" id="f-692">12</ix:nonNumeric>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer
                                relationships</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"
                                    format="ixt:num-dot-decimal" scale="3" id="f-693">1,900</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonNumeric contextRef="c-189"
                                    name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"
                                    format="ixt-sec:duryear" id="f-694">12</ix:nonNumeric>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3"
                                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"
                                    format="ixt:num-dot-decimal" scale="3" id="f-695">123,360</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                    </tr>
                </table>
            </div>
        </ix:continuation>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-605-5">
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                trade name and customer relationship intangible assets are related to MyChem&#8217;s name, customer
                loyalty and customer relationships. The developed technology intangible asset is related to processes
                and techniques for synthesizing and developing ultra-pure nucleotides. The fair value of these
                intangible assets was based on MyChem&#8217;s projected revenues and was estimated using an income
                approach, specifically the multi-period excess earnings method. Under the income approach, an intangible
                asset&#8217;s fair value is equal to the present value of future economic benefits to be derived from
                ownership of the asset. The estimated fair value was developed by discounting future net cash flows to
                their present value at market-based rates of return utilizing Level 3 inputs. The useful lives for these
                intangible assets were determined based upon the remaining period for which the assets were expected to
                contribute directly or indirectly to future cash flows. Key quantitative assumptions used in the
                determination of fair value of the developed technology intangible included revenue growth rates ranging
                from <ix:nonFraction unitRef="number" contextRef="c-190" decimals="3"
                    name="mrvi:BusinessCombinationIntangibleAssetsMeasurementInput" scale="-2" id="f-696">3.0
                </ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-191" decimals="3"
                    name="mrvi:BusinessCombinationIntangibleAssetsMeasurementInput" scale="-2" id="f-697">30.6
                </ix:nonFraction>%, a discount rate of <ix:nonFraction unitRef="number" contextRef="c-192" decimals="3"
                    name="mrvi:BusinessCombinationIntangibleAssetsMeasurementInput" scale="-2" id="f-698">16.5
                </ix:nonFraction>% and an assumed technical obsolescent curve range of <ix:nonFraction unitRef="number"
                    contextRef="c-193" decimals="3" name="mrvi:BusinessCombinationIntangibleAssetsMeasurementInput"
                    scale="-2" id="f-699">5.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-194"
                    decimals="3" name="mrvi:BusinessCombinationIntangibleAssetsMeasurementInput" scale="-2" id="f-700">
                    7.5</ix:nonFraction>%.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant
                to the terms of the MyChem SPA, the Company recognized an indemnification asset of $<ix:nonFraction
                    unitRef="usd" contextRef="c-177" decimals="-5"
                    name="us-gaap:BusinessCombinationIndemnificationAssetsAmountAsOfAcquisitionDate"
                    format="ixt:num-dot-decimal" scale="6" id="f-701">8.0</ix:nonFraction> million within other assets,
                which represented the seller&#8217;s obligation to reimburse pre-acquisition income tax liabilities
                assumed in the acquisition and was recorded within other long-term liabilities.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                carrying value of the remaining assets acquired or liabilities assumed was estimated to equal their fair
                values based on their short-term nature.</span></div>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture</span>
        </div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vector
                Laboratories, Inc.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                August 2021, the Company entered into a definitive agreement to sell Vector to Voyager Group Holdings,
                Inc. (&#8220;Voyager&#8221;), a third-party unrelated to the Company, for an all cash sale price of $
                <ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5"
                    name="us-gaap:ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries"
                    format="ixt:num-dot-decimal" scale="6" id="f-702">124.0</ix:nonFraction> million, subject to
                purchase price adjustments. The Company determined that the fair value of Vector, less estimated costs
                to sell, exceeded the book value of the Vector Disposal Group and there were no other indicators of
                asset impairment prior to the sale. The divestiture was completed in September 2021, and final net
                proceeds were $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5"
                    name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6"
                    id="f-703">120.7</ix:nonFraction> million, which were inclusive of working capital
                adjustments.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
                a result of the divestiture, during the year ended December 31, 2021, the Company recognized a pre-tax
                gain on sale of $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5"
                    name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="6" id="f-704">11.2
                </ix:nonFraction> million, net of transactions costs of $<ix:nonFraction unitRef="usd"
                    contextRef="c-198" decimals="-5"
                    name="mrvi:DisposalGroupIncludingDiscontinuedOperationTransactionCost" format="ixt:num-dot-decimal"
                    scale="6" id="f-705">0.9</ix:nonFraction> million, in the consolidated statements of
                operations.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                Company&#8217;s Protein Detection segment was comprised of Vector. The sale of Vector represents a
                strategic shift as the Company will no longer be in the protein detection business after the sale.
                However, the sale did not qualify for presentation as discontinued operations since the sale of the
                Protein Detection segment did not have a major effect on the Company&#8217;s operations or financial
                results.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                connection with the divestiture, the Company entered into a Transition Services Agreement
                (&#8220;TSA&#8221;) with Voyager to help support its ongoing operations. Under the TSA, the Company will
                provide certain transition services to Voyager, including information technology, finance and ERP,
                marketing and commercial, human resources, employee benefits, and other limited services. Depending on
                the service, the initial period ranges from <ix:nonNumeric contextRef="c-199"
                    name="mrvi:TransitionServicesAgreementInitialServicesPeriod" format="ixt-sec:durwordsen" id="f-706">
                    one month</ix:nonNumeric> to <ix:nonNumeric contextRef="c-200"
                    name="mrvi:TransitionServicesAgreementInitialServicesPeriod" format="ixt-sec:durwordsen" id="f-707">
                    five months</ix:nonNumeric> and the extension period ranges from <ix:nonNumeric contextRef="c-199"
                    name="mrvi:TransitionServicesAgreementOfferingExtensionPeriod" format="ixt-sec:durwordsen"
                    id="f-708">one month</ix:nonNumeric> to <ix:nonNumeric contextRef="c-200"
                    name="mrvi:TransitionServicesAgreementOfferingExtensionPeriod" format="ixt-sec:durwordsen"
                    id="f-709">eight months</ix:nonNumeric>. Income from performing services under the TSA was recorded
                within other income in the consolidated statements of operations and was not significant for the year
                ended December 31, 2021.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                August 2020, the Company entered into an agreement with an executive of Vector whereby the executive
                received incentive units of MLSH 1. In connection with the divestiture, MLSH 1 amended this
                executive&#8217;s incentive units resulting in the recognition of incremental unit-based compensation
                expense in the Company&#8217;s consolidated financial statements of $<ix:nonFraction unitRef="usd"
                    contextRef="c-201" decimals="-5"
                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"
                    format="ixt:num-dot-decimal" scale="6" id="f-710">2.4</ix:nonFraction> million. This unit-based
                compensation expense was recorded within selling, general and administrative expenses in the
                consolidated statements of operations for the year ended December 31, 2021.</span></div>
    </ix:continuation>
    <div id="ic995976d222241b98dac88a4c1bc08e5_987"></div>
    <div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-711"
            continuedAt="f-711-1" escape="true"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Restructuring</span>
        </ix:nonNumeric>
    </div>
    <ix:continuation id="f-711-1" continuedAt="f-711-2">
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                November 2023, the Company implemented a cost realignment plan (the &#8220;Cost Realignment Plan&#8221;)
                that included the termination of approximately <ix:nonFraction unitRef="number" contextRef="c-202"
                    decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"
                    scale="-2" id="f-712">15</ix:nonFraction>% of the Company&#8217;s workforce, the termination of
                certain leases, and other actions to reduce expenses, all as part of a plan to optimize business
                operations and match them to current market conditions. The reduction in force was completed on January
                5, 2024, following the end of the sixty-day notification period required by the Worker Adjustment and
                Retraining Notification Act. The Company expects the remaining actions under the Cost Realignment Plan
                to be substantially complete during the first quarter of 2024. </span></div>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-711-2" continuedAt="f-711-3">
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-713"
            escape="true">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company&#8217;s restructuring charges by segment and unallocated corporate costs, which are recorded
                    as restructuring expenses on the consolidated statements of operations, were as follows for the year
                    ended December&#160;31, 2023 (in thousands):</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt;text-align:justify">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:37.225%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.647%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.534%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.647%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.534%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.647%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.534%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.647%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.534%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.651%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance
                                    and Other Employee Costs</span></div>
                        </td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock-Based
                                    Compensation Expense (Benefit)</span></div>
                        </td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Facility
                                    and Other Exit Costs</span></div>
                        </td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Professional
                                    Fees and Other</span></div>
                        </td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span>
                            </div>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nucleic
                                    Acid Production</span></div>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3"
                                    name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="3" id="f-714">
                                    2,470</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3"
                                    name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-715">168
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3"
                                    name="us-gaap:BusinessExitCosts1" scale="3" id="f-716">638</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3"
                                    name="us-gaap:OtherRestructuringCosts" scale="3" id="f-717">190</ix:nonFraction>
                                &#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3"
                                    name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3"
                                    id="f-718">3,466</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span>
                            </div>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3"
                                    name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="3" id="f-719">
                                    1,833</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" sign="-"
                                    name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-720">269
                                </ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3"
                                    name="us-gaap:BusinessExitCosts1" format="ixt:num-dot-decimal" scale="3" id="f-721">
                                    1,351</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3"
                                    name="us-gaap:OtherRestructuringCosts" scale="3" id="f-722">85</ix:nonFraction>
                                &#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3"
                                    name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3"
                                    id="f-723">3,000</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="padding-left:18pt"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span>
                            </div>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3"
                                    name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="3" id="f-724">
                                    4,303</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" sign="-"
                                    name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-725">101
                                </ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3"
                                    name="us-gaap:BusinessExitCosts1" format="ixt:num-dot-decimal" scale="3" id="f-726">
                                    1,989</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3"
                                    name="us-gaap:OtherRestructuringCosts" scale="3" id="f-727">275</ix:nonFraction>
                                &#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3"
                                    name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3"
                                    id="f-728">6,466</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="f-729"
            escape="true">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    following table summarizes the activity for accrued restructuring costs, which is recorded within
                    accrued expenses and other current liabilities on the consolidated balance sheets, for the period
                    presented (in thousands): </span></div>
            <div style="margin-bottom:12pt;margin-top:12pt;text-align:justify">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:37.225%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.647%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.534%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.647%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.534%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.647%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.534%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.647%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.534%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.651%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance
                                    and Other Employee Costs</span></div>
                        </td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock-Based
                                    Compensation Expense (Benefit)</span></div>
                        </td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Facility
                                    and Other Exit Costs</span></div>
                        </td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Professional
                                    Fees and Other</span></div>
                        </td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance
                                as of December 31, 2022</span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3"
                                    name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="f-730">
                                    &#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3"
                                    name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="f-731">
                                    &#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3"
                                    name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="f-732">
                                    &#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3"
                                    name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="f-733">
                                    &#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3"
                                    name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="f-734">
                                    &#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="padding-left:18pt"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charges</span>
                            </div>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3"
                                    name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3"
                                    id="f-735">4,303</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" sign="-"
                                    name="us-gaap:RestructuringCharges" scale="3" id="f-736">101</ix:nonFraction>
                                )</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3"
                                    name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3"
                                    id="f-737">1,989</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3"
                                    name="us-gaap:RestructuringCharges" scale="3" id="f-738">275</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3"
                                    name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3"
                                    id="f-739">6,466</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="padding-left:18pt"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash
                                    charges</span></div>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3"
                                    name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero"
                                    scale="3" id="f-740">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3"
                                    name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="3" id="f-741">101
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3"
                                    name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero"
                                    scale="3" id="f-742">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3"
                                    name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero"
                                    scale="3" id="f-743">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3"
                                    name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="3" id="f-744">101
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="padding-left:18pt"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash
                                    payments</span></div>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3"
                                    name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3"
                                    id="f-745">1,760</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3"
                                    name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="3"
                                    id="f-746">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3"
                                    name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3"
                                    id="f-747">1,989</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3"
                                    name="us-gaap:PaymentsForRestructuring" scale="3" id="f-748">4</ix:nonFraction>
                                )</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3"
                                    name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3"
                                    id="f-749">3,753</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance
                                as of December 31, 2023</span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3"
                                    name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3"
                                    id="f-750">2,543</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3"
                                    name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="f-751">
                                    &#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3"
                                    name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="3" id="f-752">
                                    &#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3"
                                    name="us-gaap:RestructuringReserve" scale="3" id="f-753">271</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3"
                                    name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3"
                                    id="f-754">2,814</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
    </ix:continuation>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
            <ix:continuation id="f-711-3">The Company does not expect to incur additional restructuring costs relating
                to the Cost Realignment Plan, however the Company expects an additional benefit totaling $
                <ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5"
                    name="mrvi:RestructuringAndRelatedCostExpectedBenefitRemaining" format="ixt:num-dot-decimal"
                    scale="6" id="f-755">1.2</ix:nonFraction> million for the forfeiture of equity awards upon the
                termination of certain impacted employees in January 2024, of which $<ix:nonFraction unitRef="usd"
                    contextRef="c-221" decimals="-5" name="mrvi:RestructuringAndRelatedCostExpectedBenefitRemaining"
                    format="ixt:num-dot-decimal" scale="6" id="f-756">0.8</ix:nonFraction> million relates to the
                Nucleic Acid Production segment and $<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5"
                    name="mrvi:RestructuringAndRelatedCostExpectedBenefitRemaining" format="ixt:num-dot-decimal"
                    scale="6" id="f-757">0.4</ix:nonFraction> million relates to unallocated corporate costs.
            </ix:continuation>
        </span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_202"></div>
    <div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-758"
            continuedAt="f-758-1" escape="true"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Goodwill
                and Intangible Assets</span></ix:nonNumeric>
    </div>
    <ix:continuation id="f-758-1" continuedAt="f-758-2">
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                Company&#8217;s goodwill of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5"
                    name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-759">326.0</ix:nonFraction>
                million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:Goodwill"
                    format="ixt:num-dot-decimal" scale="6" id="f-760">283.7</ix:nonFraction> million as of
                December&#160;31, 2023 and 2022, respectively, represents the excess of purchase consideration over the
                fair value of assets acquired and liabilities assumed. As of December&#160;31, 2023, the Company had
                <ix:nonFraction unitRef="reporting_unit" contextRef="c-1" decimals="INF"
                    name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="f-761">four
                </ix:nonFraction> reporting units, <ix:nonFraction unitRef="reporting_unit" contextRef="c-80"
                    decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0"
                    id="f-762">three</ix:nonFraction> of which are contained in the Nucleic Acid Production segment.
                During the year ended December&#160;31, 2023, the Company recorded goodwill of $<ix:nonFraction
                    unitRef="usd" contextRef="c-223" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod"
                    format="ixt:num-dot-decimal" scale="6" id="f-763">42.4</ix:nonFraction> million in connection with
                the acquisition of Alphazyme that was completed in January 2023 (see Note 2). As of December&#160;31,
                2022, the Company had <ix:nonFraction unitRef="reporting_unit" contextRef="c-15" decimals="INF"
                    name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="f-764">three
                </ix:nonFraction> reporting units, <ix:nonFraction unitRef="reporting_unit" contextRef="c-94"
                    decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0"
                    id="f-765">two</ix:nonFraction> of which were contained in the Nucleic Acid Production
                segment.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due
                to the sustained decline in its stock price and the announcement of the Cost Realignment Plan in
                November 2023, the Company performed a quantitative goodwill impairment analysis on each of its
                <ix:nonFraction unitRef="reporting_unit" contextRef="c-224" decimals="INF"
                    name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="f-766">four
                </ix:nonFraction> reporting units during the fourth quarter of 2023 and concluded that the fair value of
                goodwill exceeded its carrying value. The Company has not recognized any goodwill impairment charges in
                any of the periods presented. </span></div>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-767" escape="true">
            <div style="margin-top:9pt"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    following table summarizes the activity in the Company&#8217;s goodwill by segment for the period
                    presented (in thousands):</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:50.437%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.566%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.532%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.566%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.532%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.567%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nucleic&#160;Acid
                                Production</span></td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Biologics
                                Safety Testing</span></td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance
                                as of December 31, 2022</span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:Goodwill"
                                    format="ixt:num-dot-decimal" scale="3" id="f-768">163,740</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:Goodwill"
                                    format="ixt:num-dot-decimal" scale="3" id="f-769">119,928</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Goodwill"
                                    format="ixt:num-dot-decimal" scale="3" id="f-770">283,668</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3"
                                    name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3"
                                    id="f-771">42,361</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3"
                                    name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="3"
                                    id="f-772">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                    name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3"
                                    id="f-773">42,361</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance
                                as of December 31, 2023</span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:Goodwill"
                                    format="ixt:num-dot-decimal" scale="3" id="f-774">206,101</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:Goodwill"
                                    format="ixt:num-dot-decimal" scale="3" id="f-775">119,928</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill"
                                    format="ixt:num-dot-decimal" scale="3" id="f-776">326,029</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible
                assets are being amortized on a straight-line basis, which reflects the expected pattern in which the
                economic benefits of the intangible assets are being obtained, over an estimated useful life ranging
                from <ix:nonNumeric contextRef="c-229" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife"
                    format="ixt-sec:duryear" id="f-777">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-230"
                    name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-778">14
                </ix:nonNumeric> years.</span></div>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-758-2">
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-779"
            escape="true">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    following are components of finite-lived intangible assets and accumulated amortization as of the
                    periods presented (in thousands):</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:34.280%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.595%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.384%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:12.496%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.384%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.595%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.384%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.595%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.384%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:12.503%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                31, 2023</span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br />Carrying<br />Amount</span>
                        </td>
                        <td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br />Amortization</span>
                        </td>
                        <td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br />Carrying<br />Amount</span>
                        </td>
                        <td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br />Useful<br />Life</span>
                        </td>
                        <td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br />Average<br />Remaining<br />Amortization<br />Period</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt" />
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span>
                        </td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt" />
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in
                                years)</span></td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in
                                years)</span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade
                                Names</span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal"
                                    scale="3" id="f-780">7,800</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization"
                                    format="ixt:num-dot-decimal" scale="3" id="f-781">6,369</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3"
                                    id="f-782">1,431</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonNumeric contextRef="c-232"
                                        name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"
                                        id="f-783">3</ix:nonNumeric> - <ix:nonNumeric contextRef="c-233"
                                        name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"
                                        id="f-784">10</ix:nonNumeric>
                                </span></div>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonNumeric contextRef="c-231"
                                    name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"
                                    format="ixt-sec:duryear" id="f-785">2.8</ix:nonNumeric>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents
                                and Developed Technology</span></td>
                        <td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal"
                                    scale="3" id="f-786">319,649</ix:nonFraction>&#160;
                            </span></td>
                        <td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization"
                                    format="ixt:num-dot-decimal" scale="3" id="f-787">109,800</ix:nonFraction>&#160;
                            </span></td>
                        <td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3"
                                    id="f-788">209,849</ix:nonFraction>&#160;
                            </span></td>
                        <td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonNumeric contextRef="c-235"
                                        name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"
                                        id="f-789">10</ix:nonNumeric> - <ix:nonNumeric contextRef="c-236"
                                        name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"
                                        id="f-790">14</ix:nonNumeric>
                                </span></div>
                        </td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonNumeric contextRef="c-234"
                                    name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"
                                    format="ixt-sec:duryear" id="f-791">8.9</ix:nonNumeric>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer
                                Relationships</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal"
                                    scale="3" id="f-792">22,313</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization"
                                    format="ixt:num-dot-decimal" scale="3" id="f-793">12,606</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3"
                                    id="f-794">9,707</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonNumeric contextRef="c-238"
                                        name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"
                                        id="f-795">10</ix:nonNumeric> - <ix:nonNumeric contextRef="c-239"
                                        name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"
                                        id="f-796">12</ix:nonNumeric>
                                </span></div>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonNumeric contextRef="c-237"
                                    name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"
                                    format="ixt-sec:duryear" id="f-797">5.9</ix:nonNumeric>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span>
                        </td>
                        <td
                            style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal"
                                    scale="3" id="f-798">349,762</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="padding:0 1pt" />
                        <td
                            style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization"
                                    format="ixt:num-dot-decimal" scale="3" id="f-799">128,775</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="padding:0 1pt" />
                        <td
                            style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3"
                                    id="f-800">220,987</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonNumeric contextRef="c-5"
                                    name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"
                                    format="ixt-sec:duryear" id="f-801">8.7</ix:nonNumeric>
                            </span></td>
                    </tr>
                </table>
            </div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:34.280%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.595%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.384%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:12.496%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.384%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.595%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.384%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.595%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.384%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:12.503%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                31, 2022</span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="margin-top:2pt;text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross</span>
                            </div>
                            <div style="text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying</span>
                            </div>
                            <div style="margin-bottom:2pt;text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span>
                            </div>
                        </td>
                        <td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="margin-top:2pt;text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated</span>
                            </div>
                            <div style="margin-bottom:2pt;text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortization</span>
                            </div>
                        </td>
                        <td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="margin-top:2pt;text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net</span>
                            </div>
                            <div style="text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying</span>
                            </div>
                            <div style="margin-bottom:2pt;text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span>
                            </div>
                        </td>
                        <td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="margin-top:2pt;text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Estimated</span>
                            </div>
                            <div style="text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Useful</span>
                            </div>
                            <div style="margin-bottom:2pt;text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Life</span>
                            </div>
                        </td>
                        <td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="margin-top:2pt;text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span>
                            </div>
                            <div style="text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span>
                            </div>
                            <div style="text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining</span>
                            </div>
                            <div style="text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortization</span>
                            </div>
                            <div style="margin-bottom:2pt;text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Period</span>
                            </div>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt" />
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span>
                        </td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt" />
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in
                                years)</span></td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in
                                years)</span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade
                                Names</span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal"
                                    scale="3" id="f-802">7,580</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization"
                                    format="ixt:num-dot-decimal" scale="3" id="f-803">5,746</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3"
                                    id="f-804">1,834</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonNumeric contextRef="c-241"
                                        name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"
                                        id="f-805">3</ix:nonNumeric> - <ix:nonNumeric contextRef="c-242"
                                        name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"
                                        id="f-806">10</ix:nonNumeric>
                                </span></div>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonNumeric contextRef="c-240"
                                    name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"
                                    format="ixt-sec:duryear" id="f-807">3.5</ix:nonNumeric>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents
                                and Developed Technology</span></td>
                        <td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal"
                                    scale="3" id="f-808">288,649</ix:nonFraction>&#160;
                            </span></td>
                        <td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization"
                                    format="ixt:num-dot-decimal" scale="3" id="f-809">85,058</ix:nonFraction>&#160;
                            </span></td>
                        <td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3"
                                    id="f-810">203,591</ix:nonFraction>&#160;
                            </span></td>
                        <td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonNumeric contextRef="c-244"
                                        name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"
                                        id="f-811">10</ix:nonNumeric> - <ix:nonNumeric contextRef="c-245"
                                        name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"
                                        id="f-812">14</ix:nonNumeric>
                                </span></div>
                        </td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonNumeric contextRef="c-243"
                                    name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"
                                    format="ixt-sec:duryear" id="f-813">9.5</ix:nonNumeric>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer
                                Relationships</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal"
                                    scale="3" id="f-814">21,853</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization"
                                    format="ixt:num-dot-decimal" scale="3" id="f-815">10,615</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3"
                                    id="f-816">11,238</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="text-align:center"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonNumeric contextRef="c-247"
                                        name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"
                                        id="f-817">10</ix:nonNumeric> - <ix:nonNumeric contextRef="c-248"
                                        name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"
                                        id="f-818">12</ix:nonNumeric>
                                </span></div>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonNumeric contextRef="c-246"
                                    name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"
                                    format="ixt-sec:duryear" id="f-819">6.5</ix:nonNumeric>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span>
                        </td>
                        <td
                            style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal"
                                    scale="3" id="f-820">318,082</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="padding:0 1pt" />
                        <td
                            style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization"
                                    format="ixt:num-dot-decimal" scale="3" id="f-821">101,419</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="padding:0 1pt" />
                        <td
                            style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3"
                                    id="f-822">216,663</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonNumeric contextRef="c-6"
                                    name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"
                                    format="ixt-sec:duryear" id="f-823">9.3</ix:nonNumeric>
                            </span></td>
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During
                the first quarter of 2023, the Company recorded intangible assets of $<ix:nonFraction unitRef="usd"
                    contextRef="c-249" decimals="-5"
                    name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"
                    format="ixt:num-dot-decimal" scale="6" id="f-824">31.7</ix:nonFraction>&#160;million in connection
                with the acquisition of Alphazyme that was completed in January 2023 (see Note 2).</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-5"
                    name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-825">24.8
                </ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-5"
                    name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-826">21.5
                </ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-5"
                    name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-827">12.4
                </ix:nonFraction> million of amortization expense from intangible assets directly linked with revenue
                generating activities within cost of revenue in the consolidated statements of operations for the years
                ended December&#160;31, 2023, 2022 and 2021, respectively. Amortization expense for intangible assets
                that are not directly related to sales generating activities of $<ix:nonFraction unitRef="usd"
                    contextRef="c-253" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets"
                    format="ixt:num-dot-decimal" scale="6" id="f-828">2.6</ix:nonFraction> million, $<ix:nonFraction
                    unitRef="usd" contextRef="c-254" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets"
                    format="ixt:num-dot-decimal" scale="6" id="f-829">2.8</ix:nonFraction> million and $<ix:nonFraction
                    unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets"
                    format="ixt:num-dot-decimal" scale="6" id="f-830">5.9</ix:nonFraction> million was recorded as
                selling, general and administrative expenses for the years ended December&#160;31, 2023, 2022 and 2021,
                respectively. </span></div>
        <ix:nonNumeric contextRef="c-1"
            name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-831"
            escape="true">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
                    of December&#160;31, 2023, the estimated future amortization expense for finite-lived intangible
                    assets were as follows (in thousands):</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:83.233%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.567%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span>
                        </td>
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"
                                    format="ixt:num-dot-decimal" scale="3" id="f-832">27,478</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span>
                        </td>
                        <td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"
                                    format="ixt:num-dot-decimal" scale="3" id="f-833">27,335</ix:nonFraction>&#160;
                            </span></td>
                        <td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"
                                    format="ixt:num-dot-decimal" scale="3" id="f-834">27,098</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span>
                        </td>
                        <td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"
                                    format="ixt:num-dot-decimal" scale="3" id="f-835">26,082</ix:nonFraction>&#160;
                            </span></td>
                        <td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"
                                    format="ixt:num-dot-decimal" scale="3" id="f-836">25,862</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span>
                        </td>
                        <td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"
                                    format="ixt:num-dot-decimal" scale="3" id="f-837">87,132</ix:nonFraction>&#160;
                            </span></td>
                        <td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                estimated amortization expense</span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3"
                                    id="f-838">220,987</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_205"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-839" continuedAt="f-839-1"
            escape="true"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Fair
                Value Measurements</span></ix:nonNumeric>
    </div>
    <ix:continuation id="f-839-1" continuedAt="f-839-2">
        <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="f-840"
            escape="true">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    following table summarizes the Company&#8217;s financial assets and liabilities that are measured at
                    fair value on a recurring basis by level within the fair value hierarchy as of the periods presented
                    (in thousands):</span></div>
            <div style="margin-top:12pt;text-align:justify">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:49.779%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.632%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair
                                Value Measurements as of December 31, 2023</span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level
                                1</span></td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level
                                2</span></td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level
                                3</span></td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="padding-left:18pt"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money
                                    market funds</span></div>
                        </td>
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3"
                                    name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-841">
                                    418,685</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3"
                                    name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="f-842">&#8212;
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3"
                                    name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="f-843">&#8212;
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3"
                                    name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-844">
                                    418,685</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest
                                rate cap</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3"
                                    name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="f-845">&#8212;
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3"
                                    name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-846">
                                    8,559</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3"
                                    name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="f-847">&#8212;
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3"
                                    name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-848">
                                    8,559</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                assets</span></td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3"
                                    name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-849">
                                    418,685</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3"
                                    name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-850">
                                    8,559</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3"
                                    name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="f-851">&#8212;
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-852">
                                    427,244</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr style="height:14pt">
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span>
                        </td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current
                                portion of contingent consideration</span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3"
                                    name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent"
                                    format="ixt:fixed-zero" scale="3" id="f-853">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3"
                                    name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent"
                                    format="ixt:fixed-zero" scale="3" id="f-854">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3"
                                    name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3"
                                    id="f-855">131</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3"
                                    name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="3"
                                    id="f-856">131</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent
                                consideration, non-current</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3"
                                    name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent"
                                    format="ixt:fixed-zero" scale="3" id="f-857">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3"
                                    name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent"
                                    format="ixt:fixed-zero" scale="3" id="f-858">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3"
                                    name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent"
                                    format="ixt:num-dot-decimal" scale="3" id="f-859">1,872</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3"
                                    name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent"
                                    format="ixt:num-dot-decimal" scale="3" id="f-860">1,872</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                liabilities</span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3"
                                    name="us-gaap:BusinessCombinationContingentConsiderationLiability"
                                    format="ixt:fixed-zero" scale="3" id="f-861">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3"
                                    name="us-gaap:BusinessCombinationContingentConsiderationLiability"
                                    format="ixt:fixed-zero" scale="3" id="f-862">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3"
                                    name="us-gaap:BusinessCombinationContingentConsiderationLiability"
                                    format="ixt:num-dot-decimal" scale="3" id="f-863">2,003</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3"
                                    name="us-gaap:BusinessCombinationContingentConsiderationLiability"
                                    format="ixt:num-dot-decimal" scale="3" id="f-864">2,003</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
            <div style="margin-bottom:12pt;margin-top:12pt;text-align:justify">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:49.779%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.632%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair
                                Value Measurements as of December 31, 2022</span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level
                                1</span></td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level
                                2</span></td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level
                                3</span></td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest
                                rate cap</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3"
                                    name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="f-865">&#8212;
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3"
                                    name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-866">
                                    11,362</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3"
                                    name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="f-867">&#8212;
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3"
                                    name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-868">
                                    11,362</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent
                Consideration</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                connection with the acquisition of Alphazyme (see Note 2), the Company is required to make contingent
                payments to the sellers of up to $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5"
                    name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal"
                    scale="6" id="f-869">75.0</ix:nonFraction> million, subject to achieving certain revenue thresholds.
                The preliminary fair value of the liability for the contingent payments recognized upon the acquisition
                as part of the purchase accounting opening balance sheet totaled $<ix:nonFraction unitRef="usd"
                    contextRef="c-140" decimals="-5"
                    name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred"
                    format="ixt:num-dot-decimal" scale="6" id="f-870">5.3</ix:nonFraction> million. The preliminary fair
                value of the contingent consideration was determined using a Monte-Carlo simulation-based model
                discounted to present value. Assumptions used in this calculation are expected revenue, a discount rate
                of <ix:nonFraction unitRef="number" contextRef="c-272" decimals="3"
                    name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2"
                    id="f-871">17.8</ix:nonFraction>% and various probability factors. The ultimate settlement of the
                contingent consideration could deviate from current estimates based on the actual results of these
                financial measures. The contingent consideration has <ix:nonFraction unitRef="payment"
                    contextRef="c-148" decimals="INF"
                    name="mrvi:BusinessCombinationContingentConsiderationNumberOfPayments" format="ixt-sec:numwordsen"
                    scale="0" id="f-872">three</ix:nonFraction> performance payments spanning over <ix:nonNumeric
                    contextRef="c-140" name="mrvi:BusinessCombinationContingentConsiderationPaymentPeriod"
                    format="ixt-sec:durwordsen" id="f-873">three years</ix:nonNumeric> beginning 2024. This liability is
                considered to be a Level 3 financial liability that is remeasured each reporting period. Changes in fair
                value of contingent consideration are recognized as a gain or loss and recorded within change in
                estimated fair value of contingent consideration in the consolidated statements of operations. During
                the year ended December&#160;31, 2023, the Company recorded a decrease of $<ix:nonFraction unitRef="usd"
                    contextRef="c-141" decimals="-5" sign="-"
                    name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"
                    format="ixt:num-dot-decimal" scale="6" id="f-874">3.3</ix:nonFraction>&#160;million in the estimated
                fair value of contingent consideration. This was due to a change in estimates associated with Alphazyme
                revenue projections reaching thresholds that would trigger a contingent payment per the Alphazyme
                SPA.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                connection with the acquisition of MyChem (see Note 2), the Company is required to make contingent
                payments to the sellers of up to $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5"
                    name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal"
                    scale="6" id="f-875">40.0</ix:nonFraction> million, subject to achieving certain revenue thresholds.
                The preliminary fair value of the liability for the contingent payments recognized upon the acquisition
                as part of the purchase accounting opening balance sheet totaled $<ix:nonFraction unitRef="usd"
                    contextRef="c-164" decimals="-5"
                    name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred"
                    format="ixt:num-dot-decimal" scale="6" id="f-876">7.8</ix:nonFraction> million. The preliminary fair
                value of the contingent consideration was determined using a Monte-Carlo simulation-based model
                discounted to present value. Assumptions used in this calculation are expected revenue, a discount rate
                of <ix:nonFraction unitRef="number" contextRef="c-273" decimals="3"
                    name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2"
                    id="f-877">16.9</ix:nonFraction>% and various probability factors. The ultimate settlement of the
                contingent consideration could deviate from current estimates based on the actual results of these
                financial measures. The contingent consideration projected year of payment was 2023. This liability is
                considered to be a Level 3 financial liability that is remeasured each reporting period. Changes in fair
                value of contingent consideration are recognized as a gain or loss and recorded within change in
                estimated fair value of contingent consideration in the consolidated statements of operations. During
                the second quarter of 2022, the Company recorded a $<ix:nonFraction unitRef="usd" contextRef="c-274"
                    decimals="-5" sign="-"
                    name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"
                    format="ixt:num-dot-decimal" scale="6" id="f-878">7.8</ix:nonFraction> million decrease in the
                estimated fair value of contingent consideration. This was due to a change in the estimate associated
                with MyChem revenue projections reaching thresholds that would trigger a contingent payment per the
                MyChem SPA. The contingent consideration expired as of December 31, 2022 and the revenue thresholds were
                not achieved.</span></div>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:nonNumeric contextRef="c-1"
        name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="f-879"
        escape="true">
        <ix:continuation id="f-839-2">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    following table provides a reconciliation of liabilities measured at fair value on a recurring basis
                    using significant unobservable inputs (Level 3) for the periods presented (in thousands):</span>
            </div>
            <div style="margin-bottom:12pt;margin-top:12pt;text-align:justify">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:83.233%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.567%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent
                                Consideration</span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance
                                as of December 31, 2021</span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:BusinessCombinationContingentConsiderationLiability"
                                    format="ixt:fixed-zero" scale="3" id="f-880">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent
                                consideration related to the acquisition of MyChem</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3"
                                    name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred"
                                    format="ixt:num-dot-decimal" scale="3" id="f-881">7,800</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change
                                in estimated fair value of contingent consideration</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-"
                                    name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"
                                    format="ixt:num-dot-decimal" scale="3" id="f-882">7,800</ix:nonFraction>)</span>
                        </td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance
                                as of December 31, 2022</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:BusinessCombinationContingentConsiderationLiability"
                                    format="ixt:fixed-zero" scale="3" id="f-883">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent
                                consideration related to the acquisition of Alphazyme</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3"
                                    name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred"
                                    format="ixt:num-dot-decimal" scale="3" id="f-884">5,289</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change
                                in estimated fair value of contingent consideration</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                                    name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"
                                    format="ixt:num-dot-decimal" scale="3" id="f-885">3,286</ix:nonFraction>)</span>
                        </td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance
                                as of December 31, 2023</span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:BusinessCombinationContingentConsiderationLiability"
                                    format="ixt:num-dot-decimal" scale="3" id="f-886">2,003</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:continuation>
    </ix:nonNumeric>
    <div id="ic995976d222241b98dac88a4c1bc08e5_208"></div>
    <div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-887"
            continuedAt="f-887-1" escape="true"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Balance
                Sheet Components </span></ix:nonNumeric>
    </div>
    <ix:continuation id="f-887-1" continuedAt="f-887-2">
        <div style="margin-top:12pt"><span
                style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span>
        </div>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-888"
            escape="true">
            <div style="margin-top:6pt"><span
                    style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory
                    consisted of the following as of the periods presented (in thousands):</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:66.835%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.566%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.532%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.567%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                31, 2023</span></td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                31, 2022</span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw
                                materials</span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal"
                                    scale="3" id="f-889">19,338</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal"
                                    scale="3" id="f-890">13,486</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal"
                                    scale="3" id="f-891">12,680</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal"
                                    scale="3" id="f-892">21,950</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished
                                goods</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal"
                                    scale="3" id="f-893">19,379</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal"
                                    scale="3" id="f-894">7,716</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                inventory</span></td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryNet"
                                    format="ixt:num-dot-decimal" scale="3" id="f-895">51,397</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InventoryNet"
                                    format="ixt:num-dot-decimal" scale="3" id="f-896">43,152</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
        <div style="margin-top:12pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property
                and equipment</span></div>
        <ix:continuation id="f-577-2">
            <div style="margin-top:6pt"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property
                    and equipment consist</span><span
                    style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed
                    of the following as of the periods presented</span><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
                    (in thousands):</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:66.835%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.566%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.532%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.567%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                31, 2023</span></td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                31, 2022</span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance
                                    lease right-of-use assets</span></div>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"
                                    format="ixt:num-dot-decimal" scale="3" id="f-897">78,599</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization"
                                    format="ixt:fixed-zero" scale="3" id="f-898">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold
                                improvements</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3"
                                    name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3"
                                    id="f-899">24,874</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3"
                                    name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3"
                                    id="f-900">20,095</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture,
                                fixtures, and equipment</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3"
                                    name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3"
                                    id="f-901">48,793</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3"
                                    name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3"
                                    id="f-902">35,907</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3"
                                    name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3"
                                    id="f-903">3,211</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3"
                                    name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3"
                                    id="f-904">3,004</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3"
                                    name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3"
                                    id="f-905">155,477</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3"
                                    name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3"
                                    id="f-906">59,006</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less
                                accumulated depreciation</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"
                                    format="ixt:num-dot-decimal" scale="3" id="f-907">32,214</ix:nonFraction>)</span>
                        </td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"
                                    format="ixt:num-dot-decimal" scale="3" id="f-908">19,502</ix:nonFraction>)</span>
                        </td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3"
                                    name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3"
                                    id="f-909">123,263</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3"
                                    name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3"
                                    id="f-910">39,504</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction
                                in-progress</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3"
                                    name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3"
                                    id="f-911">39,637</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3"
                                    name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3"
                                    id="f-912">13,190</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                property and equipment, net</span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3"
                                    id="f-913">162,900</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3"
                                    id="f-914">52,694</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:continuation>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation
                expense totaled approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5"
                    name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-915">12.9</ix:nonFraction>
                million, $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:Depreciation"
                    format="ixt:num-dot-decimal" scale="6" id="f-916">7.6</ix:nonFraction> million and $<ix:nonFraction
                    unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:Depreciation"
                    format="ixt:num-dot-decimal" scale="6" id="f-917">6.4</ix:nonFraction> million for the years ended
                December&#160;31, 2023, 2022 and 2021, respectively.</span></div>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-887-2">
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other
                assets</span></div>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" id="f-918" escape="true">
            <div style="margin-top:6pt"><span
                    style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other
                    assets consisted of the following as of the periods presented (in thousands):</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:66.835%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.566%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.532%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.567%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                31, 2023</span></td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                31, 2022</span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating
                                    lease right-of-use assets</span></div>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3"
                                    id="f-919">59,746</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3"
                                    id="f-920">63,896</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest
                                rate cap</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-921">8,559</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-922">11,362</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnification
                                    asset (see Note 2)</span></div>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="mrvi:BusinessCombinationIndemnificationAssetsCarryingValue"
                                    format="ixt:num-dot-decimal" scale="3" id="f-923">6,388</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="mrvi:BusinessCombinationIndemnificationAssetsCarryingValue"
                                    format="ixt:num-dot-decimal" scale="3" id="f-924">7,682</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid
                                lease payments</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="mrvi:PrepaidLeasePayments" format="ixt:fixed-zero" scale="3" id="f-925">
                                    &#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="mrvi:PrepaidLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-926">
                                    27,253</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:OtherAssetsMiscellaneousNoncurrent" format="ixt:num-dot-decimal"
                                    scale="3" id="f-927">2,929</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:OtherAssetsMiscellaneousNoncurrent" format="ixt:num-dot-decimal"
                                    scale="3" id="f-928">5,396</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                other assets</span></td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-929">77,622</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-930">115,589</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
        <div style="margin-top:12pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued
                expenses and other current liabilities</span></div>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-931"
            escape="true">
            <div style="margin-top:6pt"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued
                    expenses </span><span
                    style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consisted
                    of the following as of the periods presented</span><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
                    (in thousands):</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:66.835%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.566%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.532%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.567%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                31, 2023</span></td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                31, 2022</span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued
                                    MyChem Retention Payments, current portion (see Note 2)</span></div>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3"
                                    name="mrvi:AccruedRetentionPaymentsCurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-932">19,446</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3"
                                    name="mrvi:AccruedRetentionPaymentsCurrent" format="ixt:fixed-zero" scale="3"
                                    id="f-933">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee
                                related</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal"
                                    scale="3" id="f-934">12,905</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal"
                                    scale="3" id="f-935">19,873</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued
                                interest payable</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-936">9,202</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-937">7,700</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating
                                    lease liabilities, current portion</span></div>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-938">6,780</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-939">6,269</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued
                                    restructuring costs (see Note 3)</span></div>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="mrvi:AccruedRestructuringCostsCurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-940">2,814</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="mrvi:AccruedRestructuringCostsCurrent" format="ixt:fixed-zero" scale="3"
                                    id="f-941">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional
                                services</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-942">2,277</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-943">4,093</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer
                                deposits</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="mrvi:ContractWithCustomerLiabilityCurrentCustomerDeposits"
                                    format="ixt:num-dot-decimal" scale="3" id="f-944">2,156</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="mrvi:ContractWithCustomerLiabilityCurrentCustomerDeposits"
                                    format="ixt:num-dot-decimal" scale="3" id="f-945">1,665</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales
                                and use tax liability</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:SalesAndExciseTaxPayableCurrent" format="ixt:num-dot-decimal"
                                    scale="3" id="f-946">1,001</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:SalesAndExciseTaxPayableCurrent" format="ixt:num-dot-decimal"
                                    scale="3" id="f-947">1,029</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory
                                holdback liability</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="mrvi:InventoryHoldbackLiabilityCurrent" format="ixt:fixed-zero" scale="3"
                                    id="f-948">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="mrvi:InventoryHoldbackLiabilityCurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-949">10,000</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-950">3,656</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-951">2,742</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                accrued expenses and other current liabilities</span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-952">60,237</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-953">53,371</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
        <div style="margin-top:12pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other
                long-term liabilities</span></div>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" id="f-954"
            escape="true">
            <div style="margin-top:6pt"><span
                    style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other
                    long-term liabilities consisted of the following as of the periods presented (in thousands):</span>
            </div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:66.835%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.566%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.532%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.567%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                31, 2023</span></td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                31, 2022</span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating
                                    lease liabilities, non-current</span></div>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal"
                                    scale="3" id="f-955">47,510</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal"
                                    scale="3" id="f-956">51,556</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition
                                    related tax liability (see Note 2)</span></div>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="mrvi:BusinessCombinationTaxLiabilityNoncurrent" format="ixt:num-dot-decimal"
                                    scale="3" id="f-957">6,388</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="mrvi:BusinessCombinationTaxLiabilityNoncurrent" format="ixt:num-dot-decimal"
                                    scale="3" id="f-958">7,682</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued
                                    Alphayzme Retention Payments, non-current (see Note 2)</span></div>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3"
                                    name="mrvi:AccruedRetentionPaymentsNoncurrent" format="ixt:num-dot-decimal"
                                    scale="3" id="f-959">3,202</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3"
                                    name="mrvi:AccruedRetentionPaymentsNoncurrent" format="ixt:fixed-zero" scale="3"
                                    id="f-960">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent
                                    consideration, non-current</span></div>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent"
                                    format="ixt:num-dot-decimal" scale="3" id="f-961">1,872</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent"
                                    format="ixt:fixed-zero" scale="3" id="f-962">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued
                                    MyChem Retention Payments, non-current (see Note 2)</span></div>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-3"
                                    name="mrvi:AccruedRetentionPaymentsNoncurrent" format="ixt:fixed-zero" scale="3"
                                    id="f-963">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3"
                                    name="mrvi:AccruedRetentionPaymentsNoncurrent" format="ixt:num-dot-decimal"
                                    scale="3" id="f-964">9,324</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="mrvi:OtherLiabilitiesMiscellaneousNoncurrent" scale="3" id="f-965">522
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="mrvi:OtherLiabilitiesMiscellaneousNoncurrent" scale="3" id="f-966">413
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                other long-term liabilities</span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-967">59,494</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-968">68,975</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
    </ix:continuation>
    <div id="ic995976d222241b98dac88a4c1bc08e5_211"></div>
    <div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:GovernmentAssistanceTextBlock" id="f-969" continuedAt="f-969-1"
            escape="true"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Government
                Assistance</span></ix:nonNumeric>
    </div>
    <ix:continuation id="f-969-1" continuedAt="f-969-2">
        <div style="margin-top:12pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cooperative
                Agreement</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                May 2022, TriLink entered into a cooperative agreement (the &#8220;Cooperative Agreement&#8221;) with
                the U.S. Department of Defense, as represented by the Joint Program Executive Office for Chemical,
                Biological, Radiological and Nuclear Defense on behalf of the Biomedical Advanced Research and
                Development Authority (&#8220;BARDA&#8221;), within the U.S. Department of Health and Human Services
                (&#8220;HHS&#8221;), to advance the development of domestic manufacturing capabilities and to expand
                TriLink&#8217;s domestic production capacity in its San Diego manufacturing campus (the &#8220;Flanders
                San Diego Facility&#8221;) for products critical to the development and manufacture of mRNA vaccines and
                therapeutics. The Cooperative Agreement has since transitioned from the U.S. Department of Defense to
                the HHS as of January 2023. The Flanders San Diego Facility consists of <ix:nonFraction
                    unitRef="building" contextRef="c-288" decimals="INF"
                    name="mrvi:LesseeOperatingLeaseNumberOfBuildingsLeased" format="ixt-sec:numwordsen" scale="0"
                    id="f-970">two</ix:nonFraction> buildings (&#8220;Flanders I&#8221; and &#8220;Flanders II&#8221;),
                however, the Cooperative Agreement is exclusively involved in Flanders I.</span></div>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-969-2">
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                Cooperative Agreement requires the Company to provide the U.S. Government with conditional priority
                access and certain preferred pricing obligations for a <ix:nonNumeric contextRef="c-289"
                    name="mrvi:GovernmentAssistancePriorityAccessPeriod" format="ixt-sec:durwordsen" id="f-971">10-year
                </ix:nonNumeric> period from the completion of the construction project for the production of a medical
                countermeasure (or a component thereof) that the Company manufactures in the Flanders San Diego Facility
                during a declared public health emergency.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant
                to certain requirements, BARDA awarded TriLink an amount equal to $<ix:nonFraction unitRef="usd"
                    contextRef="c-289" decimals="-5"
                    name="mrvi:GovernmentAssistanceExpectationOfReimbursementAmountFromGovernment"
                    format="ixt:num-dot-decimal" scale="6" id="f-972">38.8</ix:nonFraction> million or <ix:nonFraction
                    unitRef="number" contextRef="c-290" decimals="2"
                    name="mrvi:GovernmentAssistancePercentageOfReimbursableCosts" scale="-2" id="f-973">50
                </ix:nonFraction>% of the construction and validation costs currently budgeted for the Flanders San
                Diego Facility. The contract period of performance is May 2022 through January 2034, which is the
                effective date of the Cooperative Agreement through the anticipated expiration of the <ix:nonNumeric
                    contextRef="c-289" name="mrvi:GovernmentAssistancePriorityAccessPeriod" format="ixt-sec:durwordsen"
                    id="f-974">10-year</ix:nonNumeric> conditional priority access period. Amounts reimbursed are
                subject to audit and may be recaptured by the HHS in certain circumstances.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During
                the year ended December&#160;31, 2023, the Company has received $<ix:nonFraction unitRef="usd"
                    contextRef="c-291" decimals="-5" name="us-gaap:GovernmentAssistanceAmount"
                    format="ixt:num-dot-decimal" scale="6" id="f-975">12.9</ix:nonFraction> million of <ix:nonNumeric
                    contextRef="c-291"
                    name="mrvi:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"
                    id="f-976">reimbursements</ix:nonNumeric> under the Cooperative Agreement with an equal offset
                recorded to property and equipment on the consolidated balance sheet. As of December&#160;31, 2023, the
                Company has recorded a receivable of $<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-5"
                    name="us-gaap:GovernmentContractReceivable" format="ixt:num-dot-decimal" scale="6" id="f-977">1.1
                </ix:nonFraction> million, with an equal offset to property and equipment on the consolidated balance
                sheet.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During
                the year ended December&#160;31, 2022, the Company has received $<ix:nonFraction unitRef="usd"
                    contextRef="c-293" decimals="-5" name="us-gaap:GovernmentAssistanceAmount"
                    format="ixt:num-dot-decimal" scale="6" id="f-978">18.1</ix:nonFraction> million of <ix:nonNumeric
                    contextRef="c-293"
                    name="mrvi:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumerationNotDisclosedFlag"
                    id="f-979">reimbursements</ix:nonNumeric> under the Cooperative Agreement, with offsets recorded to:
                (i) prepaid lease payments associated with Flanders I within <span style="-sec-ix-hidden:f-980">other
                    assets</span> of $<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-5"
                    name="us-gaap:GovernmentAssistanceAmountCumulative" format="ixt:num-dot-decimal" scale="6"
                    id="f-981">17.0</ix:nonFraction> million; and (ii) <span style="-sec-ix-hidden:f-982">property and
                    equipment</span> of $<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-5"
                    name="us-gaap:GovernmentAssistanceAmountCumulative" format="ixt:num-dot-decimal" scale="6"
                    id="f-983">1.1</ix:nonFraction> million. As of December&#160;31, 2022, the Company has recorded a
                receivable of $<ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-5"
                    name="us-gaap:GovernmentContractReceivable" format="ixt:num-dot-decimal" scale="6" id="f-984">8.2
                </ix:nonFraction> million, with an equal offset recorded to prepaid lease payments associated with
                Flanders I within other assets on the consolidated balance sheet.</span></div>
    </ix:continuation>
    <div id="ic995976d222241b98dac88a4c1bc08e5_214"></div>
    <div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-986" continuedAt="f-986-1"
            escape="true">
            <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeFinanceLeasesTextBlock" id="f-985" continuedAt="f-985-1"
                escape="true"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Leases</span>
            </ix:nonNumeric>
        </ix:nonNumeric>
    </div>
    <ix:continuation id="f-986-1" continuedAt="f-986-2">
        <ix:continuation id="f-985-1" continuedAt="f-985-2">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All
                    of the Company's facilities, including office, laboratory and manufacturing space, are occupied
                    under long-term non-cancelable lease arrangements with various expiration dates through 2038, some
                    of which include options to extend up to <ix:nonNumeric contextRef="c-230"
                        name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear" id="f-987">20
                    </ix:nonNumeric> years. The Company does not have any leases that include residual value guarantees.
                </span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                    January 2023, the Company assumed Alphazyme&#8217;s existing facility lease in Jupiter, Florida, in
                    connection with the acquisition of Alphazyme (see Note 2). The lease term began in January 2023 and
                    will end in January 2032. The lease is for <ix:nonNumeric contextRef="c-297"
                        name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-988">10
                    </ix:nonNumeric> years with the option to extend for <ix:nonFraction unitRef="extension_option"
                        contextRef="c-297" decimals="INF" name="mrvi:LesseeOperatingLeaseNumberOfExtensionOptions"
                        format="ixt-sec:numwordsen" scale="0" id="f-989">one</ix:nonFraction> additional <ix:nonNumeric
                        contextRef="c-297" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"
                        id="f-990">5-year</ix:nonNumeric> period. </span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                    February 2023, the Company entered into an agreement to expand the existing Alphazyme facility lease
                    for additional space. The lease term will run concurrently with and as part of the initial lease
                    term.</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                    March 2023 and June 2023, the Company&#8217;s leases for Flanders I and Flanders II, respectively,
                    commenced. The Company entered into the lease agreement in August 2021. The leases are for
                    <ix:nonNumeric contextRef="c-298" name="us-gaap:LesseeOperatingLeaseTermOfContract"
                        format="ixt-sec:durwordsen" id="f-991">
                        <ix:nonNumeric contextRef="c-299" name="us-gaap:LesseeOperatingLeaseTermOfContract"
                            format="ixt-sec:durwordsen" id="f-992">eleven years</ix:nonNumeric>
                    </ix:nonNumeric> with the option to extend for <ix:nonFraction unitRef="extension_option"
                        contextRef="c-298" decimals="INF" name="mrvi:LesseeOperatingLeaseNumberOfExtensionOptions"
                        format="ixt-sec:numwordsen" scale="0" id="f-993">
                        <ix:nonFraction unitRef="extension_option" contextRef="c-299" decimals="INF"
                            name="mrvi:LesseeOperatingLeaseNumberOfExtensionOptions" format="ixt-sec:numwordsen"
                            scale="0" id="f-994">one</ix:nonFraction>
                    </ix:nonFraction> additional <ix:nonNumeric contextRef="c-298"
                        name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-995">
                        <ix:nonNumeric contextRef="c-299" name="us-gaap:LesseeOperatingLeaseRenewalTerm"
                            format="ixt-sec:durwordsen" id="f-996">5-year</ix:nonNumeric>
                    </ix:nonNumeric> period. The Company is reasonably certain to execute the renewal option and has,
                    therefore, recognized this as part of its ROU assets and lease liabilities. The lease includes
                    tenant improvement provisions, rent abatement clauses, and escalating rent payments over the life of
                    the lease.</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                    December 2023, as part of the Cost Realignment Plan, the Company terminated a facility lease in San
                    Diego, California and recorded a non-cash loss for early lease termination in the consolidated
                    statements of operations (see Note 3).</span></div>
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company has a $<ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-5"
                        name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6"
                        id="f-997">0.5</ix:nonFraction> million outstanding letter of credit as security for a lease
                    agreement for a facility in San Diego, California, which reduced the availability of credit under
                    the Revolving Credit Facility (see Note 10).</span></div>
        </ix:continuation>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-986-2" continuedAt="f-986-3">
        <ix:continuation id="f-985-2" continuedAt="f-985-3">
            <ix:nonNumeric contextRef="c-1" name="mrvi:AssetsAndLiabilitiesLesseeTableTextBlock" id="f-998"
                escape="true">
                <div style="margin-top:6pt;text-align:justify"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                        following table presents supplemental balance sheet information related to the Company's leases
                        as of the periods presented below (in thousands):</span></div>
                <div style="margin-bottom:12pt;margin-top:6pt;text-align:justify">
                    <table
                        style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                        <tr>
                            <td style="width:1.0%" />
                            <td style="width:26.279%" />
                            <td style="width:0.1%" />
                            <td style="width:1.0%" />
                            <td style="width:38.724%" />
                            <td style="width:0.1%" />
                            <td style="width:0.1%" />
                            <td style="width:0.532%" />
                            <td style="width:0.1%" />
                            <td style="width:1.0%" />
                            <td style="width:14.566%" />
                            <td style="width:0.1%" />
                            <td style="width:0.1%" />
                            <td style="width:0.532%" />
                            <td style="width:0.1%" />
                            <td style="width:1.0%" />
                            <td style="width:14.567%" />
                            <td style="width:0.1%" />
                        </tr>
                        <tr>
                            <td colspan="3" style="padding:0 1pt" />
                            <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <div style="text-align:center"><span
                                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Line
                                        Item in the Consolidated Balance Sheets</span></div>
                            </td>
                            <td colspan="3" style="padding:0 1pt" />
                            <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                    31, 2023</span></td>
                            <td colspan="3" style="padding:0 1pt" />
                            <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                    31, 2022</span></td>
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Right-of-use
                                    assets</span></td>
                            <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance
                                    leases</span></td>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span
                                        style="-sec-ix-hidden:f-999"><span style="-sec-ix-hidden:f-1000">Property and
                                            equipment, net</span></span></span></td>
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal"
                                        scale="3" id="f-1001">75,382</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                        name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:fixed-zero" scale="3"
                                        id="f-1002">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating
                                    leases</span></td>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span
                                        style="-sec-ix-hidden:f-1003"><span style="-sec-ix-hidden:f-1004">Other
                                            assets</span></span></span></td>
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal"
                                        scale="3" id="f-1005">59,746</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                        name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal"
                                        scale="3" id="f-1006">63,896</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="6"
                                style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                    right-of-use assets</span></td>
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="mrvi:FinanceAndOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal"
                                        scale="3" id="f-1007">135,128</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                        name="mrvi:FinanceAndOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal"
                                        scale="3" id="f-1008">63,896</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr style="height:14pt">
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current
                                    lease liabilities</span></td>
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance
                                    leases</span></td>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current
                                    portion of finance lease liabilities</span></td>
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-1009">633
                                    </ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                        name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:fixed-zero" scale="3"
                                        id="f-1010">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating
                                    leases</span></td>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span
                                        style="-sec-ix-hidden:f-1011"><span style="-sec-ix-hidden:f-1012">Accrued
                                            expenses and other current liabilities</span></span></span></td>
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal"
                                        scale="3" id="f-1013">6,780</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                        name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal"
                                        scale="3" id="f-1014">6,269</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="6"
                                style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                    current lease liabilities</span></td>
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="mrvi:FinanceAndOperatingLeaseLiabilityCurrent"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1015">7,413</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                        name="mrvi:FinanceAndOperatingLeaseLiabilityCurrent"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1016">6,269</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr style="height:14pt">
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current
                                    lease liabilities</span></td>
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance
                                    leases</span></td>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance
                                    lease liabilities, less current portion</span></td>
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal"
                                        scale="3" id="f-1017">31,897</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                        name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3"
                                        id="f-1018">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating
                                    leases</span></td>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span
                                        style="-sec-ix-hidden:f-1019"><span style="-sec-ix-hidden:f-1020">Other
                                            long-term liabilities</span></span></span></td>
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal"
                                        scale="3" id="f-1021">47,510</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                        name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal"
                                        scale="3" id="f-1022">51,556</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="6"
                                style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                    non-current lease liabilities</span></td>
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td
                                style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="mrvi:FinanceAndOperatingLeaseLiabilityNonCurrent"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1023">79,407</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td
                                style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                        name="mrvi:FinanceAndOperatingLeaseLiabilityNonCurrent"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1024">51,556</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                    </table>
                </div>
            </ix:nonNumeric>
            <ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-1025" continuedAt="f-1025-1"
                escape="true">
                <div style="margin-top:6pt;text-align:justify"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                        components of the net lease costs reflected in the Company's consolidated statements of
                        operations were as follows for the periods presented (in thousands):</span></div>
                <div style="margin-bottom:12pt;margin-top:6pt;text-align:justify">
                    <table
                        style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
                        <tr>
                            <td style="width:1.0%" />
                            <td style="width:50.512%" />
                            <td style="width:0.1%" />
                            <td style="width:1.0%" />
                            <td style="width:14.589%" />
                            <td style="width:0.1%" />
                            <td style="width:0.1%" />
                            <td style="width:0.386%" />
                            <td style="width:0.1%" />
                            <td style="width:1.0%" />
                            <td style="width:14.589%" />
                            <td style="width:0.1%" />
                            <td style="width:0.1%" />
                            <td style="width:0.533%" />
                            <td style="width:0.1%" />
                            <td style="width:1.0%" />
                            <td style="width:14.591%" />
                            <td style="width:0.1%" />
                        </tr>
                        <tr>
                            <td colspan="3" style="padding:0 1pt" />
                            <td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year
                                    Ended December 31,</span></td>
                        </tr>
                        <tr>
                            <td colspan="3" style="padding:0 1pt" />
                            <td colspan="3"
                                style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                            </td>
                            <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                            <td colspan="3"
                                style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                            </td>
                            <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                            <td colspan="3"
                                style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span>
                            </td>
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance
                                    lease costs:</span></td>
                            <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation
                                    of leased assets</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="mrvi:FinanceLeaseDepreciation" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1026">3,217</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="mrvi:FinanceLeaseDepreciation" format="ixt:fixed-zero" scale="3"
                                        id="f-1027">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="mrvi:FinanceLeaseDepreciation" format="ixt:fixed-zero" scale="3"
                                        id="f-1028">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest
                                    on lease liabilities</span></td>
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:FinanceLeaseInterestExpense" format="ixt:num-dot-decimal"
                                        scale="3" id="f-1029">1,696</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:FinanceLeaseInterestExpense" format="ixt:fixed-zero" scale="3"
                                        id="f-1030">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:FinanceLeaseInterestExpense" format="ixt:fixed-zero" scale="3"
                                        id="f-1031">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                    finance lease costs</span></td>
                            <td colspan="2"
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="mrvi:FinanceLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1032">
                                        4,913</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="mrvi:FinanceLeaseCost" format="ixt:fixed-zero" scale="3" id="f-1033">
                                        &#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="mrvi:FinanceLeaseCost" format="ixt:fixed-zero" scale="3" id="f-1034">
                                        &#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr style="height:15pt">
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating
                                    lease costs</span></td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1035">12,417</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1036">8,800</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1037">8,792</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable
                                    lease costs</span></td>
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1038">3,940</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1039">2,742</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1040">1,759</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                    lease costs</span></td>
                            <td
                                style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1041">
                                        21,270</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td
                                style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1042">
                                        11,542</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td
                                style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1043">
                                        10,551</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                    </table>
                </div>
                <div style="margin-top:6pt;text-align:justify"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                        weighted average remaining lease term and weighted average discount rate related to the
                        Company's ROU assets and lease liabilities for its leases were as follows as of the periods
                        presented below:</span></div>
                <div style="margin-top:12pt;text-align:justify">
                    <table
                        style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                        <tr>
                            <td style="width:1.0%" />
                            <td style="width:66.835%" />
                            <td style="width:0.1%" />
                            <td style="width:1.0%" />
                            <td style="width:14.566%" />
                            <td style="width:0.1%" />
                            <td style="width:0.1%" />
                            <td style="width:0.532%" />
                            <td style="width:0.1%" />
                            <td style="width:1.0%" />
                            <td style="width:14.567%" />
                            <td style="width:0.1%" />
                        </tr>
                        <tr>
                            <td colspan="3" style="padding:0 1pt" />
                            <td colspan="3"
                                style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                    31, 2023</span></td>
                            <td colspan="3" style="padding:0 1pt" />
                            <td colspan="3"
                                style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                    31, 2022</span></td>
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted
                                    average remaining lease term (in years):</span></td>
                            <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance
                                    leases</span></td>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonNumeric contextRef="c-5"
                                        name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1"
                                        format="ixt-sec:duryear" id="f-1044">14.2</ix:nonNumeric>
                                </span></td>
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <div style="text-align:right"><span
                                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span>
                                </div>
                            </td>
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating
                                    leases</span></td>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonNumeric contextRef="c-5"
                                        name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1"
                                        format="ixt-sec:duryear" id="f-1045">7.3</ix:nonNumeric>
                                </span></td>
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonNumeric contextRef="c-6"
                                        name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1"
                                        format="ixt-sec:duryear" id="f-1046">7.9</ix:nonNumeric>
                                </span></td>
                        </tr>
                        <tr style="height:15pt">
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 19pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted
                                    average discount rate:</span></td>
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance
                                    leases</span></td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3"
                                        name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2"
                                        id="f-1047">8.4</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                            </td>
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span>
                            </td>
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating
                                    leases</span></td>
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3"
                                        name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2"
                                        id="f-1048">6.7</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                            </td>
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="number" contextRef="c-6" decimals="3"
                                        name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2"
                                        id="f-1049">6.5</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                            </td>
                        </tr>
                    </table>
                </div>
                <div style="text-align:justify"><span
                        style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span>
                </div>
                <div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*</span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.5pt">The
                        Company did not have any finance leases as of December&#160;31, 2022.</span></div>
            </ix:nonNumeric>
        </ix:continuation>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-986-3">
        <ix:continuation id="f-985-3">
            <ix:continuation id="f-1025-1">
                <div style="margin-top:6pt;text-align:justify"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental
                        information concerning the cash flow impact arising from the Company's leases recorded in the
                        Company's consolidated statements of cash flows is detailed in the following table for the
                        periods presented (in thousands):</span></div>
                <div style="margin-bottom:12pt;margin-top:6pt;text-align:justify">
                    <table
                        style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                        <tr>
                            <td style="width:1.0%" />
                            <td style="width:50.437%" />
                            <td style="width:0.1%" />
                            <td style="width:1.0%" />
                            <td style="width:14.566%" />
                            <td style="width:0.1%" />
                            <td style="width:0.1%" />
                            <td style="width:0.532%" />
                            <td style="width:0.1%" />
                            <td style="width:1.0%" />
                            <td style="width:14.566%" />
                            <td style="width:0.1%" />
                            <td style="width:0.1%" />
                            <td style="width:0.532%" />
                            <td style="width:0.1%" />
                            <td style="width:1.0%" />
                            <td style="width:14.567%" />
                            <td style="width:0.1%" />
                        </tr>
                        <tr>
                            <td colspan="3" style="padding:0 1pt" />
                            <td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year
                                    Ended December 31,</span></td>
                        </tr>
                        <tr>
                            <td colspan="3" style="padding:0 1pt" />
                            <td colspan="3"
                                style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                            </td>
                            <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                            <td colspan="3"
                                style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                            </td>
                            <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                            <td colspan="3"
                                style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span>
                            </td>
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash
                                    paid for amounts included in lease liabilities:</span></td>
                            <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing
                                    cash flows used for finance leases</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-1050">332
                                    </ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:fixed-zero" scale="3"
                                        id="f-1051">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:fixed-zero" scale="3"
                                        id="f-1052">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating
                                    cash flows used for finance leases</span></td>
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:FinanceLeaseInterestPaymentOnLiability"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1053">1,696</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:fixed-zero"
                                        scale="3" id="f-1054">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:fixed-zero"
                                        scale="3" id="f-1055">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating
                                    cash flows used for operating leases</span></td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1056">10,306</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1057">7,049</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1058">6,335</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr style="height:15pt">
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash
                                    transactions:</span></td>
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use
                                    assets obtained in exchange for new finance lease liabilities</span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1059">32,862</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"
                                        format="ixt:fixed-zero" scale="3" id="f-1060">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"
                                        format="ixt:fixed-zero" scale="3" id="f-1061">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use
                                    assets obtained in exchange for new operating lease liabilities</span></td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1062">3,931</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1063">17,513</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"
                                        format="ixt:fixed-zero" scale="3" id="f-1064">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                    </table>
                </div>
            </ix:continuation>
            <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"
                id="f-1065" escape="true">
                <div style="margin-top:6pt;text-align:justify"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
                        of December&#160;31, 2023, the Company expects that its future minimum lease payments will
                        become due and payable as follows (in thousands):</span></div>
                <div style="margin-bottom:12pt;margin-top:6pt;text-align:justify">
                    <table
                        style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                        <tr>
                            <td style="width:1.0%" />
                            <td style="width:50.437%" />
                            <td style="width:0.1%" />
                            <td style="width:1.0%" />
                            <td style="width:14.566%" />
                            <td style="width:0.1%" />
                            <td style="width:0.1%" />
                            <td style="width:0.532%" />
                            <td style="width:0.1%" />
                            <td style="width:1.0%" />
                            <td style="width:14.566%" />
                            <td style="width:0.1%" />
                            <td style="width:0.1%" />
                            <td style="width:0.532%" />
                            <td style="width:0.1%" />
                            <td style="width:1.0%" />
                            <td style="width:14.567%" />
                            <td style="width:0.1%" />
                        </tr>
                        <tr>
                            <td colspan="3" style="padding:0 1pt" />
                            <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance
                                    Leases</span></td>
                            <td colspan="3" style="padding:0 1pt" />
                            <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating
                                    Leases</span></td>
                            <td colspan="3" style="padding:0 1pt" />
                            <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span>
                            </td>
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span>
                            </td>
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1066">3,327</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1067">10,224</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="mrvi:FinanceLeaseAndOperatingLeaseLiabilityToBePaidYearOne"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1068">13,551</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span>
                            </td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1069">3,427</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1070">10,392</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="mrvi:FinanceLeaseAndOperatingLeaseLiabilityToBePaidYearTwo"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1071">13,819</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span>
                            </td>
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1072">3,530</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1073">10,039</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="mrvi:FinanceLeaseAndOperatingLeaseLiabilityToBePaidYearThree"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1074">13,569</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span>
                            </td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1075">3,636</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1076">8,561</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="mrvi:FinanceLeaseAndOperatingLeaseLiabilityToBePaidYearFour"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1077">12,197</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span>
                            </td>
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1078">3,745</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1079">8,666</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="mrvi:FinanceLeaseAndOperatingLeaseLiabilityToBePaidYearFive"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1080">12,411</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span>
                            </td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1081">40,357</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1082">25,432</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="mrvi:FinanceLeaseAndOperatingLeaseLiabilityToBePaidAfterYearFive"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1083">65,789</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                    minimum lease payments</span></td>
                            <td colspan="2"
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal"
                                        scale="3" id="f-1084">58,022</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1085">73,314</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="mrvi:FinanceLeaseAndOperatingLeaseLiabilityToBePaid"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1086">131,336</ix:nonFraction>
                                    &#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:
                                    interest</span></td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1087">25,492</ix:nonFraction>
                                    )</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1088">19,024</ix:nonFraction>
                                    )</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="mrvi:FinanceLeaseAndOperatingLeaseLiabilityUndiscountedExcessAmount"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1089">44,516</ix:nonFraction>
                                    )</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                    lease liabilities</span></td>
                            <td
                                style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1090">32,530</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td
                                style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1091">54,290</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td
                                style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                        name="mrvi:FinanceLeaseAndOperatingLeaseLiability" format="ixt:num-dot-decimal"
                                        scale="3" id="f-1092">86,820</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                    </table>
                </div>
            </ix:nonNumeric>
        </ix:continuation>
    </ix:continuation>
    <div id="ic995976d222241b98dac88a4c1bc08e5_217"></div>
    <div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-1093"
            continuedAt="f-1093-1" escape="true"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Commitments
                and Contingencies</span></ix:nonNumeric>
    </div>
    <ix:continuation id="f-1093-1" continuedAt="f-1093-2">
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unconditional
                Purchase Obligations</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                the ordinary course of business, we enter into certain unconditional purchase obligations with our
                suppliers. These are agreements to purchase products and services that are enforceable, legally binding,
                and specify terms that include provisions with respect to quantities, pricing and timing of
                purchases.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts
                purchased under these obligations totaled $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5"
                    name="us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases" format="ixt:num-dot-decimal"
                    scale="6" id="f-1094">3.0</ix:nonFraction> million for the year ended December&#160;31, 2023. Such
                amounts were <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5"
                    name="us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases" format="ixt:fixed-zero" scale="3"
                    id="f-1095">
                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5"
                        name="us-gaap:UnrecordedUnconditionalPurchaseObligationPurchases" format="ixt:fixed-zero"
                        scale="3" id="f-1096">not</ix:nonFraction>
                </ix:nonFraction> material for the years ended December&#160;31, 2022 and 2021. </span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
                of December&#160;31, 2023, future minimum commitments under these obligations totaled $<ix:nonFraction
                    unitRef="usd" contextRef="c-5" decimals="-5"
                    name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"
                    format="ixt:num-dot-decimal" scale="6" id="f-1097">3.3</ix:nonFraction> million which relates to the
                year ending December&#160;31, 2024. </span></div>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal
                Proceedings</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                Company is involved in various legal proceedings arising in the normal course of business. The Company
                accrues for a loss contingency when it determines that it is probable, after consultation with counsel,
                that a liability has been incurred and the amount of such loss can be reasonably estimated. The Company
                believes that the results of any such contingencies, either individually or in the aggregate, will not
                have a material adverse effect on the Company&#8217;s consolidated financial position, results of
                operations or cash flows.</span></div>
        <div style="margin-top:12pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnification
                Agreements</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                the ordinary course of business, we may provide indemnification of varying scope and terms to vendors,
                lessors, customers and other parties with respect to certain matters including, but not limited to,
                losses arising out of breach of such agreements or </span></div>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-1093-2">
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from
                intellectual property infringement claims made by third parties, and losses arising from breach of
                representations, warranties and covenants to counterparties set forth in agreements with such parties.
                We have also agreed to our directors and officers to the maximum extent permitted under applicable state
                laws pursuant to standard director and officer indemnification agreements and our corporate charter and
                bylaws. The maximum potential amount of future payments that we could be required to make under these
                indemnification agreements is, in many cases, unlimited. We have not incurred any material costs as a
                result of such indemnifications and are not currently aware of any indemnification claims.</span></div>
    </ix:continuation>
    <div id="ic995976d222241b98dac88a4c1bc08e5_220"></div>
    <div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-1098" continuedAt="f-1098-1"
            escape="true"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Long-Term
                Debt</span></ix:nonNumeric>
    </div>
    <ix:continuation id="f-1098-1" continuedAt="f-1098-2">
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit
                Agreement</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                October 2020, Maravai Intermediate Holdings, LLC (&#8220;Intermediate&#8221;), a wholly-owned subsidiary
                of Topco LLC, along with certain of its subsidiaries (together with Intermediate, the
                &#8220;Borrowers&#8221;), entered into a credit agreement (as amended, the &#8220;Credit
                Agreement&#8221;), which provides for a term loan facility and a revolving credit facility. In January
                2022, the Company entered into an amendment (the &#8220;Amendment&#8221;) to refinance the term loan and
                to replace London Interbank Offered Rate (&#8220;LIBOR&#8221;) with a Term Secured Overnight Financing
                Rate (&#8220;SOFR&#8221;) based rate.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
                amended, the Credit Agreement provides for a $<ix:nonFraction unitRef="usd" contextRef="c-301"
                    decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity"
                    format="ixt:num-dot-decimal" scale="6" id="f-1099">600.0</ix:nonFraction> million term loan
                facility, maturing October 2027 (the &#8220;Tranche B Term Loan&#8221;), and a $<ix:nonFraction
                    unitRef="usd" contextRef="c-302" decimals="INF"
                    name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6"
                    id="f-1100">180.0</ix:nonFraction> million revolving credit facility (the &#8220;Revolving Credit
                Facility&#8221;). The interest rate margins applicable to the Tranche B Term Loan and Revolving Credit
                Facility is <ix:nonFraction unitRef="number" contextRef="c-303" decimals="INF"
                    name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1101">3.00</ix:nonFraction>
                %, with respect to each Term SOFR-based loan, and <ix:nonFraction unitRef="number" contextRef="c-304"
                    decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1102">2.00
                </ix:nonFraction>%, with respect to each Base Rate-based loan. Further, the interest rate floor for Base
                Rate term loans, Term SOFR-based term loans, and Term SOFR-based revolving loans are <ix:nonFraction
                    unitRef="number" contextRef="c-305" decimals="INF" name="mrvi:DebtInstrumentInterestRateFloor"
                    scale="-2" id="f-1103">1.50</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-306"
                    decimals="INF" name="mrvi:DebtInstrumentInterestRateFloor" scale="-2" id="f-1104">0.50
                </ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-307" decimals="INF"
                    name="mrvi:DebtInstrumentInterestRateFloor" scale="-2" id="f-1105">0.00</ix:nonFraction>%,
                respectively. </span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
                of December&#160;31, 2023, the interest rate on the Tranche B Term Loan was <ix:nonFraction
                    unitRef="number" contextRef="c-308" decimals="INF"
                    name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1106">8.40
                </ix:nonFraction>% per annum.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                Credit Agreement also provides for a $<ix:nonFraction unitRef="usd" contextRef="c-309" decimals="INF"
                    name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6"
                    id="f-1107">20.0</ix:nonFraction> million limit for letters of credit. As of December&#160;31, 2023,
                the Company had a $<ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-5"
                    name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="f-1108">
                    0.5</ix:nonFraction> million outstanding letter of credit as security for a lease agreement, which
                reduced the availability of credit under the Revolving Credit Facility by $<ix:nonFraction unitRef="usd"
                    contextRef="c-300" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount"
                    format="ixt:num-dot-decimal" scale="6" id="f-1109">0.5</ix:nonFraction> million.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings
                under the Credit Agreement are unconditionally guaranteed by Topco LLC, together with the existing and
                future material domestic subsidiaries of Topco LLC (subject to certain exceptions), as specified in the
                respective guaranty agreements. Borrowings under the Credit Agreement are also secured by a
                first-priority lien and security interest in substantially all of the assets (subject to certain
                exceptions) of existing and future material domestic subsidiaries of Topco LLC that are loan
                parties.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                accounting related to entering into the Amendment was evaluated on a creditor-by-creditor basis to
                determine whether each transaction should be accounted for as a modification or extinguishment. Certain
                creditors under the Tranche B Term Loan did not participate in this refinancing transaction, were repaid
                their principal and interest of $<ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-5"
                    name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-1110">8.5
                </ix:nonFraction> million and ceased being creditors of the Company and the repayment of their related
                outstanding debt balances has been accounted for as an extinguishment of debt. Proceeds of borrowings
                from new lenders of $<ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-5"
                    name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-1111">8.5
                </ix:nonFraction> million were accounted for as a new debt financing. The Company recorded a loss on
                extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-5" sign="-"
                    name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-1112">
                    0.2</ix:nonFraction>&#160;million in the accompanying consolidated statements of operations during
                the year ended December 31, 2022. For the remainder of the creditors, this transaction was accounted for
                as a modification because the change in present value of cash flows between the <ix:nonFraction
                    unitRef="loan" contextRef="c-313" decimals="INF" name="mrvi:NumberOfTermLoans"
                    format="ixt-sec:numwordsen" scale="0" id="f-1113">two</ix:nonFraction> term loans before and after
                the transaction was less than 10% on a creditor-by-creditor basis. As part of the refinancing, the
                Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-5"
                    name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-1114">0.9
                </ix:nonFraction> million of various costs, of which an insignificant amount was related to an original
                issuance discount, and were all capitalized in the accompanying balance sheet within long-term debt and
                are subject to amortization over the term of the refinanced debt as an adjustment to interest expense
                using the effective interest method.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
                also incurred $<ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-5"
                    name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-1115">0.3
                </ix:nonFraction> million of financing-related fees related to the Revolving Credit Facility in
                connection with the debt refinancing activities in January 2022. As of December&#160;31, 2023,
                unamortized debt issuance costs totaled $<ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-5"
                    name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="f-1116">1.4
                </ix:nonFraction> million and are recorded as assets within other assets on the accompanying
                consolidated balance sheet as there is <ix:nonFraction unitRef="usd" contextRef="c-316" decimals="INF"
                    name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="f-1117">no</ix:nonFraction>
                balance outstanding related to the Revolving Credit Facility.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing
                with the fiscal year ended December 31, 2021, and each fiscal year thereafter, the Credit Agreement
                requires that we make mandatory prepayments on the Tranche B Term Loan principal upon certain excess
                cash flow, subject to certain step-downs based on the Company&#8217;s first lien net leverage ratio. The
                excess cash flow shall be reduced to <ix:nonFraction unitRef="number" contextRef="c-317" decimals="2"
                    name="mrvi:DebtInstrumentExcessCashRatioPercentage" scale="-2" id="f-1118">25</ix:nonFraction>% or
                <ix:nonFraction unitRef="number" contextRef="c-318" decimals="2"
                    name="mrvi:DebtInstrumentExcessCashRatioPercentage" scale="-2" id="f-1119">0</ix:nonFraction>% of
                the calculated excess cash flow if the Company&#8217;s first lien net leverage ratio was equal to or
                less than <ix:nonFraction unitRef="number" contextRef="c-317" decimals="INF"
                    name="mrvi:DebtInstrumentCovenantLeverageRatio" scale="0" id="f-1120">4.75</ix:nonFraction>:1.00 or
                <ix:nonFraction unitRef="number" contextRef="c-308" decimals="INF"
                    name="mrvi:DebtInstrumentCovenantLeverageRatio" scale="0" id="f-1121">4.25</ix:nonFraction>:1.00,
                respectively, however, no prepayment shall be required to the extent excess cash flow calculated for the
                respective period is equal to or less than $<ix:nonFraction unitRef="usd" contextRef="c-308"
                    decimals="-5" name="mrvi:DebtInstrumentCovenantExcessCashThresholdAmount"
                    format="ixt:num-dot-decimal" scale="6" id="f-1122">10.0</ix:nonFraction> million. As of
                December&#160;31, 2023, the Company&#8217;s first lien net leverage ratio was less than <ix:nonFraction
                    unitRef="number" contextRef="c-308" decimals="INF" name="mrvi:DebtInstrumentCovenantLeverageRatio"
                    scale="0" id="f-1123">4.25</ix:nonFraction>:1.00. Thus, a mandatory prepayment on the Tranche B Term
                Loan out of our excess cash flow was not required.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                Tranche B Term Loan is repayable in quarterly payments of $<ix:nonFraction unitRef="usd"
                    contextRef="c-319" decimals="-5" name="us-gaap:DebtInstrumentPeriodicPayment"
                    format="ixt:num-dot-decimal" scale="6" id="f-1124">1.4</ix:nonFraction> million which began in
                March&#160;2022, with all remaining outstanding principal due in October&#160;2027. The Tranche B Term
                Loan includes prepayment provisions that allow the Company, </span></div>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-1098-2">
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at
                our option, to repay all or a portion of the principal amount at any time. The Revolving Credit Facility
                allows the Company to repay and borrow from time to time until October&#160;2025, at which time all
                amounts borrowed must be repaid. Subject to certain exceptions and limitations, we are required to repay
                borrowings under the Tranche B Term Loan and Revolving Credit Facility with the proceeds of certain
                occurrences, such as the incurrence of debt, certain equity contributions and certain asset sales or
                dispositions.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued
                interest under the Credit Agreement is payable by us (a)&#160;quarterly in arrears with respect to Base
                Rate loans, (b)&#160;at the end of each interest rate period (or at each three-month interval in the
                case of loans with interest periods greater than three months) with respect to Term SOFR Rate loans,
                (c)&#160;on the date of any repayment or prepayment and (d)&#160;at maturity (whether by acceleration or
                otherwise). An annual commitment fee is applied to the daily unutilized amount under the Revolving
                Credit Facility at <ix:nonFraction unitRef="number" contextRef="c-320" decimals="INF"
                    name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="f-1125">0.375
                </ix:nonFraction>% per annum, with one stepdown to <ix:nonFraction unitRef="number" contextRef="c-321"
                    decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="f-1126">
                    0.25</ix:nonFraction>% per annum based on Intermediate&#8217;s first lien net leverage ratio
                calculation. </span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                Credit Agreement contains certain covenants, including, among other things, covenants limiting our
                ability to incur or prepay certain indebtedness, pay dividends or distributions, dispose of assets,
                engage in mergers and consolidations, make acquisitions or other investments and make changes to the
                nature of the business. Additionally, the Credit Agreement also requires us to maintain a certain net
                leverage ratio if the outstanding debt balance on the Revolving Credit Facility exceeds <ix:nonFraction
                    unitRef="number" contextRef="c-316" decimals="3"
                    name="mrvi:DebtInstrumentCovenantLeverageRatioOutstandingBalanceThresholdPercentage" scale="-2"
                    id="f-1127">35.0</ix:nonFraction>% of the aggregate amount of available credit of $<ix:nonFraction
                    unitRef="usd" contextRef="c-302" decimals="INF"
                    name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6"
                    id="f-1128">180.0</ix:nonFraction> million. The Company was in compliance with these covenants as of
                December&#160;31, 2023.</span></div>
        <div style="margin-top:12pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest
                Rate Cap</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                the first quarter of 2021, the Company entered into an interest rate cap agreement to manage a portion
                of its variable interest rate risk on its outstanding long-term debt. The contract, which was effective
                March 31, 2021, entitles the Company to receive from the counterparty at each calendar quarter end the
                amount, if any, by which a specified defined floating market rate exceeds the cap strike interest rate,
                applied to the contract&#8217;s notional amount of $<ix:nonFraction unitRef="usd" contextRef="c-322"
                    decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6"
                    id="f-1129">415.0</ix:nonFraction>&#160;million The floating rate of interest is reset at the end of
                each three month period. The contract was set to expire on March 31, 2023. </span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                May 2022, the Company amended the interest rate cap agreement, effective June 30, 2022, to increase the
                contract&#8217;s notional amount to $<ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-5"
                    name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1130">500.0
                </ix:nonFraction>&#160;million and to extend the maturity date to January 19, 2025. Additionally, the
                floating rate option changed from a LIBOR-based rate to a SOFR-based rate. Other provisions remained
                unchanged as a result of the amendment. Premiums paid to amend the interest rate cap agreement were
                immaterial.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                interest rate cap agreement has not been designated as a hedging relationship and has been recognized on
                the consolidated balance sheet at fair value of $<ix:nonFraction unitRef="usd" contextRef="c-324"
                    decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6"
                    id="f-1131">8.6</ix:nonFraction>&#160;million within other assets with changes in fair value
                recognized within interest expense in the consolidated statements of operations. Proceeds from the
                interest rate cap agreement are reflected in cash flows used in financing activities in the consolidated
                statements of cash flows.</span></div>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-1132" escape="true">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company&#8217;s long-term debt consisted of the following as of the periods presented (in
                    thousands):</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:66.835%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.566%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.532%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.567%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                31, 2023</span></td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                31, 2022</span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tranche
                                B Term Loan</span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-3"
                                    name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1133">533,120</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3"
                                    name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1134">538,560</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized
                                debt issuance costs</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1135">8,973</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1136">11,123</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                long-term debt</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebt"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1137">524,147</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebt"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1138">527,437</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:
                                current portion</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1139">5,440</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1140">5,440</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                long-term debt, less current portion</span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1141">518,707</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1142">521,997</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There
                were <ix:nonFraction unitRef="usd" contextRef="c-316" decimals="INF" name="us-gaap:LineOfCredit"
                    format="ixt:fixed-zero" scale="0" id="f-1143">
                    <ix:nonFraction unitRef="usd" contextRef="c-326" decimals="INF" name="us-gaap:LineOfCredit"
                        format="ixt:fixed-zero" scale="0" id="f-1144">no</ix:nonFraction>
                </ix:nonFraction> balances outstanding on the Company&#8217;s Revolving Credit Facility as of
                December&#160;31, 2023 and 2022.</span></div>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-1145"
            escape="true">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
                    of December&#160;31, 2023, the aggregate future principal maturities of the Company&#8217;s debt
                    obligations based on contractual due dates were as follows (in thousands):</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:83.233%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.567%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span>
                        </td>
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1146">5,440</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1147">5,440</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1148">5,440</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1149">516,800</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                long-term debt</span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1150">533,120</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_223"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-1151"
            continuedAt="f-1151-1" escape="true"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Stockholders&#8217;
                Equity</span></ix:nonNumeric>
    </div>
    <ix:continuation id="f-1151-1" continuedAt="f-1151-2">
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment
                and Restatement of Certificate of Incorporation</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                November 2020, in connection with the Organizational Transactions, the Company&#8217;s certificate of
                incorporation was amended and restated to, among other things, provide for the (i) authorization of
                <ix:nonFraction unitRef="shares" contextRef="c-327" decimals="INF"
                    name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1152">
                    500,000,000</ix:nonFraction> shares of Class A common stock with a par value of $<ix:nonFraction
                    unitRef="usdPerShare" contextRef="c-327" decimals="INF"
                    name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1153">0.01</ix:nonFraction> per
                share; (ii) authorization of <ix:nonFraction unitRef="shares" contextRef="c-328" decimals="INF"
                    name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1154">
                    300,000,000</ix:nonFraction> shares of Class B common stock with a par value of $<ix:nonFraction
                    unitRef="usdPerShare" contextRef="c-328" decimals="INF"
                    name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1155">0.01</ix:nonFraction> per
                share; (iii) authorization of <ix:nonFraction unitRef="shares" contextRef="c-329" decimals="INF"
                    name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1156">
                    50,000,000</ix:nonFraction> shares of preferred stock with a par value of $<ix:nonFraction
                    unitRef="usdPerShare" contextRef="c-329" decimals="INF"
                    name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-1157">0.01</ix:nonFraction>
                per share.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders
                of Class A and Class B common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="c-11"
                    decimals="INF" name="mrvi:CommonStockNumberOfVotes" format="ixt-sec:numwordsen" scale="0"
                    id="f-1158">
                    <ix:nonFraction unitRef="vote" contextRef="c-13" decimals="INF" name="mrvi:CommonStockNumberOfVotes"
                        format="ixt-sec:numwordsen" scale="0" id="f-1159">one</ix:nonFraction>
                </ix:nonFraction> vote per share. Except as otherwise required in the Certificate of Incorporation or by
                applicable law, the holders of Class A common stock and Class B common stock shall vote together as a
                single class on all matters on which stockholders are generally entitled to vote. Holders of the Class A
                common stock are entitled to receive dividends, and upon the Company&#8217;s dissolution or liquidation,
                after payment in full of all amounts required to be paid to creditors and to the holders of preferred
                stock having liquidation preferences, if any, the holders of shares of Class A common stock will be
                entitled to receive the Company&#8217;s pro rata remaining assets available for distribution. Holders of
                Maravai&#8217;s Class B common stock are not entitled to receive dividends and will not be entitled to
                receive any distributions upon dissolution or liquidation of Maravai. Holders of Class A and Class B
                common stock do not have preemptive or subscription rights. As of December&#160;31, 2023, no preferred
                stock was outstanding.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
                are required to, at all times, maintain (i) a <ix:nonFraction unitRef="number" contextRef="c-330"
                    decimals="INF" name="mrvi:ConversionOfStockConversionRatio" format="ixt-sec:numwordsen" scale="0"
                    id="f-1160">one</ix:nonFraction>-to-one ratio between the number of shares of Class A common stock
                outstanding and the number of LLC Units owned by us and (ii) a <ix:nonFraction unitRef="number"
                    contextRef="c-331" decimals="INF" name="mrvi:ConversionOfStockConversionRatio"
                    format="ixt-sec:numwordsen" scale="0" id="f-1161">one</ix:nonFraction>-to-one ratio between the
                number of shares of Class B common stock owned by the MLSH 1 and the number of LLC Units owned by the
                MLSH 1. We may issue shares of Class B common stock only to the extent necessary to maintain these
                ratios. Shares of Class B common stock are transferable only together with an equal number of LLC Units
                if we, at the election of MLSH 1, exchange LLC Units for shares of Class A common stock. All Class B
                common stock that is transferred shall be automatically retired and cancelled and shall no longer be
                outstanding.</span></div>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchanges
                and Secondary Offerings</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">April
                2021 Exchange and Secondary Offering</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                April 2021, MLSH 1 executed an exchange of <ix:nonFraction unitRef="shares" contextRef="c-332"
                    decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"
                    format="ixt:num-dot-decimal" scale="0" id="f-1162">17,665,959</ix:nonFraction> Topco LLC units (the
                &#8220;LLC Units&#8221;) (paired with the corresponding shares of Class B common stock) in return for
                <ix:nonFraction unitRef="shares" contextRef="c-332" decimals="INF"
                    name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"
                    format="ixt:num-dot-decimal" scale="0" id="f-1163">17,665,959</ix:nonFraction> shares of the
                Company&#8217;s Class A common stock. The corresponding shares of Class B common stock were subsequently
                cancelled and retired. The Company immediately completed a secondary offering (&#8220;April 2021
                Secondary Offering&#8221;) of <ix:nonFraction unitRef="shares" contextRef="c-332" decimals="INF"
                    name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0"
                    id="f-1164">20,700,000</ix:nonFraction> shares of its Class A common stock by MLSH 1 and Maravai
                Life Sciences Holdings 2, LLC (&#8220;MLSH 2&#8221;), which included <ix:nonFraction unitRef="shares"
                    contextRef="c-333" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction"
                    format="ixt:num-dot-decimal" scale="0" id="f-1165">3,034,041</ix:nonFraction> shares of Class A
                common stock previously held by MLSH 2, which included the full exercise of the underwriters&#8217;
                option to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-334" decimals="INF"
                    name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0"
                    id="f-1166">2,700,000</ix:nonFraction> additional shares of Class A common stock, at a price of $
                <ix:nonFraction unitRef="usdPerShare" contextRef="c-335" decimals="2"
                    name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-1167">31.25</ix:nonFraction> per
                share.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                selling stockholders were responsible for the underwriting discounts and commissions of the April 2021
                Secondary Offering and received all of the net proceeds of $<ix:nonFraction unitRef="usd"
                    contextRef="c-336" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction"
                    format="ixt:num-dot-decimal" scale="6" id="f-1168">624.2</ix:nonFraction> million from the sale of
                shares of Class A common stock. The Company was responsible for the offering costs associated with the
                April 2021 Secondary Offering of $<ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-5"
                    name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-1169">1.0
                </ix:nonFraction> million which were recorded within selling, general and administrative expenses in the
                consolidated statements of operations.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">September
                2021 Exchange and Secondary Offering</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                September 2021, MLSH 1 executed an exchange of <ix:nonFraction unitRef="shares" contextRef="c-337"
                    decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"
                    format="ixt:num-dot-decimal" scale="0" id="f-1170">17,068,559</ix:nonFraction> LLC Units (paired
                with the corresponding shares of Class B common stock) in return for <ix:nonFraction unitRef="shares"
                    contextRef="c-337" decimals="INF"
                    name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"
                    format="ixt:num-dot-decimal" scale="0" id="f-1171">17,068,559</ix:nonFraction> shares of the
                Company&#8217;s Class A common stock. The corresponding shares of Class B common stock were subsequently
                cancelled and retired. Shortly after the exchange, the Company completed a secondary offering
                (&#8220;September 2021 Secondary Offering&#8221;) of <ix:nonFraction unitRef="shares" contextRef="c-337"
                    decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction"
                    format="ixt:num-dot-decimal" scale="0" id="f-1172">20,000,000</ix:nonFraction> shares of its Class A
                common stock by MLSH 1 and MLSH 2, which included <ix:nonFraction unitRef="shares" contextRef="c-338"
                    decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction"
                    format="ixt:num-dot-decimal" scale="0" id="f-1173">2,931,441</ix:nonFraction> shares of Class A
                common stock previously held by MLSH 2 at a price of $<ix:nonFraction unitRef="usdPerShare"
                    contextRef="c-339" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-1174">50.00
                </ix:nonFraction> per share.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                selling stockholders were responsible for the underwriting discounts and commissions of the September
                2021 Secondary Offering and received all of the net proceeds of $<ix:nonFraction unitRef="usd"
                    contextRef="c-340" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction"
                    format="ixt:num-dot-decimal" scale="6" id="f-1175">977.5</ix:nonFraction> million from the sale of
                shares of Class A common stock. The Company was responsible for the offering costs associated with the
                September 2021 Secondary Offering of $<ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-5"
                    name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-1176">0.9
                </ix:nonFraction> million which were recorded within selling, general and administrative expenses in the
                consolidated statements of operations.</span></div>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash
                Contribution, Exchange, and Forfeiture Agreement</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                December 2021, the Company entered into a Cash Contribution, Exchange and Forfeiture Agreement (the
                &#8220;Contribution Agreement&#8221;) with Topco LLC and MLSH 1, a related party. Pursuant to the
                Contribution Agreement, the Company contributed $<ix:nonFraction unitRef="usd" contextRef="c-341"
                    decimals="-5" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="6"
                    id="f-1177">110.0</ix:nonFraction>&#160;million of cash to Topco LLC in exchange for <ix:nonFraction
                    unitRef="shares" contextRef="c-342" decimals="INF"
                    name="mrvi:NoncontrollingInterestCommonUnitsAcquired" format="ixt:num-dot-decimal" scale="0"
                    id="f-1178">2,732,919</ix:nonFraction> newly-issued units LLC Units of Topco LLC at a price per unit
                of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-342" decimals="2"
                    name="mrvi:NoncontrollingInterestCommonUnitsAcquiredPricePerShare" scale="0" id="f-1179">40.25
                </ix:nonFraction>, which was equal to the 50-day volume-weighted average price of the Company&#8217;s
                Class A common stock as </span></div>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-1151-2">
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">calculated
                on December 31, 2021. Immediately following the contribution, the Company and MLSH 1 agreed to forfeit
                <ix:nonFraction unitRef="number" contextRef="c-343" decimals="INF"
                    name="mrvi:NoncontrollingInterestCommonUnitForfeiturePercentage" scale="-2" id="f-1180">2.036
                </ix:nonFraction>% of their respective LLC Units of Topco LLC and an equal number of shares of the
                Company&#8217;s Class B common stock, par value $<ix:nonFraction unitRef="usdPerShare"
                    contextRef="c-344" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0"
                    id="f-1181">0.01</ix:nonFraction> per share, for no consideration. The purpose of the Contribution
                Agreement was to reduce the excess cash that had accumulated at the Company as a result of quarterly tax
                distributions it has received from Topco LLC since its IPO.</span></div>
        <div style="margin-top:12pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Structuring
                Transactions</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                connection with the Company&#8217;s acquisition of Alphazyme (see Note 2), the Company undertook a
                series of structuring transactions (the &#8220;Structuring Transactions&#8221;), including:</span></div>
        <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On
                January 18, 2023, the Company acquired all of the outstanding membership interests in Alphazyme (see
                Note 2).</span></div>
        <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On
                January 19, 2023, the Company entered into a contribution agreement (the &#8220;Contribution
                Agreement&#8221;) with Alphazyme Holdings, Inc. (&#8220;Alphazyme Holdings&#8221;), a wholly owned
                subsidiary of the Company, pursuant to which the Company contributed all such membership interests in
                Alphazyme (the &#8220;Alphazyme Membership Interest&#8221;) to Alphazyme Holdings.</span></div>
        <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On
                January 22, 2023, Alphazyme Holdings entered into a contribution and exchange agreement (the
                &#8220;Contribution and Exchange Agreement&#8221;) with Topco LLC, pursuant to which it contributed all
                of the Alphazyme Membership Interests to TopCo LLC in exchange for <ix:nonFraction unitRef="shares"
                    contextRef="c-345" decimals="INF" name="mrvi:NoncontrollingInterestCommonUnitsAcquired"
                    format="ixt:num-dot-decimal" scale="0" id="f-1182">5,059,134</ix:nonFraction> newly-issued LLC Units
                of Topco LLC at a price per unit of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-345"
                    decimals="2" name="mrvi:NoncontrollingInterestCommonUnitsAcquiredPricePerShare" scale="0"
                    id="f-1183">13.87</ix:nonFraction>, which was equal to the <ix:nonNumeric contextRef="c-346"
                    name="mrvi:WeightedAveragePricePeriodUsedForCalculation" format="ixt-sec:durwordsen" id="f-1184">
                    50-day</ix:nonNumeric> volume-weighted average price of the Company&#8217;s Class A common stock as
                calculated on January 18, 2023 (the &#8220;Contribution and Exchange&#8221;).</span></div>
        <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Immediately
                following the Contribution and Exchange, the Company entered into a forfeiture agreement (the
                &#8220;Forfeiture Agreement&#8221;) with Alphazyme Holdings, TopCo LLC and MLSH 1, a related party,
                pursuant to which each of the Company (together with Alphazyme Holdings) and MLSH 1 agreed to forfeit
                <ix:nonFraction unitRef="shares" contextRef="c-347" decimals="INF"
                    name="mrvi:NoncontrollingInterestCommonUnitsForfeited" format="ixt:num-dot-decimal" scale="0"
                    id="f-1185">5,059,134</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-348"
                    decimals="INF" name="mrvi:NoncontrollingInterestCommonUnitsForfeited" format="ixt:num-dot-decimal"
                    scale="0" id="f-1186">4,871,970</ix:nonFraction> LLC Units, respectively, representing
                <ix:nonFraction unitRef="number" contextRef="c-346" decimals="INF"
                    name="mrvi:NoncontrollingInterestCommonUnitForfeiturePercentage" scale="-2" id="f-1187">3.7
                </ix:nonFraction>% of the Company&#8217;s (together with Alphazyme Holdings) and MLSH 1&#8217;s
                respective LLC Units of Topco LLC, and an equal number of shares of the Company&#8217;s Class B common
                stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-349" decimals="2"
                    name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-1188">0.01</ix:nonFraction> per
                share, were forfeited by MLSH 1, in each case for no consideration. </span></div>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These
                were considered transactions between entities under common control. As a result, the consolidated
                financial statements for periods prior to the these transactions have been adjusted to combine the
                previously separate entities for presentation purposes.</span></div>
    </ix:continuation>
    <div id="ic995976d222241b98dac88a4c1bc08e5_226"></div>
    <div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-1189" continuedAt="f-1189-1"
            escape="true"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Net
                (Loss) Income Per Class A Common Share Attributable to Maravai LifeSciences Holdings, Inc.</span>
        </ix:nonNumeric>
    </div>
    <ix:continuation id="f-1189-1" continuedAt="f-1189-2">
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic
                net (loss) income per Class A common share has been calculated by dividing net (loss) income for the
                period, adjusted for net (loss) income attributable to non-controlling interests, by the weighted
                average number of Class A common shares outstanding during the period. Diluted net (loss) income per
                Class A common share gives effect to potentially dilutive securities by application of the treasury
                stock method or if-converted method, as applicable. Diluted net (loss) income per Class A common share
                attributable to the Company is computed by adjusting the net (loss) income and the weighted average
                number of Class A common shares outstanding to give effect to potentially diluted securities. In periods
                in which the Company reports a net loss attributable to Maravai LifeSciences Holdings, Inc., diluted net
                loss per Class A common share attributable to the Company is the same as basic net loss per Class A
                common share attributable to the Company, since dilutive equity instruments are not assumed to have been
                issued if their effect is anti-dilutive. The Company reported a net loss attributable to Maravai
                LifeSciences Holdings, Inc. for the year ended December&#160;31, 2023.</span></div>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-1189-2">
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"
            id="f-1190" escape="true">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    following table presents the computation of basic and diluted net (loss) income per common share
                    attributable to the Company for the periods presented (in thousands, except per share
                    amounts):</span></div>
            <div style="margin-top:12pt;text-align:justify">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:62.243%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.631%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year
                                Ended December 31,</span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                        </td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                        </td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                                    (loss) income</span></div>
                        </td>
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                                    name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-1191">138,375
                                </ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProfitLoss"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1192">490,663</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:ProfitLoss"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1193">469,250</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:
                                    loss (income) attributable to common non-controlling interests</span></div>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                                    name="mrvi:NetIncomeLossAttributableToCommonNoncontrollingInterest"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1194">19,346</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                    name="mrvi:NetIncomeLossAttributableToCommonNoncontrollingInterest"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1195">270,458</ix:nonFraction>)</span>
                        </td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                    name="mrvi:NetIncomeLossAttributableToCommonNoncontrollingInterest"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1196">287,213</ix:nonFraction>)</span>
                        </td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                                    (loss) income attributable to Maravai LifeSciences Holdings, Inc.&#8212;basic</span>
                            </div>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                                    name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1197">119,029</ix:nonFraction>)</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                    name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1198">220,205</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                    name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1199">182,037</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                                    (loss) income effect of dilutive securities:</span></div>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect
                                of dilutive employee stock purchase plan, RSUs and options</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                    name="us-gaap:DilutiveSecurities" format="ixt:fixed-zero" scale="3" id="f-1200">
                                    &#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                    name="us-gaap:DilutiveSecurities" scale="3" id="f-1201">87</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                    name="us-gaap:DilutiveSecurities" scale="3" id="f-1202">132</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect
                                of the assumed conversion of Class B common stock</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                    name="mrvi:DilutiveSecuritiesEffectOnBasicEarningsPerShareConversionOfClassBCommonStock"
                                    format="ixt:fixed-zero" scale="3" id="f-1203">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                    name="mrvi:DilutiveSecuritiesEffectOnBasicEarningsPerShareConversionOfClassBCommonStock"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1204">205,984</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                    name="mrvi:DilutiveSecuritiesEffectOnBasicEarningsPerShareConversionOfClassBCommonStock"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1205">220,187</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                                    (loss) income attributable to Maravai LifeSciences Holdings,
                                    Inc.&#8212;diluted</span></div>
                        </td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                                    name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1206">119,029</ix:nonFraction>)</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                    name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1207">426,276</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                    name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1208">402,356</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr style="height:14pt">
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span>
                        </td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted
                                    average Class A common shares outstanding&#8212;basic</span></div>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3"
                                    name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1209">131,919</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3"
                                    name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1210">131,545</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3"
                                    name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1211">114,791</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted
                                average effect of dilutive securities:</span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect
                                of dilutive employee stock purchase plan, RSUs and options</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3"
                                    name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"
                                    format="ixt:fixed-zero" scale="3" id="f-1212">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3"
                                    name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"
                                    scale="3" id="f-1213">109</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3"
                                    name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"
                                    scale="3" id="f-1214">153</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect
                                of the assumed conversion of Class B common stock</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3"
                                    name="mrvi:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfCommonStock"
                                    format="ixt:fixed-zero" scale="3" id="f-1215">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3"
                                    name="mrvi:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfCommonStock"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1216">123,669</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3"
                                    name="mrvi:IncrementalCommonSharesAttributableToDilutiveEffectOfConversionOfCommonStock"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1217">142,859</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted
                                    average Class A common shares outstanding&#8212;diluted</span></div>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3"
                                    name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1218">131,919</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3"
                                    name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1219">255,323</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3"
                                    name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1220">257,803</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr style="height:14pt">
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net
                                    (loss) income per Class A common share attributable to Maravai LifeSciences
                                    Holdings, Inc.:</span></div>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span>
                        </td>
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-"
                                    name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1221">0.90</ix:nonFraction>
                                )</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2"
                                    name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1222">1.67</ix:nonFraction>
                                &#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2"
                                    name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1223">1.59</ix:nonFraction>
                                &#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span>
                        </td>
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-"
                                    name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1224">0.90</ix:nonFraction>
                                )</span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2"
                                    name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1225">1.67</ix:nonFraction>
                                &#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-16" decimals="2"
                                    name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1226">1.56</ix:nonFraction>
                                &#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares
                of Class B common stock do not share in the earnings or losses of the Company, and are therefore not
                participating securities. As such, a separate presentation of basic and diluted net (loss) income per
                share for Class B common stock under the two-class method has not been presented.</span></div>
        <ix:nonNumeric contextRef="c-1"
            name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"
            id="f-1227" escape="true">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    following table presents potentially dilutive securities excluded from the computation of diluted
                    net (loss) income per share for the periods presented because their effect would have been
                    anti-dilutive for the periods presented (in thousands):</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:62.243%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.631%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year
                                Ended December 31,</span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                        </td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                        </td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted
                                stock units</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-350" decimals="-3"
                                    name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1228">3,181</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-351" decimals="-3"
                                    name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"
                                    scale="3" id="f-1229">74</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-352" decimals="-3"
                                    name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"
                                    format="ixt:fixed-zero" scale="3" id="f-1230">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock
                                options</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-353" decimals="-3"
                                    name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1231">4,246</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-354" decimals="-3"
                                    name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1232">2,769</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-355" decimals="-3"
                                    name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"
                                    scale="3" id="f-1233">355</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares
                                estimated to be purchased under employee stock purchase plan</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-356" decimals="-3"
                                    name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"
                                    format="ixt:fixed-zero" scale="3" id="f-1234">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-357" decimals="-3"
                                    name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"
                                    scale="3" id="f-1235">13</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-358" decimals="-3"
                                    name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"
                                    scale="3" id="f-1236">12</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares
                                of Class B common stock</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-359" decimals="-3"
                                    name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1237">119,094</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-360" decimals="-3"
                                    name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"
                                    format="ixt:fixed-zero" scale="3" id="f-1238">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-361" decimals="-3"
                                    name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"
                                    format="ixt:fixed-zero" scale="3" id="f-1239">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3"
                                    name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1240">126,521</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3"
                                    name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1241">2,856</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3"
                                    name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"
                                    scale="3" id="f-1242">367</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares
                underlying contingently issuable awards that have not met the necessary conditions as of the end of a
                reporting period are not included in the calculation of diluted net (loss) income per Class A common
                share attributable to the Company for that period. The Company had contingently issuable PSUs
                outstanding that did not meet the market and performance conditions as of December&#160;31, 2023 and
                2022 and, therefore, were excluded from the calculation of diluted net (loss) income per Class A common
                share attributable to the Company. The maximum number of potentially dilutive shares that could be
                issued upon vesting for such awards was insignificant as of December&#160;31, 2023 and 2022. These
                amounts were also excluded from the potentially dilutive securities in the table above. The Company had
                no contingently issuable PSUs outstanding as of December&#160;31, 2021.</span></div>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_229"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"
            id="f-1243" continuedAt="f-1243-1" escape="true"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Equity
                Incentive Plans</span></ix:nonNumeric>
    </div>
    <ix:continuation id="f-1243-1" continuedAt="f-1243-2">
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based
                Compensation</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                November 2020, the Company&#8217;s board of directors adopted the 2020 Omnibus Incentive Plan (the
                &#8220;2020 Plan&#8221;). The 2020 Plan provides for an automatic increase in the number of shares
                reserved for issuance thereunder on January 1 of each of the first <ix:nonNumeric contextRef="c-362"
                    name="mrvi:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticAnnualIncreasePeriod"
                    format="ixt-sec:duryear" id="f-1244">10</ix:nonNumeric> calendar years during the term of the 2020
                Plan, by the lesser of (i) <ix:nonFraction unitRef="number" contextRef="c-362" decimals="2"
                    name="mrvi:ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreasePercentageFactor"
                    scale="-2" id="f-1245">4</ix:nonFraction>% of the total number of shares of Class A common stock
                outstanding on each December 31 immediately prior to the date of increase or (ii) such number of shares
                of Class A common stock determined by our board of directors or compensation committee. Shares of Class
                A common stock subject to an award that expires or is cancelled, forfeited, exchanged, settled in cash
                or otherwise terminated without delivery of shares and shares withheld to pay the exercise price of, or
                to satisfy the withholding obligations with respect to, an award will again be available for delivery
                pursuant to other awards under the 2020 Plan.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All
                awards granted under the 2020 Plan are intended to be treated as (i) stock options, including incentive
                stock options (&#8220;ISOs&#8221;), (ii) stock appreciation rights (&#8220;SARs&#8221;), (iii)
                restricted share awards (&#8220;RSAs&#8221;), (iv) restricted stock units (&#8220;RSUs&#8221;), (v)
                performance awards, (vi) dividend equivalents, or (vii) other stock or cash awards as may be determined
                by the plan&#8217;s administrator from time to time. The term of each option award shall be no more than
                <ix:nonNumeric contextRef="c-362"
                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"
                    format="ixt-sec:duryear" id="f-1246">10</ix:nonNumeric> years from the date of grant. The exercise
                price of a stock option shall not be less than <ix:nonFraction unitRef="number" contextRef="c-362"
                    decimals="INF"
                    name="mrvi:ShareBasedCompensationArrangementByShareBasedPaymentAwardStandardExercisePricePercentageOfFairValue"
                    scale="-2" id="f-1247">100</ix:nonFraction>% (or, in the case of an ISO granted to a ten percent
                stockholder, <ix:nonFraction unitRef="number" contextRef="c-362" decimals="INF"
                    name="mrvi:ShareBasedCompensationArrangementByShareBasedPaymentAwardTenPercentStockHolderExercisePricePercentageOfFairValue"
                    scale="-2" id="f-1248">110</ix:nonFraction>%) of the fair market value of the shares on the date of
                grant. As of December&#160;31, 2023, only stock options, RSUs and PSUs have been issued.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                November 2020, the Company adopted the 2020 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) to
                assist employees in acquiring a stock ownership interest in the Company and to encourage them to remain
                in the employment of the Company. The ESPP permits eligible employees to purchase shares of Class A
                common stock at a discount through payroll deductions during specified <ix:nonNumeric contextRef="c-363"
                    name="mrvi:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"
                    format="ixt-sec:durwordsen" id="f-1249">six-month</ix:nonNumeric> purchase periods. The price of
                shares purchased under the ESPP is equal to the lower of the grant date price less a <ix:nonFraction
                    unitRef="number" contextRef="c-363" decimals="INF"
                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"
                    scale="-2" id="f-1250">15</ix:nonFraction>% discount or a <ix:nonFraction unitRef="number"
                    contextRef="c-363" decimals="INF"
                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"
                    scale="-2" id="f-1251">15</ix:nonFraction>% discount to the market closing price on the date of
                purchase. </span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation
                expense recognized for the ESPP was insignificant for all periods presented.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                Company began issuing PSUs during 2022 to certain executive employees under the 2020 Plan. Certain PSUs
                vest only if the executive employee satisfies a service-based vesting condition and market condition.
                The executive employee must remain employed through the third anniversary of the grant date. The award
                is eligible to vest based on the achievement of certain price targets of the Company&#8217;s stock price
                over a defined performance period. Certain other PSUs are subject to a performance condition being
                satisfied. The award is eligible to vest upon achievement of certain revenue-based performance goals and
                are subject to continued service over a defined performance period. </span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation
                expense recognized for these PSUs were insignificant for the years ended December&#160;31, 2023 and
                2022. There was <ix:nonFraction unitRef="usd" contextRef="c-364" decimals="INF"
                    name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-1252">
                    no</ix:nonFraction> compensation expense related to PSUs during the year ended December 31,
                2021.</span></div>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock
                Options</span></div>
        <ix:nonNumeric contextRef="c-1"
            name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-1253" escape="true">
            <div style="margin-top:6pt"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    following table summarizes information related to stock options:</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:45.752%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:11.637%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.532%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:11.637%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.532%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:11.637%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.532%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:11.641%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number
                                of Stock Options<br />(in thousands)</span></td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted
                                Average Exercise Price per Stock Option</span></td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted
                                Average Remaining Contractual Life<br />(in years)</span></td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate
                                Intrinsic Value<br />(in thousands)</span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding
                                as of December 31, 2022</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1254">2,893</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"
                                    scale="0" id="f-1255">26.45</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonNumeric contextRef="c-15"
                                    name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"
                                    format="ixt-sec:duryear" id="f-1256">8.9</ix:nonNumeric>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"
                                    format="ixt:fixed-zero" scale="3" id="f-1257">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1258">2,270</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2"
                                    name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"
                                    scale="0" id="f-1259">14.76</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"
                                    scale="3" id="f-1260">858</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2"
                                    name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"
                                    scale="0" id="f-1261">25.11</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding
                                as of December 31, 2023</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1262">4,305</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"
                                    scale="0" id="f-1263">20.55</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonNumeric contextRef="c-1"
                                    name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"
                                    format="ixt-sec:duryear" id="f-1264">8.5</ix:nonNumeric>
                            </span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"
                                    scale="3" id="f-1265">19</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable
                                as of December 31, 2023</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1266">1,456</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"
                                    scale="0" id="f-1267">24.76</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonNumeric contextRef="c-1"
                                    name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"
                                    format="ixt-sec:duryear" id="f-1268">7.7</ix:nonNumeric>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"
                                    format="ixt:fixed-zero" scale="3" id="f-1269">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                Company uses the Black-Scholes option pricing model to estimate the fair value of each option grant on
                the date of grant or any other measurement date. The assumptions and estimates are as follows:</span>
        </div>
        <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected
                term</span><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
                - The expected term represents the period that stock-based awards are expected to be outstanding and is
                determined using the simplified method. Our historical share option exercise information is limited due
                to a lack of sufficient data points and does not provide a reasonable basis upon which to estimate an
                expected term.</span></div>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-1243-2" continuedAt="f-1243-3">
        <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected
                volatility</span><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
                - The expected volatility was derived from the historical stock volatilities of peer public companies
                within our industry that are considered to be comparable to our business over a period equivalent to the
                expected term of the stock-based awards, since our stock trading history is limited.</span></div>
        <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-free
                interest rate</span><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
                - The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the date of grant
                for zero-coupon U.S. Treasury notes with maturities approximately equal to the stock-based awards&#8217;
                expected term.</span></div>
        <div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected
                dividend yield</span><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">
                - The expected dividend yield is <ix:nonFraction unitRef="number" contextRef="c-365" decimals="INF"
                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"
                    format="ixt:fixed-zero" scale="0" id="f-1270">zero</ix:nonFraction> as we have no plans to make
                dividend payments.</span></div>
        <ix:nonNumeric contextRef="c-1"
            name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-1271"
            escape="true">
            <div style="margin-top:12pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A
                    summary of the assumptions used to estimate the fair value of stock option grants for the years
                    presented is as follows:</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:50.437%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.566%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.532%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.566%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.532%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:14.567%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year
                                Ended December 31,</span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                        </td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                        </td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected
                                volatility</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-365" decimals="3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"
                                    scale="-2" id="f-1272">48.0</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-366" decimals="3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"
                                    scale="-2" id="f-1273">51.3</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-367" decimals="3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"
                                    scale="-2" id="f-1274">57.2</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free
                                interest rate</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-365" decimals="3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"
                                    scale="-2" id="f-1275">3.6</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-366" decimals="3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"
                                    scale="-2" id="f-1276">2.8</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-367" decimals="3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"
                                    scale="-2" id="f-1277">1.0</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected
                                term (in years)</span></td>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonNumeric contextRef="c-365"
                                    name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"
                                    format="ixt-sec:duryear" id="f-1278">6.5</ix:nonNumeric>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonNumeric contextRef="c-366"
                                    name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"
                                    format="ixt-sec:duryear" id="f-1279">6.1</ix:nonNumeric>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonNumeric contextRef="c-367"
                                    name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"
                                    format="ixt-sec:duryear" id="f-1280">6.1</ix:nonNumeric>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected
                                dividend yield</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-365" decimals="3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"
                                    format="ixt:fixed-zero" scale="-2" id="f-1281">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-366" decimals="3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"
                                    format="ixt:fixed-zero" scale="-2" id="f-1282">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-367" decimals="3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"
                                    format="ixt:fixed-zero" scale="-2" id="f-1283">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based
                compensation expense related to stock options was $<ix:nonFraction unitRef="usd" contextRef="c-365"
                    decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal"
                    scale="6" id="f-1284">11.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd"
                    contextRef="c-366" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense"
                    format="ixt:num-dot-decimal" scale="6" id="f-1285">8.1</ix:nonFraction> million and $<ix:nonFraction
                    unitRef="usd" contextRef="c-367" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense"
                    format="ixt:num-dot-decimal" scale="6" id="f-1286">4.6</ix:nonFraction> million for the years ended
                December&#160;31, 2023, 2022 and 2021, respectively. The total fair value of stock options vested was $
                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5"
                    name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"
                    format="ixt:num-dot-decimal" scale="6" id="f-1287">11.9</ix:nonFraction> million, $<ix:nonFraction
                    unitRef="usd" contextRef="c-15" decimals="-5"
                    name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"
                    format="ixt:num-dot-decimal" scale="6" id="f-1288">7.7</ix:nonFraction> million and $<ix:nonFraction
                    unitRef="usd" contextRef="c-16" decimals="-5"
                    name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"
                    format="ixt:num-dot-decimal" scale="6" id="f-1289">4.3</ix:nonFraction> million for the years ended
                December&#160;31, 2023, 2022 and 2021, respectively.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
                of December&#160;31, 2023, the total unrecognized stock-based compensation related to stock options was
                $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5"
                    name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"
                    format="ixt:num-dot-decimal" scale="6" id="f-1290">26.3</ix:nonFraction> million, which is expected
                be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="c-365"
                    name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"
                    format="ixt-sec:duryear" id="f-1291">2.7</ix:nonNumeric> years.</span></div>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted
                Stock Units</span></div>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"
            id="f-1292" escape="true">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    Company has granted restricted stock unit awards to employees and non-employee directors and
                    contractors. The following table summarizes information related to RSUs:</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:65.322%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:15.322%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:15.323%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted
                                Stock Units<br />(in thousands)</span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted
                                Average Fair Value per RSU at Grant Date</span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance
                                as of December 31, 2022</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-368" decimals="-3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1293">1,331</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-368" decimals="2"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"
                                    scale="0" id="f-1294">21.04</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-369" decimals="-3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1295">3,507</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-369" decimals="2"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"
                                    scale="0" id="f-1296">13.66</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="shares" contextRef="c-369" decimals="-3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"
                                    scale="3" id="f-1297">278</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-369" decimals="2"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"
                                    scale="0" id="f-1298">23.66</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="shares" contextRef="c-369" decimals="-3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"
                                    scale="3" id="f-1299">616</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-369" decimals="2"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"
                                    scale="0" id="f-1300">20.30</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance
                                as of December 31, 2023</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-370" decimals="-3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1301">3,944</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-370" decimals="2"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"
                                    scale="0" id="f-1302">15.35</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based
                compensation expense related to RSUs was $<ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-5"
                    name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6"
                    id="f-1303">20.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-371"
                    decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal"
                    scale="6" id="f-1304">8.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd"
                    contextRef="c-372" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense"
                    format="ixt:num-dot-decimal" scale="6" id="f-1305">0.8</ix:nonFraction> million for the years ended
                December&#160;31, 2023, 2022 and 2021, respectively. The total fair value of RSUs vested was $
                <ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-5"
                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"
                    format="ixt:num-dot-decimal" scale="6" id="f-1306">5.0</ix:nonFraction> million, $<ix:nonFraction
                    unitRef="usd" contextRef="c-371" decimals="-5"
                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"
                    format="ixt:num-dot-decimal" scale="6" id="f-1307">1.0</ix:nonFraction> million and $0.9 million for
                the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
                of December&#160;31, 2023, the total unrecognized equity-based compensation related to RSUs was $
                <ix:nonFraction unitRef="usd" contextRef="c-370" decimals="-5"
                    name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"
                    format="ixt:num-dot-decimal" scale="6" id="f-1308">43.7</ix:nonFraction> million, which is expected
                be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="c-369"
                    name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"
                    format="ixt-sec:duryear" id="f-1309">2.0</ix:nonNumeric> years.</span></div>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unit-Based
                Compensation</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior
                to the IPO, the Company&#8217;s parent, MLSH 1, granted unit-based awards (&#8220;MLSH 1 Incentive
                Units&#8221;) to certain executives of the Company in the form of non-vested units. </span></div>
        <div style="margin-top:12pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MLSH
                1 Incentive Units</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior
                to the Organizational Transactions, Topco LLC entered into agreements with certain executives and board
                members whereby those employees and board members were granted incentive units in MLSH 1, a related
                party. All MLSH 1 Incentive Unit awards were subject to a market condition which is subject to the
                achievement of a certain investment return threshold that increased on a compounding basis annually and
                a service condition subject to their continued employment. Certain MLSH 1 Incentive Unit awards
                contained a performance condition tied to the achievement of certain cash distribution multiples. All
                vested MLSH 1 Incentive Unit awards are subject to repurchase for fair value at MLSH 1&#8217;s option
                upon a voluntary or involuntary separation event that is not deemed to be for cause. </span></div>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-1243-3">
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                MLSH 1 Incentive Unit awards that include market and service conditions provide for cliff-vesting
                generally over <span style="-sec-ix-hidden:f-1310">four</span> or <ix:nonNumeric contextRef="c-374"
                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"
                    format="ixt-sec:durwordsen" id="f-1311">five years</ix:nonNumeric>. The MLSH 1 Incentive Unit awards
                that include market and performance conditions provide for full vesting upon meeting the performance
                condition. The fair value of MLSH 1 Incentive Unit awards was measured at the grant date and recognized
                as expense over the requisite service period for the awards.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                connection with the divestiture of its Protein Detection business, the Company recognized incremental
                unit-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-5"
                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"
                    format="ixt:num-dot-decimal" scale="6" id="f-1312">2.4</ix:nonFraction> million related to an
                amended agreement with an executive of Vector (see Note 2). This unit-based compensation expense was
                recorded within selling, general and administrative expenses in the consolidated statements of
                operations for the year ended December 31, 2021.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unit-based
                compensation expense related to MLSH 1 Incentive Unit awards was approximately $<ix:nonFraction
                    unitRef="usd" contextRef="c-375" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense"
                    format="ixt:num-dot-decimal" scale="6" id="f-1313">0.2</ix:nonFraction> million, $<ix:nonFraction
                    unitRef="usd" contextRef="c-376" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense"
                    format="ixt:num-dot-decimal" scale="6" id="f-1314">0.7</ix:nonFraction> million and $<ix:nonFraction
                    unitRef="usd" contextRef="c-201" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense"
                    format="ixt:num-dot-decimal" scale="6" id="f-1315">3.9</ix:nonFraction> million for the years ended
                December&#160;31, 2023, 2022 and 2021, respectively.</span></div>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"
            id="f-1316" escape="true">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MLSH
                    1 Incentive Unit award activity during year ended December&#160;31, 2023 is as follows:</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:65.322%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:15.322%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:15.323%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number
                                of Unvested MLSH 1 Incentive Units<br />(in thousands)</span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted
                                Average Grant Date Fair Value Per Unit</span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance
                                as of December 31, 2022</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-377" decimals="-3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"
                                    scale="3" id="f-1317">77</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-377" decimals="2"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"
                                    scale="0" id="f-1318">24.34</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="shares" contextRef="c-375" decimals="-3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"
                                    scale="3" id="f-1319">12</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-375" decimals="2"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"
                                    scale="0" id="f-1320">20.08</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="shares" contextRef="c-375" decimals="-3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"
                                    scale="3" id="f-1321">33</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-375" decimals="2"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"
                                    scale="0" id="f-1322">22.24</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance
                                as of December 31, 2023</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="shares" contextRef="c-378" decimals="-3"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"
                                    scale="3" id="f-1323">32</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usdPerShare" contextRef="c-378" decimals="2"
                                    name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"
                                    scale="0" id="f-1324">28.15</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
                of December&#160;31, 2023, total unrecognized compensation cost related to unvested MLSH 1 Incentive
                Units subject to service condition is $<ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-5"
                    name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"
                    format="ixt:num-dot-decimal" scale="6" id="f-1325">0.1</ix:nonFraction> million which is expected to
                be recognized over a weighted average period of <ix:nonNumeric contextRef="c-375"
                    name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"
                    format="ixt-sec:duryear" id="f-1326">1.0</ix:nonNumeric> year.</span></div>
        <div style="margin-top:12pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity-Based
                Compensation</span></div>
        <ix:nonNumeric contextRef="c-1"
            name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"
            id="f-1327" escape="true">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    following table summarizes the total equity-based compensation expense included in the
                    Company&#8217;s consolidated statements of operations for the periods presented (in
                    thousands):</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:61.917%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.734%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.539%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.734%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.539%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.737%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year
                                Ended December 31,</span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                        </td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                        </td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost
                                of sales</span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3"
                                    name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1328">7,324</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3"
                                    name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1329">4,192</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3"
                                    name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1330">1,915</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling,
                                general and administrative</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3"
                                    name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1331">24,650</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3"
                                    name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1332">13,349</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3"
                                    name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1333">8,263</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research
                                and development</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-3"
                                    name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1334">2,715</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-3"
                                    name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1335">1,129</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-3"
                                    name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1336">280
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring</span>
                            </div>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-3" sign="-"
                                    name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1337">101
                                </ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-383" decimals="-3"
                                    name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero"
                                    scale="3" id="f-1338">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-3"
                                    name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero"
                                    scale="3" id="f-1339">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                equity-based compensation</span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                    name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1340">34,588</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                    name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1341">18,670</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                    name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1342">10,458</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
    </ix:continuation>
    <div id="ic995976d222241b98dac88a4c1bc08e5_238"></div>
    <div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1344" continuedAt="f-1344-1"
            escape="true"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Income
                Taxes</span></ix:nonNumeric>
    </div>
    <ix:continuation id="f-1344-1" continuedAt="f-1344-2">
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
                of December&#160;31, 2023 and 2022, we are subject to U.S. federal and state income taxes with respect
                to our allocable share of any taxable income or loss of Topco LLC, as well as any stand-alone income or
                loss we generate. Topco LLC is organized as a limited liability company and treated as a partnership for
                federal tax purposes and generally does not pay income taxes on its taxable income in most
                jurisdictions. Instead, Topco LLC&#8217;s taxable income or loss is passed through to its members,
                including us.</span></div>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"
            id="f-1345" escape="true">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components
                    of income from continuing operations before income taxes for the periods presented were as follows
                    (in thousands):</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:62.243%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.631%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="15"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year
                                Ended December 31,</span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                        </td>
                        <td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                        </td>
                        <td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                    name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1346">617,681</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                    name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1347">551,472</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                    name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1348">530,853</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                    name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3"
                                    id="f-1349">55</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                    name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"
                                    format="ixt:fixed-zero" scale="3" id="f-1350">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-"
                                    name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3"
                                    id="f-1351">88</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                income from continuing operations</span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                    name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1352">617,736</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                    name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1353">551,472</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                    name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1354">530,765</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-1344-2" continuedAt="f-1344-3">
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"
            id="f-1355" escape="true">
            <div style="margin-top:6pt"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income
                    tax expense consisted of the following for the periods presented (in thousands):</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:62.243%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.631%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="15"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year
                                Ended December 31,</span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                        </td>
                        <td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                        </td>
                        <td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current
                                    tax expense</span></div>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span>
                        </td>
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                    name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="f-1356">405
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                    name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1357">16,312</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                    name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1358">9,291</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State
                                and local</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                    name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1359">756
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                    name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1360">2,173</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                    name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1361">1,623</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                    name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-1362">8
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                    name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-1363">6
                                </ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                    name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1364">3,697</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="padding-left:36pt"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                    current tax expense</span></div>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                    name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1365">1,169</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                    name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1366">18,491</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                    name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1367">14,611</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr style="height:14pt">
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred
                                    tax expense</span></div>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span>
                        </td>
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                    name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1368">663,968</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                    name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1369">39,924</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                    name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1370">36,564</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State
                                and local</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                    name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1371">90,974</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                    name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1372">2,394</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                    name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1373">10,340</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="padding-left:36pt"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                    deferred tax expense</span></div>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                    name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1374">754,942</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                    name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1375">42,318</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                    name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1376">46,904</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr style="height:14pt">
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                provision for income taxes</span></td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                    name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1377">756,111</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                    name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1378">60,809</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                    name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1379">61,515</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"
            id="f-1380" escape="true">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A
                    reconciliation between the Company&#8217;s effective tax rate and the applicable U.S. federal
                    statutory income tax rate as of the periods presented is summarized as follows:</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt;text-align:justify">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:62.243%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.630%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.631%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                31, 2023</span></td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                31, 2022</span></td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                31, 2021</span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal
                                statutory rate</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF"
                                    name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"
                                    scale="-2" id="f-1381">21.0</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-15" decimals="INF"
                                    name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"
                                    scale="-2" id="f-1382">21.0</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-16" decimals="INF"
                                    name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"
                                    scale="-2" id="f-1383">21.0</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State
                                and local taxes, net of federal benefits</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3"
                                    name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"
                                    scale="-2" id="f-1384">14.9</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-15" decimals="3"
                                    name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"
                                    scale="-2" id="f-1385">0.6</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-16" decimals="3"
                                    name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"
                                    scale="-2" id="f-1386">2.2</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred
                                tax revaluation</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3"
                                    name="mrvi:EffectiveIncomeTaxRateReconciliationDeferredTaxRevaluationPercent"
                                    scale="-2" id="f-1387">1.2</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-15" decimals="3"
                                    name="mrvi:EffectiveIncomeTaxRateReconciliationDeferredTaxRevaluationPercent"
                                    scale="-2" id="f-1388">0.3</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-16" decimals="3"
                                    name="mrvi:EffectiveIncomeTaxRateReconciliationDeferredTaxRevaluationPercent"
                                    format="ixt:fixed-zero" scale="-2" id="f-1389">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income
                                of non-controlling interest</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3"
                                    name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"
                                    scale="-2" id="f-1390">0.8</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-"
                                    name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"
                                    scale="-2" id="f-1391">10.3</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" sign="-"
                                    name="us-gaap:EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense"
                                    scale="-2" id="f-1392">11.4</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxable
                                (loss) gain on subsidiary liquidation</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3"
                                    name="mrvi:EffectiveIncomeTaxRateReconciliationGainOnLiquidationOfSubsidiaryPercent"
                                    format="ixt:fixed-zero" scale="-2" id="f-1393">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-15" decimals="3"
                                    name="mrvi:EffectiveIncomeTaxRateReconciliationGainOnLiquidationOfSubsidiaryPercent"
                                    format="ixt:fixed-zero" scale="-2" id="f-1394">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="number" contextRef="c-16" decimals="3" sign="-"
                                    name="mrvi:EffectiveIncomeTaxRateReconciliationGainOnLiquidationOfSubsidiaryPercent"
                                    scale="-2" id="f-1395">0.7</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based
                                compensation</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3"
                                    name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"
                                    format="ixt:fixed-zero" scale="-2" id="f-1396">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-15" decimals="3"
                                    name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"
                                    format="ixt:fixed-zero" scale="-2" id="f-1397">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-16" decimals="3"
                                    name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"
                                    scale="-2" id="f-1398">0.1</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research
                                and development credits</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3"
                                    name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"
                                    format="ixt:fixed-zero" scale="-2" id="f-1399">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="number" contextRef="c-15" decimals="3"
                                    name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2"
                                    id="f-1400">0.1</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="number" contextRef="c-16" decimals="3"
                                    name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2"
                                    id="f-1401">0.4</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation
                                allowance</span></td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3"
                                    name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"
                                    scale="-2" id="f-1402">87.6</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-15" decimals="3"
                                    name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"
                                    scale="-2" id="f-1403">0.1</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-16" decimals="3"
                                    name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"
                                    scale="-2" id="f-1404">0.1</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible
                                    TRA movement</span></div>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-"
                                    name="mrvi:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTaxReceivableAgreementMovementPercent"
                                    scale="-2" id="f-1405">3.0</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-15" decimals="3"
                                    name="mrvi:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTaxReceivableAgreementMovementPercent"
                                    format="ixt:fixed-zero" scale="-2" id="f-1406">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-16" decimals="3"
                                    name="mrvi:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseTaxReceivableAgreementMovementPercent"
                                    format="ixt:fixed-zero" scale="-2" id="f-1407">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3"
                                    name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments"
                                    format="ixt:fixed-zero" scale="-2" id="f-1408">&#8212;</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-"
                                    name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2"
                                    id="f-1409">0.6</ix:nonFraction>)</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-16" decimals="3"
                                    name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2"
                                    id="f-1410">0.7</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective
                                tax rate</span></td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3"
                                    name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1411">
                                    122.5</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-15" decimals="3"
                                    name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1412">
                                    11.0</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="number" contextRef="c-16" decimals="3"
                                    name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1413">
                                    11.6</ix:nonFraction>&#160;
                            </span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span>
                        </td>
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"
            id="f-1414" escape="true">
            <div style="margin-top:6pt"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred
                    income taxes reflect the net tax effects of temporary differences between the carrying amounts of
                    assets and liabilities for financial reporting purposes and the amounts used for income tax purposes
                    and operating loss and tax credit carryforwards. Significant items comprising the net deferred tax
                    assets were as follows as of the periods presented below (in thousands): </span></div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:65.322%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:15.322%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.533%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:15.323%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                31, 2023</span></td>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December
                                31, 2022</span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred
                                tax assets</span></td>
                        <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment
                                in Topco LLC</span></td>
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:DeferredTaxAssetsInvestments" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1415">595,796</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td
                            style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#ffffff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:DeferredTaxAssetsInvestments" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1416">636,498</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                            <div style="padding-left:18pt"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                                    operating loss</span></div>
                        </td>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1417">40,980</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:fixed-zero"
                                    scale="3" id="f-1418">&#8212;</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deductions
                                to be received for the Tax Receivable Agreement payments</span></td>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="mrvi:DeferredTaxAssetsDeductionsForTaxReceivableAgreement"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1419">1,408</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="mrvi:DeferredTaxAssetsDeductionsForTaxReceivableAgreement"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1420">148,681</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital
                                loss carryforward</span></td>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1421">3,256</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1422">3,265</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span>
                        </td>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:DeferredTaxAssetsOther" scale="3" id="f-1423">712</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1424">1,131</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                deferred tax assets</span></td>
                        <td colspan="3"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1425">642,152</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1426">789,575</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation
                                allowance</span></td>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1427">642,152</ix:nonFraction>)</span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal"
                                    scale="3" id="f-1428">23,776</ix:nonFraction>)</span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total
                                deferred tax assets, net of valuation allowance</span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:DeferredTaxAssetsNet" format="ixt:fixed-zero" scale="3" id="f-1429">
                                    &#8212;</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1430">765,799</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                    <tr>
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                        <td colspan="3" style="display:none" />
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
                a result of the Organizational Transactions, IPO, and subsequent exchanges and financing, we acquired
                LLC Units and recognized a deferred tax asset for the difference between the financial reporting and tax
                basis of our investment in Topco LLC </span></div>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-1344-3" continuedAt="f-1344-4">
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which
                included net deferred tax assets of $<ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-5"
                    name="us-gaap:DeferredTaxAssetsGross" format="ixt:fixed-zero" scale="6" id="f-1431">0.0 million
                </ix:nonFraction> primarily associated with: (i) $<ix:nonFraction unitRef="usd" contextRef="c-386"
                    decimals="-5" name="mrvi:DeferredTaxAssetsTemporaryBookBasisDifference" format="ixt:num-dot-decimal"
                    scale="6" id="f-1432">595.8</ix:nonFraction> million related to temporary differences in the book
                basis as compared to the tax basis of our Company&#8217;s investment in Topco LLC, (ii) $<ix:nonFraction
                    unitRef="usd" contextRef="c-386" decimals="-5"
                    name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="6"
                    id="f-1433">1.4</ix:nonFraction> million related to tax benefits from future deductions attributable
                to payments under the TRA, (iii) $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5"
                    name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" format="ixt:num-dot-decimal" scale="6"
                    id="f-1434">3.3</ix:nonFraction> million related to the capital loss carryforwards generated during
                the sale of Vector, (iv) $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5"
                    name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6"
                    id="f-1435">41.0</ix:nonFraction> million related to net operating loss carryforwards, and (v) $
                <ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-5"
                    name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6"
                    id="f-1436">642.2</ix:nonFraction> million valuation allowance on these and other items.</span>
        </div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5"
                    name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal"
                    scale="6" id="f-1437">618.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd"
                    contextRef="c-15" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount"
                    format="ixt:num-dot-decimal" scale="6" id="f-1438">0.7</ix:nonFraction> million during the years
                ended December&#160;31, 2023 and 2022, respectively. </span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                realizability of the Company&#8217;s deferred tax asset related to its investment in Topco LLC depends
                on the Company receiving allocations of tax deductions for its tax basis in the investment and on the
                Company generating sufficient taxable income to fully offset such deductions. Management assesses the
                available positive and negative evidence to estimate whether sufficient future taxable income will be
                generated to permit use of existing deferred tax assets. A significant piece of objective evidence
                evaluated during the year ended December&#160;31, 2023 was our current year and projected future pre-tax
                losses. Due to our recent history of current year and projected near-term pre-tax losses, we determined
                that the negative evidence outweighs the positive evidence and so it is more likely than not that our
                deferred tax assets will not be utilized, and therefore the Company recorded a full valuation allowance
                on its U.S. federal and state deferred tax assets. The objective negative evidence is difficult to
                overcome and limits the ability to consider other subjective evidence, such as projections of future
                growth. It is possible in the foreseeable future that there may be sufficient positive evidence, and
                that the objective negative evidence related to pre-tax losses will no longer be present, in which event
                the Company could release a portion or all of the valuation allowance. Release of any amount of
                valuation allowance would result in a benefit to income tax expense for the period the release is
                recorded, which could have a material impact on net earnings.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alphazyme
                was treated as a regarded corporation for U.S. federal and state income tax purposes at the time of
                acquisition. The Company recorded the initial contribution of Alphazyme to Topco LLC through its
                deferred tax asset related to the investment in Topco LLC, which was offset by a valuation allowance
                against the deferred tax asset. The Company also recorded a deferred tax liability for the difference
                between book basis and tax basis in the net assets of Alphazyme through purchase accounting. However,
                for the year ended December&#160;31, 2023, Alphazyme became a disregarded entity for U.S. federal and
                state income tax purposes, which became effective immediately following the acquisition and prior to the
                contribution to Topco LLC. The change in Alphazyme&#8217;s tax status resulted in an income tax benefit
                of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-"
                    name="mrvi:EffectiveIncomeTaxRateReconciliationDeferredTaxLiabilityReversalAmount"
                    format="ixt:num-dot-decimal" scale="6" id="f-1439">8.8</ix:nonFraction> million from the reversal of
                the Company&#8217;s deferred tax liability related to its ownership of Alphazyme, as well as an income
                tax expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5"
                    name="mrvi:EffectiveIncomeTaxRateReconciliationDeferredTaxAssetReversalAmount"
                    format="ixt:num-dot-decimal" scale="6" id="f-1440">17.1</ix:nonFraction> million from the impact of
                the reversal to the Company&#8217;s deferred tax asset for its investment in Topco LLC.</span></div>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="f-1442"
            escape="true">
            <ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfTaxCreditCarryforwardsTextBlock" id="f-1441"
                escape="true">
                <div style="margin-top:6pt;text-align:justify"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net
                        operating loss (&#8220;NOL&#8221;) and tax credit carryforwards as of December&#160;31, 2023
                        were as follows (in millions):</span></div>
                <div style="margin-bottom:6pt;margin-top:12pt;text-align:justify">
                    <table
                        style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
                        <tr>
                            <td style="width:1.0%" />
                            <td style="width:64.492%" />
                            <td style="width:0.1%" />
                            <td style="width:1.0%" />
                            <td style="width:15.737%" />
                            <td style="width:0.1%" />
                            <td style="width:0.1%" />
                            <td style="width:0.532%" />
                            <td style="width:0.1%" />
                            <td style="width:1.0%" />
                            <td style="width:15.739%" />
                            <td style="width:0.1%" />
                        </tr>
                        <tr>
                            <td colspan="3" style="padding:0 1pt" />
                            <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span>
                            </td>
                            <td colspan="3" style="padding:0 1pt" />
                            <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration
                                    Years</span></td>
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <div><span
                                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                                        operating losses, federal</span></div>
                            </td>
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-5"
                                        name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6"
                                        id="f-1443">36.3</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3"
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <div style="text-align:center"><span
                                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Does
                                        not expire</span></div>
                            </td>
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <div><span
                                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net
                                        operating losses, state</span></div>
                            </td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-388" decimals="-5"
                                        name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6"
                                        id="f-1444">4.7</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <div style="text-align:center"><span
                                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Varies
                                        by state</span></div>
                            </td>
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital
                                    loss carryforward</span></td>
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5"
                                        name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="6" id="f-1445">
                                        3.3</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span>
                            </td>
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax
                                    credits, federal</span></td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-5"
                                        name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1446">0.3
                                    </ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2043</span>
                            </td>
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax
                                    credits, state</span></td>
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-388" decimals="-5"
                                        name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1447">0.3
                                    </ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CA
                                    - Do not expire</span></td>
                        </tr>
                    </table>
                </div>
            </ix:nonNumeric>
        </ix:nonNumeric>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
                of December&#160;31, 2023 and 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-5"
                    decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6"
                    id="f-1448">5.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6"
                    decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6"
                    id="f-1449">6.3</ix:nonFraction> million of unrecognized tax benefits, all of which would affect the
                effective tax rate if recognized. The Company expects our unrecognized tax benefits may decrease by $
                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5"
                    name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"
                    format="ixt:num-dot-decimal" scale="6" id="f-1450">2.6</ix:nonFraction> million in the next twelve
                months due to statute expiration. The Company recognizes interest related to uncertain tax benefits as a
                component of income tax expense, including $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5"
                    name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" format="ixt:num-dot-decimal"
                    scale="6" id="f-1451">0.3</ix:nonFraction> million recognized during the year ended
                December&#160;31, 2023.</span></div>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"
            id="f-1452" escape="true">
            <div style="margin-top:6pt;text-align:justify"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                    aggregate changes in the balance of the Company&#8217;s unrecognized tax benefits were as follows
                    for the periods presented (in thousands):</span></div>
            <div style="margin-bottom:12pt;margin-top:12pt">
                <table
                    style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%">
                    <tr>
                        <td style="width:1.0%" />
                        <td style="width:61.917%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.734%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.539%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.734%" />
                        <td style="width:0.1%" />
                        <td style="width:0.1%" />
                        <td style="width:0.539%" />
                        <td style="width:0.1%" />
                        <td style="width:1.0%" />
                        <td style="width:10.737%" />
                        <td style="width:0.1%" />
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year
                                Ended December 31,</span></td>
                    </tr>
                    <tr>
                        <td colspan="3" style="padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                        </td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                        </td>
                        <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                        <td colspan="3"
                            style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span>
                        </td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance,
                                beginning of year</span></td>
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1453">6,257</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3"
                                    name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="f-1454">241</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3"
                                    name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="f-1455">220</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross
                                increases based on tax positions related to current year</span></td>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                    name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"
                                    scale="3" id="f-1456">99</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                    name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"
                                    scale="3" id="f-1457">130</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                    name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"
                                    scale="3" id="f-1458">232</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross
                                increases based on tax positions related to prior years</span></td>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                    name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"
                                    format="ixt:fixed-zero" scale="3" id="f-1459">&#8212;</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                    name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1460">6,775</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                    name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"
                                    format="ixt:fixed-zero" scale="3" id="f-1461">&#8212;</ix:nonFraction>
                            </span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross
                                decreases based on tax positions related to prior years</span></td>
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                    name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"
                                    format="ixt:num-dot-decimal" scale="3" id="f-1462">1,158</ix:nonFraction>)</span>
                        </td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                    name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"
                                    scale="3" id="f-1463">889</ix:nonFraction>)</span></td>
                        <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        <td colspan="3"
                            style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                    name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"
                                    scale="3" id="f-1464">211</ix:nonFraction>)</span></td>
                    </tr>
                    <tr>
                        <td colspan="3"
                            style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance,
                                end of year</span></td>
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3"
                                    name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1465">5,198</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3"
                                    name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3"
                                    id="f-1466">6,257</ix:nonFraction>
                            </span></td>
                        <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        <td
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                        </td>
                        <td colspan="2"
                            style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom">
                            <span
                                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                <ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3"
                                    name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="f-1467">241</ix:nonFraction>
                            </span></td>
                    </tr>
                </table>
            </div>
        </ix:nonNumeric>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-1344-4">
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                Company files income tax returns in the U.S. federal jurisdiction and various states and is not under
                audit by taxing authorities in any of these jurisdictions. With exceptions for certain states, the
                Company is no longer subject to U.S. federal, state, and local, or non-U.S. income tax examinations for
                years before 2020.</span></div>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payable
                to Related Parties Pursuant to the Tax Receivable Agreement</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
                are a party to a TRA with MLSH 1 and MLSH 2. The TRA provides for the payment by us to MLSH 1 and MLSH
                2, collectively, of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2"
                    name="mrvi:TaxReceivableAgreementPercentageOfTaxBenefitsPaid" scale="-2" id="f-1468">85
                </ix:nonFraction>% of the amount of certain tax benefits, if any, that we actually realize, or in some
                circumstances are deemed to realize, as a result of the Organizational Transactions, IPO and any
                subsequent purchases or exchanges of LLC Units of Topco LLC. The Company expects to benefit from the
                remaining <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2"
                    name="mrvi:TaxReceivableAgreementRemainingPercentage" scale="-2" id="f-1469">15</ix:nonFraction>% of
                any cash tax savings that it realizes. </span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
                recognize the amount of TRA payments expected to be paid within the next 12 months and classify this
                amount as current. This determination is based on our estimate of taxable income for the year ended
                December&#160;31, 2023. As of December&#160;31, 2023, the current liability under the TRA was $
                <ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-5" name="us-gaap:AccountsPayableCurrent"
                    format="ixt:num-dot-decimal" scale="6" id="f-1470">7.1</ix:nonFraction> million. </span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
                of December&#160;31, 2023, the Company has derecognized the remaining $<ix:nonFraction unitRef="usd"
                    contextRef="c-390" decimals="-5" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction"
                    format="ixt:num-dot-decimal" scale="6" id="f-1471">665.3</ix:nonFraction> million non-current
                liability under the TRA after concluding it was not probable that the Company will be able to realize
                the remaining tax benefits based on estimates of future taxable income. The estimation of liability
                under the TRA is by its nature imprecise and subject to significant assumptions regarding the amount,
                character, and timing of the taxable income in the future. If the Company concludes in a future period
                that the tax benefits are more likely than not to be realized and releases its valuation allowance, the
                corresponding TRA liability amounts may be considered probable at that time and recorded on the
                consolidated balance sheet and within earnings.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
                made payments of $<ix:nonFraction unitRef="usd" contextRef="c-391" decimals="-5"
                    name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6"
                    id="f-1472">42.6</ix:nonFraction> million to MLSH 1 and MLSH 2 pursuant to the TRA during the year
                ended December&#160;31, 2023, of which $<ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-5"
                    name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6"
                    id="f-1473">0.4</ix:nonFraction> million is related to interest. We made payments of $
                <ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-5"
                    name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6"
                    id="f-1474">35.3</ix:nonFraction> million to MLSH 1 and MLSH 2 pursuant to the TRA during the year
                ended December&#160;31, 2022, of which $<ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-5"
                    name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6"
                    id="f-1475">1.1</ix:nonFraction> million was related to interest. As of December&#160;31, 2023 and
                2022, our liabilities under the TRA were $<ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-5"
                    name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6"
                    id="f-1476">7.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-395"
                    decimals="-5" name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal"
                    scale="6" id="f-1477">718.2</ix:nonFraction> million, respectively.</span></div>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax
                Distributions to Topco LLC&#8217;s Owners</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Topco
                LLC is subject to an operating agreement put in place at the date of the Organizational Transactions
                (&#8220;LLC Operating Agreement&#8221;). The LLC Operating Agreement has numerous provisions related to
                allocations of income and loss, as well as timing and amounts of distributions to its owners. This
                agreement also includes a provision requiring cash distributions enabling its owners to pay their taxes
                on income passing through from Topco LLC. These tax distributions are computed based on an assumed
                income tax rate equal to the sum of (i) the maximum combined marginal federal and state income tax rate
                applicable to an individual and (ii) the net investment income tax. The assumed income tax rate ranges
                from <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3"
                    name="mrvi:AssumedEffectiveIncomeTaxRateReconciliationPercent" scale="-2" id="f-1478">46.7
                </ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3"
                    name="mrvi:AssumedEffectiveIncomeTaxRateReconciliationBusinessIncomeDeductionUnavailablePercent"
                    scale="-2" id="f-1479">54.1</ix:nonFraction>% in certain cases where the qualified business income
                deduction is unavailable. </span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                addition, under the tax rules, Topco LLC is required to allocate taxable income disproportionately to
                its unit holders. Because tax distributions are determined based on the holder of LLC Units who is
                allocated the largest amount of taxable income on a per unit basis, but are made pro rata based on
                ownership, Topco LLC is required to make tax distributions that, in the aggregate, will likely exceed
                the amount of taxes Topco LLC would have otherwise paid if it were taxed on its taxable income at the
                assumed income tax rate. Topco LLC is subject to entity level taxation in certain states and certain of
                its subsidiaries are subject to entity level U.S. and foreign income taxes. As a result, the
                accompanying consolidated statements of operations include income tax expense related to those states
                and to U.S. and foreign jurisdictions where Topco LLC or any of our subsidiaries are subject to income
                tax.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During
                the year ended December&#160;31, 2023, Topco LLC paid tax distributions of $<ix:nonFraction
                    unitRef="usd" contextRef="c-396" decimals="-5"
                    name="us-gaap:DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid"
                    format="ixt:num-dot-decimal" scale="6" id="f-1480">20.3</ix:nonFraction> million to its owners,
                including $<ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-5"
                    name="us-gaap:DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid"
                    format="ixt:num-dot-decimal" scale="6" id="f-1481">10.7</ix:nonFraction> million to us. During the
                year ended December&#160;31, 2022, Topco LLC paid tax distributions of $<ix:nonFraction unitRef="usd"
                    contextRef="c-398" decimals="-5"
                    name="us-gaap:DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid"
                    format="ixt:num-dot-decimal" scale="6" id="f-1482">310.0</ix:nonFraction> million to its owners,
                including $<ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-5"
                    name="us-gaap:DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid"
                    format="ixt:num-dot-decimal" scale="6" id="f-1483">159.8</ix:nonFraction> million to us. During the
                year ended December&#160;31, 2021, Topco LLC paid tax distributions of $<ix:nonFraction unitRef="usd"
                    contextRef="c-400" decimals="-5"
                    name="us-gaap:DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid"
                    format="ixt:num-dot-decimal" scale="6" id="f-1484">283.2</ix:nonFraction> million to its owners,
                including $<ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-5"
                    name="us-gaap:DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsPaid"
                    format="ixt:num-dot-decimal" scale="6" id="f-1485">129.7</ix:nonFraction> million to us. </span>
        </div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As
                of December&#160;31, 2023, <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF"
                    name="mrvi:TaxDistributionPayable" format="ixt:fixed-zero" scale="0" id="f-1486">no</ix:nonFraction>
                amounts for tax distributions have been accrued as such payments were made during the period.</span>
        </div>
    </ix:continuation>
    <div id="ic995976d222241b98dac88a4c1bc08e5_241"></div>
    <div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:DefinedContributionPlanTextBlock" id="f-1487"
            continuedAt="f-1487-1" escape="true"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Employee
                Benefit Plans</span></ix:nonNumeric>
    </div>
    <ix:continuation id="f-1487-1">
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                Company sponsors a 401(k) plan (the &#8220;Maravai LifeSciences 401(k) Plan&#8221;) pursuant to which
                eligible employees can elect to contribute to the 401(k) Plan, subject to certain limitations, on a
                pretax basis. The Company provides for a cash match of up to <ix:nonFraction unitRef="number"
                    contextRef="c-1" decimals="INF"
                    name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2"
                    id="f-1488">50</ix:nonFraction>% of employee contributions up to the first <ix:nonFraction
                    unitRef="number" contextRef="c-1" decimals="INF"
                    name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-1489">6
                </ix:nonFraction>% of salary.</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total
                contributions by the Company to the Maravai LifeSciences 401(k) Plan was approximately $<ix:nonFraction
                    unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized"
                    format="ixt:num-dot-decimal" scale="6" id="f-1490">2.1</ix:nonFraction> million, $<ix:nonFraction
                    unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized"
                    format="ixt:num-dot-decimal" scale="6" id="f-1491">1.6</ix:nonFraction> million and $<ix:nonFraction
                    unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized"
                    format="ixt:num-dot-decimal" scale="6" id="f-1492">1.3</ix:nonFraction> million for the years ended
                December&#160;31, 2023, 2022 and 2021, respectively.</span></div>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_244"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-1493"
            continuedAt="f-1493-1" escape="true"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Related
                Party Transactions</span></ix:nonNumeric>
    </div>
    <ix:continuation id="f-1493-1">
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MLSH
                1&#8217;s majority owner is GTCR, LLC (&#8220;GTCR&#8221;). The Company&#8217;s Executive Chairman of
                the Board, Chief Financial Officer (&#8220;CFO&#8221;) and General Counsel are executives of MLSH 1 and
                MLSH 2.</span></div>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registration
                Rights Agreement with MLSH 1 and MLSH 2</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                connection with the IPO, Company entered into a registration rights agreement with MLSH 1 and MLSH 2.
                MLSH 1 and MLSH 2 are entitled to request that the Company register their shares of capital stock on a
                long-form or short-form registration statement on one or more occasions in the future, which
                registrations may be &#8220;shelf registrations.&#8221; MLSH 1 and MLSH 2 are also entitled to
                participate in certain of our registered offerings, subject to the restrictions in the registration
                rights agreement. During 2021, the Company registered shares of Class A shares held by MLSH 1 which were
                subsequently sold in an offering as selling shareholders as well as facilitated secondary offering
                transactions related to the exchanges (see Note 11).</span></div>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange
                Agreement with MLSH 1</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                connection with the IPO, the Company entered into an exchange agreement with MLSH 1, whereby MLSH 1 may
                surrender their LLC Units to Topco LLC or, at our election, exchange its LLC Units for shares of our
                Class A common stock on a <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF"
                    name="mrvi:ConversionOfStockConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-1494">one
                </ix:nonFraction>-for-one basis, or, at our election, for cash from a substantially concurrent public
                offering or private sale. MLSH 1 is also required to deliver to us an equivalent number of shares of
                Class B common stock to effectuate an exchange. MLSH 1 executed two exchanges under this agreement
                during 2021 (see Note 11).</span></div>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payable
                to Related Parties Pursuant to the Tax Receivable Agreement</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent
                with the completion of the IPO, the Company entered into a TRA with MLSH 1 and MLSH 2. During the years
                ended December&#160;31, 2023, 2022 and 2021, the Company made TRA payments to both MLSH 1 and MLSH 2
                (see Note 14).</span></div>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash
                Contribution, Exchange and Forfeiture Agreement with MLSH 1</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                December 2021, the Company entered into a Cash Contribution, Exchange and Forfeiture Agreement with MLSH
                1 (see Note 11).</span></div>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Topco
                LLC Operating Agreement</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MLSH
                1 is party to the Topco LLC operating agreement put in place at the date of the Organizational
                Transactions. This agreement includes a provision requiring cash distributions enabling its owners to
                pay their taxes on income passing through from Topco LLC. During the years ended December&#160;31, 2023,
                2022 and 2021, the Company made distributions of $<ix:nonFraction unitRef="usd" contextRef="c-53"
                    decimals="-5"
                    name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"
                    format="ixt:num-dot-decimal" scale="6" id="f-1495">9.6</ix:nonFraction> million, $<ix:nonFraction
                    unitRef="usd" contextRef="c-43" decimals="-5"
                    name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"
                    format="ixt:num-dot-decimal" scale="6" id="f-1496">150.2</ix:nonFraction> million and $
                <ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5"
                    name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"
                    format="ixt:num-dot-decimal" scale="6" id="f-1497">153.5</ix:nonFraction> million for tax
                liabilities to MLSH 1 under this agreement, respectively.</span></div>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract
                Development and Manufacturing Agreement with Curia Global</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GTCR
                has significant influence over Curia Global (&#8220;Curia&#8221;). During the years ended
                December&#160;31, 2023 and 2022, the Company paid insignificant amounts to Curia for contract
                manufacturing and development services. During the year ended December&#160;31, 2021, the Company paid $
                <ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-5"
                    name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6"
                    id="f-1498">7.4</ix:nonFraction> million to Curia. Such amounts were included in research and
                development expenses on the consolidated statements of operations.</span></div>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Maravai
                LifeSciences Foundation</span></div>
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In
                December 2021, the Company established a new charitable foundation to promote causes tied to
                Maravai&#8217;s mission. During the year ended December 31, 2021, the Company contributed $
                <ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-5"
                    name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" format="ixt:num-dot-decimal" scale="6"
                    id="f-1499">2.0</ix:nonFraction> million to the Foundation. The Company does not control the
                Foundation&#8217;s activities, and accordingly, does not consolidate the Foundation.</span></div>
    </ix:continuation>
    <div id="ic995976d222241b98dac88a4c1bc08e5_250"></div>
    <div style="margin-top:18pt;padding-left:18pt;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span>
        <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1502"
            continuedAt="f-1502-1" escape="true"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">Segments</span>
        </ix:nonNumeric>
    </div>
    <ix:continuation id="f-1502-1" continuedAt="f-1502-2">
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating
                segments are defined as components of an enterprise about which separate financial information is
                available that is evaluated regularly by the chief operating decision maker, or decision-making group,
                in deciding how to allocate resources and in assessing performance. When determining the reportable
                segments, the Company aggregated operating segments based on their similar economic and operating
                characteristics. Segment results are presented in the same manner as we present our operations
                internally to make operating decisions and assess performance. The accounting policies for the segments
                are the </span></div>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-1502-2" continuedAt="f-1502-3">
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">same
                as those described in Significant Accounting Policies (see Note 1). The Company&#8217;s financial
                performance is reported in <ix:nonFraction unitRef="segment" contextRef="c-16" decimals="INF"
                    name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-1503">three
                </ix:nonFraction> segments. A description of each segment follows:</span></div>
        <div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Nucleic
                Acid Production</span><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:
                focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of
                customers&#8217; research, therapeutic and vaccine programs. This segment also provides research
                products for labeling and detecting proteins in cells and tissue samples.</span></div>
        <div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Biologics
                Safety Testing</span><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:
                focuses on the manufacturing and sale of host cell protein, bioprocess impurity detection, viral
                clearance prediction kits and associated products. This segment also provides services for custom
                antibody development, assay development, antibody affinity extraction and mass spectrometry that are
                utilized by our customers in their biologic drug manufacturing spectrum.</span></div>
        <div style="margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Protein
                Detection</span><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:
                focused on manufacturing and selling labeling and visual detection reagents to scientific research
                customers for their tissue-based protein detection and characterization needs. The Company completed the
                divestiture of its Protein Detection business in September 2021 (see Note 2).</span></div>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                Company has determined that adjusted earnings before interest, tax, depreciation and amortization
                (&#8220;Adjusted EBITDA&#8221;) is the profit or loss measure that the CODM uses to make resource
                allocation decisions and evaluate segment performance. Adjusted EBITDA assists management in comparing
                the segment performance on a consistent basis for purposes of business decision-making by removing the
                impact of certain items that management believes do not directly reflect the core operations and,
                therefore, are not included in measuring segment performance. The Company defines Adjusted EBITDA as net
                (loss) income before interest, taxes, depreciation and amortization, certain non-cash items and other
                adjustments that we do not consider in our evaluation of ongoing operating performance from period to
                period. Corporate costs, net of eliminations, are managed on a standalone basis and not allocated to
                segments.</span></div>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-1502-3" continuedAt="f-1502-4">
        <ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"
            id="f-1505" escape="true">
            <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock"
                id="f-1504" escape="true">
                <div style="margin-top:6pt;text-align:justify"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                        following schedule includes revenue and adjusted EBITDA for each of the Company&#8217;s
                        reportable operating segments (in thousands): </span></div>
                <div style="margin-top:12pt;text-align:justify">
                    <table
                        style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%">
                        <tr>
                            <td style="width:1.0%" />
                            <td style="width:61.972%" />
                            <td style="width:0.1%" />
                            <td style="width:1.0%" />
                            <td style="width:10.716%" />
                            <td style="width:0.1%" />
                            <td style="width:0.1%" />
                            <td style="width:0.538%" />
                            <td style="width:0.1%" />
                            <td style="width:1.0%" />
                            <td style="width:10.716%" />
                            <td style="width:0.1%" />
                            <td style="width:0.1%" />
                            <td style="width:0.538%" />
                            <td style="width:0.1%" />
                            <td style="width:1.0%" />
                            <td style="width:10.720%" />
                            <td style="width:0.1%" />
                        </tr>
                        <tr>
                            <td colspan="3" style="padding:0 1pt" />
                            <td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year
                                    Ended December 31,</span></td>
                        </tr>
                        <tr>
                            <td colspan="3" style="padding:0 1pt" />
                            <td colspan="3"
                                style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span>
                            </td>
                            <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                            <td colspan="3"
                                style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span>
                            </td>
                            <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                            <td colspan="3"
                                style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span>
                            </td>
                        </tr>
                        <tr style="height:15pt">
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue:</span>
                            </td>
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nucleic
                                    Acid Production</span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-3"
                                        name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1506">224,769</ix:nonFraction>
                                    &#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-407" decimals="-3"
                                        name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1507">813,076</ix:nonFraction>
                                    &#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-3"
                                        name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1508">712,520</ix:nonFraction>
                                    &#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics
                                    Safety Testing</span></td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-3"
                                        name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1509">64,179</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-3"
                                        name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1510">69,932</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-411" decimals="-3"
                                        name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1511">68,417</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Protein
                                    Detection</span></td>
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-3"
                                        name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                        format="ixt:fixed-zero" scale="3" id="f-1512">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-413" decimals="-3"
                                        name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                        format="ixt:fixed-zero" scale="3" id="f-1513">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-414" decimals="-3"
                                        name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1514">18,959</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total
                                    reportable segments&#8217; revenue</span></td>
                            <td colspan="2"
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-415" decimals="-3"
                                        name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1515">288,948</ix:nonFraction>
                                    &#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-3"
                                        name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1516">883,008</ix:nonFraction>
                                    &#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-417" decimals="-3"
                                        name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1517">799,896</ix:nonFraction>
                                    &#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment
                                    eliminations</span></td>
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-3" sign="-"
                                        name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3"
                                        id="f-1518">3</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-419" decimals="-3" sign="-"
                                        name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3"
                                        id="f-1519">7</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-3" sign="-"
                                        name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3"
                                        id="f-1520">656</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span>
                            </td>
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1521">288,945</ix:nonFraction>
                                    &#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1522">883,001</ix:nonFraction>
                                    &#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1523">799,240</ix:nonFraction>
                                    &#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr style="height:14pt">
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment
                                    adjusted EBITDA:</span></td>
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nucleic
                                    Acid Production</span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-3"
                                        name="mrvi:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1524">82,658</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-407" decimals="-3"
                                        name="mrvi:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1525">638,337</ix:nonFraction>
                                    &#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-3"
                                        name="mrvi:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1526">565,254</ix:nonFraction>
                                    &#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologics
                                    Safety Testing</span></td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-3"
                                        name="mrvi:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1527">46,908</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-3"
                                        name="mrvi:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1528">54,841</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-411" decimals="-3"
                                        name="mrvi:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1529">54,440</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Protein
                                    Detection</span></td>
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-3"
                                        name="mrvi:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"
                                        format="ixt:fixed-zero" scale="3" id="f-1530">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-413" decimals="-3"
                                        name="mrvi:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"
                                        format="ixt:fixed-zero" scale="3" id="f-1531">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-414" decimals="-3"
                                        name="mrvi:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1532">6,391</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total
                                    reportable segments&#8217; adjusted EBITDA</span></td>
                            <td colspan="2"
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-415" decimals="-3"
                                        name="mrvi:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1533">129,566</ix:nonFraction>
                                    &#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-3"
                                        name="mrvi:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1534">693,178</ix:nonFraction>
                                    &#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-417" decimals="-3"
                                        name="mrvi:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1535">626,085</ix:nonFraction>
                                    &#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reconciliation
                                    of total reportable segments&#8217; adjusted EBITDA to income before income
                                    taxes</span></td>
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span>
                            </td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1536">27,356</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1537">24,269</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1538">18,339</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span>
                            </td>
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-1539">
                                        12,898</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-1540">
                                        7,566</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-1541">
                                        6,413</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest
                                    expense</span></td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1542">45,892</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1543">20,414</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1544">30,260</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest
                                    income</span></td>
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1545">27,727</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1546">2,338</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:InvestmentIncomeInterest" format="ixt:fixed-zero" scale="3"
                                        id="f-1547">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate
                                    costs, net of eliminations</span></td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="mrvi:CorporateCostsNetOfEliminations" format="ixt:num-dot-decimal"
                                        scale="3" id="f-1548">64,257</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="mrvi:CorporateCostsNetOfEliminations" format="ixt:num-dot-decimal"
                                        scale="3" id="f-1549">55,378</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="mrvi:CorporateCostsNetOfEliminations" format="ixt:num-dot-decimal"
                                        scale="3" id="f-1550">43,265</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other
                                    adjustments:</span></td>
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition
                                    contingent consideration</span></td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                                        name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1551">3,286</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-"
                                        name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1552">7,800</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"
                                        format="ixt:fixed-zero" scale="3" id="f-1553">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition
                                    integration costs</span></td>
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:BusinessCombinationIntegrationRelatedCosts"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1554">12,695</ix:nonFraction>
                                    )</span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:BusinessCombinationIntegrationRelatedCosts"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1555">13,362</ix:nonFraction>
                                    )</span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:BusinessCombinationIntegrationRelatedCosts" scale="3" id="f-1556">
                                        44</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3" style="display:none" />
                            <td colspan="3" style="display:none" />
                            <td colspan="3" style="display:none" />
                            <td colspan="3" style="display:none" />
                            <td colspan="3" style="display:none" />
                            <td colspan="3" style="display:none" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-based
                                    compensation</span></td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:AllocatedShareBasedCompensationExpense"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1557">34,588</ix:nonFraction>
                                    )</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:AllocatedShareBasedCompensationExpense"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1558">18,670</ix:nonFraction>
                                    )</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:AllocatedShareBasedCompensationExpense"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1559">10,458</ix:nonFraction>
                                    )</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain
                                    on sale of business</span></td>
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3"
                                        id="f-1560">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3"
                                        id="f-1561">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1562">11,249</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3" style="display:none" />
                            <td colspan="3" style="display:none" />
                            <td colspan="3" style="display:none" />
                            <td colspan="3" style="display:none" />
                            <td colspan="3" style="display:none" />
                            <td colspan="3" style="display:none" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merger
                                    and acquisition related expenses</span></td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:BusinessCombinationAcquisitionRelatedCosts"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1563">4,392</ix:nonFraction>
                                    )</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:BusinessCombinationAcquisitionRelatedCosts"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1564">2,416</ix:nonFraction>
                                    )</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:BusinessCombinationAcquisitionRelatedCosts"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1565">1,508</ix:nonFraction>
                                    )</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing
                                    costs</span></td>
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:ProfessionalFees" format="ixt:fixed-zero" scale="3" id="f-1566">
                                        &#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1567">1,078</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:ProfessionalFees" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1568">2,383</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition
                                    related tax adjustment</span></td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                                        name="mrvi:BusinessCombinationAcquisitionRelatedTaxAdjustment"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1569">1,293</ix:nonFraction>
                                    )</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-"
                                        name="mrvi:BusinessCombinationAcquisitionRelatedTaxAdjustment" scale="3"
                                        id="f-1570">349</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="mrvi:BusinessCombinationAcquisitionRelatedTaxAdjustment"
                                        format="ixt:fixed-zero" scale="3" id="f-1571">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax
                                    Receivable Agreement liability adjustment</span></td>
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="mrvi:GainLossOnTaxReceivableAgreement" format="ixt:num-dot-decimal"
                                        scale="3" id="f-1572">668,886</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-"
                                        name="mrvi:GainLossOnTaxReceivableAgreement" format="ixt:num-dot-decimal"
                                        scale="3" id="f-1573">4,102</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="mrvi:GainLossOnTaxReceivableAgreement" format="ixt:num-dot-decimal"
                                        scale="3" id="f-1574">6,101</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief
                                    Executive Officer transition costs</span></td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                                        name="mrvi:CEOTransitionCosts" scale="3" id="f-1575">28</ix:nonFraction>)</span>
                            </td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-"
                                        name="mrvi:CEOTransitionCosts" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1576">2,426</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="mrvi:CEOTransitionCosts" format="ixt:fixed-zero" scale="3" id="f-1577">
                                        &#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <div style="padding-left:18pt"><span
                                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring
                                        costs </span><span
                                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span>
                                </div>
                            </td>
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:RestructuringCosts" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1578">6,567</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:RestructuringCosts" format="ixt:fixed-zero" scale="3" id="f-1579">
                                        &#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:RestructuringCosts" format="ixt:fixed-zero" scale="3" id="f-1580">
                                        &#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span>
                            </td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                                        name="us-gaap:OtherAdjustmentsToIncomeDiscontinuedOperations"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1581">1,763</ix:nonFraction>
                                    )</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-"
                                        name="us-gaap:OtherAdjustmentsToIncomeDiscontinuedOperations"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1582">1,814</ix:nonFraction>
                                    )</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:OtherAdjustmentsToIncomeDiscontinuedOperations"
                                        format="ixt:fixed-zero" scale="3" id="f-1583">&#8212;</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income
                                    before income taxes</span></td>
                            <td colspan="2"
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1584">617,736</ix:nonFraction>
                                    &#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1585">551,472</ix:nonFraction>
                                    &#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"
                                        format="ixt:num-dot-decimal" scale="3" id="f-1586">530,765</ix:nonFraction>
                                    &#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income
                                    tax expense</span></td>
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3"
                                        name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1587">756,111</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1588">60,809</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#ffffff;padding:0 1pt" />
                            <td colspan="2"
                                style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3"
                                        id="f-1589">61,515</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                        <tr>
                            <td colspan="3"
                                style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">
                                <div><span
                                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net
                                        (loss) income</span></div>
                            </td>
                            <td
                                style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(
                                    <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-"
                                        name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-1590">
                                        138,375</ix:nonFraction>)</span></td>
                            <td
                                style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td
                                style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3"
                                        name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-1591">
                                        490,663</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                            <td colspan="3" style="background-color:#cceeff;padding:0 1pt" />
                            <td
                                style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span>
                            </td>
                            <td
                                style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">
                                <span
                                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">
                                    <ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3"
                                        name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-1592">
                                        469,250</ix:nonFraction>&#160;
                                </span></td>
                            <td
                                style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom" />
                        </tr>
                    </table>
                </div>
                <div style="text-align:justify"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">___________________</span>
                </div>
                <div style="margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Equity-based
                        compensation benefit of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5"
                            name="mrvi:RestructuringCostsIncludedInShareBasedPaymentArrangementExpense"
                            format="ixt:num-dot-decimal" scale="6" id="f-1593">0.1</ix:nonFraction>&#160;million related
                        to forfeited equity awards in connection with the restructuring is included on the equity-based
                        compensation line item.</span></div>
            </ix:nonNumeric>
        </ix:nonNumeric>
        <div style="margin-top:12pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During
                the years ended December&#160;31, 2023 and 2022, intersegment revenue was <ix:nonFraction unitRef="usd"
                    contextRef="c-419" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax"
                    format="ixt:fixed-zero" scale="0" id="f-1594">
                    <ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-5"
                        name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero"
                        scale="0" id="f-1595">immaterial</ix:nonFraction>
                </ix:nonFraction> between the Nucleic Acid Production and Biologics Safety Testing segments. During the
                year ended December&#160;31, 2021, intersegment revenue was $<ix:nonFraction unitRef="usd"
                    contextRef="c-420" decimals="-5" sign="-"
                    name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal"
                    scale="6" id="f-1596">0.7</ix:nonFraction> million between the Nucleic Acid Production and Protein
                Detection segments. The intersegment sales and the related gross margin on inventory recorded at the end
                of the period are eliminated for consolidation purposes. Internal selling prices for intersegment sales
                are consistent with the segment&#8217;s normal retail price offered to external parties. There was
                <ix:nonFraction unitRef="usd" contextRef="c-418" decimals="INF"
                    name="us-gaap:NoninterestExpenseCommissionExpense" format="ixt:fixed-zero" scale="3" id="f-1597">
                    <ix:nonFraction unitRef="usd" contextRef="c-420" decimals="INF"
                        name="us-gaap:NoninterestExpenseCommissionExpense" format="ixt:fixed-zero" scale="3"
                        id="f-1598">
                        <ix:nonFraction unitRef="usd" contextRef="c-419" decimals="INF"
                            name="us-gaap:NoninterestExpenseCommissionExpense" format="ixt:fixed-zero" scale="3"
                            id="f-1599">no</ix:nonFraction>
                    </ix:nonFraction>
                </ix:nonFraction> commission expense recognized for intersegment sales for the years ended
                December&#160;31, 2023, 2022 and 2021. </span></div>
    </ix:continuation>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <ix:continuation id="f-1502-4">
        <div style="margin-top:6pt;text-align:justify"><span
                style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
                Company does not allocate assets to its reportable segments as they are not included in the review
                performed by the CODM for purposes of assessing segment performance and allocating resources.</span>
        </div>
    </ix:continuation>
    <div id="ic995976d222241b98dac88a4c1bc08e5_256"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_259"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            9A. Controls and Procedures</span></div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation
            of Disclosure Controls and Procedures</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under
            the supervision and with the participation of our management, including our Chief Executive Officer and
            Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure
            controls and procedures pursuant to Rule 13a-15(e) and 15(d)-15(e) under the Securities Exchange Act of
            1934, as amended (the &#8220;Exchange Act&#8221;) as of the end of the period covered by this report. Our
            disclosure controls and procedures are designed to ensure that information required to be disclosed in the
            reports that are filed or submitted under the Exchange Act is accumulated and communicated to management,
            including the Chief Executive Officer and Chief Financial Officer, to allow for timely decisions regarding
            required disclosures. In designing and evaluating the disclosure controls and procedures, management
            recognized that any controls and procedures, no matter how well designed and operated, can provide only
            reasonable assurance of achieving the desired control objectives, as ours are designed to do, and management
            necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and
            procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded
            that, as of the end of such period, the Company&#8217;s disclosure controls and procedures were effective at
            a reasonable assurance level.</span></div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s
            Report on Internal Control over Financial Reporting</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            management is responsible for establishing and maintaining adequate internal control over financial
            reporting. Our internal control over financial reporting is a process designed to provide reasonable
            assurance regarding the reliability of financial reporting and the preparation of financial statements for
            external purposes in accordance with accounting principles generally accepted in the United States. Because
            of its inherent limitations, internal control over financial reporting may not prevent or detect
            misstatements. Therefore, even those systems determined to be effective can provide only reasonable
            assurance of achieving their control objectives. </span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            management assessed the effectiveness of our internal control over financial reporting as of
            December&#160;31, 2023. In making this assessment, we used the criteria set forth by the Committee of
            Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control &#8211; Integrated Framework
            (2013 Framework). Based on its assessment, management concluded that, as of December&#160;31, 2023, the
            Company&#8217;s internal control over financial reporting was effective. Ernst &amp; Young LLP, an
            independent registered public accounting firm, has issued an auditors&#8217; report on our internal control
            over financial reporting as of December&#160;31, 2023, which is included elsewhere in this Annual Report on
            Form 10-K.</span></div>
    <div style="margin-top:12pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes
            in Internal Control over Financial Reporting</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There
            have been no changes in our internal control over financial reporting, as such term is defined in Rules
            13a-15(f) and 15d-15(f) under the Exchange Act, during the three months ended December&#160;31, 2023 that
            have materially affected, or are reasonably likely to materially affect, our internal control over financial
            reporting.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_262"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report
            of Independent Registered Public Accounting Firm</span></div>
    <div><span><br /></span></div>
    <div><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To
            the Stockholders and the Board of Directors of Maravai LifeSciences Holdings, Inc.</span></div>
    <div><span><br /></span></div>
    <div><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion
            on Internal Control Over Financial Reporting</span></div>
    <div><span><br /></span></div>
    <div style="text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            have audited Maravai LifeSciences Holdings, Inc.&#8217;s internal control over financial reporting as of
            December&#160;31, 2023, based on criteria established in Internal Control&#8212;Integrated Framework issued
            by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO
            criteria). In our opinion, Maravai LifeSciences Holdings, Inc. (the Company) maintained, in all material
            respects, effective internal control over financial reporting as of December&#160;31, 2023, based on the
            COSO criteria.</span></div>
    <div><span><br /></span></div>
    <div style="text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United
            States) (PCAOB), the consolidated balance sheets of the Company as of December&#160;31, 2023 and 2022, the
            related consolidated statements of operations, comprehensive (loss) income, changes in stockholders&#8217;
            equity and cash flows for each of the three years in the period ended December&#160;31, 2023, and the
            related notes and our report dated February&#160;29, 2024 expressed an unqualified opinion thereon.</span>
    </div>
    <div><span><br /></span></div>
    <div style="text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis
            for Opinion</span></div>
    <div><span><br /></span></div>
    <div style="text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            Company&#8217;s management is responsible for maintaining effective internal control over financial
            reporting and for its assessment of the effectiveness of internal control over financial reporting included
            in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is
            to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit.
            We are a public accounting firm registered with the PCAOB and are required to be independent with respect to
            the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of
            the Securities and Exchange Commission and the PCAOB.</span></div>
    <div style="text-align:justify"><span><br /></span></div>
    <div style="text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We
            conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and
            perform the audit to obtain reasonable assurance about whether effective internal control over financial
            reporting was maintained in all material respects.</span></div>
    <div style="text-align:justify"><span><br /></span></div>
    <div style="text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our
            audit included obtaining an understanding of internal control over financial reporting, assessing the risk
            that a material weakness exists, testing and evaluating the design and operating effectiveness of internal
            control based on the assessed risk, and performing such other procedures as we considered necessary in the
            circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div>
    <div><span><br /></span></div>
    <div style="text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition
            and Limitations of Internal Control Over Financial Reporting</span></div>
    <div><span><br /></span></div>
    <div style="text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A
            company&#8217;s internal control over financial reporting is a process designed to provide reasonable
            assurance regarding the reliability of financial reporting and the preparation of financial statements for
            external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal
            control over financial reporting includes those policies and procedures that (1) pertain to the maintenance
            of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of
            the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to
            permit preparation of financial statements in accordance with generally accepted accounting principles, and
            that receipts and expenditures of the company are being made only in accordance with authorizations of
            management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely
            detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a
            material effect on the financial statements.</span></div>
    <div style="text-align:justify"><span><br /></span></div>
    <div style="text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because
            of its inherent limitations, internal control over financial reporting may not prevent or detect
            misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the
            risk that controls may become inadequate because of changes in conditions, or that the degree of compliance
            with the policies or procedures may deteriorate.</span></div>
    <div><span><br /></span></div>
    <div><span><br /></span></div>
    <div><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/
            Ernst &amp; Young LLP</span></div>
    <div><span><br /></span></div>
    <div><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San
            Mateo, California</span></div>
    <div><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;29,
            2024</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_265"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            9B. Other Information</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insider
            Trading Arrangements</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None
            of the Company&#8217;s directors or officers (as defined in Section 16 of the Exchange Act) <ix:nonNumeric
                contextRef="c-224" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1600">
                <ix:nonNumeric contextRef="c-224" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"
                    id="f-1601">adopted</ix:nonNumeric>
            </ix:nonNumeric> or <ix:nonNumeric contextRef="c-224" name="ecd:Rule10b51ArrTrmntdFlag"
                format="ixt:fixed-false" id="f-1602">
                <ix:nonNumeric contextRef="c-224" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"
                    id="f-1603">terminated</ix:nonNumeric>
            </ix:nonNumeric> a &#8220;Rule 10b5-1 trading arrangement&#8221; or a &#8220;non-Rule 10b5-1 trading
            arrangement&#8221; (each as defined in Item 408(a) and (c) of Regulation S-K) during the Company&#8217;s
            fiscal quarter ended December&#160;31, 2023.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_268"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not
            applicable.</span></div>
    <div><span><br /></span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_271"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:18pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part
            III.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_274"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            10. Directors, Executive Officers and Corporate Governance</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            information required by this Item is incorporated by reference to the Company&#8217;s 2024 Proxy Statement
            (the &#8220;2024 Proxy Statement&#8221;) to be filed with the SEC within 120 days after December&#160;31,
            2023 in connection with the solicitation of proxies for the Company&#8217;s 2024 annual meeting of
            stockholders.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_277"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            11. Executive Compensation</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            information required by this Item is incorporated by reference to the 2024 Proxy Statement, which is
            expected to be filed no later than 120 days after the end of our fiscal year ended December&#160;31,
            2023.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_280"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span>
    </div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            information required by this Item is incorporated by reference to the 2024 Proxy Statement, which is
            expected to be filed no later than 120 days after the end of our fiscal year ended December&#160;31,
            2023.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_283"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            13. Certain Relationships and Related Transactions and Director Independence</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            information required by this Item is incorporated by reference to the 2024 Proxy Statement, which is
            expected to be filed no later than 120 days after the end of our fiscal year ended December&#160;31,
            2023.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_286"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            14. Principal Accounting Fees and Services</span></div>
    <div style="margin-top:6pt;text-align:justify"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The
            information required by this Item is incorporated by reference to the 2024 Proxy Statement, which is
            expected to be filed no later than 120 days after the end of our fiscal year ended December&#160;31,
            2023.</span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_289"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:18pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part
            IV.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_292"></div>
    <div style="-sec-extract:summary;margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            15.&#160;&#160;&#160;&#160;Exhibits and Financial Statement Schedules</span></div>
    <div style="margin-bottom:6pt;margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)
            The following documents are filed as a part of this report:</span></div>
    <div style="margin-bottom:6pt;text-indent:13.5pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Consolidated
            Financial Statements (included in Item 8):</span></div>
    <div style="margin-bottom:6pt;padding-left:49.5pt"><span
            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a
                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"
                href="#ic995976d222241b98dac88a4c1bc08e5_175">Report of Independent Registered Public Accounting
                Firm</a></span></div>
    <div style="margin-bottom:6pt;padding-left:36pt;text-indent:13.5pt"><span
            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a
                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"
                href="#ic995976d222241b98dac88a4c1bc08e5_178">Consolidated Balance Sheets</a></span></div>
    <div style="margin-bottom:6pt;padding-left:36pt;text-indent:13.5pt"><span
            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a
                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"
                href="#ic995976d222241b98dac88a4c1bc08e5_181">Consolidated Statements of Operations</a></span></div>
    <div style="margin-bottom:6pt;padding-left:36pt;text-indent:13.5pt"><span
            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a
                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"
                href="#ic995976d222241b98dac88a4c1bc08e5_184">Consolidated Statements of Comprehensive (Loss)
                Income</a></span></div>
    <div style="margin-bottom:6pt;padding-left:36pt;text-indent:13.5pt"><span
            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a
                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"
                href="#ic995976d222241b98dac88a4c1bc08e5_187">Consolidated Statements of Changes in Stockholders&#8217;
                Equity</a></span></div>
    <div style="margin-bottom:6pt;padding-left:36pt;text-indent:13.5pt"><span
            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a
                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"
                href="#ic995976d222241b98dac88a4c1bc08e5_190">Consolidated Statements of Cash Flows</a></span></div>
    <div style="margin-bottom:12pt;padding-left:36pt;text-indent:13.5pt"><span
            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a
                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"
                href="#ic995976d222241b98dac88a4c1bc08e5_193">Notes to Consolidated Financial Statements</a></span>
    </div>
    <div style="margin-bottom:6pt;padding-left:13.5pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Financial
            Statement Schedules</span></div>
    <div style="margin-bottom:6pt;padding-left:49.5pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All
            schedules have been omitted because they are not applicable or not required, or because the required
            information is included either in the consolidated financial statements or in the notes thereto.</span>
    </div>
    <div style="margin-bottom:6pt;padding-left:13.5pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Exhibits</span>
    </div>
    <div>
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:12.496%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.530%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:84.574%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3"
                    style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;Number</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="border-top:1pt solid #000;padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#167;
                    </span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323921000018/exhibit21to8-10x218xkproje.htm">Agreement
                                and Plan of Merger, dated as of August 5, 2021, among Maravai Life Sciences, Inc.,
                                Voyager Group Holdings, Inc., Maravai LifeSciences Holdings, Inc., and Maravai
                                Intermediate Holdings, LLC (incorporated by reference to Exhibit 2.1 to Maravai
                                LifeSciences Holdings, Inc.&#8217;s Form 8-K filed on August 10, 2021).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#167;
                    </span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323921000023/exhibit21-amendmentno1tome.htm">Amendment
                                No. 1, dated as of September 2, 2021, to the Agreement and Plan of Merger, dated as of
                                August 5, 2021, among Maravai Life Sciences, Inc., Voyager Group Holdings, Inc., Maravai
                                LifeSciences Holdings, Inc., and Maravai Intermediate Holdings, LLC (incorporated by
                                reference to Exhibit 2.1 to Maravai LifeSciences Holdings, Inc.&#8217;s Form 8-K filed
                                on September 3, 2021).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323922000012/exhibit23-voyagerclosingst.htm">Letter
                                Agreement, dated November 24, 2021, amending the Agreement and Plan of Merger, dated as
                                of August 5, 2021, among Maravai Life Sciences, Inc., Voyager Group Holdings, Inc.,
                                Maravai LifeSciences Holdings, Inc., and Maravai Intermediate Holdings, LLC
                                (incorporated by reference to Exhibit 2.3 to Maravai LifeSciences Holdings, Inc.'s Form
                                10-K filed on March 1, 2022).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323922000058/exhibit21-projectvoyagerxa.htm">Amendment
                                No. 2, dated as of August 30, 2022, to the Agreement and Plan of Merger, dated as of
                                August 5, 2021, among Maravai Life Sciences, LLC (f/k/a Maravai Life Sciences, Inc.),
                                Voyager Group Holdings, Inc., Vector Laboratories, Inc., Maravai LifeSciences Holdings,
                                Inc., and Maravai Intermediate Holdings, LLC (incorporated by reference to Exhibit 2.1
                                to Maravai LifeSciences Holdings, Inc.&#8217;s Form 10-Q filed on November 4,
                                2022).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000119312520303088/d31788dex31.htm">Amended
                                and Restated Certificate of Incorporation of Maravai LifeSciences Holdings, Inc. dated
                                November 19, 2020 (incorporated by reference to Exhibit 3.1 to Maravai Life Sciences
                                Holdings, Inc.&#8217;s Form 8-K filed on November 25, 2020).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000119312520303088/d31788dex32.htm">Amended
                                and Restated Bylaws of Maravai LifeSciences Holdings, Inc. dated November 19, 2020
                                (incorporated by reference to Exhibit 3.2 to Maravai Life Sciences Holdings,
                                Inc.&#8217;s Form 8-K filed on November 25, 2020).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000119312520303088/d31788dex41.htm">Registration
                                Rights Agreement, dated November 24, 2020, by and among Maravai LifeSciences Holdings,
                                Inc. and the other signatories party thereto (incorporated by reference to Exhibit 4.1
                                to Maravai LifeSciences Holdings, Inc.&#8217;s Form 8-K filed on November 25,
                                2020).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="mrvi-2023form10xkxex42xdes.htm">Description of Maravai LifeSciences Holdings,
                                Inc.&#8217;s Securities. </a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000119312520301489/d12698dex101.htm">Maravai
                                LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan (incorporated by reference to
                                Exhibit 10.1 to Maravai LifeSciences Holdings, Inc.&#8217;s Registration Statement on
                                Form S-8 filed with the Securities and Exchange Commission on November 23,
                                2020).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2+&#167;</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000014/exhibit104-mrvixformofsmac.htm">Form
                                of Senior Management Agreement - Capital Units and Incentive Units (incorporated by
                                reference to Exhibit 10.4 to Maravai LifeSciences Holdings, Inc.&#8217;s Form 10-K filed
                                on February 28, 2023).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
        </table>
    </div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="-sec-extract:summary;text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div style="-sec-extract:summary"><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div>
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:12.496%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.530%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:84.574%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3"
                    style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;Number</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+&#167;</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000014/exhibit105-mrvixformofsmai.htm">Form
                                of Senior Management Agreement - Incentive Units (incorporated by reference to Exhibit
                                10.5 to Maravai LifeSciences Holdings, Inc.&#8217;s Form 10-K filed on February 28,
                                2023).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+&#167;</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000014/exhibit106-mrvixformofamen.htm">Form
                                of Amendment to Senior Management Agreement (incorporated by reference to Exhibit 10.6
                                to Maravai LifeSciences Holdings, Inc.&#8217;s Form 10-K filed on February 28,
                                2023).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000119312520303088/d31788dex101.htm">Tax
                                Receivable Agreement, dated as of November 19, 2020, by and among Maravai LifeSciences
                                Holdings, Inc. and the other signatories party thereto (incorporated by reference to
                                Exhibit 10.1 to Maravai LifeSciences Holdings, Inc.&#8217;s Form 8-K filed on November
                                25, 2020).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000119312520303088/d31788dex102.htm">Exchange
                                Agreement, dated as of November 19, 2020, by and among Maravai LifeSciences Holdings,
                                Inc. and the other signatories party thereto (incorporated by reference to Exhibit 10.2
                                to Maravai LifeSciences Holdings, Inc.&#8217;s Form 8-K filed on November 25,
                                2020).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000119312520303088/d31788dex103.htm">Second
                                Amended and Restated Limited Liability Agreement of Maravai Topco Holdings, LLC, dated
                                as of November 19, 2020, by and among Maravai LifeSciences Holdings, Inc. and the other
                                signatories party thereto (incorporated by reference to Exhibit 10.3 to Maravai
                                LifeSciences Holdings, Inc.&#8217;s Form 8-K filed on November 25, 2020).</a></span>
                    </div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000119312520301489/d12698dex102.htm">Maravai
                                LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan (incorporated by reference
                                to Exhibit 10.2 to Maravai LifeSciences Holdings, Inc.&#8217;s Registration Statement on
                                Form S-8 filed with the Securities and Exchange Commission on November 23,
                                2020).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000119312520288872/d73061dex1012.htm">Form
                                of Director and Officer Indemnification Agreement (incorporated by reference to Exhibit
                                10.12 to Maravai LifeSciences Holdings, Inc.&#8217;s Form S-1/A filed on November 9,
                                2020). </a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11&#167;</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000119312520281158/d73061dex1015.htm">Distribution
                                Agreement, dated January 14, 2019, between Cygnus Technologies, LLC and Beijing XMJ
                                Scientific Co. Ltd. (incorporated by reference to Exhibit 10.15 to Maravai LifeSciences
                                Holdings, Inc.&#8217;s Form S-1 filed on October 29, 2020). </a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12&#167;</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000119312520281158/d73061dex1017.htm">Lease
                                Agreement, dated as of September 23, 2019, between TransDulles Center, Inc., and Glen
                                Research Corporation, as amended (incorporated by reference to Exhibit 10.17 to Maravai
                                LifeSciences Holdings, Inc.&#8217;s Form S-1 filed on October 29, 2020). </a></span>
                    </div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13&#167;</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000119312520281158/d73061dex1018.htm">Lease
                                Agreement, dated as of July 13, 2018, between 10770 Wateridge Investors LLC, and Trilink
                                Biotechnologies, LLC, as amended (incorporated by reference to Exhibit 10.18 to Maravai
                                LifeSciences Holdings, Inc.&#8217;s Form S-1 filed on October 29, 2020). </a></span>
                    </div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14&#167;</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000119312520281158/d73061dex1019.htm">Lease
                                Agreement, dated as of October 6, 2016, between Arame, LLC, and Cygnus Technologies,
                                LLC, as amended (incorporated by reference to Exhibit 10.19 to Maravai LifeSciences
                                Holdings, Inc.&#8217;s Form S-1 filed on October 29, 2020). </a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15&#167;</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="a10-kex1015xflanderslease.htm">L</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="a10-kex1015xflanderslease.htm">ease Agreement</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="a10-kex1015xflanderslease.htm">, dated </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="a10-kex1015xflanderslease.htm">August 6</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="a10-kex1015xflanderslease.htm">, 202</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="a10-kex1015xflanderslease.htm">1, </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="a10-kex1015xflanderslease.htm">by and </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="a10-kex1015xflanderslease.htm">between 10240 Flanders Investors LL</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="a10-kex1015xflanderslease.htm">C and Trilink Biotechnologies, LLC</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="a10-kex1015xflanderslease.htm">.</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1016xflandersleaseamend.htm">F</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1016xflandersleaseamend.htm">irst Amendment to Lease Agreement, dated October
                                14, 202</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1016xflandersleaseamend.htm">1, by and between 10240 </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1016xflandersleaseamend.htm">Flanders Investors LLC and Trilink
                                Biotechnologies, LLC.</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1017xflandersleaseamend.htm">Second Amendment to Lease Agreement, dated October
                                1, 2022, by and between 10240 Flanders Investors LLC and Trilink Biotechnologies,
                                LLC.</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18&#167;</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="a10-kex1018xcygnuslease.htm">Lease Agreement, date</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="a10-kex1018xcygnuslease.htm">d as of June 11, 2021, by and between </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="a10-kex1018xcygnuslease.htm">CIGG, LC and </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="a10-kex1018xcygnuslease.htm">Cygnus Technologies, LLC</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="a10-kex1018xcygnuslease.htm">.</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000119312520303088/d31788dex105.htm">Director
                                Nomination Agreement, dated as of November 24, 2020, by and among Maravai LifeSciences
                                Holdings, Inc. and the other signatories party thereto (incorporated by reference to
                                Exhibit 10.5 to Maravai LifeSciences Holdings, Inc.&#8217;s Form 8-K filed on November
                                25, 2020).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20&#167;</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000119312520281158/d73061dex1024.htm">Credit
                                Agreement, dated as of October 19, 2020, among Maravai Intermediate Holdings, LLC,
                                Cygnus Technologies, LLC, Trilink Biotechnologies, LLC, Vector Laboratories, Inc.,
                                Maravai Topco Holdings, LLC and Morgan Stanley Senior Funding, Inc. (incorporated by
                                reference to Exhibit 10.24 to Maravai LifeSciences Holdings, Inc.&#8217;s Form S-1 filed
                                on October 29, 2020).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1021xfirstamendmenttocr.htm">First </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1021xfirstamendmenttocr.htm">Amend</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1021xfirstamendmenttocr.htm">ment to Credit Agreement to Credit Agreement,
                                dated as of Augu</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1021xfirstamendmenttocr.htm">st 11, 202</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1021xfirstamendmenttocr.htm">1, </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1021xfirstamendmenttocr.htm">by</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1021xfirstamendmenttocr.htm"> M</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1021xfirstamendmenttocr.htm">a</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1021xfirstamendmenttocr.htm">ravai Intermediate Holdings, LLC</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1021xfirstamendmenttocr.htm"> and Morgan Stanley Senior Funding,
                                Inc.</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323922000004/exhibit101-amend2tocredi.htm">Second
                                Amendment to Credit Agreement, dated as of January 19, 2022, among Maravai Intermediate
                                Holdings, LLC, Cygnus Technologies, LLC, Trilink Biotechnologies, LLC, Maravai Topco
                                Holdings, LLC and Morgan Stanley Senior Funding, Inc. (incorporated by reference to
                                Exhibit 10.1 to Maravai LifeSciences Holdings Inc.&#8217;s Form 8-K filed on January 20,
                                2022).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23+&#167;</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex102-carlhullxaremploymen.htm">Amended
                                and Restated Employment Agreement of Carl W. Hull, dated May 8, 202</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex102-carlhullxaremploymen.htm">3</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex102-carlhullxaremploymen.htm">,
                                among Maravai LifeSciences H</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex102-carlhullxaremploymen.htm">oldings,
                                Inc., Maravai Intermediate Holdings, LLC and Carl W. Hull (inc</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex102-carlhullxaremploymen.htm">orporated
                                by reference to Exhibit 10.2 to Maravai LifeSciences Holdings, Inc.</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex102-carlhullxaremploymen.htm">&#8217;</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex102-carlhullxaremploymen.htm">s
                                Form 10-Q filed on May 9, 2023).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
        </table>
    </div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="-sec-extract:summary;text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div style="-sec-extract:summary"><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div>
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:12.496%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.530%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:84.574%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3"
                    style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;Number</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24+</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1024xamendmentno1toarem.htm">Amendment No.1, effective as of </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1024xamendmentno1toarem.htm">July 27, 2023</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1024xamendmentno1toarem.htm">, to the </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1024xamendmentno1toarem.htm">Amended and Restated </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1024xamendmentno1toarem.htm">Employment Agreement of Carl W. Hull, dated </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1024xamendmentno1toarem.htm">May 8, 202</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1024xamendmentno1toarem.htm">3</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1024xamendmentno1toarem.htm">, among Maravai LifeSciences Holdings, Inc.,
                                Maravai Intermediate Holdings, LLC and Carl W. Hull</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1024xamendmentno1toarem.htm">.</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25+&#167;</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex104-kevinherdexaremploym.htm">Amended
                                and Restated Employment Agreement of Kevin Herde, dated May 8, 2023, among Maravai
                                LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and Kevin Herde
                                (incorporated by reference to Exhibit 10.4 to Maravai LifeSciences Holdings,
                                Inc.&#8217;s Form 10-Q filed on May 9, 2023).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26+&#167;</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000119312520303088/d31788dex1010.htm">Employment
                                Agreement of Brian Neel, dated November 24, 2020, among Maravai LifeSciences Holdings,
                                Inc., TriLink Biotechnologies, LLC and Brian Neel (incorporated by reference to Exhibit
                                10.10 to Maravai LifeSciences Holdings, Inc.&#8217;s Form 8-K filed on November 25,
                                2020).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27+&#167;</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex106-christinedolanxaremp.htm">Amended
                                and Restated Employment Agreement of Christine Dolan, dated as of May 8, 2023 among
                                Maravai LifeSciences Holdings, Inc., Cygnus Technologies, LLC, MLSC Holdings, LLC and
                                Christine Dolan (incorporated by reference to Exhibit 10.6 to Maravai LifeSciences
                                Holdings, Inc.&#8217;s Form 10-Q filed on May 9, 2023).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28+&#167;</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex103-treymartinxaremploym.htm">Amende</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex103-treymartinxaremploym.htm">d
                                and Restated Employment Agreement of William </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex103-treymartinxaremploym.htm">&#8220;</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex103-treymartinxaremploym.htm">Trey</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex103-treymartinxaremploym.htm">&#8221;</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex103-treymartinxaremploym.htm">
                                Martin, III, </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex103-treymartinxaremploym.htm">effective</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex103-treymartinxaremploym.htm">
                                as of May </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex103-treymartinxaremploym.htm">8,
                                2023, among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and
                                William </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex103-treymartinxaremploym.htm">&#8220;</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex103-treymartinxaremploym.htm">Trey</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex103-treymartinxaremploym.htm">&#8221;</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex103-treymartinxaremploym.htm">
                            </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex103-treymartinxaremploym.htm">M</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex103-treymartinxaremploym.htm">artin,
                                III (incorporated by </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex103-treymartinxaremploym.htm">reference
                                to Exhibit 10.3 to Maravai LifeSciences Holdings, Inc.</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex103-treymartinxaremploym.htm">&#8217;</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex103-treymartinxaremploym.htm">s
                                Form 10-Q filed on May </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex103-treymartinxaremploym.htm">9,
                                2023</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex103-treymartinxaremploym.htm">).</a></span>
                    </div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29+&#167;</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex105-peterleddyxaremploym.htm">A</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex105-peterleddyxaremploym.htm">mended
                                and Restated Employment Agreement of Peter Leddy, Ph.D.</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex105-peterleddyxaremploym.htm">,
                                effective as of May 8, 2023, among Maravai LifeSciences Holdings, Inc., Maravai
                                Intermediate Holdings, LLC and Peter Leddy, Ph.D. (incorporated by reference to Exhibit
                                10.5 to Maravai LifeSciences Holdings, inc.</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex105-peterleddyxaremploym.htm">&#8217;</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex105-peterleddyxaremploym.htm">s
                            </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000039/ex105-peterleddyxaremploym.htm">Form
                                10-Q filed on May 9, 2023).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30+</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323922000048/exhibit102-rsuagreement2yr.htm">Form
                                of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (incorporated
                                by reference to Exhibit 10.2 to Maravai LifeSciences Holdings, Inc.&#8217;s Form 8-K
                                filed on October 3, 2022).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31+</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323922000048/exhibit103-rsuagreement3yr.htm">Form
                                of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (incorporated
                                by reference to Exhibit 10.3 to Maravai LifeSciences Holdings, Inc.&#8217;s Form 8-K
                                filed on October 3, 2022).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32+</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000119312520292361/d73061dex107.htm">Form
                                of Stock Option Grant Notice and Stock Option Agreement (incorporated by reference to
                                Exhibit 10.7 to Amendment No. 2 to Maravai LifeSciences Holdings, Inc.&#8217;s
                                Registration Statement on Form S-1 filed with the Securities and Exchange Commission on
                                November 13, 2020).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33+</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1033xformofoptionagreem.htm">F</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1033xformofoptionagreem.htm">orm of Stoc</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1033xformofoptionagreem.htm">k </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1033xformofoptionagreem.htm">Option Grant Notice and Stock Op</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1033xformofoptionagreem.htm">tion Agreement.</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34+</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1034xformofrsuagreement.htm">F</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1034xformofrsuagreement.htm">orm of Restrict</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1034xformofrsuagreement.htm">ed Stock Unit Grant Notice and Restricted Stock
                                Unit Agreement.</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35+</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1035xformofpsuagreement.htm">F</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1035xformofpsuagreement.htm">orm of Performance S</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1035xformofpsuagreement.htm">tock Unit Grant Notice and Performance Stock Unit
                                A</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1035xformofpsuagreement.htm">g</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1035xformofpsuagreement.htm">reement</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="aex1035xformofpsuagreement.htm">.</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36+</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit101toq22023xformame.htm">Form
                                of Amendment No. 1 to Restricted Stock Unit Grant Notice (incorporated by reference to
                                Exhibit 10.1 to Maravai LifeScien</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit101toq22023xformame.htm">ces
                                Holdings, I</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit101toq22023xformame.htm">n</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit101toq22023xformame.htm">c.</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit101toq22023xformame.htm">&#8217;</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit101toq22023xformame.htm">s
                                Form 10-Q filed on Augu</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit101toq22023xformame.htm">st
                                8,</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit101toq22023xformame.htm">
                                2023).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37+</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit102toq22023xformame.htm">F</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit102toq22023xformame.htm">orm
                                of Amendment No. 1 to Stock Option Grant Notice (incorporated by reference to Exhibit
                                10.2 to Maravai L</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit102toq22023xformame.htm">i</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit102toq22023xformame.htm">feSciences
                                Holdings, I</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit102toq22023xformame.htm">n</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit102toq22023xformame.htm">c.</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit102toq22023xformame.htm">&#8217;</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit102toq22023xformame.htm">s
                                Form 10-Q filed on August 8, 2023).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38+</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit103toq22023xamendme.htm">Amendment
                                No. 1 to Performance Stock Unit Grant </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit103toq22023xamendme.htm">Notice
                                by and between Maravai L</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit103toq22023xamendme.htm">i</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit103toq22023xamendme.htm">feSciences
                                Holdings, </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit103toq22023xamendme.htm">Inc</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit103toq22023xamendme.htm">.
                                and William E. Martin, III, dated as of July 6, 2023 (incorporated by reference to
                                Exhibit 10.3 to Maravai LifeSciences Holdings, </a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit103toq22023xamendme.htm">Inc</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit103toq22023xamendme.htm">.</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit103toq22023xamendme.htm">&#8217;</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="https://www.sec.gov/Archives/edgar/data/1823239/000182323923000081/exhibit103toq22023xamendme.htm">s
                                Form 10-Q filed on August 8, 2023).</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="mrvi-2023form10xkxex211xli.htm">List of subsidiaries of Maravai LifeSciences
                                Holdings, Inc.</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="mrvi-2023form10xkxex231xco.htm">Consent of Independent Registered Public
                                Accounting Firm.</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="mrvi-2023form10xkxex311xce.htm">Certification of the Chief Executive Officer
                                pursuant to Exchange Act Rules Rule 13a-14(a), as adopted pursuant to Section 302 of the
                                Sarbanes-Oxley Act of 2002</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="mrvi-2023form10xkxex311xce.htm">.</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="mrvi-form202310xkxex312xcf.htm">Certification of the Chief Financial Officer
                                pursuant to Exchange Act Rules Rule 13a-14(a), as adopted pursuant to Section 302 of the
                                Sarbanes-Oxley Act of 2002</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="mrvi-form202310xkxex312xcf.htm">.</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="mrvi-2023form10xkxex321xce.htm">Certification of the Chief Executive Officer
                                pursuant to 18 U.S.</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"
                                href="mrvi-2023form10xkxex321xce.htm">C. Section 1350.</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="mrvi-2023form10xkxex322xcf.htm">Certification of the Chief Financial Officer
                                pursuant to 18 U.S.C. Section 1350.</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1</span>
                    </div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="a10-kex971xclawbackpolicy.htm">C</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="a10-kex971xclawbackpolicy.htm">lawback Policy of Maravai LifeSciences Holdings,
                                I</a><a
                                style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"
                                href="a10-kex971xclawbackpolicy.htm">nc.</a></span></div>
                </td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL
                        Instance Document - the instance document does not appear in the Interactive Data File because
                        its XBRL tags are embedded within the Inline XBRL document.</span></td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL
                        Taxonomy Extension Schema Document.</span></td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL
                        Taxonomy Extension Calculation Linkbase Document.</span></td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
        </table>
    </div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="-sec-extract:summary;text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div style="-sec-extract:summary"><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div>
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:12.496%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.530%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:84.574%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3"
                    style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit&#160;Number</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3"
                    style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL
                        Extension Definition Linkbase Document.</span></td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL
                        Taxonomy Label Linkbase Document.</span></td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL
                        Taxonomy Extension Presentation Linkbase Document.</span></td>
            </tr>
            <tr style="height:3pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover
                        Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td>
            </tr>
        </table><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________</span>
    </div>
    <div style="margin-top:3pt">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:4.601%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:93.199%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The
                            certifications furnished as Exhibit 32.1 and 32.2 hereto are deemed to accompany this Annual
                            Report on Form 10-K and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of
                            the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be
                            deemed incorporated by reference in any filing under the Securities Act or the Exchange Act,
                            except as expressly set forth by specific reference in such filing.</span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates
                        a management contract or compensatory plan or agreement.</span></td>
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#167;</span>
                </td>
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibits
                            and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K and will be
                            provided on a supplemental basis to the SEC upon request.</span></div>
                </td>
            </tr>
        </table>
    </div>
    <div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">Financial
            statement schedules</span></div>
    <div style="margin-top:12pt;text-indent:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No
            financial statement schedules are provided because the information called for is not applicable or is shown
            in the financial statements or notes.</span></div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_295"></div>
    <div style="margin-top:18pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item
            16. Form 10-K Summary</span></div>
    <div style="margin-top:6pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span>
    </div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</span>
            </div>
        </div>
    </div>
    <div id="ic995976d222241b98dac88a4c1bc08e5_298"></div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:18pt;text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span>
    </div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant
            to the requirements of the Securities Act of 1934, the registrant has duly caused this Annual Report on Form
            10-K to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div>
    <div style="margin-top:12pt">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:54.016%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:10.595%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.823%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:31.066%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maravai
                        LifeSciences Holdings, Inc.</span></td>
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="6" style="padding:0 1pt" />
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/
                            William E. Martin, III</span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William
                            E. Martin, III</span></div>
                </td>
            </tr>
            <tr>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief
                            Executive Officer</span></div>
                </td>
            </tr>
        </table>
    </div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date:
            February&#160;29, 2024</span></div>
    <div><span><br /></span></div>
    <div style="text-align:center"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">***</span>
    </div>
    <div style="margin-top:12pt;text-align:center"><span><br /></span></div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</span>
            </div>
        </div>
    </div>
    <hr style="page-break-after:always" />
    <div style="min-height:45pt;width:100%">
        <div><span
                style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"><a
                    style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline"
                    href="#ic995976d222241b98dac88a4c1bc08e5_7">Table of Contents</a></span></div>
    </div>
    <div style="margin-top:12pt"><span
            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant
            to the requirements of the Securities and Exchange Act of 1934, this report has been signed below by the
            following persons on behalf of the registrant and in the capacities and on the dates indicted.</span></div>
    <div style="margin-top:12pt">
        <table
            style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%">
            <tr>
                <td style="width:1.0%" />
                <td style="width:31.842%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.385%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:31.842%" />
                <td style="width:0.1%" />
                <td style="width:0.1%" />
                <td style="width:0.385%" />
                <td style="width:0.1%" />
                <td style="width:1.0%" />
                <td style="width:31.846%" />
                <td style="width:0.1%" />
            </tr>
            <tr>
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Signature</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span>
                </td>
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief
                            Executive Officer (Principal Executive Officer)</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;29,
                            2024</span></div>
                </td>
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="margin-top:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/
                            William E. Martin, III</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="margin-bottom:2pt;margin-top:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">William
                            E. Martin, III</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="margin-top:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/
                            Kevin Herde</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief
                        Financial Officer (Principal Financial and Accounting Officer)</span></td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;29,
                            2024</span></div>
                </td>
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="margin-bottom:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kevin
                            Herde</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="margin-top:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/
                            Carl Hull</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive
                            Chairman of the Board</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;29,
                            2024</span></div>
                </td>
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="margin-bottom:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Carl
                            Hull</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="margin-top:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/
                            Anat Ashkenazi</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;29,
                            2024</span></div>
                </td>
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="margin-bottom:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anat
                            Ashkenazi</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="margin-top:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/
                            Sean Cunningham</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;29,
                            2024</span></div>
                </td>
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="margin-bottom:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sean
                            Cunningham</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="margin-top:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/
                            Benjamin Daverman</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;29,
                            2024</span></div>
                </td>
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="margin-bottom:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benjamin
                            Daverman</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="margin-top:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/
                            John DeFord</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;29,
                            2024</span></div>
                </td>
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="margin-bottom:2pt;margin-top:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">John
                            DeFord, Ph.D.</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="margin-top:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/
                            Susannah Gray</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;29,
                            2024</span></div>
                </td>
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="margin-bottom:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Susannah
                            Gray</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="margin-top:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/
                            Jessica Hopfield</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;29,
                            2024</span></div>
                </td>
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="margin-bottom:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jessica
                            Hopfield, Ph.D.</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="margin-top:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/
                            Gregory T. Lucier</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;29,
                            2024</span></div>
                </td>
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="margin-bottom:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gregory
                            T. Lucier</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="margin-top:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/
                            Luke Marker</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;29,
                            2024</span></div>
                </td>
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="margin-bottom:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Luke
                            Marker</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="margin-top:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/
                            Constantine Mihas</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;29,
                            2024</span></div>
                </td>
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="margin-bottom:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Constantine
                            Mihas</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
            <tr style="height:14pt">
                <td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">
                    <div style="margin-top:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/
                            Murali K. Prahalad</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span
                        style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle">
                    <div style="text-align:center"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;29,
                            2024</span></div>
                </td>
            </tr>
            <tr style="height:15pt">
                <td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">
                    <div style="margin-bottom:2pt"><span
                            style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Murali
                            K. Prahalad</span></div>
                </td>
                <td colspan="3" style="padding:0 1pt" />
                <td colspan="3" style="padding:0 1pt" />
            </tr>
        </table>
    </div>
    <div style="height:45pt;position:relative;width:100%">
        <div style="bottom:0;position:absolute;width:100%">
            <div style="text-align:center"><span
                    style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142</span>
            </div>
        </div>
    </div>
</body>

</html>